var images_info;if (!images_info) images_info =[]; images_info["53"]={"53000":{"type":"graphic_diagnosticimage","displayName":"Talc granulomatosis CT","title":"Talc granulomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Talc granulomatosis</div><div class=\"cntnt\"><img style=\"width:349px; height:231px;\" src=\"images/PULM/53000_Talc_granulomatosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Talc granulomatosis in an intravenous drug&nbsp;user with multiple, partially confluent, bilateral micronodules.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53000 Version 3.0</div></div></div>"},"53002":{"type":"graphic_figure","displayName":"Melanoma - Impact of T stage on prognosis","title":"Melanoma - Impact of T stage on prognosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Melanoma - Impact of T stage on prognosis</div><div class=\"cntnt\"><img style=\"width:439px; height:639px;\" src=\"images/ONC/53002_Melanoma-T.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twenty-year survival rates comparing the different T categories (top) and the stage groupings (bottom) for stages I and II melanoma.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 53002 Version 10.0</div></div></div>"},"53003":{"type":"graphic_diagnosticimage","displayName":"CT of nonmucinous minimally invasive adenocarcinoma","title":"CT of nonmucinous minimally invasive adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of nonmucinous minimally invasive adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:333px; height:348px;\" src=\"images/ONC/53003_CT_nonmuc_min_invas_adeno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial 2-mm CT section shows a peripheral, predominantly ground-glass, part-solid nodule in the right upper lobe that includes a 4 x 3 mm solid component (arrow), which corresponded to invasion by pathology.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53003 Version 10.0</div></div></div>"},"53004":{"type":"graphic_table","displayName":"Duke criteria for IE II","title":"Modified Duke criteria for diagnosis of infective endocarditis - Table B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Duke criteria for diagnosis of infective endocarditis - Table B</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Positive blood cultures for IE (one of the following):</td> </tr> <tr> <td class=\"indent2\"><strong>Typical microorganisms consistent with IE from two separate blood cultures:</strong></td> </tr> <tr> <td class=\"indent3\"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class=\"indent3\">Viridans streptococci</td> </tr> <tr> <td class=\"indent3\"><em>Streptococcus gallolyticus</em> (formerly <em>S. bovis</em>), including nutritional variant strains (<em>Granulicatella</em> spp and <em>Abiotrophia defectiva</em>)</td> </tr> <tr> <td class=\"indent3\">HACEK group: <em>Haemophilus</em> spp, <em>Aggregatibacter</em> (formerly <em>Actinobacillus actinomycete comitants</em>), <em>Cardiobacterium hominis</em>, <em>Eikenella</em> spp, and <em>Kingella kingae</em></td> </tr> <tr> <td class=\"indent3\">Community-acquired enterococci, in the absence of a primary focus; <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Persistently positive blood culture:</strong></td> </tr> <tr> <td class=\"indent3\">For organisms that are typical causes of IE: At least two positive blood cultures from blood samples drawn &#62;12 hours apart</td> </tr> <tr> <td class=\"indent3\">For organisms that are more commonly skin contaminants:&nbsp;Three or a majority of&nbsp;&#8805;4 separate blood cultures (with first and last drawn at least one hour apart)</td> </tr> <tr> <td class=\"indent2\"><strong>Single positive blood culture for <em>Coxiella burnetii</em> or phase I IgG antibody titer &#62;1:800</strong>*</td> </tr> <tr> <td class=\"subtitle2_single\">Evidence of endocardial involvement (one of the following):</td> </tr> <tr> <td class=\"indent2\"><strong>Echocardiogram positive for IE:</strong></td> </tr> <tr> <td class=\"indent3\">Vegetation (oscillating intracardiac mass on a&nbsp;valve or on supporting structures,&nbsp;in the path of regurgitant jets, or on implanted material, in the absence of an alternative anatomic explanation) <strong>OR</strong></td> </tr> <tr> <td class=\"sublist4_start\">Abscess <strong>OR</strong></td> </tr> <tr> <td class=\"sublist4_start\">New partial dehiscence of prosthetic valve&nbsp;</td> </tr> <tr> <td class=\"indent2\"><strong>New valvular regurgitation</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">Increase in or change in preexisting murmur not sufficient</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\">Predisposition: Intravenous drug use or presence of a predisposing heart condition (prosthetic heart valve or a valve lesion associated with significant regurgitation or turbulence of blood flow)</td> </tr> <tr> <td class=\"indent1\">Fever: Temperature &#8805;38.0&#176;C (100.4&#176;F)</td> </tr> <tr> <td class=\"indent1\">Vascular phenomena: Major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions</td> </tr> <tr> <td class=\"indent1\">Immunologic phenomena: Glomerulonephritis, Osler nodes, Roth spots, or rheumatoid factor</td> </tr> <tr> <td class=\"indent1\">Microbiologic evidence: Positive blood cultures that&nbsp;do not meet major criteria <strong>OR</strong> serologic evidence of active infection with organism consistent with IE</td> </tr> <tr> <td class=\"indent1\">(Echocardiographic minor criteria eliminated)*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IE: infective endocarditis; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography.<br />* Modifications from the previous published Duke criteria are noted by the asterisk.</div><div class=\"graphic_reference\">Reproduced with permission from: Li JS, Sexton DJ, Mick N, et al. Clin Infect Dis 2000; 30:633. Copyright &copy; 2000 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 53004 Version 8.0</div></div></div>"},"53006":{"type":"graphic_figure","displayName":"Cervical dermatomes","title":"Cervical dermatomes","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Cervical dermatomes</div><div class=\"cntnt\"><img style=\"width:542px; height:552px;\" src=\"images/NEURO/53006_Cervical_dermatomes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the cervical and T1 dermatomes. There is no C1 dermatome. Patients with nerve root syndromes may have pain, paresthesias, and diminished sensation in the dermatome of the nerve that is involved.</div><div id=\"graphicVersion\">Graphic 53006 Version 3.0</div></div></div>"},"53007":{"type":"graphic_figure","displayName":"Vascular supply optic nerve","title":"Arterial supply to optic nerve","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Arterial supply to optic nerve</div><div class=\"cntnt\"><img style=\"width:464px; height:619px;\" src=\"images/NEURO/53007_Vascular_supply_optic_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from: Baig, MN, Lubow, M, Immesoete, P, et al. Vision loss after spine surgery: review of the literature and recommendations. Neurosurg Focus 2007; 23:15.</div><div id=\"graphicVersion\">Graphic 53007 Version 1.0</div></div></div>"},"53008":{"type":"graphic_table","displayName":"Distrib nodal metastases","title":"Distribution of nodal metastasis<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of nodal metastasis<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1\" rowspan=\"3\">Subsites</td>\n    <td class=\"subtitle1\" colspan=\"12\">Pathological node assessment (percent cases with positive nodes)</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle2\" colspan=\"2\">Level I</td>\n    <td class=\"subtitle2\" colspan=\"2\">Level II</td>\n    <td class=\"subtitle2\" colspan=\"2\">Level III</td>\n    <td class=\"subtitle2\" colspan=\"2\">Level IV</td>\n    <td class=\"subtitle2\" colspan=\"2\">Level V</td>\n    <td class=\"subtitle2\" colspan=\"2\">RP</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n    <td class=\"subtitle3\">N0</td>\n    <td class=\"subtitle3\">N+</td>\n  </tr>\n  <tr>\n    <td>Pyriform sinus</td>\n    <td>0</td>\n    <td>6.3</td>\n    <td>15</td>\n    <td>72</td>\n    <td>7.7</td>\n    <td>72</td>\n    <td>0</td>\n    <td>47</td>\n    <td>0</td>\n    <td>7.6</td>\n    <td>0</td>\n    <td>9</td>\n  </tr>\n  <tr>\n    <td>Pharyngeal wall</td>\n    <td>0</td>\n    <td>20</td>\n    <td>9</td>\n    <td> 84</td>\n    <td>18</td>\n    <td>72</td>\n    <td>0</td>\n    <td>40</td>\n    <td>0</td>\n    <td>21</td>\n    <td>16</td>\n    <td>21</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_footnotes\">RP: retropharyngeal.</div><div class=\"graphic_reference\">1. McLaughlin MP, Mendenhall WM, Mancuso AA, et al. Retropharyngeal adenopathy as a predictor of outcome in squamous cell carcinoma of the head and neck. Head Neck 1995; 17:190.<br> 2. Candela, FC, Kothari, K, Shah, JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990; 12:197.</div><div id=\"graphicVersion\">Graphic 53008 Version 1.0</div></div></div>"},"53009":{"type":"graphic_picture","displayName":"Nonatrophic gastritis","title":"Non-atrophic active gastritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-atrophic active gastritis</div><div class=\"cntnt\"><img style=\"width:432px; height:541px;\" src=\"images/ONC/53009_Nonatrophic_gastritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mononuclear leukocytes (arrowhead) infiltrate the stroma. The gastric glands are well preserved. Polymorphonuclear leukocytes (arrow) infiltrate the epithelial lining.</div><div id=\"graphicVersion\">Graphic 53009 Version 1.0</div></div></div>"},"53010":{"type":"graphic_table","displayName":"Definitions of LD","title":"Definitions of learning disability","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of learning disability</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">US Office of Education</td> </tr> <tr> <td class=\"indent1\">The term \"specific learning disability\" means a disorder in one or more basic psychological processes involved in understanding or in using language, spoken or written, which may manifest itself in an imperfect ability to listen, speak, read, write, spell, or do mathematical calculations. The term includes such conditions as perceptual handicaps, brain injury, minimal brain dysfunction, dyslexia, and developmental aphasia. Such terms do not include children who have learning disabilities which are primarily the result of visual, hearing, or motor handicaps, of mental retardation, of emotional disturbance, or of environmental, cultural, or economic disadvantage.</td> </tr> <tr> <td class=\"subtitle1_single\">National Joint Commission on Learning Disabilities</td> </tr> <tr> <td class=\"indent1\">\"Learning disabilities\" is a general term that refers to a heterogeneous group of disorders manifested by significant difficulties in the acquisition and use of listening, speaking, reading, writing, reasoning, or mathematical skills.</td> </tr> <tr> <td class=\"indent1\">These disorders are intrinsic to the individual, presumed to be due to central nervous system dysfunction, and may occur across the life span. Problems in self-regulatory behaviors, social perception, and social interaction may exist with learning disabilities but do not, by themselves, constitute a learning disability.</td> </tr> <tr> <td class=\"indent1\">Although learning disabilities may occur concomitantly with other disabilities (eg, sensory impairment, mental retardation, serious emotional disturbance), or with extrinsic influences (such as cultural differences, insufficient or inappropriate instruction), they are not the result of those conditions or influences.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>United States Office of Education. Definition and criteria for defining students as learning disabled. Federal Register, 42:250, US Government Printing Office, Washington, DC, 1977. p.65083.</LI>&#xD;&#xA;<LI>National Joint Committee on Learning Disabilities (NJCLD). Operationalizing the NJCLD definition of learning disabilities for ongoing assessment in schools. American Speech-Language Hearing Association 1997. Available at: <A spellcheck=true href=\"http://www.asha.org/policy/RP1998-00130\" target=_blank>www.asha.org/policy/RP1998-00130</A> (Accessed on July 27, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 53010 Version 8.0</div></div></div>"},"53011":{"type":"graphic_table","displayName":"Glucocorticoid replacement","title":"Glucocorticoid doses for physiologic replacement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glucocorticoid doses for physiologic replacement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Preparation</td> <td class=\"subtitle1\">Physiologic replacement dose*</td> </tr> <tr> <td>Hydrocortisone</td> <td>7 to 12&nbsp;mg/m<sup>2</sup>/day PO</td> </tr> <tr> <td>Cortisone acetate</td> <td>10&nbsp;to&nbsp;16 mg/m<sup>2</sup>/day PO</td> </tr> <tr> <td>Prednisolone</td> <td><span style=\"color: black;\">2&nbsp;to&nbsp;3 </span>mg/m<sup>2</sup>/day PO</td> </tr> <tr> <td>Dexamethasone</td> <td>0.5 mg/m<sup>2</sup>/day PO</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PO: per os (by mouth).<br />* Recommended doses for daily physiologic replacement of glucocorticoid for patients with primary adrenal insufficiency other than congenital adrenal hyperplasia.<SPAN style=\"COLOR: black\"> The&nbsp;oral dose&nbsp;somewhat higher than the normal daily cortisol secretion rate, because of the short half-life of hydrocortisone given orally and its partial destruction by gastric acidity.&nbsp;The </SPAN>optimal dose must be titrated for each patient based on clinical response and growth rate. Infants with congenital adrenal hyperplasia require higher starting doses (refer to UpToDate content on congenital adrenal hyperplasia). </div><div id=\"graphicVersion\">Graphic 53011 Version 5.0</div></div></div>"},"53013":{"type":"graphic_table","displayName":"Differential dx flushing","title":"Differential diagnosis of flushing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of flushing</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Autonomic-mediated</td> </tr> <tr> <td class=\"sublist1_start\">Thermoregulatory flushing</td> </tr> <tr> <td class=\"sublist1\">Fever</td> </tr> <tr> <td class=\"sublist1\">Exercise</td> </tr> <tr> <td class=\"sublist1\">Heat exposure (environmental or ingestion)</td> </tr> <tr> <td>Menopause</td> </tr> <tr> <td>Emotional flushing</td> </tr> <tr> <td class=\"sublist1_start\">Neurologic</td> </tr> <tr> <td class=\"sublist1\">CNS tumor</td> </tr> <tr> <td class=\"sublist1\">Autonomic epilepsy</td> </tr> <tr> <td class=\"sublist1\">Cluster headache</td> </tr> <tr> <td class=\"sublist1\">Spinal cord injury</td> </tr> <tr> <td class=\"sublist1\">Parkinson disease</td> </tr> <tr> <td class=\"sublist1\">Multiple sclerosis</td> </tr> <tr> <td class=\"sublist1\">Autonomic hyperreflexia/orthostatic hypotension</td> </tr> <tr> <td class=\"sublist1\">Auriculotemporal (Frey) syndrome</td> </tr> <tr> <td class=\"sublist1\">Trigeminal neuralgia</td> </tr> <tr> <td class=\"sublist1\">Migraine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Vasodilator-mediated</td> </tr> <tr> <td>Rosacea</td> </tr> <tr> <td>Medications (ie, calcium channel blockers, nicotinic acid)</td> </tr> <tr> <td>Food ingestion</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Carcinoid syndrome</td> </tr> <tr> <td>Systemic mastocytosis</td> </tr> <tr> <td>Pheochromocytoma</td> </tr> <tr> <td>Medullary thyroid carcinoma</td> </tr> <tr> <td>Serotonin syndrome</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td>VIPoma</td> </tr> <tr> <td>Renal cell carcinoma</td> </tr> <tr> <td>Dumping syndrome</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Bronchogenic carcinoma</td> </tr> <tr> <td>Androgen deficiency in men</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53013 Version 2.0</div></div></div>"},"53014":{"type":"graphic_diagnosticimage","displayName":"ARDS PA","title":"Acute respiratory distress syndrome","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Acute respiratory distress syndrome</div><div class=\"cntnt\"><img style=\"width:468px; height:415px;\" src=\"images/PULM/53014_ARDS_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest&nbsp;radiograph showing diffuse, bilateral, alveolar infiltrates without cardiomegaly in a patient with ARDS.</div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 53014 Version 3.0</div></div></div>"},"53015":{"type":"graphic_waveform","displayName":"EEG temporal lobe seizure","title":"Ictal recording of a patient with left temporal lobe epilepsy","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Ictal recording of a patient with left temporal lobe epilepsy</div><div class=\"cntnt\"><img style=\"width:565px; height:271px;\" src=\"images/NEURO/53015_EEG_temporal_lobe_seizure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the buildup of rhythmic activity over the left temporal region. Rhythmicity and evolution are important features of focal seizures.</div><div id=\"graphicVersion\">Graphic 53015 Version 2.0</div></div></div>"},"53016":{"type":"graphic_table","displayName":"Gemcitabine and cisplatin for metastatic urothelial cancer","title":"Gemcitabine and cisplatin (GC) for metastatic urothelial cancer*<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and cisplatin (GC) for metastatic urothelial cancer*<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 28 days.<br /> Total cycles: 6 (maximum)*.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Gemcitabine</strong></td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) (concentration no more than 40 mg/mL) and administer over 30 to 60 minutes.</td> <td>Days 1, 8, and 15</td> </tr> <tr> <td><strong>Cisplatin</strong></td> <td>70 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over two hours<sup>&#916;</sup>. Do not administer with aluminum needles or sets.</td> <td>Day 2</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> Due to the potential for nephrotoxicity associated with cisplatin, pretreatment hydration with 1 to 2 L of fluid is recommended prior to cisplatin administration; adequate post hydration and urinary output (&#62;100 mL/hour) should be maintained for 24 hours after administration<sup>[2]</sup>. Refer to UpToDate topic on \"Cisplatin-induced nephrotoxicity\", section on Prevention.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW on days 1, 8, and 15, and HIGH on day 2. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> Routine prophylaxis not indicated. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not justified (estimated risk of febrile neutropenia &#60;20 percent<sup>[1]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". [Not applicable.]</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for preexisting baseline renal or liver dysfunction:</strong> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial<sup>[1]</sup>. A lower starting dose of gemcitabine may be needed for patients with liver impairment. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess electrolytes, renal, and liver function weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess changes in neurologic function prior to each cycle.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Each cycle should not begin until the WBC is &#8805;3000/microL and platelet count is &#8805;100,000/microL<sup>[1]</sup>. Gemcitabine should be withheld on day 8 and/or day 15 of the scheduled treatment if the WBC is less than 2000/microL or the platelet count is less than 50,000/microL<sup>[1]</sup>. If the day 8 or 15 dose of gemcitabine is omitted, the treatment cycle may be shortened to 21 days.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurologic toxicity:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatotoxicity:</strong> Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Nephrotoxicity:</strong> Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Thrombotic microangiopathy:</strong> Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count; WBC: white blood cell count; ANC: absolute neutrophil count.<br />* An alternative regimen uses a three-week cycle consisting of gemcitabine (1200 mg/m<SUP>2</SUP>) on days 1 and 8 and cisplatin (75 mg/m<SUP>2</SUP>) on day 2 for a median of six cycles<SUP>[4]</SUP>.<br />Δ Alternatively, may dilute in 2 L 5 percent dextrose in half or one-third normal saline containing 37.5 g of mannitol and infuse over a six to eight hour period<SUP>[2]</SUP>. Do not administer with aluminum needles or sets.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>van der Maase H, et al. J Clin Oncol 2000; 17:3068.</li>&#xD;&#xA;    <li>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 1, 2016).</li>&#xD;&#xA;    <li>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on May 1, 2016).</li>&#xD;&#xA;    <li>Adamo V, et al. Oncology 2005; 69:391.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53016 Version 30.0</div></div></div>"},"53017":{"type":"graphic_table","displayName":"DKA neuro state children","title":"Bedside evaluation of neurologic state of children with diabetic ketoacidosis (DKA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bedside evaluation of neurologic state of children with diabetic ketoacidosis (DKA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Minor criteria (moderately suspicious findings)</td> </tr> <tr> <td class=\"indent1\">Headache*</td> </tr> <tr> <td class=\"indent1\">Vomiting*</td> </tr> <tr> <td class=\"indent1\">Irritability, lethargy, or not easily aroused from sleep (if not readily explained by a history of sleep deprivation)*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Elevated blood pressure (eg, diastolic BP &#62;90 mmHg)</td> </tr> <tr> <td class=\"subtitle1_single\">Major criteria (very suspicious findings)</td> </tr> <tr> <td class=\"indent1\">Abnormal or deteriorating mental status after initiation of therapy, agitated behavior, or fluctuating level of consciousness</td> </tr> <tr> <td class=\"indent1\">Incontinence inappropriate for age</td> </tr> <tr> <td class=\"indent1\">Changes in pupillary response or other cranial nerve palsy<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Inappropriate slowing of heart rate (eg, decline more than 20 beats per minute that is not attributable to improved intravascular volume or sleep state)</td> </tr> <tr> <td class=\"indent1\">Rapidly rising serum sodium concentration</td> </tr> <tr> <td class=\"indent1\">Decreased oxygen saturation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abnormal neurogenic respiratory pattern (eg, grunting, tachypnea, Cheyne-Stokes respiration, apneustic breathing)</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment suggested for:</td> </tr> <tr> <td class=\"indent1\">Child with <strong>risk factors</strong> for cerebral edema (age &#60;5 years, first presentation of DKA, or severe acidosis) and <ul class=\"decimal_heading\"> <li>One or more of the minor criteria listed above, if not otherwise explained* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Any</strong> child with DKA and <ul class=\"decimal_heading\"> <li>Two or more minor criteria (if not otherwise explained) </li> <li>Or any major criteria </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment consists of:</td> </tr> <tr> <td class=\"indent1\">Reduce the rate of fluid administration</td> </tr> <tr> <td class=\"indent1\">Give mannitol, 0.25 to 1 g/kg intravenously over 20 minutes. The mannitol dose may be repeated in two hours, if there is no initial response.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The protocol describes the authors' approach to assessment and management of cerebral edema in children and adolescents with DKA. This approach will lead to treatment of some children who do not have cerebral edema, but this is appropriate because of the low risks of treatment and potential benefits of early treatment in preventing the morbidity and mortality associated with cerebral edema.</div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; BP: blood pressure; mmHg: millimeters of mercury; CN: cranial nerves.<br />* Headache and vomiting are most suspicious if they develop or recur during treatment for DKA.<br />&para; Key steps are to evaluate extraocular movements (CN III, IV, and VI), and pupillary dilation and reactivity (CN II and III).</div><div class=\"graphic_reference\">Courtesy of Morey Haymond, MD, and George Jeha, MD.</div><div id=\"graphicVersion\">Graphic 53017 Version 7.0</div></div></div>"},"53018":{"type":"graphic_picture","displayName":"Engorged tick comparison","title":"Tick comparison","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tick comparison</div><div class=\"cntnt\"><img style=\"width:346px; height:295px;\" src=\"images/PC/53018_Engorged_tick_comparison.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top row) Ixodes scapularis (dammini), the deer tick which transmits Lyme disease. Left to right: nymph (immature), adult male, adult female, engorged adult female. Nymphs are most common May through July. Adults appear in the fall and early spring. (Bottom row) Dermacentor variabilis, the American dog tick, which is not thought to transmit Lyme disease. Left to right: adult male, adult female, engorged adult female. Adults are most common in May, June , and July. Note that the adult dog ticks are somewhat larger than adult deer ticks, and have characteristic white markings on the dorsal (top) side.</div><div class=\"graphic_reference\">Reproduced with permission from: Lyme Disease Research Laboratory, Maine Medical Center Research Institute, 13 Charles Street, Portland, ME 04102.</div><div id=\"graphicVersion\">Graphic 53018 Version 1.0</div></div></div>"},"53020":{"type":"graphic_picture","displayName":"Diffuse alveolar damage DAH","title":"Diffuse alveolar damage with alveolar hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse alveolar damage with alveolar hemorrhage</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/53020_Diffuse_alveolar_damage_DAH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of diffuse alveolar damage, as can occur in the acute respiratory distress syndrome. The alveolar septa are edematous but without acute inflammation. Hyaline membranes are lining the alveolar spaces (arrow), and alveolar hemorrhage is present.</div><div class=\"graphic_reference\">Courtesy of Marvin I Schwarz, MD.</div><div id=\"graphicVersion\">Graphic 53020 Version 2.0</div></div></div>"},"53021":{"type":"graphic_picture","displayName":"Photoaging topical tretinoin","title":"Efficacy of topical tretinoin in the treatment of photoaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of topical tretinoin in the treatment of photoaging</div><div class=\"cntnt\"><img style=\"width:370px; height:279px;\" src=\"images/DERM/53021_Photoag_top_tret.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Improvement of signs of photodamage after long-term treatment with tretinoin 0.05% emollient cream.<br />(A) Baseline.<br />(B) After 24 months of treatment.</div><div class=\"graphic_reference\">Reproduced with permission from: Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin. Am J Clin Dermatol 2005; 6:245. Copyright &copy; 2005 Adis Data Information BV.</div><div id=\"graphicVersion\">Graphic 53021 Version 5.0</div></div></div>"},"53022":{"type":"graphic_table","displayName":"OARS institutional questionnaire","title":"OARS multidimensional functional assessment questionnaire: Institutional version","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">OARS multidimensional functional assessment questionnaire: Institutional version</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Social resources</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">1. Are you single (never married), married, widowed, divorced, or separated?</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Single (never married)</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Married</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Widowed</td> </tr> <tr> <td class=\"indent1\">4</td> <td>Divorced</td> </tr> <tr> <td class=\"indent1\">5</td> <td>Separated</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr> <td colspan=\"2\">(If \"2\" ask a.) </td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>a. Does your spouse live here also?</strong></td> </tr> <tr> <td class=\"indent3\">1</td> <td>Yes</td> </tr> <tr> <td class=\"indent3\">0</td> <td>No</td> </tr> <tr> <td class=\"indent3\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">2. In the past year about how often did you leave here to visit your family and/or friends for weekends or holidays, or to go on shopping trips or outings?</td> </tr> <tr> <td class=\"indent1\">4</td> <td>Once a week or more</td> </tr> <tr> <td class=\"indent1\">3</td> <td>One to three times a month</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Less than once a month or only on holidays</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Never</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">3. How many people do you know well enough to visit with in their homes?</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Five or more</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Three or four</td> </tr> <tr> <td class=\"indent1\">1</td> <td>One or two</td> </tr> <tr> <td class=\"indent1\">0</td> <td>None</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">4. About how many times did you talk to someone - friends, relatives, or others - on the telephone in the past week (either you called them or they called you)? (If subject has no phone, question still applies.)</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Once a day or more</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Two to six times</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Not at all</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">5. How many times in the past week did you visit with someone, either with people who live here or people who visited you here?</td> </tr> <tr> <td class=\"indent1\">3</td> <td>Once a day or more</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Two to six times</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Once</td> </tr> <tr> <td class=\"indent1\">0</td> <td>Not at all</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">6. Do you have someone you can trust and confide in?</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">0</td> <td>No</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">7. Do you find yourself feeling lonely quite often, sometimes, or almost never?</td> </tr> <tr> <td class=\"indent1\">0</td> <td>Quite often</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Sometimes</td> </tr> <tr> <td class=\"indent1\">2</td> <td>Almost never</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">8. Do you see your relatives and friends as often as you want to, or not?</td> </tr> <tr> <td class=\"indent1\">1</td> <td>As often as wants to</td> </tr> <tr> <td class=\"indent1\">0</td> <td>Not as often as wants to</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">9. Is there someone outside this place who would give you any help at all if you were sick or disabled, for example your husband/wife, a member of your family, or a friend?</td> </tr> <tr> <td class=\"indent1\">1</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">0</td> <td>No one is willing and able to help</td> </tr> <tr> <td class=\"indent1\">-</td> <td>Not answered</td> </tr> <tr> <td colspan=\"3\">(If \"Yes\" ask a. <strong>and</strong> b.)</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>a. Is there someone outside this place who would take care of you as long as needed, or only for a short time, or only someone who would help you now and then (for example, taking you to the doctor, or fixing lunch occasionally, etc)?</strong></td> </tr> <tr> <td class=\"indent3\">3</td> <td colspan=\"2\">Someone who would take care of subject indefinitely (as long as needed)</td> </tr> <tr> <td class=\"indent3\">2</td> <td colspan=\"2\">Someone who would take care of subject for a short time (a few weeks to six months)</td> </tr> <tr> <td class=\"indent3\">1</td> <td colspan=\"2\">Someone who would help the subject now and then (taking him/her to the doctor or fixing lunch, etc)</td> </tr> <tr> <td class=\"indent3\">-</td> <td colspan=\"2\">Not answered</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>b. Who is this person?</strong></td> </tr> <tr> <td class=\"indent3\" colspan=\"3\">Name:</td> </tr> <tr> <td class=\"indent3\" colspan=\"3\">Relationship:</td> </tr> <tr> <td class=\"indent3\" colspan=\"3\"><strong>Code:</strong> Spouse = 1, Sibling = 2, Offspring = 3, Grandchild = 4, Other kin = 5, Friend = 6, Other = 7</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Copyright © 1975, 1988 Duke University, Center for the Study of Aging and Human Development. All rights reserved. May not be used for financial gain. When reporting on information gathered through this measure please acknowledge the source: Older Americans Resources and Services MFAQ. Permission for use in major studies should be obtained from the Duke Aging Center (see site address below). Further information can be obtained from the website: <A spellcheck=true href=\"https://sites.duke.edu/centerforaging/\" target=_blank>https://sites.duke.edu/centerforaging/</A>. Click on Services, then click on Older Americans ..., and from the manual referenced there.</div><div id=\"graphicVersion\">Graphic 53022 Version 4.0</div></div></div>"},"53023":{"type":"graphic_table","displayName":"SAPS II","title":"Simplified acute physiologic score II (SAPS II)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simplified acute physiologic score II (SAPS II)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Variable\n   </td>\n   <td  class=\"subtitle1\">\n   Range\n   </td>\n   <td  class=\"subtitle1\">\n   Points\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"6\">\n   Patient age\n   </td>\n   <td>&#60;40 years</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>40-59 years</td>\n   <td>7</td>\n   </tr>\n   <tr>\n   <td>60-69 years</td>\n   <td>12</td>\n   </tr>\n   <tr>\n   <td>70-74 years</td>\n   <td>15</td>\n   </tr>\n   <tr>\n   <td>75-79 years</td>\n   <td>16</td>\n   </tr>\n   <tr>\n   <td>&#8805;80 years</td>\n   <td>18</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Type of admission\n   </td>\n   <td>Scheduled surgery</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>Medical</td>\n   <td>6</td>\n   </tr>\n   <tr>\n   <td>Unscheduled surgery</td>\n   <td>8</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Temperature\n   </td>\n   <td>&#60;39&#176;C, &#60;102.2&#176;F</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>&#8805;39&#176;C, &#8805;102.2&#176;F</td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"4\">\n   Systolic blood pressure\n   </td>\n   <td>&#8805;200 mmHg</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td>100-199 mmHg</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>70-99 mmHg</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>&#60;70 mmHg</td>\n   <td>13</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Heart rate\n   </td>\n   <td>&#8805;160 bpm</td>\n   <td>7</td>\n   </tr>\n   <tr>\n   <td>120-159 bpm</td>\n   <td>4</td>\n   </tr>\n   <tr>\n   <td>70-119 bpm</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>40-69 bpm</td>\n   <td>2</td>\n   </tr>\n   <tr>\n   <td>&#60;40 bpm</td>\n   <td>11</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Glasgow coma scale\n   </td>\n   <td>14-15</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>11-13</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>9-10</td>\n   <td>7</td>\n   </tr>\n   <tr>\n   <td>6-8</td>\n   <td>13</td>\n   </tr>\n   <tr>\n   <td>&#60;6</td>\n   <td>26</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Urine output\n   </td>\n   <td>&#8805;1 L/24 hr</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>0.5-0.999 L/24 hr</td>\n   <td>4</td>\n   </tr>\n   <tr>\n   <td>&#60;0.5 L/24 hr</td>\n   <td>11</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   White blood cell count\n   </td>\n   <td>&#60;1000 /mm<sup>3</sup></td>\n   <td>12</td>\n   </tr>\n   <tr>\n   <td>1000-19,000 /mm<sup>3</sup></td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>&#8805;20,000 /mm<sup>3</sup></td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Blood urea nitrogen\n   </td>\n   <td>&#8805;30 mmol/L, &#8805;84 mg/dL</td>\n   <td>10</td>\n   </tr>\n   <tr>\n   <td>10-29.9 mmol/L, 28-83 mg/dL</td>\n   <td>6</td>\n   </tr>\n   <tr>\n   <td>&#60;10 mmol/L, &#60;28 mg/dL</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Potassium level\n   </td>\n   <td>&#60;3 mEq/L</td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td>3-4.9 mEq/L</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>&#8805;5 mEq/L</td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Sodium level\n   </td>\n   <td>&#60;125 mEq/L</td>\n   <td>5</td>\n   </tr>\n   <tr>\n   <td>125-144 mEq/L</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>&#8805;145 mEq/L</td>\n   <td>1</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Bicarbonate level\n   </td>\n   <td>&#60;15 mEq/L</td>\n   <td>6</td>\n   </tr>\n   <tr>\n   <td>15-19 mEq/L</td>\n   <td>3</td>\n   </tr>\n   <tr>\n   <td>&#8805;20 mEq/L</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Bilirubin level\n   </td>\n   <td>&#60;4 mg/dL, &#60;68.4 micromol/L</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td>4-5.9 mg/dL, 68.4-102.5 micromol/L</td>\n   <td>4</td>\n   </tr>\n   <tr>\n   <td>&#8805;6 mg/dL, &#8805;102.6 micromol/L</td>\n   <td>9</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   PaO2/FiO2 (if mechanically ventilated or receiving CPAP)\n   </td>\n   <td>&#60;100 mmHg</td>\n   <td>11</td>\n   </tr>\n   <tr>\n   <td>100-199 mmHg</td>\n   <td>9</td>\n   </tr>\n   <tr>\n   <td>&#8805;200 mmHg</td>\n   <td>6</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   AIDS\n   </td>\n   <td>Yes</td>\n   <td>17</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Metastatic carcinoma\n   </td>\n   <td>Yes</td>\n   <td>9</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Hematologic malignancy\n   </td>\n   <td>Yes</td>\n   <td>10</td>\n   </tr>\n   <tr>\n   <td>No</td>\n   <td>0</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: Le Gall, JR, Lemeshow, S, Saulnier, F, et al. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270:2957.</div><div id=\"graphicVersion\">Graphic 53023 Version 1.0</div></div></div>"},"53024":{"type":"graphic_table","displayName":"WHO tumors of the thymus","title":"WHO histologic typing of tumors of the thymus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO histologic typing of tumors of the thymus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Epithelial tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Thymoma</td> </tr> <tr> <td class=\"indent2\">Type A </td> </tr> <tr> <td class=\"indent2\">Type AB </td> </tr> <tr> <td class=\"indent2\">Type B1 </td> </tr> <tr> <td class=\"indent2\">Type B2 </td> </tr> <tr> <td class=\"indent2\">Type B3 </td> </tr> <tr> <td class=\"indent2\">Micronodular thymoma with lymphoid stroma&nbsp;</td> </tr> <tr> <td class=\"indent2\">Metaplastic thymoma&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Thymic carcinoma</td> </tr> <tr> <td class=\"indent2\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"indent2\">Basaloid carcinoma</td> </tr> <tr> <td class=\"indent2\">Mucoepidermoid carcinoma </td> </tr> <tr> <td class=\"indent2\">Lymphoepithelioma-like carcinoma</td> </tr> <tr> <td class=\"indent2\">Sarcomatoid carcinoma </td> </tr> <tr> <td class=\"indent2\">Clear cell carcinoma</td> </tr> <tr> <td class=\"indent2\">Adenocarcinomas</td> </tr> <tr> <td class=\"indent2\">NUT carcinoma</td> </tr> <tr> <td class=\"indent2\">Undifferentiated carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Neuroendocrine tumors</td> </tr> <tr> <td class=\"indent1\">Typical carcinoid tumor</td> </tr> <tr> <td class=\"indent1\">Atypical carcinoid tumor</td> </tr> <tr> <td class=\"indent1\">Large cell neuroendocrine carcinoma</td> </tr> <tr> <td class=\"indent1\">Small cell carcinoma </td> </tr> <tr> <td class=\"subtitle1_single\">Germ cell tumors of the mediastinum</td> </tr> <tr> <td class=\"indent1\">Seminoma </td> </tr> <tr> <td class=\"indent1\">Embryonal carcinoma</td> </tr> <tr> <td class=\"indent1\">Yolk sac tumour</td> </tr> <tr> <td class=\"indent1\">Choriocarcinoma</td> </tr> <tr> <td class=\"indent1\">Mature teratoma</td> </tr> <tr> <td class=\"indent1\">Immature teratoma</td> </tr> <tr> <td class=\"indent1\">Mixed germ cell tumour</td> </tr> <tr> <td class=\"indent1\">Germ cell tumour with somatic type solid malignancy&nbsp;</td> </tr> <tr> <td class=\"indent1\">Germ cell tumour with associated haematological malignancy&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphomas of the mediastinum</td> </tr> <tr> <td class=\"indent1\">Primary mediastinal large B-cell lymphoma</td> </tr> <tr> <td class=\"indent1\">Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Other mature B-cell lymphomas</td> </tr> <tr> <td class=\"indent1\">T lymphoblastic lymphoma/leukemia</td> </tr> <tr> <td class=\"indent1\">Anaplastic large cell lymphoma and other rare mature T- and NK-cell lymphomas</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma</td> </tr> <tr> <td class=\"subtitle1_single\">Soft tissue tumors of the mediastinum</td> </tr> <tr> <td class=\"indent1\">Thymolipoma</td> </tr> <tr> <td class=\"indent1\">Lipoma</td> </tr> <tr> <td class=\"indent1\">Liposarcoma</td> </tr> <tr> <td class=\"indent1\">Solitary fibrous tumor</td> </tr> <tr> <td class=\"indent1\">Synovial sarcoma&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vascular neoplasms (lymphangioma, haemangioma, epithelioid hemangioendothelioma, angiosarcoma)&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Histiocytic and dendritic cell neoplasms of the mediastinum</td> </tr> <tr> <td class=\"indent1\">Langerhans cell lesions (thymic Langerhans cell histiocytosis, Langerhans cell sarcoma)</td> </tr> <tr> <td class=\"indent1\">Histiocytic sarcoma</td> </tr> <tr> <td class=\"indent1\">Follicular dendritic cell sarcoma</td> </tr> <tr> <td class=\"indent1\">Interdigitating dendritic cell sarcoma</td> </tr> <tr> <td class=\"indent1\">Fibroblastic reticular cell tumour&nbsp;</td> </tr> <tr> <td class=\"indent1\">Indeterminate dendritic cell tumour</td> </tr> <tr> <td class=\"subtitle1_single\">Myeloid sarcoma and extramedullary acute myeloid leukemia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NUT: nuclear protein in testis.</div><div class=\"graphic_reference\">Data from: Tumours of the thymus: WHO classification of tumors of the thymus. In: WHO Classification of tumours of the lung, pleura, thymus and heart, Travis WD, Brambilla E, Burke EP, et al (Eds), IARC Press, Lyon, France 2015.</div><div id=\"graphicVersion\">Graphic 53024 Version 6.0</div></div></div>"},"53025":{"type":"graphic_picture","displayName":"Acrochordon - close view","title":"Acrochordon (also known as skin tag or soft fibroma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acrochordon (also known as skin tag or soft fibroma)</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/53025_Acrochordon_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pedunculated, soft papule is present in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53025 Version 4.0</div></div></div>"},"53026":{"type":"graphic_diagnosticimage","displayName":"Breast MRI of silicone implant","title":"Breast MRI of silicone implant","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Breast MRI of silicone implant</div><div class=\"cntnt\"><img style=\"width:498px; height:516px;\" src=\"images/SURG/53026_Br_MRI_silicone_implant_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breast MRI is useful for the assessment of silicone implant integrity.<br />(A) Axial image of a intact subglandular silicone implant with radial folds (normal infolding of the implant envelope).<br />(B) Axial image of subglandular silicone implant shows curvilinear low signal within the silicone corresponding to a collapsed envelope (linguine sign) consistent with an intracapsular rupture.<br />(C) Axial image shows rupture of the envelope and capsule with extrusion of silicone into surrounding breast tissue consistent with an extracapsular rupture.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 53026 Version 4.0</div></div></div>"},"53027":{"type":"graphic_figure","displayName":"Blood supply to the urethra","title":"Blood supply to the urethra","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Blood supply to the urethra</div><div class=\"cntnt\"><img style=\"width:504px; height:459px;\" src=\"images/SURG/53027_Blood-supply-to-the-urethra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The uretha is supplied proximally by the bulbar arteries, which are branches of the penile artery. The distal urethra is perfused by retrograde flow from the dorsal penile artery.<br />By convention, the surfaces of the penis are defined with the penis extended cranially; the urethra is ventrally located.</div><div id=\"graphicVersion\">Graphic 53027 Version 3.0</div></div></div>"},"53029":{"type":"graphic_picture","displayName":"African tick bite fever lesion","title":"Rash of African tick bite fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash of African tick bite fever</div><div class=\"cntnt\"><img style=\"width:409px; height:265px;\" src=\"images/ID/53029_African_tick_bite_fever_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A solitary lesion is visible with a central eschar. Multiple lesions can be present.</div><div class=\"graphic_reference\">Courtesy of Daniel J Sexton, MD.</div><div id=\"graphicVersion\">Graphic 53029 Version 1.0</div></div></div>"},"53033":{"type":"graphic_picture","displayName":"Hamman Rich High","title":"Acute interstitial pneumonia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:288px; height:189px;\" src=\"images/PULM/53033_Hamman_Rich_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of acute interstitial pneumonia (Hamman-Rich disease) shows marked alveolar septal thickening resulting from proliferating spindle cells. There is only a minor infiltrate of mononuclear inflammatory cells. The thickened alveolar septa are lined by hyperplastic pneumocytes.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 53033 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"53034":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM CT III","title":"Patient with Weber-Osler-Rendu syndrome presents with bilateral AVMs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with Weber-Osler-Rendu syndrome presents with bilateral AVMs</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/PULM/53034_Pulm_AVM_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan demonstrates a right upper lobe AVM.</div><div class=\"graphic_footnotes\">AVM: arteriovenous malformation; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53034 Version 3.0</div></div></div>"},"53035":{"type":"graphic_waveform","displayName":"Advanced case 6 with answer","title":"Mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Mitral stenosis</div><div class=\"cntnt\"><img style=\"width:540px; height:319px;\" src=\"images/CARD/53035_Advancedcase6withanswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram showing the two major findings of mitral stenosis: right ventricular hypertrophy and marked&nbsp;left atrial abnormality (enlargement). The presence of right ventricular hypertrophy with sinus rhythm&nbsp;is indicated by the tall R in V1 (as part of a qR complex) with right axis deviation. Incomplete right bundle branch block is also seen as evidenced by the rsR' in lead V2, and the prominent S waves in leads V5 and V6 with normal QRS duration. The large negative component of the P wave in lead VI (an anterior-posterior lead) indicates left atrial enlargement; the tall (&gt;2.5 mm) P wave in lead II suggests concurrent right atrial enlargement due, in this case, to secondary pulmonary hypertension. The ST and T wave abnormalities are nonspecific. Electrocardiographic signs of right ventricular hypertrophy with atrial fibrillation also raise strong consideration of mitral stenosis. </div><div class=\"graphic_reference\">Courtesy of Ary Goldberger.</div><div id=\"graphicVersion\">Graphic 53035 Version 4.0</div></div></div>"},"53036":{"type":"graphic_picture","displayName":"Lymphocyte depletion HL","title":"Lymphocyte depletion Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocyte depletion Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:252px; height:285px;\" src=\"images/HEME/53036_Lymph_depletion_HL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous Reed-Sternberg cells are seen in a background of fibrosis.</div><div class=\"graphic_reference\">From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 53036 Version 2.0</div></div></div>"},"53038":{"type":"graphic_table","displayName":"Evaluation shoulder pain","title":"Differential history and examination of the shoulder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential history and examination of the shoulder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History and epidemiology</td> <td class=\"subtitle1\">Examination findings</td> <td class=\"subtitle1\">Likely diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Generally age &#62;40</p> <p>Pain increases with reaching</p> Frequent repetitive activity at or above shoulder</td> <td> <p>Subacromial tenderness</p> <p>Pain with Apley scratch tests</p> <p>Normal passive range of motion</p> <p>Normal strength but pain with testing midarc abduction and/or external rotation</p> Pain with impingement testing (Neer and Hawkins tests)</td> <td>Rotator cuff tendinopathy (very common)</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Same as rotator cuff tendinopathy, but weakness present</p> Midde aged and older</td> <td>Same as rotator cuff tendinopathy but weakness often present with resisted abduction and/or external rotation</td> <td>Rotator cuff tear</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Past history of rotator cuff tendinopathy, diabetes, or immobility for any reason</p> Complaint of decreased motion +/- pain</td> <td>Significant decrease in range of motion, both active and passive</td> <td>Adhesive capsulitis</td> </tr> <tr class=\"divider_bottom\"> <td>Past history of shoulder trauma</td> <td>Decrease in range of motion - both active and passive</td> <td>Glenohumoral osteoarthritis (uncommon)</td> </tr> <tr class=\"divider_bottom\"> <td>Pain increases when carrying objects with elbows bent (eg, shopping bags) or lifting overhead</td> <td> <p>Bicipital groove tenderness</p> Pain with resisted elbow flexion or supination</td> <td>Biceps tendinopathy</td> </tr> <tr class=\"divider_bottom\"> <td>Sudden increase in shoulder pain with \"Popeye\" deformity (ie, prominent ipsilateral distal bicep)</td> <td> <p>Obvious biceps deformity</p> Pain with resisted elbow flexion or supination</td> <td>Biceps tendon rupture</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Recent fall onto adducted arm</p> Focal AC joint pain</td> <td> <p>AC joint tenderness with possible stepoff</p> <p>Pain with adduction of injured arm</p> Clavicle elevation on x-ray with higher grade sprain</td> <td>Acromioclavicular injury</td> </tr> <tr class=\"divider_bottom\"> <td>Focal AC joint pain without recent trauma</td> <td> <p>AC joint tenderness</p> Pain with adduction of injured arm</td> <td>Acromioclavicular osteoarthritis</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Generally age &#60;40</p> <p>Overhead athletes</p> Nonspecific symptoms</td> <td> <p>Sulcus test shows increased motion</p> Apprehension, relocation, and release tests positive</td> <td>Multidirectional shoulder instability (may have concomitant rotator cuff tear)</td> </tr> <tr class=\"divider_bottom\"> <td>Poor muscular development, frequent repetitive to-and-fro motion (eg, ironing), and direct pressure (eg, backpack) are common causes</td> <td>Superiomedial scapular border tender (performed with ipsilateral arm adducted)</td> <td>Subscapular bursitis</td> </tr> <tr> <td>Sedentary (eg, works at desk job); poor posture with rounded upper back</td> <td> <p>Abnormal, uncoordinated scapulothoracic and glenohumoral motion</p> <p>Wall push off may reveal mild scapular winging</p> Stabilization of scapula by examiner improves shoulder strength</td> <td>Scapular stabilizer muscle weakness</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53038 Version 3.0</div></div></div>"},"53041":{"type":"graphic_diagnosticimage","displayName":"Normal pancreas EUS","title":"Endoscopic ultrasound image of a normal pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic ultrasound image of a normal pancreas</div><div class=\"cntnt\"><img style=\"width:333px; height:307px;\" src=\"images/GAST/53041_Normal_pancreas_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the uniform gray parenchyma of the body of the pancreas (BP) without lobulations. The main pancreatic duct (PD) is uniform in diameter and measures less than 2 mm. The adjacent structure is the splenic vein (SV).</div><div class=\"graphic_reference\">Courtesy of Michael B Wallace, MD, MPH. SV BP PD.</div><div id=\"graphicVersion\">Graphic 53041 Version 4.0</div></div></div>"},"53043":{"type":"graphic_picture","displayName":"Finger flexion extension PI","title":"Finger flexion/extension","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Finger flexion/extension</div><div class=\"cntnt\"><img style=\"width:474px; height:249px;\" src=\"images/PI/53043_Finger_flexion_extension_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold both hands with fingers pointing toward ceiling. Roll tips of all fingers down slowly to make a fist. Hold for 5 seconds. Relax fingers. Repeat 10 times.</div><div id=\"graphicVersion\">Graphic 53043 Version 3.0</div></div></div>"},"53044":{"type":"graphic_diagnosticimage","displayName":"Healing of fractures of olecranon and radial head","title":"Healing of fractures of olecranon and radial head","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Healing of fractures of olecranon and radial head</div><div class=\"cntnt\"><img style=\"width:502px; height:586px;\" src=\"images/EM/53044_Heal_frac_olec_rad_head.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Post-reduction radiographs show full reduction of the radial neck and 2 to 3 millimeters of separation of the proximal ulna.<br> (C) Healing 3 weeks after reduction.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 53044 Version 3.0</div></div></div>"},"53045":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of acardiac twin","title":"Ultrasound of acardiac twin","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Ultrasound of acardiac twin</div><div class=\"cntnt\"><img style=\"width:485px; height:345px;\" src=\"images/OBGYN/53045_Ultrasoundacardictwin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal view of an acardiac twin shows poorly developed cranium (arrow). In the expected region of the fetal heart (arrowhead), a cystic area is visible without cardiac activity. The subcutaneous tissues are severely edematous.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 53045 Version 4.0</div></div></div>"},"53046":{"type":"graphic_diagnosticimage","displayName":"Subcostal coronal view tetralogy of Fallot","title":"Subcostal coronal view of tetralogy of Fallot (TOF)","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Subcostal coronal view of tetralogy of Fallot (TOF)</div><div class=\"cntnt\"><img style=\"width:488px; height:342px;\" src=\"images/PEDS/53046_Sub_coron_view_tetr_Fallot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This still frame from an echocardiographic video clip of a subcostal coronal view highlights the infundibular hypertrophy in this patient with TOF. The arrows identify the muscle bundles in the right ventricle outflow tract (RVOT).</div><div class=\"graphic_footnotes\">RV: right ventricle; RA: right atrium.</div><div id=\"graphicVersion\">Graphic 53046 Version 3.0</div></div></div>"},"53047":{"type":"graphic_figure","displayName":"ST segment resolution outcome","title":"Rapid ST segment resolution after thrombolysis is associated with a better outcome","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Rapid ST segment resolution after thrombolysis is associated with a better outcome</div><div class=\"cntnt\"><img style=\"width:472px; height:248px;\" src=\"images/CARD/53047_ST_segment_resolution_outco.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After a two-year follow-up, patients with rapid ST segment resolution after thrombolysis had a higher incidence of reinfarction (27 versus 9 percent), but a lower incidence of heart failure, mortality, and mortality and/or HF (3 versus 22 percent) compared to those without rapid ST segment resolution.</div><div class=\"graphic_reference\">Data from: Matetzky S, Freimark D, Chouraqui P, et al. J Am Coll Cardiol 1998; 32:1326.</div><div id=\"graphicVersion\">Graphic 53047 Version 2.0</div></div></div>"},"53048":{"type":"graphic_table","displayName":"Infant hip imaging overview","title":"Use of various imaging modalities in the evaluation and management of selected hip problems in infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Use of various imaging modalities in the evaluation and management of selected hip problems in infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Plain radiograph</td> <td class=\"subtitle1\">Ultrasonography</td> <td class=\"subtitle1\">Computed tomography</td> <td class=\"subtitle1\">Magnetic resonance imaging</td> <td class=\"subtitle1\">Conventional arthrography</td> </tr> <tr> <td rowspan=\"3\"><strong>Developmental dysplasia of the hip</strong></td> <td rowspan=\"3\"> <p>Diagnosis in children &#62;4 months</p> Findings:<br /> <ul> <li>Superolateral displacement of the femur </li> </ul> </td> <td> <p>Evaluation of infants &#60;4 months who are high risk or have equivocal clinical findings</p> Findings:<br /> <ul> <li>Superolateral displacement of the femoral head </li> <li>Alpha angle less than 60&#176; </li> <li>Instability of hip (able to move in and out of socket) </li> </ul> </td> <td>Preoperative assessment</td> <td>Preoperative assessment</td> <td>Intraoperative confirmation of femoral head position</td> </tr> <tr> <td>Monitoring treatment</td> <td>Postoperative follow-up</td> <td>Evaluation of postsurgical reduction</td> <td>Intraoperative visualization of structures interfering with reduction</td> </tr> <tr> <td>Follow-up of patients treated with abduction splints (eg, Pavlik harness)</td> <td>&nbsp;</td> <td>Monitoring for long-term sequelae</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td><strong>Proximal femoral focal deficiency</strong></td> <td> <p>Diagnosis</p> Findings:<br /> <ul> <li>Short femur with dysmorphic or absent head and neck </li> <li>Delayed appearance or nonappearance of the femoral capital ossification center </li> </ul> </td> <td>NA</td> <td>NA</td> <td> <p>Early diagnosis, extent of involvement</p> Findings:<br /> <ul> <li>Incompletely ossified femoral head </li> <li>Demonstrates cartilage structure of acetabulum and upper femur </li> </ul> </td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.</div><div id=\"graphicVersion\">Graphic 53048 Version 4.0</div></div></div>"},"53049":{"type":"graphic_figure","displayName":"Coronavirus structure","title":"Model of coronavirus structure: A schematic diagram of virion structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Model of coronavirus structure: A schematic diagram of virion structure</div><div class=\"cntnt\"><img style=\"width:395px; height:399px;\" src=\"images/ID/53049_Coronavirusstrctr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing the major structural proteins of the coronavirus virion.</div><div class=\"graphic_footnotes\">S: spike protein; M: membrane protein; E: envelope protein; N: nucleocapsid protein.</div><div class=\"graphic_reference\">Reproduced with permission from: Masters PS, Perlman S. Coronaviridae. In: Fields Virology, 6th edition, Knipe DM, Howley PM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 53049 Version 13.0</div></div></div>"},"53050":{"type":"graphic_table","displayName":"Potential interventions of Lipo","title":"Potential interventions for lipodystrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential interventions for lipodystrophy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lipoatrophy</td> </tr> <tr> <td>Switch thymidine analogue (stavudine or&nbsp;zidovudine) to abacavir or&nbsp;tenofovir</td> </tr> <tr> <td>Injectable fillers for facial lipoatrophy </td> </tr> <tr> <td>Pioglitazone (in patients with insulin resistance)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Fat accumulation</td> </tr> <tr> <td>Diet and exercise</td> </tr> <tr> <td>Metformin (in patients with diabetes mellitus)</td> </tr> <tr> <td>Tesamorelin</td> </tr> <tr> <td>Surgery (eg, liposuction of dorsocervical fat pad or reduction mammoplasty)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53050 Version 4.0</div></div></div>"},"53051":{"type":"graphic_table","displayName":"Causes of tall R wave V1 V2","title":"Causes of tall R wave in V1/V2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of tall R wave in V1/V2</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Physiologic or positional factors\n   </td>\n   </tr>\n   <tr>\n   <td>Misplacement of chest leads</td>\n   </tr>\n   <tr>\n   <td>Normal variants</td>\n   </tr>\n   <tr>\n   <td>Displacement of heart toward right chest (dextroversion) - congenital or acquired</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Myocardial injury\n   </td>\n   </tr>\n   <tr>\n   <td>Posterior and/or lateral MI myocardial infarction</td>\n   </tr>\n   <tr>\n   <td>Duchenne muscular dystrophy</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Ventricular enlargement\n   </td>\n   </tr>\n   <tr>\n   <td>Right ventricular hypertrophy (usually with right axis deviation)</td>\n   </tr>\n   <tr>\n   <td>Hypertrophic cardiomyopathy</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Altered ventricular depolarization\n   </td>\n   </tr>\n   <tr>\n   <td>Right ventricular conduction abnormalities</td>\n   </tr>\n   <tr>\n   <td>Wolff-Parkinson-White patterns (due to posterior or lateral wall preexcitation)</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 53051 Version 1.0</div></div></div>"},"53054":{"type":"graphic_figure","displayName":"Embryology of kidney","title":"Embryology of the kidney","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Embryology of the kidney</div><div class=\"cntnt\"><img style=\"width:558px; height:408px;\" src=\"images/OBGYN/53054_Embryology_of_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Relationship of the intermediate mesoderm of the pronephric, mesonephric, and metanephric systems. In cervical and upper thoracic regions intermediate mesoderm is segmented; in lower thoracic, lumbar, and sacral regions it forms a solid, unsegmented mass of tissue, the nephrogenic cord. Note the longitudinal collecting duct, formed initially by the pronephros but later by the mesonephros. B) Excretory tubules of the pronephric and mesonephric systems in a 5-week-old embryo.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler, T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169;2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53054 Version 1.0</div></div></div>"},"53056":{"type":"graphic_diagnosticimage","displayName":"Open book pelvic fracture","title":"Open book pelvic fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open book pelvic fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:372px;\" src=\"images/EM/53056_Open_book_fx2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This open-book pelvis fracture was sustained in a motor vehicle collision. The fracture was associated with a posterior urethral injury.</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 53056 Version 2.0</div></div></div>"},"53057":{"type":"graphic_table","displayName":"Classification of MEN1","title":"Classification of multiple endocrine neoplasia type 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of multiple endocrine neoplasia type 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Type 1</td> </tr> <tr> <td class=\"indent1\">Primary hyperparathyroidism (&#62;90 percent)</td> </tr> <tr> <td class=\"sublist2_start\">Pituitary tumors (10 to 20 percent)</td> </tr> <tr> <td class=\"sublist2\">Prolactinoma</td> </tr> <tr> <td class=\"sublist2\">Growth hormone-secreting</td> </tr> <tr> <td class=\"sublist2\">Corticotropin-secreting</td> </tr> <tr> <td class=\"sublist2\">Non-hormone-secreting</td> </tr> <tr> <td class=\"sublist2_start\">Enteropancreatic tumors (60 to 70 percent)</td> </tr> <tr> <td class=\"sublist2\">Gastrinoma (Zollinger-Ellison syndrome)</td> </tr> <tr> <td class=\"sublist2\">Insulinoma</td> </tr> <tr> <td class=\"sublist2\">Vasoactive-intestinal polypeptide-secreting</td> </tr> <tr> <td class=\"sublist2\">Glucagonoma</td> </tr> <tr> <td class=\"sublist2\">Pancreatic polypeptide-secreting</td> </tr> <tr> <td class=\"sublist2\">Non-hormone-secreting</td> </tr> <tr> <td class=\"indent1\">Other</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53057 Version 6.0</div></div></div>"},"53058":{"type":"graphic_picture","displayName":"Endosc acute lye ingestion","title":"Endoscopy in acute lye ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopy in acute lye ingestion</div><div class=\"cntnt\"><img style=\"width:228px; height:665px;\" src=\"images/GAST/53058_Endosc_acute_lye_ingestion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Esophagus reveals progressive circumferential mucosal ulceration and exudates (Grade 2B). B) Stomach at the level of the incisura reveals diffuse deep ulceration with hemorrhage and exudates (Grade 2B). C) Duodenum only reveals erythema and edema (Grade 1). In this patient, endoscopy was performed eight hours after ingestion in order to stage the disease. A nasogastric tube was left in place during and after the procedure (A).</div><div class=\"graphic_reference\">Courtesy of Maximilian Lee, MD.</div><div id=\"graphicVersion\">Graphic 53058 Version 1.0</div></div></div>"},"53060":{"type":"graphic_diagnosticimage","displayName":"Small bowel leiomyoma CT","title":"Small bowel leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel leiomyoma</div><div class=\"cntnt\"><img style=\"width:401px; height:330px;\" src=\"images/GAST/53060_Small_bowel_leiomyoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative CT scan shows a lobulated and cystic mass related to a loop of ileum. The small bowel leiomyoma has a focus of hemorrhage and necrosis (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 53060 Version 3.0</div></div></div>"},"53062":{"type":"graphic_table","displayName":"Characteristic grief depres","title":"Characteristics of grief versus depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of grief versus depression</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">&nbsp;</td>\n<td class=\"subtitle1\">Grief</td>\n<td class=\"subtitle1\">Depression</td>\n</tr>\n\n<tr>\n<td>Definition</td>\n<td>Feelings and behaviors that result from a particular loss</td>\n<td>Depressed mood, decreased interest and pleasure, appetite and sleep disturbance, psychomotor agitation or retardation, decreased concentration, loss of energy, feelings of worthlessness, guilt, hopelessness, helplessness, and thoughts of death with impairment of functioning lasting at least two weeks</td>\n</tr>\n\t\n<tr>\n<td rowspan=\"2\">Symptoms and signs</td>\n<td rowspan=\"2\">Somatic distress, sleep and appetite disturbance, diminished concentration, social withdrawal, sighing</td>\n<td>Hopelessness, helplessness, anhedonia, worthlessness, guilt, suicidal ideation most useful diagnostic clues</td>\n</tr>\n<tr>\n\t<td>Somatic distress, sleep and appetite disturbance, diminished concentration, social withdrawal, sighing are also common</td>\n</tr>\n\n<tr>\n<td rowspan=\"4\">Other differentiating factors</td>\n<td>Patient retains capacity for pleasure</td>\n<td>Nothing is enjoyable</td>\n</tr>\n\n<tr>\n<td>Comes in waves</td>\n<td>Constant</td>\n</tr>\n\t\n<tr>\n<td>Passive wishes for death</td>\n<td>Intense, persistent suicidal thoughts</td>\n</tr>\n\n<tr>\n<td>Able to look forward to the future</td>\n<td>No sense of anything to look forward to</td>\n</tr>\n\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Block, SD. Psychological issues in end of life care. Journal of Palliative Medicine 2006; 9:751. Copyright &#169;2006 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 53062 Version 2.0</div></div></div>"},"53064":{"type":"graphic_table","displayName":"Features of NF1 by age","title":"Features of neurofibromatosis type 1 as a function of the age when they may first be apparent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of neurofibromatosis type 1 as a function of the age when they may first be apparent</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Birth through age 2</td> </tr> <tr> <td class=\"indent1\">Caf&#233;-au-lait spots, pseudoarthrosis, sphenoid wing dysplasia, optic pathway gliomas, plexiform neurofibromas (rarely)</td> </tr> <tr> <td class=\"subtitle1_single\">Ages 2 through 6</td> </tr> <tr> <td class=\"indent1\">Axillary freckling, Lisch nodules, optic pathway gliomas, other CNS tumors, learning disabilities or speech delay, plexiform neurofibromas</td> </tr> <tr> <td class=\"subtitle1_single\">6 to 10 years</td> </tr> <tr> <td class=\"indent1\">Learning disabilites, attention deficit disorders, scoliosis, plexiform neurofibromas, increased risk of other cancer types (eg, rhabdomyosarcomas), headaches</td> </tr> <tr> <td class=\"subtitle1_single\">Adolescence</td> </tr> <tr> <td class=\"indent1\">Subcutaneous and cutaneous neurofibromas, malignant transformation of preexisting plexiform neurofibromas, isolated MPNST, hypertension</td> </tr> <tr> <td class=\"subtitle1_single\">Adulthood</td> </tr> <tr> <td class=\"indent1\">Increasing number of cutaneous and subcutaneous neurofibromas, MPNST, hypertension</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; MPNST: malignant peripheral nerve sheath tumors.</div><div class=\"graphic_reference\">Modified and updated from: Plon SE, Riccardo VM. In: Oksi's Pediatrics: Principles and Practice, McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 53064 Version 8.0</div></div></div>"},"53065":{"type":"graphic_table","displayName":"Lower extremity splints","title":"Lower extremity splints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lower extremity splints</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Splint</td>\n\n      <td class=\"subtitle1\">Indication</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Knee splint</td>\n\n      <td>Knee injuries</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Jones compression</td>\n\n      <td>Knee and calf injuries</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Posterior ankle splint</td>\n\n      <td>Distal leg, ankle, tarsal, and metatarsal fractures</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Reduced dislocations, severe sprains</td>\n    </tr>\n    <tr>\n\n      <td>Stirrup splint</td>\n\n      <td>Ankle fractures</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Bulky foot compression dressing</td>\n\n      <td>Calcaneal fractures</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>Foot injuries</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Buddy taping</td>\n\n      <td>Phalangeal fractures of the toes</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53065 Version 1.0</div></div></div>"},"53071":{"type":"graphic_figure","displayName":"Anterior posterior triangle","title":"Triangles of the female perineum","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Triangles of the female perineum</div><div class=\"cntnt\"><img style=\"width:500px; height:467px;\" src=\"images/OBGYN/53071_Anterior_posterior_triangle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53071 Version 1.0</div></div></div>"},"53073":{"type":"graphic_figure","displayName":"Stool diary blank","title":"Stool diary","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Stool diary</div><div class=\"cntnt\"><img style=\"width:553px; height:611px;\" src=\"images/PEDS/53073_Stool_diary_blank.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53073 Version 1.0</div></div></div>"},"53074":{"type":"graphic_picture","displayName":"Lupus vulgaris histopathology","title":"Lupus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus vulgaris</div><div class=\"cntnt\"><img style=\"width:296px; height:274px;\" src=\"images/DERM/53074_Lupus_vulg_histopath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratosis, pseudoepitheliomatous hyperplasia, and tuberculoid granulomas are evident in this specimen from a lesion of lupus vulgaris.</div><div class=\"graphic_reference\">Courtesy of Dr. Ma. Flordeliz Abad-Casintahan.</div><div id=\"graphicVersion\">Graphic 53074 Version 1.0</div></div></div>"},"53075":{"type":"graphic_algorithm","displayName":"Sudden weakness in children","title":"Sudden weakness in children","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Sudden weakness in children</div><div class=\"cntnt\"><img style=\"width:491px; height:268px;\" src=\"images/EM/53075_Suddenweaknessalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SAH: subarachnoid hemorrhage; EDH: epidural hematoma; SDH: subdural hematoma.</div><div class=\"graphic_reference\">Adapted with permission from: Tsarouhas N, Decker JM. Weakness. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53075 Version 14.0</div></div></div>"},"53077":{"type":"graphic_table","displayName":"Infertility history","title":"The infertility history","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The infertility history</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ovulation</td> </tr> <tr> <td>Menstrual regularity and presence of moliminal symptoms</td> </tr> <tr> <td class=\"sublist1_start\">Home confirmation of ovulation</td> </tr> <tr> <td class=\"sublist1\">- Over-the-counter kits, basal body temperatures</td> </tr> <tr> <td class=\"sublist1_start\">Presence of other endocrine conditions</td> </tr> <tr> <td class=\"sublist1\">- Thyroid disease, hyperprolactinemia, hyperandrogenemia</td> </tr> <tr> <td>Symptoms of premature menopause</td> </tr> <tr> <td>Family history of infertility or premature ovarian failure</td> </tr> <tr> <td class=\"subtitle1_single\">Tubal or uterine factors</td> </tr> <tr> <td>History of pelvic inflammatory disease, endometriosis, or ectopic pregnancy</td> </tr> <tr> <td>History of pelvic adhesions or surgeries</td> </tr> <tr> <td>Tubal or uterine surgeries</td> </tr> <tr> <td>Uterine fibroids or congenital anomalies</td> </tr> <tr> <td class=\"subtitle1_single\">Male factor</td> </tr> <tr> <td class=\"sublist1_start\">Partner's medical history</td> </tr> <tr> <td class=\"sublist1\">- Chronic illnesses, endocrine disease, orchiitis</td> </tr> <tr> <td>History of testicular surgery or trauma</td> </tr> <tr> <td>History of prior paternity</td> </tr> <tr> <td>Other urologic or ejaculatory problems</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53077 Version 3.0</div></div></div>"},"53078":{"type":"graphic_figure","displayName":"Circadian hormones in asthma","title":"Circadian changes in hormone levels in asthma","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Circadian changes in hormone levels in asthma</div><div class=\"cntnt\"><img style=\"width:560px; height:321px;\" src=\"images/PULM/53078_Circadian_hormones_in_asthm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean changes in peak expiratory flow rate (PEFR) and the plasma concentrations of cortisol, epinephrine, cyclic AMP, and histamine over a 24-hour period in patients with nocturnal asthma. The nadir in PEFR, which occurs at 4 AM, is associated with low levels of cortisol and epinephrine and high levels of the bronchoconstrictor mediator, histamine.</div><div class=\"graphic_reference\">Redrawn from Barnes, P, Fitzgerald, G, Brown, M, N Engl J Med 1980; 303:263.</div><div id=\"graphicVersion\">Graphic 53078 Version 1.0</div></div></div>"},"53080":{"type":"graphic_figure","displayName":"Pancreaticojejunostomy reconstruction","title":"Pancreaticojejunostomy reconstruction","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Pancreaticojejunostomy reconstruction</div><div class=\"cntnt\"><img style=\"width:486px; height:654px;\" src=\"images/SURG/53080_Pancreatic_anastomosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Howard A. Reber, MD.</div><div id=\"graphicVersion\">Graphic 53080 Version 2.0</div></div></div>"},"53081":{"type":"graphic_movie","displayName":"Ultrasound median nerve movement in sagittal view","title":"Ultrasound median nerve movement in sagittal view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound median nerve movement in sagittal view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/53081_USmediannerveconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:442px; height:334px;\" src=\"images/NEURO/53081_USmediannerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a sagittal view of the median nerve at the wrist (proximal is to the left) with a normal subject flexing and extending the fingers. Note that the flexor digitorum superficialis (FDS) and flexor digitorum profundus (FDP) tendons and the median nerve (N) all move in the same directions, but that the tendons show greater excursions during these movements.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 53081 Version 2.0</div></div></div>"},"53082":{"type":"graphic_picture","displayName":"Pathologic phimosis","title":"Pathologic phimosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathologic phimosis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/PEDS/53082_Pathologic_phimosis_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53082 Version 2.0</div></div></div>"},"53083":{"type":"graphic_figure","displayName":"Cheatle slit in ileum","title":"Cheatle slit in ileum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cheatle slit in ileum</div><div class=\"cntnt\"><img style=\"width:280px; height:210px;\" src=\"images/SURG/53083_Cheatle-slit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53083 Version 1.0</div></div></div>"},"53086":{"type":"graphic_table","displayName":"Mnemonic vacuum extraction","title":"Mnemonic for vacuum extraction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mnemonic for vacuum extraction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>A</td> <td><span style=\"font-weight: bold;\">A</span>sk for help; <span style=\"font-weight: bold;\">a</span>ddress the patient (inform her about what you are going to do and get informed consent); <span style=\"font-weight: bold;\">a</span>ssess <span style=\"font-weight: bold;\">a</span>nesthesia needs</td> </tr> <tr> <td>B</td> <td><span style=\"font-weight: bold;\">B</span>ladder empty</td> </tr> <tr> <td>C</td> <td><span style=\"font-weight: bold;\">C</span>ervix fully dilated</td> </tr> <tr> <td>D</td> <td><span style=\"font-weight: bold;\">D</span>etermine fetal position and think shoulder <span style=\"font-weight: bold;\">d</span>ystocia</td> </tr> <tr> <td>E</td> <td><span style=\"font-weight: bold;\">E</span>xtractor and resuscitation <span style=\"font-weight: bold;\">e</span>quipment ready</td> </tr> <tr> <td>F</td> <td>Apply cup on the <span style=\"font-weight: bold;\">f</span>lexion point</td> </tr> <tr> <td>G</td> <td><span style=\"font-weight: bold;\">G</span>entle traction in the proper axis</td> </tr> <tr> <td>H</td> <td><span style=\"font-weight: bold;\">H</span>alt traction when the contraction is over; <span style=\"font-weight: bold;\">h</span>alt the procedure if it is not progressing normally</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified from: Deutchman, M. Vacuum extraction: A necessary skill. Am Fam Physician 2000; 62:1270.</div><div id=\"graphicVersion\">Graphic 53086 Version 2.0</div></div></div>"},"53088":{"type":"graphic_diagnosticimage","displayName":"Chrn thromboemboli angio II","title":"Right-sided pulmonary angiogram","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Right-sided pulmonary angiogram</div><div class=\"cntnt\"><img style=\"width:503px; height:360px;\" src=\"images/PULM/53088_Chrn_thromboemboli_angio_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compared to the anterior view (A), the lateral view (B) more clearly shows complete obstruction of the right lower lobe artery immediately below the superior segment and right middle lobe arteries.</div><div class=\"graphic_reference\">Courtesy of Peter F Fedullo, MD.</div><div id=\"graphicVersion\">Graphic 53088 Version 2.0</div></div></div>"},"53089":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic pleural effs MRI","title":"Hemorrhagic pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic pleural effusion</div><div class=\"cntnt\"><img style=\"width:287px; height:343px;\" src=\"images/PULM/53089_Hemorrhagic_pleural_effs_MR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhagic effusion in patient with malignant mesothelioma. MRI of the chest, sagittal sequence in supine patient.&nbsp;A liquid level is evident, forming a \"hematocrit effect.\" The red blood cells have a high signal due to intracellular methemoglobin.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53089 Version 3.0</div></div></div>"},"53090":{"type":"graphic_figure","displayName":"Secretin regulation of HCO3","title":"Secretin regulation of bicarbonate secretion","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Secretin regulation of bicarbonate secretion</div><div class=\"cntnt\"><img style=\"width:454px; height:500px;\" src=\"images/GAST/53090_Secretin_regulation_of_HCO3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The presence of gastric acid in the duodenum stimulates the release of secretin from duodenal endocrine cells. Secretin acts through the bloodstream on the pancreatic duct cells to release bicarbonate for neutralization of acid.</div><div class=\"graphic_reference\">Courtesy of Cleveland Clinic Foundation.</div><div id=\"graphicVersion\">Graphic 53090 Version 1.0</div></div></div>"},"53091":{"type":"graphic_picture","displayName":"Hysterosc myomectomy chips","title":"Hysteroscopic myomectomy: Copious leiomyoma shavings (chips)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic myomectomy: Copious leiomyoma shavings (chips)</div><div class=\"cntnt\"><img style=\"width:380px; height:317px;\" src=\"images/OBGYN/53091_Hysterosc_myomectomy_chips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts multiple leiomyoma shavings (chips) that were removed during a hysteroscopic myomectomy.</div><div class=\"graphic_reference\">Courtesy of Linda D Bradley, MD.</div><div id=\"graphicVersion\">Graphic 53091 Version 2.0</div></div></div>"},"53092":{"type":"graphic_picture","displayName":"Ichthyosiform sarcoidosis","title":"Ichthyosiform sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ichthyosiform sarcoidosis</div><div class=\"cntnt\"><img style=\"width:296px; height:432px;\" src=\"images/DERM/53092_Ichthyosiform_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ichthyosiform sarcoidosis. Infiltrated plaques with hyperpigmented polygonal scales, involving the foot and anterior leg are present.</div><div id=\"graphicVersion\">Graphic 53092 Version 1.0</div></div></div>"},"53093":{"type":"graphic_diagnosticimage","displayName":"Thyroid ultrasound of a multinodular goiter","title":"Thyroid ultrasound of a multinodular goiter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound of a multinodular goiter</div><div class=\"cntnt\"><img style=\"width:432px; height:301px;\" src=\"images/ENDO/53093_Multinodular_goiter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal view of the right lobe (+ --- + &amp; X --- X) showing a multinodular goiter with both cystic (C) and solid (S) nodules. The nodule (arrow) with punctate bright, white spots is suspicious.</div><div id=\"graphicVersion\">Graphic 53093 Version 3.0</div></div></div>"},"53094":{"type":"graphic_table","displayName":"Life expectancy by age","title":"Life expectancy by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Life expectancy by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Ages in years</td> </tr> <tr> <td class=\"subtitle2\">70</td> <td class=\"subtitle2\">75</td> <td class=\"subtitle2\">80</td> <td class=\"subtitle2\">85</td> <td class=\"subtitle2\">90</td> <td class=\"subtitle2\">95</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Women - years of expected life</td> </tr> <tr> <td class=\"indent1\">Top 25th percentile</td> <td class=\"centered\">21.3</td> <td class=\"centered\">17</td> <td class=\"centered\">13</td> <td class=\"centered\">9.6</td> <td class=\"centered\">6.8</td> <td class=\"centered\">4.8</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td class=\"centered\">15.7</td> <td class=\"centered\">11.9</td> <td class=\"centered\">8.6</td> <td class=\"centered\">5.9</td> <td class=\"centered\">3.9</td> <td class=\"centered\">2.7</td> </tr> <tr> <td class=\"indent1\">Lowest 25th percentile</td> <td class=\"centered\">9.5</td> <td class=\"centered\">6.8</td> <td class=\"centered\">4.6</td> <td class=\"centered\">2.9</td> <td class=\"centered\">1.8</td> <td class=\"centered\">1.1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Men - years of expected life</td> </tr> <tr> <td class=\"indent1\">Top 25th percentile</td> <td class=\"centered\">18</td> <td class=\"centered\">14.2</td> <td class=\"centered\">10.8</td> <td class=\"centered\">7.9</td> <td class=\"centered\">5.8</td> <td class=\"centered\">4.3</td> </tr> <tr> <td class=\"indent1\">50th percentile</td> <td class=\"centered\">12.4</td> <td class=\"centered\">9.3</td> <td class=\"centered\">6.7</td> <td class=\"centered\">4.7</td> <td class=\"centered\">3.2</td> <td class=\"centered\">2.3</td> </tr> <tr> <td class=\"indent1\">Lowest 25th percentile</td> <td class=\"centered\">6.7</td> <td class=\"centered\">4.9</td> <td class=\"centered\">3.3</td> <td class=\"centered\">2.2</td> <td class=\"centered\">1.5</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285:2750.</div><div id=\"graphicVersion\">Graphic 53094 Version 2.0</div></div></div>"},"53095":{"type":"graphic_figure","displayName":"Time to recovery in patients with unipolar major depression","title":"Time to recovery in patients with unipolar major depression","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Time to recovery in patients with unipolar major depression</div><div class=\"cntnt\"><img style=\"width:468px; height:314px;\" src=\"images/PSYCH/53095_Timerecovermajordepr3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time to recovery from the first (squares, N = 314) and second (triangles, N = 181) prospectively observed episodes of major depression in patients with major depressive disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: Coryell W, HS Akiskal, AC Leon, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arch Gen Psychiatry 1994; 51:405. Copyright © 1994 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53095 Version 9.0</div></div></div>"},"53096":{"type":"graphic_figure","displayName":"Talar fracture classification","title":"Hawkins classification of talar neck fractures","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Hawkins classification of talar neck fractures</div><div class=\"cntnt\"><img style=\"width:490px; height:438px;\" src=\"images/EM/53096_Talarfxclassification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Type I, nondisplaced fracture of the talar neck. <br />(B) Type II, displaced talar neck fracture with subluxation or dislocation of the subtalar joint. <br />(C) Type III, displaced talar neck fracture with associated dislocation of the talar body from both the subtalar and tibiotalar joints. <br />(D) Type IV, as suggested by Canale and Kelly, displaced talar neck fracture with an associated dislocation of the talar body from subtalar and tibiotalar joints and dislocation of the head and neck fragment from the talonavicular joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53096 Version 12.0</div></div></div>"},"53097":{"type":"graphic_diagnosticimage","displayName":"Chronic pancreatititis EUS","title":"Chronic pancreatitis seen on endoscopic ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic pancreatitis seen on endoscopic ultrasound</div><div class=\"cntnt\"><img style=\"width:333px; height:306px;\" src=\"images/GAST/53097_Chronic_pancreatititis_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic pancreatitis seen through endoscopic ultrasound. Note the lobulated parenchyma (Lob), hyperechoic strands (HS), and irregular main pancreatic duct (PD).</div><div class=\"graphic_reference\">Courtesy of Michael B Wallace, MD, MPH.</div><div id=\"graphicVersion\">Graphic 53097 Version 3.0</div></div></div>"},"53101":{"type":"graphic_picture","displayName":"Meconium stained membranes","title":"Meconium stained fetal membranes","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Meconium stained fetal membranes</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/53101_Meconium_stained_membranes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to meconium pigment in membranes.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53101 Version 2.0</div></div></div>"},"53102":{"type":"graphic_table","displayName":"Class infantile seizures","title":"Proposed classification of infantile seizures (2 to 24 months)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed classification of infantile seizures (2 to 24 months)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Astatic\n   </td>\n   </tr>\n   <tr>\n   <td>Sudden loss of muscle tone that may be focal (eg, head nod), hemibody or generalized (eg, fall or drop attack)</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Behavioral\n   </td>\n   </tr>\n   <tr>\n   <td>Abrupt change in behavior without other overt features (usually becomes quiet-hypomotor), occasionally autonomic signs (pallor, cyanosis, etc.)</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Clonic\n   </td>\n   </tr>\n   <tr>\n   <td>Clonic jerking, usually of extremities or eyelids, occasionally followed by tonic posturing.</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Infantile spasms\n   </td>\n   </tr>\n   <tr>\n   <td>May be myoclonic or brief tonic flexor (adduction of arms with forward flexion of head and trunk) or extensor (abduction of arms with backward extension of head and trunk) spasms. These often occur in clusters.</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Tonic\n   </td>\n   </tr>\n   <tr>\n   <td>Symmetric or asymmetric posturing (occasional \"fencer posture\"), may be followed by focal or generalized clonic activity.</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Versive\n   </td>\n   </tr>\n   <tr>\n   <td>A forced and sustained tonic deviation of the eyes that is usually associated with ipsilateral turning of the head and rotation of the trunk.</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Unclassified\n   </td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted form Nordii, DR, Bazil, CW, Scheur, ML, Pedley, TA, Epilepsia 1997; 38:553 and Acharya, JN, Wylie, E, Luders, HO, et al, Neurology 1997; 48:189.</div><div id=\"graphicVersion\">Graphic 53102 Version 1.0</div></div></div>"},"53103":{"type":"graphic_figure","displayName":"Gait cycle","title":"Gait cycle","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Gait cycle</div><div class=\"cntnt\"><img style=\"width:522px; height:215px;\" src=\"images/PEDS/53103_Gait_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gait cycle has four phases: Heel-strike to foot-flat (contact), foot-flat to heel-off (mid-stance), heel-off to toe-off (propulsion), and toe-off to heel-strike (swing).</div><div id=\"graphicVersion\">Graphic 53103 Version 1.0</div></div></div>"},"53104":{"type":"graphic_picture","displayName":"Alopecia areata beard","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:380px; height:333px;\" src=\"images/DERM/53104_Alopecia_areata_beard.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This man's alopecia areata is limited to his beard.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53104 Version 2.0</div></div></div>"},"53105":{"type":"graphic_picture","displayName":"Red cells in the spleen","title":"Red blood cell deformation in splenic cords","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Red blood cell deformation in splenic cords</div><div class=\"cntnt\"><img style=\"width:338px; height:252px;\" src=\"images/HEME/53105_Red_cells_in_the_spleen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron microphotograph of normal murine red blood cell passing from a splenic cord (below) through the sinusoidal barrier and into the splenic sinusoid (above). Note the deformation necessary to squeeze through the slit in the sinusoidal wall and how a surface area depleted spherocyte would be incapable of transversing the barrier.</div><div class=\"graphic_reference\">Courtesy of Mohandas Narla, ScD.</div><div id=\"graphicVersion\">Graphic 53105 Version 3.0</div></div></div>"},"53107":{"type":"graphic_figure","displayName":"Ramipril post revascularization","title":"Ramipril improves outcome after revascularization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ramipril improves outcome after revascularization</div><div class=\"cntnt\"><img style=\"width:450px; height:341px;\" src=\"images/CARD/53107_Ramiprilpostrevasculariza.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 159 patients with chronic stable angina and reduced left ventricular function undergoing revascularization with angioplasty or bypass surgery, Kaplan-Meier plot shows that ramapril signficantly reduces the triple-composite end point (cardiac death, acute myocardial infarction, or clinical heart failure) compared&nbsp;with placebo (10 versus 23 percent, p = 0.03).</div><div class=\"graphic_reference\">Data from Kjoller-Hansen L, Steffensen R, Grande P. J Am Coll Cardiol 2000; 35:881.</div><div id=\"graphicVersion\">Graphic 53107 Version 3.0</div></div></div>"},"53109":{"type":"graphic_picture","displayName":"Surgical drainage of dorsal subcutaneous abscess of the hand","title":"Surgical drainage of dorsal subcutaneous abscess of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical drainage of dorsal subcutaneous abscess of the hand</div><div class=\"cntnt\"><img style=\"width:395px; height:584px;\" src=\"images/SURG/53109_Surg_drain_sub_abscess_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal skin of the hand is loosely anchored to the underlying tissue, which allows the spread of infection into two potential spaces: the dorsal subcutaneous space, which is superficial to the extensor tendons, and the dorsal subaponeurotic space, which is deep to the extensor tendons.<br />Panels A through C demonstrate surgical drainage of a subcutaneous abscess of the dorsum of the right hand:<br />(A) Preoperative appearance.<br />(B) Intraoperative appearance.<br />(C) Postoperative appearance.<br />Panel D shows a more extensive dorsal subaponeurotic abscess. Patients who require extensive debridement may need additional surgical procedures to resurface the resulting soft tissue defect. </div><div id=\"graphicVersion\">Graphic 53109 Version 5.0</div></div></div>"},"53110":{"type":"graphic_picture","displayName":"Porokeratosis ptychotropica","title":"Porokeratosis ptychotropica","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis ptychotropica</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53110_Porokeratosis_ptychotropica.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly plaques are present in the gluteal fold.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53110 Version 3.0</div></div></div>"},"53111":{"type":"graphic_figure","displayName":"Naegleria life cycle","title":"<EM>Naegleria</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\"><EM>Naegleria</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:516px; height:620px;\" src=\"images/ID/53111_Naegleria_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Naegleria fowleri</em> has three stages, cysts <strong>(1)</strong>, trophozoites <strong>(2)</strong>, and flagellated forms <strong>(3)</strong>, in its life cycle. The trophozoites replicate by promitosis (nuclear membrane remains intact) <strong>(4)</strong>. <em>N. fowleri</em> is found in fresh water, soil, thermal discharges of power plants, heated swimming pools, hydrotherapy and medicinal pools, aquariums, and sewage. Trophozoites can turn into temporary nonfeeding flagellated forms, which usually revert back to the trophozoite stage. Trophozoites infect humans or animals by penetrating the nasal mucosa <strong>(5)</strong> and migrating to the brain <strong>(6)</strong> via the olfactory nerves causing primary amebic meningoencephalitis (PAM). <em>N. fowleri</em> trophozoites are found in cerebrospinal fluid (CSF) and tissue, while flagellated forms are occasionally found in CSF. Cysts are not seen in brain tissue.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites: Naegleria. Available at: <a href=\"http://www.cdc.gov/parasites/naegleria/biology.html\" target=\"_blank\">http://www.cdc.gov/parasites/naegleria/biology.html</a>.</div><div id=\"graphicVersion\">Graphic 53111 Version 3.0</div></div></div>"},"53112":{"type":"graphic_figure","displayName":"Sinusoidal events","title":"Sinusoidal events during fibrosing liver injury","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Sinusoidal events during fibrosing liver injury</div><div class=\"cntnt\"><img style=\"width:488px; height:325px;\" src=\"images/GAST/53112_Sinusoidal_events.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in the subendothelial space of Disse and sinusoid as fibrosis develops in response to liver injury include alterations in both cellular responses and extracellular matrix composition. Stellate cell activation leads to accumulation of scar (fibril-forming) matrix. This in turn contributes to the loss of hepatocyte microvilli and sinusoidal endothelial fenestrae, which result in deterioration of hepatic function. Kupffer cell (macrophage) activation accompanies liver injury and contributes to paracrine activation of stellate cells.</div><div class=\"graphic_reference\">Courtesy of Scott L Friedman, MD.</div><div id=\"graphicVersion\">Graphic 53112 Version 1.0</div></div></div>"},"53114":{"type":"graphic_figure","displayName":"Rx sexual dys in uremic women","title":"Approach to sexual dysfunction in uremic women","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Approach to sexual dysfunction in uremic women</div><div class=\"cntnt\"><img style=\"width:482px; height:369px;\" src=\"images/NEPH/53114_Rx_sexual_dys_in_uremic_wom.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Palmer, B. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10:1366. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53114 Version 2.0</div></div></div>"},"53118":{"type":"graphic_figure","displayName":"Regulation sarcolemma function","title":"Regulation of the calcium transient at the sarcolemma membrane","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Regulation of the calcium transient at the sarcolemma membrane</div><div class=\"cntnt\"><img style=\"width:563px; height:348px;\" src=\"images/CARD/53118_Regulation_sarcolemma_funct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the regulation of the calcium transient at the sarcolemma membrane. Calcium moves across the sarcolemma via the sodium-calcium exchanger (which uses the favorable electrochemical gradient for sodium to drive passive calcium transport) and the L-type calcium channel. Hormones and drugs that can affect this process include digoxin (which inhibits the Na-K-ATPase pump), epinephrine and isoproterenol (which bind the the beta receptor and activate adenylyl cyclase, leading to the formation of cyclic AMP), epinephrine and phenylephrine (which bind to the alpha receptor and activate phospholipase C), and milrinone and the methylxanthines (which are phosphodiesterase inhibitors, thereby slowing the metabolism of cyclic AMP and prolonging the beta adrenergic effect).</div><div class=\"graphic_footnotes\">DAG: diacylglycerol; IP3: inositol triphosphate.</div><div class=\"graphic_reference\">Courtesy of Timothy W Smith, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53118 Version 1.0</div></div></div>"},"53119":{"type":"graphic_table","displayName":"Intraosseous cannula placement site by patient age","title":"Intraosseous cannula placement site by patient age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraosseous cannula placement site by patient age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient age</td> <td class=\"subtitle1\">Intraosseous site</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Infant (under 1 year)</td> <td>Proximal tibia</td> </tr> <tr class=\"divider_bottom\"> <td>Distal femur</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Child (1-12 years)</td> <td>Proximal tibia*</td> </tr> <tr class=\"divider_bottom\"> <td>Distal tibia or fibula</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Skeletally immature adolescent<sup>&#182;</sup> (12-18 years)</td> <td>Proximal tibia*</td> </tr> <tr> <td>Distal tibia or fibula</td> </tr> <tr class=\"divider_bottom\"> <td>Sternum<sup>&#916;</sup></td> </tr> <tr> <td rowspan=\"4\">Over 18 years</td> <td>Proximal tibia*</td> </tr> <tr> <td>Proximal humerus<sup>&#9674;</sup></td> </tr> <tr> <td>Distal tibia or fibula</td> </tr> <tr> <td>Sternum<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Battery-powered or impact-driven devices are typically required to place an intraosseous cannula through the bony cortex of the proximal tibia in patients older than six years of age.<br />¶ Age at full skeletal maturity varies according to gender and individual patient characteristics.<br />Δ Sternal intraosseous cannula placement should only be attempted using devices specifically designed for that placement site.<br /><FONT class=lozenge>◊</FONT> The proximal humerus site should only be used in skeletally mature patients.</div><div id=\"graphicVersion\">Graphic 53119 Version 5.0</div></div></div>"},"53120":{"type":"graphic_picture","displayName":"Frenuloplasty for ankyloglossia","title":"Frenuloplasty for ankyloglossia","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Frenuloplasty for ankyloglossia</div><div class=\"cntnt\"><img style=\"width:584px; height:316px;\" src=\"images/ALLRG/53120_Frenuloplasty_ankyloglossia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal division of a tethering lingual frenulum with bipolar electrosurgical scissors.<br> (B) Division of anterior fibers of the genioglossus muscle to release &quot;posterior&quot; ankyloglossia.</div><div id=\"graphicVersion\">Graphic 53120 Version 1.0</div></div></div>"},"53121":{"type":"graphic_table","displayName":"Radiation toxicity cerebrovascular","title":"Radiation toxicity: Cerebrovascular system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation toxicity: Cerebrovascular system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Degree 1</td> <td class=\"subtitle1\">Degree 2</td> <td class=\"subtitle1\">Degree 3</td> <td class=\"subtitle1\">Degree 4</td> </tr> <tr> <td>Nausea</td> <td>Mild</td> <td>Moderate</td> <td>Intense</td> <td>Excruciating</td> </tr> <tr> <td>Vomiting</td> <td>Once/day</td> <td>2 to 5 times/day</td> <td>6 to 10/day</td> <td>&#62;10/day</td> </tr> <tr> <td>Anorexia</td> <td>Able to eat</td> <td>Decreased intake</td> <td>Minimal intake</td> <td>Parenteral nutrition needed</td> </tr> <tr> <td>Fatigue</td> <td>Able to work</td> <td>Work impaired</td> <td>Assistance for ADL</td> <td>Cannot do ADL</td> </tr> <tr> <td>Temp (&#176;C)</td> <td>&#60;38</td> <td>38 to 40</td> <td>&#62;40 for &#60;24 hours</td> <td>&#62;40 for &#62;24 hours</td> </tr> <tr> <td>Headache</td> <td>Minimal</td> <td>Moderate</td> <td>Intense</td> <td>Excruciating</td> </tr> <tr> <td>BP (mmHg)</td> <td>&#62;100/70</td> <td>&#60;100/70</td> <td>&#60;90/60</td> <td>&#60;80 systolic</td> </tr> <tr> <td>Neurologic deficits*</td> <td>Barely detected</td> <td>Easily detected</td> <td>Prominent</td> <td>Life-threatening LOC</td> </tr> <tr> <td>Cognitive deficits<sup>&#182;</sup></td> <td>Minor loss</td> <td>Moderate loss</td> <td>Major impairment</td> <td>Complete impairment</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADL: activities of daily living; Temp: temperature; BP: blood pressure; LOC: loss of consciousness.<br />* Reflexes (including corneal), papilledema, seizures, ataxia, other motor and sensory signs.<br />¶ Impaired memory, reasoning, or judgement.</div><div class=\"graphic_reference\">Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037. Copyright &copy; 2004 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 53121 Version 21.0</div></div></div>"},"53123":{"type":"graphic_diagnosticimage","displayName":"US appendicitis in pregnancy1","title":"Sonogram of appendicitis in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sonogram of appendicitis in pregnancy</div><div class=\"cntnt\"><img style=\"width:207px; height:250px;\" src=\"images/OBGYN/53123_US_appendicitis_pregnancy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right lower quadrant in a woman with appendicitis who is six weeks pregnant. Note the markedly thick-walled appendix (calipers) measuring 16 mm.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 53123 Version 3.0</div></div></div>"},"53124":{"type":"graphic_table","displayName":"Contraind main Rx prost CA","title":"Relative contraindications to the main treatment options for early prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative contraindications to the main treatment options for early prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">External beam radiation therapy </td> </tr> <tr> <td>Previous pelvic irradiation</td> </tr> <tr> <td>Active inflammatory disease of the rectum</td> </tr> <tr> <td>Very low bladder capacity</td> </tr> <tr> <td>Chronic moderate or severe diarrhea from any cause</td> </tr> <tr> <td class=\"subtitle1_single\">Brachytherapy </td> </tr> <tr> <td>Previous pelvic irradiation</td> </tr> <tr> <td>Large-volume gland</td> </tr> <tr> <td>Marked voiding symptoms</td> </tr> <tr> <td>Large or high-grade tumor burdens*</td> </tr> <tr> <td>Chronic moderate or severe diarrhea</td> </tr> <tr> <td>Active inflammatory disease of the rectum</td> </tr> <tr> <td class=\"subtitle1_single\">Radical prostatectomy </td> </tr> <tr> <td>Higher medical operative risk</td> </tr> <tr> <td>Neurogenic bladder</td> </tr> <tr> <td class=\"subtitle1_single\">Active surveillance</td> </tr> <tr> <td>Patients with high prostate cancer anxiety</td> </tr> <tr> <td>High-grade tumors (&#62; Gleason 6); not stage T1c</td> </tr> <tr> <td>Prolonged expected survival</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Brachytherapy may be indicated in combination with external beam RT.</div><div class=\"graphic_reference\">Modified&nbsp;from: Vogelzang NJ, Scardino PT, Shipley WU, et al. Comprehensive textbook of genitourinary oncology, 3rd Edition. Lippincott Williams &amp; Wilkins 2005.</div><div id=\"graphicVersion\">Graphic 53124 Version 13.0</div></div></div>"},"53126":{"type":"graphic_table","displayName":"Evaluation of pancytopenia in children","title":"Assessment of children presenting with pancytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of children presenting with pancytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Careful physical examination for dysmorphic features</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory testing</td> </tr> <tr> <td class=\"indent1\">Complete blood count</td> </tr> <tr> <td class=\"indent1\">Serum aminotransferases</td> </tr> <tr> <td class=\"sublist2_start\">Viral serologies</td> </tr> <tr> <td class=\"sublist2\">HIV</td> </tr> <tr> <td class=\"sublist2\">Cytomegalovirus</td> </tr> <tr> <td class=\"sublist2\">Epstein-Barr virus</td> </tr> <tr> <td class=\"sublist2\">Hepatitis</td> </tr> <tr> <td class=\"sublist2\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Serum folate and vitamin B12 concentrations</td> </tr> <tr> <td class=\"indent1\">Hemoglobin F levels</td> </tr> <tr> <td class=\"indent1\">Cytogenetic studies on bone marrow*</td> </tr> <tr> <td class=\"indent1\">Diepoxybutane screen for Fanconi anemia</td> </tr> <tr> <td class=\"indent1\">Telomere length analysis of leukocyte subsets for dyskeratosis congenita</td> </tr> <tr> <td class=\"indent1\">CD55/59 screen for paroxysmal nocturnal hemoglobinuria</td> </tr> <tr> <td class=\"indent1\">Red blood cell phenotyping</td> </tr> <tr> <td class=\"indent1\">HLA tissue typing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* FISH analysis is also performed by some providers, and is specifically recommended if conventional cytogenetic studies are limited because of inadequate metaphases in the bone marrow sample. The most frequent anomalies include trisomy 8, trisomy 6, 5q-, and anomalies of chromosome 7 (monosomy) and 13<sup>[1]</sup>.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rovo A, Tichelli A, Dufour C. Diagnosis of acquired aplastic anemia. Bone Marrow Transplantation 2013; 48:162.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53126 Version 7.0</div></div></div>"},"53127":{"type":"graphic_algorithm","displayName":"Metabolic defects-methylmalonic aciduria and propionic acidemia","title":"Metabolic defects in methylmalonic aciduria and propionic acidemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metabolic defects in methylmalonic aciduria and propionic acidemia</div><div class=\"cntnt\"><img style=\"width:261px; height:429px;\" src=\"images/PEDS/53127_MMA_and_PA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PA: propionic acidemia; MMA: methylmalonic aciduria.</div><div id=\"graphicVersion\">Graphic 53127 Version 3.0</div></div></div>"},"53128":{"type":"graphic_table","displayName":"Baylor steroid protocol","title":"Steroid protocol, Baylor College of Medicine Liver Transplant Unit","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Steroid protocol, Baylor College of Medicine Liver Transplant Unit</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>Induction (prior to transplant)</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 40 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Anhepatic phase</td>\n\t\t\t\t\t<td>Solu-Cortef&#174; (IV) 1 g</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 1</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 200 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 2</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 160 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 3</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 120 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 4</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 80 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 5</td>\n\t\t\t\t\t<td>Solu-Medrol&#174; (IV) 40 mg</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Post-op day 6</td>\n\t\t\t\t\t<td>Prednisone (oral) 20 mg</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53128 Version 1.0</div></div></div>"},"53130":{"type":"graphic_picture","displayName":"Gastric neuroendocrine tumor CPC Endosc","title":"Gastric neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Gastric neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:517px; height:227px;\" src=\"images/GAST/53130_GastriccarcinoidCPCEndos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A total of three nodular-appearing lesions were seen in the body of the stomach, measuring between 5 by 5 mm&nbsp;and 15 by 5 mm. Two had small ulcerations (arrows), which were presumably the site of bleeding. Image A represents a frontal view, and image B is during retroflexion.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 53130 Version 3.0</div></div></div>"},"53131":{"type":"graphic_picture","displayName":"Endocervical polyp","title":"Endocervical polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endocervical polyp</div><div class=\"cntnt\"><img style=\"width:344px; height:432px;\" src=\"images/OBGYN/53131_Endocervical_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A blue speculum has been placed in the vagina. An endocervical polyp can be seen protruding from and obscuring the external cervical os. Blood vessels are visible on the surface of the polyp.</div><div class=\"graphic_reference\">Courtesy of Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 53131 Version 1.0</div></div></div>"},"53132":{"type":"graphic_table","displayName":"Physical properties O2 air helium","title":"Physical properties of oxygen, air, and helium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical properties of oxygen, air, and helium</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">&nbsp;</td>\n\n\n      <td class=\"subtitle1\">Density</td>\n\n\n      <td class=\"subtitle1\">Viscosity</td>\n\n\n      <td class=\"subtitle1\">Thermoconductivity</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      <td class=\"subtitle2\">(g/L)</td>\n\n\n      <td class=\"subtitle2\">(&#181;poise)</td>\n\n\n      <td class=\"subtitle2\">(&#181;cal &#183; cm &#183; s\n&#183; &deg;K)</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Oxygen</td>\n\n\n      <td>1.429</td>\n\n\n      <td>192.6</td>\n\n\n      <td>58.5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Air</td>\n\n\n      <td>1.293</td>\n\n\n      <td>170.8</td>\n\n\n      <td>58.0</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Helium</td>\n\n\n      <td>0.179</td>\n\n\n      <td>188.7</td>\n\n\n      <td>352.0</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53132 Version 2.0</div></div></div>"},"53133":{"type":"graphic_picture","displayName":"Limbal form of VKC","title":"Limbal signs in vernal keratoconjunctivitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Limbal signs in vernal keratoconjunctivitis</div><div class=\"cntnt\"><img style=\"width:394px; height:258px;\" src=\"images/RHEUM/53133_VKC_limbal_signs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the \"limbal\" form of vernal keratoconjunctivitis (VKC), the pathology centers around the limbus, which is the border between the cornea and conjunctiva. The abnormality consists of the formation of whitish aggregates of inflammatory cells at the border of the cornea (arrows).</div><div id=\"graphicVersion\">Graphic 53133 Version 3.0</div></div></div>"},"53134":{"type":"graphic_figure","displayName":"MAP kinase pathway","title":"Mitogen-activated protein (MAP) kinase pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitogen-activated protein (MAP) kinase pathway</div><div class=\"cntnt\"><img style=\"width:402px; height:633px;\" src=\"images/ONC/53134_MAPkinasepathwayed.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RTK: receptor tyrosine kinase.</div><div id=\"graphicVersion\">Graphic 53134 Version 10.0</div></div></div>"},"53135":{"type":"graphic_table","displayName":"Safety instructions for patients receiving radioiodine treatment","title":"Safety instructions for patients receiving radioiodine treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Safety instructions for patients receiving radioiodine treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"2\"><em>To be given verbally and in writing and edited as appropriate for the patient.</em></td> </tr> <tr> <td>Dear Patient (name):</td> <td>Date:</td> </tr> <tr> <td colspan=\"2\">With regard to your radioiodine therapy, please consider the following.</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>STEP 1:</strong> Talk with your doctor or a member of the Radioiodine Treatment Team about:</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Why treated women must avoid pregnancy for a period of time and not breastfeed </li> <li>When treated men can consider fathering a child </li> <li>Who will give you the radioiodine therapy, and where and when this will happen </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>STEP 2:</strong> Make preparations before treatment and talk with your doctor or a member of the Radioiodine Treatment Team about the following specific items.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Obtaining:</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Wipes and/or toilet paper that can be flushed down the toilet </li> <li>Disposable gloves if others will be helping to take care of you </li> <li>Heavy duty (doubled if possible), leak proof, specified plastic trash bags for tissues, paper towels, and other things that may be contaminated and trashed </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">For your travel:</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>If you are well enough, it is best to drive yourself </li> <li>If you ride with someone else, confirm she is not pregnant, and maintain a distance of &#62;3 feet (use the back seat on opposite side of the driver) </li> <li>When and where you can take necessary trips </li> <li>When it is safe to use public transportation </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">For home:</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Living or working with a pregnant woman </li> <li>Associations with children </li> <li>Inability to control your urine or bowels </li> <li>Using special medical equipment, such as catheters, ostomy bags, or anything that could be contaminated by your body fluids </li> <li>Getting sick easily (throwing up or getting woozy) </li> <li>Not being able to go directly home; arrangements must be made through your treatment team. Hotel and motel stays are not recommended. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>STEP 3.</strong> Your doctor or member of the Radioiodine Treatment Team will discuss with you the following items and fill in the number of days related to each.</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Days that you need to stay &#62;3 feet away from your adult family members and caregivers for at least 18 hours a day, and at least 6 feet away as much as possible: ______________ </li> <li>Days that you need to stay &#62;6 feet away from babies, children younger than 16 years old and pregnant women: ______________ </li> <li>Days that you need to stay away from work and close contact with others in public places (movies, shopping, etc): ______________ </li> <li>Days that you need to stay away from school or daycare (includes both teachers and students): ______________ </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>STEP 4.</strong> Recommendations for after therapy.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">At home: specific recommendations</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ask your doctor for the number of days to: <ul> <li>Sleep alone in a bed that is &#62;6 feet away from another person, and, if possible, use a separate bedroom or sleeping room all by yourself </li> <li>Not kiss anyone </li> <li>Not have sexual activity </li> <li>Move your bowels every day and use a laxative if you need help </li> <li>Empty your bladder (urinate) every hour or so during the day of, and day after your radioiodine treatment; follow your doctor's advice on how much to drink </li> <li>Use wipes (preferably flushable) to clean the toilet seat after use; men should sit down to urinate and use wipes to remove splatter of urine; wipe yourself dry after urinating so that you do not drip </li> <li>For a phone you share with others, after use, wipe off the mouthpiece, or, while using, cover the phone with a plastic bag that, after use, is placed in specified plastic trash bag </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">At home: general recommendations, especially for patients sharing a bathroom</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>Flush the toilet after each time you use it; flush toilet paper and wipes </li> <li>Always wash your hands well after using the toilet </li> <li>Rinse the sink and wash your hands after brushing your teeth to wash away the saliva (spit) </li> <li>Do not share your toothbrush, razor, face cloth, towel, food or drinks, spoons, forks, glasses, and dishes </li> <li>Shower every day for at least the first 2 days after your treatment </li> <li>Do not cook for other people. If cooking is necessary, use plastic gloves and dispose of in the specified plastic trash bag. </li> <li>Wash your dishes in a dishwasher or by hand; it is better not to use disposable (throw-away) dishes, which must be put into a specified plastic trash bag </li> <li>Try to flush any tissues or any other items that contain anything from your body, such as blood, down the toilet; items that cannot be flushed, such as menstrual pads, bandages, paper/plastic dishes, spoons, forks, and paper towels, should be put in the specified plastic trash bag </li> <li>Wash your underwear, pajamas, sheets, and any clothes that contain sweat, blood, or urine by themselves. Use a standard washing machine; you do not need to use bleach and do not need extra rinses. </li> <li>Have anyone who helps you clean up vomit, blood, urine, or stool wear plastic gloves; the gloves should then be put in the specified trash plastic bag </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"2\">Trash recommendations</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Keep the specified plastic trash bags separate from other trash; keep the bags away from children and animals </li> <li>A member of your Radioiodine Treatment Team will tell you how and when to get rid of the specified plastic trash bag. You may be asked to bring the bag back to your treatment facility, or, after 80 days, the bag may be removed as other trash bags. </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_single\" colspan=\"2\">Pets</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <ul> <li>Usually pets will not receive enough radiation to harm them. But do not sleep with pets (ask your doctor for how long) since your saliva, perspiration, or other secretions may be carried away by the pet. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Outside the home</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Ask your doctor or a member of the Radioiodine Treatment Team when: <ul> <li>It will be safe to eat out, go shopping, and attend events such as religious services, parties, and movies </li> <li>You will be able to return to work and to care for or teach others </li> <li>It would be safe to donate blood </li> <li>Special or longer distance travel is possible. (Note: For up to 3 months or more following radioiodine treatment you may set off radiation detectors at: national borders, airports, bus and train stations, tunnels, bridges, trash collection sites, and even your place of employment. A member of your Radioiodine Treatment Team will issue you a letter or card describing the therapy and the phone number of a person knowledgeable about your treatment (usually at the treating facility) in case local law enforcement agents need to check on this information. You should keep the letter or card containing the information with you whenever you are traveling for at least 3 months.) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Emergency care</td> </tr> <tr> <td colspan=\"2\"> <ul> <li>You will get an information card or letter at the time of your treatment that will show the date, type, and amount of radioiodine that you were treated with; carry this card with you at all times for at least 3 months following your treatment </li> <li>If you are in a traffic accident or any other medical emergency during the first week after your treatment, you should show this card to the medical people to let them know about the date and dose of your radioiodine treatment </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\"><strong>IMPORTANT INFORMATION FOR PATIENTS ON RISKS OF RADIATION</strong></td> </tr> <tr> <td colspan=\"2\"> <p>Radiation exposure to others should always be as low as reasonably achievable, a goal often abbreviated as ALARA. If you follow the above advice, the radiation from you to others is likely to be less than what they receive from radiation in nature over a year's time.</p> <p>Please phone us if you have any questions, and particularly if: </p> <ul> <li>Any of the above instructions cannot be followed and/or if </li> <li>You see anything that may have accidentally or unavoidably increased exposure of others to radiation </li> </ul> <br /> <p>We welcome your input on how we can improve our methods and advice to patients.</p> </td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Phone:</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Sincerely yours,</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: The American Thyroid Association Taskforce on Radioiodine Safety. Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131-I: Practice Recommendations of the American Thyroid Association. Thyroid 2011; 21:335. Copyright © 2011 Mary Ann Liebert Publishers.</div><div id=\"graphicVersion\">Graphic 53135 Version 3.0</div></div></div>"},"53136":{"type":"graphic_figure","displayName":"Wound healing granulation","title":"Wound healing granulation","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Wound healing granulation</div><div class=\"cntnt\"><img style=\"width:511px; height:679px;\" src=\"images/SURG/53136_Wound_healing_gran_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Granulation tissue has two major components: cells and proliferating capillaries. The cells are mostly fibroblasts, myofibroblasts, and macrophages. The macrophages are derived from monocytes and macrophages. The fibroblasts and myofibroblasts derive from mesenchymal stem cells, and the capillaries arise from adjacent vessels by division of the lining endothelial cells (detail), in a process termed angiogenesis. Endothelial cells put out cell extensions, called pseudopodia, that grow toward the wound site. Cytoplasmic growth enlarges the pseudopodia, and eventually the cells divide. Vacuoles formed in the daughter cells eventually fuse to create a new lumen. The entire process continues until the sprout encounters another capillary, with which it will connect. At its peak, granulation tissue is the most richly vascularized tissue in the body.<br> (B) Once repair has been achieved, most of the newly formed capillaries are obliterated and then reabsorbed, leaving a pale avascular scar.<br> (C) A photomicrograph of granulation tissue shows thin-walled vessels embedded in a loose connective tissue matrix containing mesenchymal cells and occasional inflammatory cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53136 Version 1.0</div></div></div>"},"53137":{"type":"graphic_figure","displayName":"Flexor digitorum profundus avulsion fracture (jersey finger)","title":"Flexor digitorum profundus avulsion fracture (jersey finger)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flexor digitorum profundus avulsion fracture (jersey finger)</div><div class=\"cntnt\"><img style=\"width:336px; height:170px;\" src=\"images/EM/53137_Jerseyfinger.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexor digitorum profundus avulsion fracture of the distal phalanx (jersey finger). This bony avulsion is apparent on radiographs, indicating the extent of proximal migration.</div><div class=\"graphic_reference\">Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53137 Version 11.0</div></div></div>"},"53139":{"type":"graphic_table","displayName":"CRT versus chemo LAPC","title":"Trials of chemotherapy versus chemoradiotherapy followed by chemotherapy in locally advanced pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trials of chemotherapy versus chemoradiotherapy followed by chemotherapy in locally advanced pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Author; year</td> <td class=\"subtitle1\">Fluorouracil&nbsp;plus arms</td> <td class=\"subtitle1\">n</td> <td class=\"subtitle1\">RT dose</td> <td class=\"subtitle1\">Outcome</td> </tr> <tr> <td rowspan=\"2\">Hazel J; 1981</td> <td>Fluorouracil&nbsp;+ semustine</td> <td>15</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS 7.8 versus 7.3 months (NSS)</td> </tr> <tr> <td> <p>RT + fluorouracil 500 mg/m<sup>2</sup> weekly</p> <p>Post CRT:&nbsp;Fluorouracil + semustine</p> </td> <td>15</td> <td>46 Gy</td> </tr> <tr> <td rowspan=\"2\">Klaassen D; 1985</td> <td>Fluorouracil&nbsp;weekly bolus</td> <td>44</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS 8.2 versus 8.3 months (NSS)</td> </tr> <tr> <td> <p>RT +&nbsp;fluorouracil 600 mg/m<sup>2</sup> days 1 to 3 only</p> <p>Post CRT:&nbsp;Fluorouracil weekly bolus</p> </td> <td>47</td> <td>40 Gy</td> </tr> <tr> <td rowspan=\"2\">GITSG; 1988</td> <td>Fluorouracil&nbsp;+ streptozocin + mitomycin</td> <td>21</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS significantly better with CRT (42 versus 32 weeks)</td> </tr> <tr> <td> <p>RT +&nbsp;fluorouracil 350 mg/m<sup>2</sup> per day, first three + last three days RT</p> <p>Post CRT:&nbsp;Fluorouracil + streptozocin + mitomycin</p> </td> <td>22</td> <td>54 Gy</td> </tr> <tr> <td rowspan=\"2\">Chauffert B; 2006</td> <td>Gemcitabine</td> <td>60</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS significantly better with chemotherapy alone (14.3 versus 8.4 months)</td> </tr> <tr> <td> <p>RT + infus&nbsp;fluorouracil + cisplatin days 1 to 5 every week</p> <p>Post CRT: Gemcitabine</p> </td> <td>59</td> <td>60 Gy</td> </tr> <tr> <td rowspan=\"2\">Loehrer P; 2011</td> <td>Gemcitabine</td> <td>37</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS significantly better with CRT (11.1 versus 9.2 months)</td> </tr> <tr> <td>RT plus gemcitabine</td> <td>34</td> <td>50.4 Gy</td> </tr> <tr> <td rowspan=\"2\"> <p>Hammel P;</p> <p>2016</p> </td> <td> <p>Nonprogressors after four months of chemotherapy (gemcitabine with or without erlotinib)*:</p> <p>Same&nbsp;chemotherapy&nbsp;times two months</p> </td> <td>136&nbsp;</td> <td>&nbsp;</td> <td rowspan=\"2\">Median OS not better with CRT&nbsp;(15.2 versus 16.5 months)</td> </tr> <tr> <td>RT plus capecitabine</td> <td>133</td> <td>54 Gy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT: radiation therapy; CRT: chemoradiotherapy; OS: overall survival; NSS: differences not statistically significant; GITSG: Gastrointestinal Tumor Study Group.<br />* LAP07 trial; 449 patients initially enrolled to gemcitabine with or without erlotinib; the 269 patients without progression after four months of chemotherapy then underwent a second randomization to the same chemotherapy for two months&nbsp;or RT plus capecitabine. Median&nbsp;OS was calculated from the date of the first randomization. </div><div id=\"graphicVersion\">Graphic 53139 Version 6.0</div></div></div>"},"53140":{"type":"graphic_figure","displayName":"Neural crest and embryogenesis","title":"The common embryogenesis of chromaffin cells and sympathetic ganglion cells from primitive cells of the neural crest","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">The common embryogenesis of chromaffin cells and sympathetic ganglion cells from primitive cells of the neural crest</div><div class=\"cntnt\"><img style=\"width:545px; height:296px;\" src=\"images/ONC/53140_Neural_crest_and_embryogene.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Although the adrenal medulla is well developed by 12 weeks of gestation, most of the chromaffin tissue in the fetus is present in scattered extramedullary paraaortic paraganglia, the largest of which are termed the organs of Zuckerkandl. After birth, these paraganglia gradually atrophy, disappearing by&nbsp;two to three&nbsp;years of age. The various tumors that can arise from any site along the migratory path of the cells of the autonomic nervous system are in boxes. The chromaffin cells located in the paraganglia predominantly produce norepinephrine while those in the adrenal medulla typically secrete a greater quantity of epinephrine than norepinephrine.</div><div id=\"graphicVersion\">Graphic 53140 Version 2.0</div></div></div>"},"53142":{"type":"graphic_form","displayName":"Asthma action plan PI","title":"Asthma action plan","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Asthma action plan</div><div class=\"cntnt\"><img style=\"width:614px; height:791px;\" src=\"images/PI/53142_Asthma_action_plan_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 53142 Version 3.0</div></div></div>"},"53143":{"type":"graphic_table","displayName":"Chronic diarrhea stool type","title":"Common causes of chronic diarrhea classified by typical stool characteristics, irrespective of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of chronic diarrhea classified by typical stool characteristics, irrespective of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Watery diarrhea </td> </tr> <tr> <td class=\"subtitle2_single\">Osmotic diarrhea </td> </tr> <tr> <td class=\"indent1\">Functional diarrhea (sometimes watery) </td> </tr> <tr> <td class=\"indent1\">Carbohydrate malabsorption (lactose intolerance, mucosal disease, congenital disaccharidase deficiencies) &nbsp;</td> </tr> <tr> <td class=\"indent1\">Magnesium, phosphate, sulfate ingestion </td> </tr> <tr> <td class=\"subtitle2_single\">Secretory diarrhea </td> </tr> <tr> <td class=\"indent1\">Laxative abuse (nonosmotic laxatives) </td> </tr> <tr> <td class=\"indent1\">Bacterial toxins </td> </tr> <tr> <td class=\"indent1\">Bile acid malabsorption (post cholecystecomy ileal) </td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease </td> </tr> <tr> <td class=\"indent1\">Autoimmune enteropathy (isolated or IPEX syndrome) </td> </tr> <tr> <td class=\"indent1\">Vasculitis </td> </tr> <tr> <td class=\"indent1\">Drugs and poisons </td> </tr> <tr> <td class=\"indent1\">Disordered motility (Hirshsprung's disease, pseudoobstruction) </td> </tr> <tr> <td class=\"indent1\">Neuroendocrine tumors (gastrin, VIP, carcinoid, mastocytosis) </td> </tr> <tr> <td class=\"indent1\">Neoplasia </td> </tr> <tr> <td class=\"indent1\">Addison's disease </td> </tr> <tr> <td class=\"indent1\">Epidemic secretory diarrhea (brainerd diarrhea) </td> </tr> <tr> <td class=\"indent1\">Idiopathic secretory diarrhea </td> </tr> <tr> <td class=\"indent1\">Congenital secretory diarrheas </td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory diarrhea </td> </tr> <tr> <td>Inflammatory bowel disease (ulcerative colitis, Crohn's disease, microscopic [lymphocytic and collagenous] colitis, diverticulitis)</td> </tr> <tr> <td>Infectious diseases (ulcerating viral infections, enteric bacterial pathogens, parasites)</td> </tr> <tr> <td>Ischemic colitis</td> </tr> <tr> <td>Radiation colitis</td> </tr> <tr> <td>Neoplasia (colon cancer, Lymphoma)</td> </tr> <tr> <td class=\"subtitle1_single\">Fatty diarrhea </td> </tr> <tr> <td>Malabsorption syndromes (mucosal diseases [eg, celiac], short-bowel syndrome, post-resection diarrhea, mesenteric ischemia)</td> </tr> <tr> <td>Maldigestion (pancreatic insufficiency [eg, cystic fibrosis], bile acid deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Schiller, LR. Chronic diarrhea. Gastroenterology 2004; 127:287. Copyright ©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 53143 Version 2.0</div></div></div>"},"53145":{"type":"graphic_figure","displayName":"Person having an ECG PI","title":"Person having an ECG","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Person having an ECG</div><div class=\"cntnt\"><img style=\"width:522px; height:488px;\" src=\"images/PI/53145_Person-having-an-ECG-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a man having an ECG (also called an electrocardiogram or EKG). He has patches, called &quot;electrodes,&quot; stuck onto his chest, arms, and legs. Wires run from the electrodes to the ECG machine. An ECG measures the electrical activity in the heart.</div><div id=\"graphicVersion\">Graphic 53145 Version 2.0</div></div></div>"},"53146":{"type":"graphic_figure","displayName":"Inguinal hernia reduction 1","title":"Reducing an indirect inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Reducing an indirect inguinal hernia</div><div class=\"cntnt\"><img style=\"width:473px; height:588px;\" src=\"images/EM/53146_Inguinalherniareduction1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Anatomy of an indirect inguinal hernia. B) Gas and stool are first &quot;milked out&quot; of the bowel to reduce its size. C) Constant pressure is applied for up to 5 minutes (distal to proximal) to reduce the hernia.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Henretig FM. Inguinal hernia reduction. In: Textbook of pediatric emergency medicine procedures, 2nd ed, Lippincott Williams &amp; Wilkins&nbsp;2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53146 Version 11.0</div></div></div>"},"53147":{"type":"graphic_diagnosticimage","displayName":"Gastrointestinal leiomyoma EUS","title":"Gastrointestinal leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal leiomyoma</div><div class=\"cntnt\"><img style=\"width:468px; height:365px;\" src=\"images/GAST/53147_Gastrointestinal_leiomyoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endosonographic view of a leiomyoma. Note that the lesion arises from the muscularis propria (layer 4) and the hypoechoic, homogenous and well demarcated appearance.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 53147 Version 3.0</div></div></div>"},"53148":{"type":"graphic_figure","displayName":"Estrogen treshold hypothesis","title":"Estrogen threshold hypothesis","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Estrogen threshold hypothesis</div><div class=\"cntnt\"><img style=\"width:512px; height:237px;\" src=\"images/OBGYN/53148_Estrogen_treshold_hypothesi.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Barbieri, RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166:740. Copyright &#169; 1992 Elsevier.</div><div id=\"graphicVersion\">Graphic 53148 Version 1.0</div></div></div>"},"53149":{"type":"graphic_diagnosticimage","displayName":"Tubal pregnancy adnexal mass","title":"Tubal pregnancy as adnexal mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubal pregnancy as adnexal mass</div><div class=\"cntnt\"><img style=\"width:364px; height:515px;\" src=\"images/OBGYN/53149_Tubal_preg_adnexal_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two examples of ectopic pregnancy presenting as an extraovarian adnexal mass (arrows).</div><div class=\"graphic_footnotes\">U: uterus; O: ovary.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 53149 Version 3.0</div></div></div>"},"53150":{"type":"graphic_table","displayName":"Etiology of septic arthritis by age","title":"Most common causes of bacterial arthritis in children according to age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common causes of bacterial arthritis in children according to age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Most common bacteria</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">&#60;3 months</td> <td><em>Staphylococcus aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td>Group B <em>Streptococcus</em> (<em>Streptococcus agalactiae</em>)</td> </tr> <tr> <td>Gram-negative bacilli</td> </tr> <tr class=\"divider_bottom\"> <td><em>Neisseria gonorrhoeae</em></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">3 months to 3 years</td> <td><em>S. aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td><em>Kingella kingae</em></td> </tr> <tr> <td>Group A <em>Streptococcus</em> (<em>Streptococcus pyogenes</em>)</td> </tr> <tr> <td><em>Streptococcus pneumoniae</em></td> </tr> <tr class=\"divider_bottom\"> <td><em>Haemophilus influenzae</em> type b (Hib) (in incompletely immunized children in regions with low Hib immunization rates)</td> </tr> <tr> <td rowspan=\"4\">&#62;3 years</td> <td><em>S. aureus</em> (MSSA and MRSA)</td> </tr> <tr> <td>Group A <em>Streptococcus</em></td> </tr> <tr> <td><em>S. pneumoniae</em></td> </tr> <tr> <td><em>N. gonorrhoeae</em> (in sexually active adolescents)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <em>S. aureus</em>; MRSA: methicillin-resistant <em>S. aureus</em>.</div><div id=\"graphicVersion\">Graphic 53150 Version 8.0</div></div></div>"},"53151":{"type":"graphic_diagnosticimage","displayName":"Pleural effusion lung transplant PA","title":"Pleural effusion after lung transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural effusion after lung transplantation</div><div class=\"cntnt\"><img style=\"width:335px; height:356px;\" src=\"images/PULM/53151_Pleural_effusion_lung_TPL_P.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph taken on the 10th postoperative day in a patient who received a left, single-lung transplant. A left, predominantly subpulmonic pleural effusion of small to moderate size is present (arrow). The effusion resolved by the next week. Surveillance transbronchial biopsy revealed minimal acute rejection that did not require treatment.</div><div class=\"graphic_reference\">Courtesy of Marc A Judson, MD</div><div id=\"graphicVersion\">Graphic 53151 Version 3.0</div></div></div>"},"53153":{"type":"graphic_figure","displayName":"Dissection of greater omentum","title":"Dissection of greater omentum","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Dissection of greater omentum</div><div class=\"cntnt\"><img style=\"width:524px; height:448px;\" src=\"images/SURG/53153_Greater_omentum_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastrectomy is initiated by dividing the greater omentum and removing the portion associated with the portion of stomach to be resected.</div><div id=\"graphicVersion\">Graphic 53153 Version 3.0</div></div></div>"},"53154":{"type":"graphic_table","displayName":"Pediatric office resuscitation supplies","title":"Pediatric office resuscitation supplies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric office resuscitation supplies</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Essential*</td> </tr> <tr> <td class=\"subtitle2_single\">Equipment</td> </tr> <tr> <td class=\"subtitle3_single\">Airway</td> </tr> <tr> <td class=\"indent2\">Oxygen delivery system</td> </tr> <tr> <td class=\"indent2\">Oxygen masks<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Portable suction device with rigid and flexible catheters<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Nebulizer or metered dose inhaler with spacer/mask</td> </tr> <tr> <td class=\"indent2\">Self-inflating bag-valve-mask<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent2\">Oropharyngeal airways (sizes 00-5)</td> </tr> <tr> <td class=\"indent2\">Pulse oximeter</td> </tr> <tr> <td class=\"subtitle3_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent2\">Sphygmomanometer with infant, child, adult, and thigh cuffs</td> </tr> <tr> <td class=\"indent2\">Resuscitation guide (eg, Broselow&#174; tape or precalculated weight-based equipment and drug sheets)</td> </tr> <tr> <td class=\"indent2\">Backboard/cardiac arrest board</td> </tr> <tr> <td class=\"indent2\">Sterile dressings</td> </tr> <tr> <td class=\"indent2\">Splints</td> </tr> <tr> <td class=\"subtitle3_single\">Personal protective equipment</td> </tr> <tr> <td class=\"indent2\">Latex-free gloves</td> </tr> <tr> <td class=\"indent2\">Surgical masks</td> </tr> <tr> <td class=\"indent2\">Eye covers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Gowns</td> </tr> <tr> <td class=\"subtitle2_single\">Medications<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent2\">Oxygen</td> </tr> <tr> <td class=\"indent2\">Albuterol (MDI or inhalational)</td> </tr> <tr> <td class=\"indent2\">Epinephrine (1 mg/mL [1:1000])</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Strongly suggested*</td> </tr> <tr> <td class=\"subtitle2_single\">Equipment</td> </tr> <tr> <td class=\"subtitle3_single\">Airway</td> </tr> <tr> <td class=\"indent2\">Suction catheters (5-16F)</td> </tr> <tr> <td class=\"indent2\">Yankauer suction tip</td> </tr> <tr> <td class=\"indent2\">Laryngoscope handle (pediatric, adult)</td> </tr> <tr> <td class=\"indent2\">Laryngoscope blades (sizes 0-2 straight, 2-3 curved)</td> </tr> <tr> <td class=\"indent2\">Endotracheal tubes (uncuffed 2.5-5.5, cuffed 4-8)</td> </tr> <tr> <td class=\"indent2\">Stylets (pediatric, adult)</td> </tr> <tr> <td class=\"indent2\">End-tidal carbon dioxide detector</td> </tr> <tr> <td class=\"subtitle3_single\">Vascular access and fluid administration</td> </tr> <tr> <td class=\"indent2\">Latex-free tourniquet</td> </tr> <tr> <td class=\"indent2\">Butterfly needles (19-25 gauge)</td> </tr> <tr> <td class=\"indent2\">Over-needle IV catheters (14-24 gauge)</td> </tr> <tr> <td class=\"indent2\">Intraosseous needles<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent2\">Tape and arm boards</td> </tr> <tr> <td class=\"indent2\">IV tubing, microdrip fluid reservoir</td> </tr> <tr> <td class=\"subtitle3_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent2\">Automated external defibrillator with pediatric capability</td> </tr> <tr> <td class=\"indent2\">Point of care glucose test</td> </tr> <tr> <td class=\"indent2\">Cervical collars (small/large)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Heating source (overhead warmer/heat lamp)</td> </tr> <tr> <td class=\"subtitle2_single\">Medications and fluids<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent2\">Activated charcoal without sorbitol</td> </tr> <tr> <td class=\"indent2\">Antibiotics</td> </tr> <tr> <td class=\"indent2\">Anticonvulsants (lorazepam, diazepam)</td> </tr> <tr> <td class=\"indent2\">Corticosteroids (oral/parenteral)</td> </tr> <tr> <td class=\"indent2\">Dextrose (4 mg/mL [25%])</td> </tr> <tr> <td class=\"indent2\">Dextrose 5% and 0.45 NS solution (500 mL bags)</td> </tr> <tr> <td class=\"indent2\">Diphenhydramine (50 mg/mL, parenteral)</td> </tr> <tr> <td class=\"indent2\">Epinephrine (0.1 mg/mL [1:10,000])</td> </tr> <tr> <td class=\"indent2\">Atropine sulfate (0.1 mg/mL)</td> </tr> <tr> <td class=\"indent2\">Naloxone (0.4 mg/mL)</td> </tr> <tr> <td class=\"indent2\">NS or lactated Ringer's solution (500 mL bags)</td> </tr> <tr> <td class=\"indent2\">Sodium bicarbonate (0.5 mEq/mL [4.2%])</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; NS: normal saline.<br />* Essential supplies are recommended for all office practices that provide primary pediatric care. Strongly suggested supplies are essential if advanced emergency medical system response time to the practice is greater than 10 minutes.<br />¶ Venturi and nonrebreather oxygen masks with reservoirs in infant, child, and adult sizes.<br />Δ Wall or portable suction with tonsil tip suction catheter and bulb syringe.<br /><FONT class=lozenge>◊</FONT> 450 and 1000 mL reservoir self-inflating resuscitation bags with infant, child, and adult masks.<br />§ Manual intraosseous needles (16 and 18 gauge) or 15 gauge intraosseous needles of varying lengths with driver (eg, EZ-IO®).<br />¥ Medications and fluids require regular inspection to ensure that they are properly packaged and not expired. Parenteral lorazepam requires refrigeration.</div><div class=\"graphic_reference\">Data from: Committee on Pediatric Emergency Medicine, Frush, K. Policy Statement: preparation for emergencies in the offices of pediatricians and pediatric primary care providers. Pediatrics 2007; 120:200.</div><div id=\"graphicVersion\">Graphic 53154 Version 5.0</div></div></div>"},"53155":{"type":"graphic_figure","displayName":"P450 oxidoreductase deficiency","title":"Apparent combined CYP17A1 and CYP21A2 deficiency (P450 oxidoreductase deficiency)","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Apparent combined CYP17A1 and CYP21A2 deficiency (P450 oxidoreductase deficiency)</div><div class=\"cntnt\"><img style=\"width:609px; height:425px;\" src=\"images/ENDO/53155_P450_oxidoreductase.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53155 Version 1.0</div></div></div>"},"53156":{"type":"graphic_picture","displayName":"Cowpox lesion","title":"Cowpox lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cowpox lesion</div><div class=\"cntnt\"><img style=\"width:356px; height:281px;\" src=\"images/NEURO/53156_Cowpox_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesion on the right fifth finger. The black central eschar with surrounding oedema and erythema was associated with ascending lymphangitis and regional lymphadenitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Lawn SD, Planche T, Riley P, et al. A Black necrotic ulcer. Lancet 2003; 361:1518. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 53156 Version 2.0</div></div></div>"},"53158":{"type":"graphic_diagnosticimage","displayName":"Large septated fetal cystic hygroma with hydrops","title":"Axial image of the fetal head of an early second trimester fetus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial image of the fetal head of an early second trimester fetus</div><div class=\"cntnt\"><img style=\"width:346px; height:330px;\" src=\"images/OBGYN/53158_Large_septated_cystic_hygro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surrounding the fetal cranium is a large septated cystic hygroma. The fluid extends beyond the nuchal region and diffusely involves the skin throughout the fetus.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 53158 Version 3.0</div></div></div>"},"53160":{"type":"graphic_diagnosticimage","displayName":"Muscular metastases melanoma","title":"Intramuscular metastases from melanoma","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Intramuscular metastases from melanoma</div><div class=\"cntnt\"><img style=\"width:493px; height:178px;\" src=\"images/ONC/53160_Muscular_metastases_melanom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT images demonstrating invasion of muscle tissue by metastases from melanoma. Left panel: invasion of the right lateral abdominal wall; right panel, invasion of the posterior aspect of the iliopsoas muscle.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 53160 Version 3.0</div></div></div>"},"53161":{"type":"graphic_table","displayName":"Allergen reduction PI","title":"Basic measures to control exposure to indoor allergens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic measures to control exposure to indoor allergens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indoor allergen </td> <td class=\"subtitle1\">Recommendations for reducing exposure </td> </tr> <tr> <td rowspan=\"3\">Animal dander </td> <td>Remove animal from house, or at minimum, keep animal out of patient's bedroom. Keep pet in a room with a HEPA filter, and replace the filter as recommended by the manufacturer.</td> </tr> <tr> <td>Cover air ducts that lead to bedroom with filters. Replace filters as recommended by the manufacturer.</td> </tr> <tr> <td>Use air filters and vacuums with HEPA filters. Replace the filter as recommended by the manufacturer.</td> </tr> <tr> <td rowspan=\"7\">Dust mites </td> <td class=\"sublist1_start\">Less costly</td> </tr> <tr> <td class=\"sublist1\">Encase mattress, pillows, and box spring in allergen-impermeable covers. Finely woven covers for pillows and duvets are preferable. </td> </tr> <tr> <td class=\"sublist1\">Wash bedding weekly in warm water with detergent or use electric dryer on hot setting. </td> </tr> <tr> <td class=\"sublist1\">Reduce indoor humidity to &#60;50%.</td> </tr> <tr> <td class=\"sublist1_start\">More costly </td> </tr> <tr> <td class=\"sublist1\">Remove carpets from the bedroom.</td> </tr> <tr> <td class=\"sublist1\">Replace old upholstered furniture with leather, vinyl, or wood.</td> </tr> <tr> <td rowspan=\"4\">Cockroaches </td> <td>Use poison bait or traps to control. Consult professional exterminator for severe infestation.</td> </tr> <tr> <td>Periodically clean home thoroughly.</td> </tr> <tr> <td>Encase all food fully, and do not store garbage or papers inside the home.</td> </tr> <tr> <td>Fix water leaks.</td> </tr> <tr> <td rowspan=\"4\">Indoor mold </td> <td>Clean moldy surfaces with dilute bleach solution.</td> </tr> <tr> <td>Fix water leaks.</td> </tr> <tr> <td>Reduce indoor humidity to &#60;50%. Avoid use of humidifiers.</td> </tr> <tr> <td>Evaporative (or swamp) coolers should be avoided or cleaned regularly.</td> </tr> <tr> <td rowspan=\"4\">Rodents </td> <td>Consult a professional exterminator.</td> </tr> <tr> <td>Periodically clean home thoroughly.</td> </tr> <tr> <td>All food should be stored in sealed containers. Do not store garbage inside.</td> </tr> <tr> <td>Repair holes in walls, doors, floors, and block other entry points.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The measures that can effectively reduce exposure are different for each indoor allergen. Those listed are suggested but have not been verified to be effective in isolation. Studies showing greatest benefit from indoor allergen remediation were those that adapted the measures to each patient's individual sensitivities and addressed all of&nbsp;the patient's allergies simultaneously.</div><div class=\"graphic_footnotes\">HEPA: high-efficiency particulate air.</div><div class=\"graphic_reference\">Adapted from: The Allergy Report. American Academy of Allergy, Asthma, and Immunology (www.aaaai.org).</div><div id=\"graphicVersion\">Graphic 53161 Version 4.0</div></div></div>"},"53163":{"type":"graphic_algorithm","displayName":"Fever neutropenia reassessment after four days","title":"Reassessment of the high-risk patient with persistent neutropenic fever after four days of empiric therapy","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Reassessment of the high-risk patient with persistent neutropenic fever after four days of empiric therapy</div><div class=\"cntnt\"><img style=\"width:592px; height:563px;\" src=\"images/ID/53163_Febrneutropeniareedt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; CT: computed tomography; MRI: magnetic resonance imaging.<br> * We consider patients to be high-risk if they have either of the following characteristics: neutropenia (ANC &lt;500 cells/microL following cytotoxic chemotherapy) anticipated to last &gt;7 days OR significant comorbid conditions. It should be noted that in the Infectious Diseases Society of America guidelines, an ANC ≤100 cells/microL is used as the cutoff for high-risk neutropenia.<br> Δ Fever in a neutropenic patient is defined as a single temperature &gt;38.3°C (101°F) or a sustained temperature &gt;38.0°C (100.4°F) for &gt;1 hour.<br> <span class=lozenge>◊</span> Limited data to support recommendation.</div><div class=\"graphic_reference\">Adapted with permission from: Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52(4):e56-93. Copyright © 2011 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/CID/\" target=_blank>http://www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 53163 Version 14.0</div></div></div>"},"53164":{"type":"graphic_figure","displayName":"Angina meds MOA PI","title":"How medicines prevent or treat angina","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">How medicines prevent or treat angina</div><div class=\"cntnt\"><img style=\"width:538px; height:550px;\" src=\"images/PI/53164_Anginamedsedit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some angina medicines work by expanding the walls of the coronary arteries, so that more blood can get through. Other angina medicines work by reducing the amount of work the heart has to do. That way the heart muscle needs less blood.</div><div id=\"graphicVersion\">Graphic 53164 Version 4.0</div></div></div>"},"53165":{"type":"graphic_picture","displayName":"Thumb movements","title":"Thumb movements  ","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Thumb movements  </div><div class=\"cntnt\"><img style=\"width:526px; height:212px;\" src=\"images/EM/53165_Thumbmovements.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb is rotated 90 degrees&nbsp;to the other digits. Thus, abduction and adduction occur in a sagittal plane and flexion and extension occur in a coronal plane. Opposition, the action bringing the tip of the thumb in contact with the pads of the other fingers, is the most complex movement. The components of opposition are abduction and medial rotation at the carpometacarpal joint and flexion of the metacarpophalangeal joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53165 Version 12.0</div></div></div>"},"53166":{"type":"graphic_table","displayName":"Pathophysiology gynecomastia","title":"Pathophysiologic mechanisms for gynecomastia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathophysiologic mechanisms for gynecomastia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Absolute increase in free estrogens</td> </tr> <tr> <td class=\"sublist1_start\">Direct secretion from:</td> </tr> <tr> <td class=\"sublist1\">Maternal-placental-fetal unit</td> </tr> <tr> <td class=\"sublist1\">Testes</td> </tr> <tr> <td class=\"sublist1\">Adrenal glands</td> </tr> <tr> <td>Extraglandular aromatization of precursors</td> </tr> <tr> <td>Displacement from sex hormone-binding globulin</td> </tr> <tr> <td>Decreased metabolism</td> </tr> <tr> <td>Exogenous estrogen administration</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased endogenous free androgens</td> </tr> <tr> <td>Decreased secretion</td> </tr> <tr> <td>Increased metabolism</td> </tr> <tr> <td class=\"subtitle1_single\">Relative increase in free estrogen/free androgen ratio</td> </tr> <tr> <td class=\"subtitle1_single\">Androgen insensitivity</td> </tr> <tr> <td>Congenital defects in androgen receptor structure and function</td> </tr> <tr> <td>Displacement of androgens from breast androgen receptors by certain drugs</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Estrogen-like effect of drugs</td> </tr> <tr> <td>Possible enhanced sensitivity of breast tissue</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.</div><div id=\"graphicVersion\">Graphic 53166 Version 3.0</div></div></div>"},"53168":{"type":"graphic_picture","displayName":"Fibrin plug eso varix Endosc","title":"Fibrin plug on an esophageal varix","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Fibrin plug on an esophageal varix</div><div class=\"cntnt\"><img style=\"width:516px; height:217px;\" src=\"images/GAST/53168_Fibrin_plug_eso_varix_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Upper endoscopy reveals two chains of varices (9 and 5 o'clock). A yellowish fibrin plug is visible in the 9 o'clock varix indicating the site of recent bleeding. Right panel: Close-up view of the fibrin plug.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 53168 Version 2.0</div></div></div>"},"53169":{"type":"graphic_table","displayName":"IgA normal values by age","title":"Immunoglobulin A (IgA) normal values by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunoglobulin A (IgA) normal values by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Mean normal IgA &#177; range (mg/dL)</td> <td class=\"subtitle1\">Percent of adult level &#177; range</td> </tr> <tr> <td>Newborn</td> <td>2&#177;3</td> <td>1&#177;2</td> </tr> <tr> <td>1 to 3 months</td> <td>21&#177;13</td> <td>11&#177;7</td> </tr> <tr> <td>4 to 6 months</td> <td>28&#177;18</td> <td>14&#177;9</td> </tr> <tr> <td>7 to 12 months</td> <td>37&#177;18</td> <td>19&#177;9</td> </tr> <tr> <td>13 to 24 months</td> <td>50&#177;24</td> <td>25&#177;12</td> </tr> <tr> <td>25 to 36 months</td> <td>71&#177;37</td> <td>36&#177;19</td> </tr> <tr> <td>3 to 5 years</td> <td>93&#177;27</td> <td>47&#177;14</td> </tr> <tr> <td>6 to 8 years</td> <td>124&#177;45</td> <td>62&#177;23</td> </tr> <tr> <td>9 to 11 years</td> <td>131&#177;60</td> <td>66&#177;30</td> </tr> <tr> <td>12 to 16 years</td> <td>148&#177;63</td> <td>74&#177;32</td> </tr> <tr> <td>Adults</td> <td>200&#177;61</td> <td>100&#177;31</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Stiehm ER, Fudenberg HH. Pediatrics 1966; 37:715 and Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency Disorders: General Considerations. In: Immunologic Disorders in Infants and Children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004, p.307.</div><div id=\"graphicVersion\">Graphic 53169 Version 4.0</div></div></div>"},"53171":{"type":"graphic_figure","displayName":"Jejunoileal bypass","title":"Jejunoileal bypass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jejunoileal bypass</div><div class=\"cntnt\"><img style=\"width:339px; height:526px;\" src=\"images/SURG/53171_Jejunoileal_bypass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The jejunoileal bypass (also called the intestinal bypass) is performed by dividing the jejunum close to the ligament of Treitz and connecting it a short distance proximal to the ileocecal valve, thereby diverting a long segment of small bowel, resulting in malabsorption. This procedure is no longer performed due to the high complication rate and frequent need for revisional surgery.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 53171 Version 5.0</div></div></div>"},"53172":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare - multiple papules","title":"Disseminated granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:316px;\" src=\"images/DERM/53172_Disseminated_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 40 year-old patient presented with over 100 discrete 1-2 mm erythematous papules over the arms and legs with just a few similar lesions on the trunk.</div><div id=\"graphicVersion\">Graphic 53172 Version 2.0</div></div></div>"},"53173":{"type":"graphic_picture","displayName":"Vitiligo - periocular","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53173_Vitiligoperiocular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A depigmented patch of vitiligo is present on the periocular skin. Note associated loss of pigment in the eyebrow and eyelashes.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53173 Version 3.0</div></div></div>"},"53176":{"type":"graphic_figure","displayName":"Neonatal extracranial and intracranial birth injuries","title":"Neonatal extracranial and intracranial birth injuries","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Neonatal extracranial and intracranial birth injuries</div><div class=\"cntnt\"><img style=\"width:540px; height:356px;\" src=\"images/OBGYN/53176_Newborn_extracranial_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Volpe JJ. Neurology of the Newborn, 4<SUP>th</SUP> ed, WB Saunders, Philadelphia 2001.</div><div id=\"graphicVersion\">Graphic 53176 Version 11.0</div></div></div>"},"53177":{"type":"graphic_picture","displayName":"Actinic keratosis","title":"Actinic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actinic keratosis</div><div class=\"cntnt\"><img style=\"width:432px; height:304px;\" src=\"images/ONC/53177_actinickeratosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Muliple actinic keratoses present as rough scaly red macules on sun-damaged skin.</div><div class=\"graphic_reference\">Reproduced from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology. Common and Serious Diseases. (4th Ed), McGraw-Hill, New York 2001. p.220.</div><div id=\"graphicVersion\">Graphic 53177 Version 4.0</div></div></div>"},"53178":{"type":"graphic_table","displayName":"Comb chemo rhabdomyosarcoma","title":"Current standard chemotherapy regimens for newly diagnosed patients with rhabdomyosarcoma<SUP>*</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Current standard chemotherapy regimens for newly diagnosed patients with rhabdomyosarcoma<SUP>*</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prognosis group<sup>&#182;</sup></td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose<sup>&#916;</sup></td> <td class=\"subtitle1\">Schedule</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Low risk</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\"> <p>Subset A</p> <p>Excellent prognosis</p> <p>(&#62;85% EFS)</p> </td> <td class=\"divider_bottom\" rowspan=\"8\">Embryonal and alveolar&nbsp;fusion-negative tumors: <ul class=\"decimal_heading\"> <li>Stage 1&nbsp;CG I/II </li> <li>Stage 1&nbsp;CG III orbital </li> <li>Stage 2&nbsp;CG I/II </li> </ul> </td> <td colspan=\"3\">VA per subset A regimen D9602 &times; 15 cycles (45 weeks)<sup>[1]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>Weekly during weeks 0 to 8, 12 to 20, 24 to 32, 36 to 44</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>Every three weeks during weeks 0 through 45<sup>&#9674;</sup></td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td colspan=\"3\">VAC/VA per subset A regimen ARST0331 &times; eight cycles (24 weeks)<sup>&#167;</sup><sup>[2,3]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>Weekly during weeks 1 to 9, 13 to 21</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>Every three weeks during weeks 1 to 22<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> with mesna and as needed hematopoietic growth factor support<sup>&#165;</sup></td> <td>Every three weeks during weeks 1 to 10 for a total of four doses</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\"> <p>Subset B</p> <p>Very good prognosis</p> <p>(70 to 85% EFS)</p> </td> <td class=\"divider_bottom\" rowspan=\"4\">Embryonal and alveolar&nbsp;fusion-negative tumors: <ul class=\"decimal_heading\"> <li>Stage 1&nbsp;CG III non-orbit </li> <li>Stage 3&nbsp;CG I/II </li> </ul> </td> <td colspan=\"3\">VAC &times; 14 cycles (40 weeks)<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>Weekly during weeks 1 to 13, 16, 19 to 25, 28, 31 to 37</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>Every three weeks during weeks 1 through 40<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> with mesna and hematopoietic growth factor support<sup>&#165;</sup></td> <td>Every three weeks during weeks 1 through 40</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate risk</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"10\"> <p>Good prognosis</p> <p>(50 to 70% EFS)</p> </td> <td class=\"divider_bottom\" rowspan=\"10\">Embryonal and alveolar&nbsp;fusion-negative tumors: <ul class=\"decimal_heading\"> <li>Stage 2, 3&nbsp;CG III </li> <li>Metastatic disease, age &#60;10 years </li> </ul> Alveolar&nbsp;fusion-positive tumors:<sup>&#135;</sup> <ul class=\"decimal_heading\"> <li>CG&nbsp;I to III </li> </ul> </td> <td colspan=\"3\">VAC &times; 14 cycles (40 weeks)<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>Weekly during weeks 1 to 13, 19 to 25, 31 to 37, 40</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>Every three weeks during weeks 1 through 40<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> with mesna and hematopoietic growth factor support<sup>&#165;</sup></td> <td>Every three weeks during weeks 1 through 40</td> </tr> <tr> <td colspan=\"3\"><strong>OR</strong></td> </tr> <tr> <td colspan=\"3\">VAC/VI 14 cycles (40 weeks)<sup>&#134;[5]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>On weeks 1 to 13, 16, 17, 19, 20, 22 to 26, 28, 31 to 34, 37, 38, 40</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>On weeks 1, 7, 13, 22, 28, 34, 40</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> with mesna and hematopoietic growth factor support<sup>&#165;</sup></td> <td>On weeks 1, 7, 13, 22, 28, 34, 40</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Irinotecan</td> <td>50 mg/m<sup>2</sup> days 1 to 5</td> <td>On weeks 4, 10, 16, 19, 25, 31, 37</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">High risk</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\"> <p>Poor prognosis</p> <p>(&#60;30% EFS)</p> </td> <td rowspan=\"4\">Embryonal and alveolar fusion-negative tumors: <ul class=\"decimal_heading\"> <li>Metastatic disease, age &#62;10 years </li> </ul> Alveolar&nbsp;fusion-positive tumors: <ul class=\"decimal_heading\"> <li>Metastatic disease, any age </li> </ul> </td> <td colspan=\"3\">VAC &times; 14 cycles (40 weeks)<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>1.5 mg/m<sup>2</sup> (max 2 mg)</td> <td>Weekly during weeks 1 to 13, 19 to 25, 31 to 37</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> <td>0.045 mg/kg (max 2.5 mg)</td> <td>Every three weeks during weeks 1 through 40<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>1200 mg/m<sup>2</sup> with mesna and hematopoietic growth factor support<sup>&#165;</sup></td> <td>Every three weeks during weeks 1 through 40</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A pediatric oncologist with expertise in the soft tissue sarcoma field should be contacted for current standard therapy schemas. <br />The risk group descriptions in this table are based upon the results of historically completed trials using the&nbsp;EFS estimates of the individual patient groups. Current Children's Oncology Group (COG) protocols can deviate from theses definitions for protocol purposes (refer to&nbsp;text).</div><div class=\"graphic_footnotes\">EFS: event-free survival; CG: clinical group; RT: radiation therapy; IRS: Intergroup Rhabdomyosarcoma Study.<br />* RT, when indicated, is started at week 13 of chemotherapy as standard of care.<br />¶ Refer to the UpToDate table on rhabdomyosarcoma prognostic stratification for prognosis group definitions.<br />Δ Doses are for adults and children over the age of three. Dose reductions are necessary for younger children.<br /><FONT class=lozenge>◊</FONT> Omit dactinomycin on&nbsp;weeks 15 and 18 for patients beginning RT at week 12; weeks 16 and 20 for patients beginning RT at week 13; and weeks 30 and 33 for patients beginning RT at week 28.<br />§ This regimen is preferred for stage 1&nbsp;CG IIb/c and CG&nbsp;II stage 2.<br />¥ Lower doses of cyclophosphamide per ARST0531<SUP>[4]</SUP> than were used in IRS-IV and the D series protocols (1200 mg/m<SUP>2</SUP> versus 2200 mg/m<SUP>2</SUP>).<SUP>[2,3]</SUP><br />‡ Tumors that have an alveolar histology but are fusion negative should be treated with the VAC only regimen. There&nbsp;are not adequate data to conclude that VAC/VI is as effective.<br />† The VAC/VI regimen cannot yet be recommended for patients 40 years of age with metastatic (CG IV, stage 4) embryonal tumors. In this group, VAC alone is preferred.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011; 29:1312.</LI>&#xD;&#xA;<LI>Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2014; 32:3547.</LI>&#xD;&#xA;<LI>Malempati S, Hawkins DS. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 2012; 59:5.</LI>&#xD;&#xA;<LI>VAC doses and schedule are modified from the most recent Children's Oncology Group (COG) protocol for intermediate risk disease, ARST0531 Regimen A (NCT00354835). Available at: <A href=\"https://clinicaltrials.gov/ct2/show/NCT00354835?term=ARST+0531&amp;rank=1\" target=_blank>https://clinicaltrials.gov/ct2/show/NCT00354835?term=ARST+0531&amp;rank=1</A> (Accessed on February 26, 2016); or Hawkins DS, Anderson JR, Mascarenhas L, et al. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 2014: 32:5s, Abstract 10004.</LI>&#xD;&#xA;<LI>VAC/VI doses and schedule are based on COG protocol ARST1431, Regimen A (NCT02567435). Available at: <A href=\"https://clinicaltrials.gov/ct2/show/NCT02567435?term=ARST1431&amp;rank=1\" target=_blank>https://clinicaltrials.gov/ct2/show/NCT02567435?term=ARST1431&amp;rank=1</A> (Accessed on June 8, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 53178 Version 10.0</div></div></div>"},"53179":{"type":"graphic_table","displayName":"MPT for multiple myeloma","title":"Melphalan, prednisone, and thalidomide (MPT) for multiple myeloma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Melphalan, prednisone, and thalidomide (MPT) for multiple myeloma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 56 days (6 weeks). </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route*</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Melphalan</td> <td>0.25 mg/kg by mouth</td> <td>Take on an empty stomach (one hour prior to or two hours after meals).</td> <td>Days 1 through 4, every six weeks</td> </tr> <tr> <td>Prednisone</td> <td>2 mg/kg by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1 through 4, every six weeks</td> </tr> <tr class=\"divider_bottom\"> <td>Thalidomide<sup>&#182;</sup></td> <td>100 or 200 mg by mouth<sup>&#916;</sup></td> <td>Take with water on an empty stomach at least one hour after the evening meal.</td> <td>Daily continuously, with the final dose on day 4 of the last cycle</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW or VERY LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for thrombosis</strong></td> <td colspan=\"3\"> <ul> <li>Without prophylaxis, the MPT regimen is associated with a 12% rate of thrombosis or embolism. As such, routine thromboprophylaxis is recommended for all patients.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on thalidomide plus melphalan and prednisone. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (rate of severe infection 13%).<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Reduction in the initial dose of melphalan is required for patients with moderate to severe renal insufficiency.<sup>[3,4]</sup> If myelotoxicity does not occur, the dose may be increased in subsequent courses. No dose adjustments are needed for liver dysfunction. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pregnancy warning</strong><sup>&#182;</sup></td> <td colspan=\"3\"> <ul> <li>Thalidomide can result in severe, life-threatening human birth defects. Strict birth control regulations are in place for all patients taking thalidomide.<sup>[5]</sup> Pregnancy testing is required within 24 hours prior to initiation of thalidomide therapy. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential, serum electrolytes, and serum uric acid. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess fluid status, blood pressure, and central nervous system status. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs of neuropathy monthly for the first three months, then periodically thereafter. Neuropathic complications commonly include constipation. As such, many clinicians provide a prophylactic bowel regimen for patients taking thalidomide. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Pregnancy testing should be performed weekly during the first four weeks, and then every two to four weeks, depending on menstrual cycle regularity. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Melphalan should be administered with caution if the ANC is &#60;3000/microL or the platelet count is &#60;100,000/microL. Thalidomide should be withheld if the absolute neutrophil count falls below 750/microL. Restart after ANC recovers to &#62;1500/microL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hypersensitivity</strong></td> <td colspan=\"3\"> <ul> <li>Hypersensitivity reactions are rare in patients receiving MPT. However, if they occur, especially if there are signs of anaphylaxis, they can recur with subsequent treatment. If a hypersensitivity reaction develops, MPT should not be administered again. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Rash</strong></td> <td colspan=\"3\"> <ul> <li>Thalidomide has been associated with rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If a rash develops, thalidomide should be discontinued and the rash further evaluated. Thalidomide should not be administered again if the rash is exfoliative, purpuric, bullous, or if SJS or TEN is suspected. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Thalidomide should be discontinued or dose reduced if a patient develops parasthesias accompanied by pain, motor deficit, or interference with activities of daily living. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* The dose of these medications is commonly rounded to the nearest tablet/capsule size.<br />¶ In the United States, the use of thalidomide is subject to the THALOMID REMS program (<A href=\"http://www.thalomidrems.com/\" target=_blank>www.THALOMIDREMS.com</A>) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.<br />Δ Overall survival with thalidomide doses &gt;200 mg per day (max 400 mg per day) were not different from doses ≤200 mg per day.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Facon T, et al. Lancet 2007; 370:1209.</LI>&#xD;&#xA;<LI>Lyman GH, et al. J Clin Oncol 2007; 25:5490.</LI>&#xD;&#xA;<LI>Melphalan. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI>&#xD;&#xA;<LI>Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p.97, 170.</LI>&#xD;&#xA;<LI>Thalidomide. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 6, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 53179 Version 18.0</div></div></div>"},"53180":{"type":"graphic_table","displayName":"Pain synd chemo","title":"Acute pain syndromes associated with chemotherapy and/or hormonal therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute pain syndromes associated with chemotherapy and/or hormonal therapy</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Syndrome\n   </td>\n   <td  class=\"subtitle1\">\n   Description\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Chemotherapy-induced headaches\n   </td>\n   <td>Common after treatment with intrathecal methotrexate for leukemia, lymphoma, or leptomeningeal carcinomatosis, all trans retinoic acid (ATRA) for leukemia</td>\n   </tr>\n   <tr>\n   <td>May be associated with vomiting, nuchal rigidity, fever, irritability, and lethargy</td>\n   </tr>\n   <tr>\n   <td>May last for several days or longer, and may or may not occur with repeated administration</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Arthralgia and myalgia\n   </td>\n   <td>Pain in joints or muscles</td>\n   </tr>\n   <tr>\n   <td>Reported by 20 percent of patients treated with paclitaxel</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Palmar-plantar erythrodysesthesia (hand-foot syndrome)\n   </td>\n   <td>Painful rash on the palms and soles following administration of specific chemotherapies (particularly liposomal doxorubicin and capecitabine)</td>\n   </tr>\n   <tr>\n   <td>Rash may progress to bullous formation and desquamation</td>\n   </tr>\n   <tr>\n   <td>Postchemotherapy acute limb ischemia (Raynaud's phenomenon)</td>\n   <td>Reduced blood supply to the fingers and toes, described in survivors of testicular cancer, who were treated with bleomycin, vinblastine, and cisplatin</td>\n   </tr>\n   <tr>\n   <td>Fluoropyrimidine-induced angina</td>\n   <td>Fluorouracil (FU) and capecitabine increase risk of cardiac ischemic episodes, presumably resulting from coronary vasospasm</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Postchemotherapy gynecomastia\n   </td>\n   <td>Prevalent when receiving chemotherapy for testicular cancer</td>\n   </tr>\n   <tr>\n   <td>Painful and usually transitory</td>\n   </tr>\n   <tr>\n   <td>Steroid-induced perineal burning</td>\n   <td>Perineal burning: has been described immediately (within 30 seconds) after intravenous steroid infusion</td>\n   </tr>\n   <tr>\n   <td>Diffuse bone pain</td>\n   <td>Known to occur with all trans-retinoic acid (ATRA)</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Flare syndrome in advanced prostate cancer, after initiation of LHRH agonist alone\n   </td>\n   <td>Characterized by increased bone pain, at times associated with added risk of cord compression, bladder outlet obstruction and hypercoagulability</td>\n   </tr>\n   <tr>\n   <td>Can result from treatment with LHRH (lutenising hormone releasing hormone) agonist therapy</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Flare syndrome in advanced breast cancer\n   </td>\n   <td>Characterized by diffuse musculoskeletal pain, skin erythema, change in liver function studies and hypercalcemia</td>\n   </tr>\n   <tr>\n   <td>Can result from initial administration of tamoxifen or other estrogen receptor agonists</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Interferon-associated myalgias\n   </td>\n   <td>Pain in joints, possibly accompanied by fever and severe fatigue, appearing shortly after initial diagnosis</td>\n   </tr>\n   <tr>\n   <td>Typically decreases in severity after repeated dosing</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 53180 Version 1.0</div></div></div>"},"53181":{"type":"graphic_figure","displayName":"Osteoporosis anatomy PI","title":"Bones affected by osteoporosis","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Bones affected by osteoporosis</div><div class=\"cntnt\"><img style=\"width:506px; height:422px;\" src=\"images/PI/53181_Osteoporosis_anat_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bones in this picture are called &quot;vertebrae.&quot; The one on the left is healthy. Its spongy center has lots of hard fibers that are connected to each other. The one on the right has osteoporosis. Its spongy center has fewer, thinner fibers that are no longer connected. The surrounding shell of compact bone is thinner. This makes the vertebra weak. That's why it got crushed under the weight it was holding.</div><div id=\"graphicVersion\">Graphic 53181 Version 6.0</div></div></div>"},"53182":{"type":"graphic_figure","displayName":"Band snare cartoon","title":"Cartoon depicting the band and snare technique for endoscopic mucosal resection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cartoon depicting the band and snare technique for endoscopic mucosal resection</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/GAST/53182_Band_snare_cartoon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lesion (A) is raised with a submucosal injection (B). The banding hood is used to deploy a band ligation (C), which encapsulates the lesion (D).</div><div class=\"graphic_reference\">Courtesy of Christopher Gostout, MD.</div><div id=\"graphicVersion\">Graphic 53182 Version 3.0</div></div></div>"},"53183":{"type":"graphic_table","displayName":"Causes of bowel obstruction","title":"Causes of bowel obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bowel obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lesion</td> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Risk factors</td> </tr> <tr> <td rowspan=\"9\"><strong>Extrinsic lesions</strong></td> <td>Adhesions</td> <td>Prior surgery, diverticulitis, Crohn disease, VP shunt, peritonitis (eg, tuberculous peritonitis)</td> </tr> <tr> <td>Hernia (congenital, acquired)</td> <td>Abdominal wall hernia, inguinal hernia, femoral hernia, diaphragmatic hernia</td> </tr> <tr> <td>Volvulus</td> <td>Chronic constipation, congenital abnormal mesenteric attachments</td> </tr> <tr> <td>Intra-abdominal abscess</td> <td>Diverticulitis, appendicitis, Crohn disease</td> </tr> <tr> <td>Peritoneal carcinomatosis</td> <td>Ovarian cancer, colon cancer, gastric cancer</td> </tr> <tr> <td>Endometriosis</td> <td>&nbsp;</td> </tr> <tr> <td>Sclerosing mesenteritis</td> <td>Prior surgery, abdominal trauma, autoimmune disorders, malignancy, neuroendocrine tumor</td> </tr> <tr> <td>Desmoid tumor/other soft tissue sarcoma (rare)</td> <td>&nbsp;</td> </tr> <tr> <td>Superior mesenteric artery syndrome</td> <td>Rapid weight loss</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"21\"><strong>Intrinsic lesions</strong></td> <td>Congenital malformations, atresia, duplication</td> <td>See appropriate topic reviews</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Large bowel neoplasm</td> </tr> <tr> <td class=\"sublist1\">Adenocarcinoma</td> <td class=\"sublist_other\">Hereditary colorectal cancer syndromes (HNPCC, FAP), inflammatory bowel disease, bowel irradiation, others (see appropriate topic reviews)</td> </tr> <tr> <td class=\"sublist1\">Desmoid</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Carcinoid</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Neuroendocrine tumor</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Lymphoma</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Small bowel neoplasm*</td> </tr> <tr> <td class=\"sublist1\">Adenocarcinoma</td> <td class=\"sublist_other\">Hereditary cancer syndomes (HNPCC, FAP, Peutz-Jeghers, MUTYH-associated polyposis, attenuated FAP)</td> </tr> <tr> <td class=\"sublist1\">Leiomyosarcoma</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Paraganglioma</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Schwannoma</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Metastatic disease</td> <td class=\"sublist_other\">Melanoma, breast cancer, cervical cancer, colon cancer (see appropriate topic reviews)</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal stromal tumor</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Neuroendocrine tumor</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Lymphoma</td> <td class=\"sublist_other\">Chronic inflammation</td> </tr> <tr> <td class=\"sublist1\">Benign lesions</td> <td class=\"sublist_other\">Peutz-Jeghers polyps, xanthomatosis, leiomyoma</td> </tr> <tr> <td>Anastomotic stricture</td> <td>Prior intestinal surgery</td> </tr> <tr> <td>Inflammatory stricture</td> <td>Crohn disease, diverticular disease, NSAID enteropathy</td> </tr> <tr> <td>Ischemic stricture</td> <td>Peripheral artery disease, aortic surgery, colon resection</td> </tr> <tr> <td>Radiation enteritis/stricture</td> <td>Prior abdominal or pelvic irradiation</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"12\"><strong>Intraluminal obstruction of normal bowel</strong></td> <td>Intussusception*</td> <td>Small bowel tumor (see above)</td> </tr> <tr> <td>Gallstones</td> <td>Cholecystitis</td> </tr> <tr> <td>Congenital webs</td> <td>&nbsp;</td> </tr> <tr> <td>Feces or meconium</td> <td>Cystic fibrosis, severe constipation</td> </tr> <tr> <td>Bezoar (phytobezoar, pharmacobezoar)</td> <td>Intestinal motility disorders</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Intramural hematoma</td> </tr> <tr> <td class=\"sublist1\">Traumatic</td> <td class=\"sublist_other\">Blunt abdominal trauma</td> </tr> <tr> <td class=\"sublist1\">Spontaneous</td> <td class=\"sublist_other\">Antithrombotic therapy</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Foreign body</td> </tr> <tr> <td class=\"sublist1\">Ingested</td> <td class=\"sublist_other\">Psychiatric disturbance</td> </tr> <tr> <td class=\"sublist1\">Medical device migration</td> <td class=\"sublist_other\">PEG tube, jejunal tube</td> </tr> <tr> <td>Parasites</td> <td><em>Ascaris lumbricoides</em>, <em>Strongyloides stercoralis</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VP: ventriculoperitoneal; HNPCC: hereditary nonpolyposis colorectal cancer; FAP: familial adenomatous polyposis; NSAID: nonsteroidal anti-inflammatory drug; PEG: percutaneous endoscopic gastrostomy.<br />* May be due to an intrinsic lesion serving as a lead point.</div><div id=\"graphicVersion\">Graphic 53183 Version 5.0</div></div></div>"},"53184":{"type":"graphic_table","displayName":"Formula selection I","title":"Formula selection for children and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formula selection for children and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Formula description</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Examples (listed alphabetically, not comprehensive)</td> </tr> <tr> <td rowspan=\"4\">Intact gut</td> <td rowspan=\"4\"> <p>0.67 to 1.3&nbsp;kcal/mL</p> <p>Blenderized (homogenized food)</p> <p>Intact carbohydrate, protein and fat</p> <p>Polymeric</p> <p>Usually isotonic</p> <p>Contain fiber</p> </td> <td>1-10 years</td> <td>Compleat Pediatric; Compleat Pediatric Reduced Calorie; Nourish; Liquid Hope; RealFood Blends.</td> </tr> <tr> <td>&#62;10 years (adult)</td> <td>Compleat</td> </tr> <tr> <td>1-10 years</td> <td>Boost Kid Essentials; Nutren Jr; PediaSure</td> </tr> <tr> <td>&#62;10 years (adults)</td> <td>Boost; Ensure; Nutren 1.0; Osmolite</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Lactose intolerance</td> <td rowspan=\"2\"> <p>1 to 1.2 kcal/mL</p> <p>Intact carbohydrate, protein and fat</p> <p>Polymeric</p> <p>Most are isotonic</p> <p>Lactose-free</p> </td> <td>1-10 years</td> <td>Boost Kid Essentials; Nutren Jr; PediaSure</td> </tr> <tr> <td>&#62;10 years (adults)</td> <td>Boost; Ensure; Nutren 1.0; Osmolite</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Diarrhea, constipation, or expected long term use</td> <td rowspan=\"2\"> <p>1 to 1.2 kcal/mL</p> <p>Intact carbohydrate, protein and fat</p> <p>Polymeric</p> <p>Most are isotonic</p> <p>Lactose-free</p> <p>Contain fiber</p> </td> <td>1-10 years</td> <td>Boost Kid Essentials with fiber; Nutren Jr with fiber; PediaSure with fiber</td> </tr> <tr> <td>&#62;10 years (adults)</td> <td>Boost with fiber; Ensure; Jevity; Nutren 1.0 with fiber</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Increased protein needs</td> <td> <p>1 to 1.2 kcal/mL</p> <p>Contain approximately 30 percent more protein than standard versions</p> <p>Intact carbohydrate, protein and fat</p> <p>Polymeric</p> <p>Usually isotonic</p> <p>Lactose-free</p> </td> <td rowspan=\"2\">&#62;10 years (adults)</td> <td>Boost High Protein; Ensure High Protein; IsoSource HN; Osmolite HN; Promote; Nutren Replete</td> </tr> <tr> <td>Contain fiber</td> <td>FiberSource HN; Jevity Plus; Promote with fiber; Nutren Replete with fiber</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Volume restriction (calorie dense)</td> <td> <p>1.5 kcal/mL</p> <p>May contain MCT oil</p> <p>May contain increased protein</p> <p>May have higher osmolalities</p> <p>Most contain intact carbohydrate and protein</p> <p>Polymeric</p> <p>Lactose free</p> <p>Available with and without fiber</p> </td> <td>1-10 years</td> <td> <p>Boost Kid Essentials 1.5; Pediasure 1.5</p> </td> </tr> <tr> <td>1.5 kcal/mL</td> <td rowspan=\"2\">&#62;10 years (adult)</td> <td>Ensure Plus; IsoSource 1.5; Nutren 1.5; Osmolite 1.5; Jevity 1.5 (with fiber only); Glucerna 1.5</td> </tr> <tr> <td>2 kcal/mL</td> <td>NovaSource Renal 2.0; Nutren 2.0; TwoCal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCT: medium-chain triglycerides.</div><div id=\"graphicVersion\">Graphic 53184 Version 9.0</div></div></div>"},"53185":{"type":"graphic_figure","displayName":"Appendectomy open","title":"Open appendectomy","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Open appendectomy</div><div class=\"cntnt\"><img style=\"width:535px; height:716px;\" src=\"images/SURG/53185_Appendectomy_open.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53185 Version 1.0</div></div></div>"},"53186":{"type":"graphic_figure","displayName":"Gluteal and sciatic hernias","title":"Gluteal and sciatic hernias","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Gluteal and sciatic hernias</div><div class=\"cntnt\"><img style=\"width:541px; height:392px;\" src=\"images/SURG/53186_Lumbar_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sciatic hernias are rare. The hernia can pass through the greater sciatic foramen above (1) or below (2) the pyriformis muscle or through the lesser sciatic foramen medial to the sciatic nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Lillemoe KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53186 Version 3.0</div></div></div>"},"53187":{"type":"graphic_picture","displayName":"Double balloon endoscopy system","title":"Double balloon endoscopy system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Double balloon endoscopy system</div><div class=\"cntnt\"><img style=\"width:407px; height:573px;\" src=\"images/GAST/53187_Double_balloon_endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double balloon endoscopy system showing the endoscope, overtube, and balloons (panel A) as well as the pump and controller for balloon inflation and deflation (panel B).</div><div class=\"graphic_reference\">Reproduced with permission from: Professor Dr. Christian Ell.</div><div id=\"graphicVersion\">Graphic 53187 Version 1.0</div></div></div>"},"53188":{"type":"graphic_picture","displayName":"Elastosis perforans serpiginosa - arm","title":"Elastosis perforans serpiginosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Elastosis perforans serpiginosa</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53188_Elast_perforans_serp_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic papules in a serpiginous distribution are present on the arm of this patient with elastosis perforans serpiginosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53188 Version 4.0</div></div></div>"},"53190":{"type":"graphic_figure","displayName":"Gastrojejunostomy","title":"Gastrojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastrojejunostomy</div><div class=\"cntnt\"><img style=\"width:396px; height:459px;\" src=\"images/SURG/53190_Gastrojejunostomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An end-to-side gastrojejunostomy can be fashioned to bypass an obstructed segment of&nbsp;duodenum using sutures or staples.</div><div id=\"graphicVersion\">Graphic 53190 Version 2.0</div></div></div>"},"53192":{"type":"graphic_table","displayName":"CAPOX plus bevacizumab regimen","title":"Capecitabine and oxaliplatin (CAPOX) with bevacizumab for metastatic colorectal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Capecitabine and oxaliplatin (CAPOX) with bevacizumab for metastatic colorectal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bevacizumab</td> <td>7.5 mg/kg IV</td> <td>Dilute into a total volume of 100 mL normal saline* and administer the first dose over 90 minutes following oxaliplatin. If tolerated, then administer second dose over 60 minutes after oxaliplatin. If tolerated, then administer all subsequent doses over 30 minutes before oxaliplatin.</td> <td>Day 1</td> </tr> <tr> <td>Oxaliplatin</td> <td>130 mg/m<sup>2</sup> IV</td> <td>Dilute in 500 mL 5% dextrose in water (D5W)* and administer over two hours.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Capecitabine<sup>&#182;</sup></td> <td>850 mg/m<sup>2</sup> per dose by mouth</td> <td>Twice daily (total dose 1700 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets.<sup>&#916;</sup></td> <td>Evening of day 1 to morning of day 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin plus bevacizumab: MODERATE. </li> <li>Capecitabine: LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topics on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\" and \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated (estimated risk of febrile neutropenia &#60;5%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Maneuvers to prevent neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Prolongation of the oxaliplatin infusion time from two to six hours may mitigate acute neurotoxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>QT prolongation and ventricular arrhythmias have been reported after oxaliplatin. ECG monitoring is recommended if therapy is initiated in patients with heart failure, bradyarrhythmias, coadministration of drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to initiating oxaliplatin. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes (especially potassium and magnesium) and liver and renal function every three weeks prior to treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in blood pressure, urine protein concentration, neurologic function, and risk for bleeding prior to each treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Delay treatment one week if the total white blood cell count is &#60;3000/microL, ANC is &#60;1500/microL, or the platelets count is &#60;100,000/microL on day 1. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce the doses of oxaliplatin and capecitabine by 10 to 20%. Subsequent treatment cycles should be delayed until ANC &#8805;1500/microL and platelets &#8805;75,000/microL. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original trial, oxaliplatin dose was decreased by 25% for grade 3 paresthesias and dysesthesias lasting longer than seven days, and the drug discontinued for grade 4 or persistent grade 3 paresthesia/dysesthesias.<sup>[1]</sup> The United States Prescribing Information suggests dose reduction for persistent NCI-CTC grade 2 neurosensory events (sensory alteration or paresthesias including tingling but not interfering with activities of daily living [ADLs]) and discontinuation of oxaliplatin for persistent grade 3 (objective sensory loss or paresthesias including tingling interfering with function but not ADLs) or grade 4 neurosensory events.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Oxaliplatin has rarely been associated with pulmonary toxicity. Withhold oxaliplatin for unexplained pulmonary symptoms until interstitial lung disease or pulmonary fibrosis is excluded. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse gastrointestinal toxicity; restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> After recovery, reduce the dose of oxaliplatin by 25% after the first episode of grade 3 or worse diarrhea or mucositis. Reduce the capecitabine dose by 25% in subsequent cycles at the first occurrence of grade 2 or 3 toxicity, and by 50% at the second occurrence of a given grade 2 or grade 3 toxicity or at the first occurrence of a grade 4 event. Discontinue capecitabine permanently if, despite dose reduction, a given toxicity occurs for the third time at grade 2 or grade 3, or a second time at grade 4.<sup>[3]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity (including heptotoxicity)</strong></td> <td colspan=\"3\"> <ul> <li>Interrupt capecitabine and delay oxaliplatin for any grade 2 or worse non-neurologic toxicity (except alopecia); restart treatment only after complete recovery or improvement to &#8804;grade 1.<sup>[3]</sup> Reduce the dose of oxaliplatin by 25% for drug-related grade 3 toxicity. </li> <li>For capecitabine: <ul> <li>Grade 2: For the first, second, and third occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75% of the starting dose; third occurrence, 50% of the starting dose).<sup>[5]</sup> For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. </li> <li>Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75% of the starting dose; second occurrence, 50% of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. </li> <li>Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50% of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for first recurrence of grade 4 toxicity. </li> </ul> </li> <li>Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS).<sup>[4]</sup> Bevacizumab should not be administered within 28 days of surgery, and it should be suspended prior to elective surgery. </li> <li>Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Doses of capecitabine that are omitted for toxicity are not replaced. The patient should resume planned treatment cycles at the modified dose.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram; CBC: complete blood count; INR: international normalized ratio; ANC: absolute neutrophil count; NCI-CTC: National Cancer Institute Common Toxicity Criteria.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />¶ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />Δ Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cassidy J, et al. J Clin Oncol. 2004; 22:2084.</LI>&#xD;&#xA;<LI>Oxaliplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Nehls O, et al. Br J Cancer 2008; 989:309.</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 53192 Version 36.0</div></div></div>"},"53195":{"type":"graphic_diagnosticimage","displayName":"Intraarticular metatarsal head fracture","title":"Intraarticular metatarsal head fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraarticular metatarsal head fracture</div><div class=\"cntnt\"><img style=\"width:347px; height:468px;\" src=\"images/RHEUM/53195_Intraarticular_mt_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fracture into the joint space of the fourth metatarsal is indicated by the arrow.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.</div><div id=\"graphicVersion\">Graphic 53195 Version 2.0</div></div></div>"},"53198":{"type":"graphic_figure","displayName":"Distal response to furosemide","title":"Loop diuretic-induced increase in distal tubule sodium reabsorption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Loop diuretic-induced increase in distal tubule sodium reabsorption</div><div class=\"cntnt\"><img style=\"width:448px; height:278px;\" src=\"images/NEPH/53198_Distalresponsetofurosemi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diuretic responsiveness in patients previously treated with placebo or the loop diuretic, furosemide. The subjects who had been treated with furosemide had a lesser increase in the fractional excretion of sodium (FENa) after the administration of furosemide (left panel) but a greater natriuretic response to the addition of chlorothiazide (right panel). These findings are compatible with increased tubular sodium reabsorption at the thiazide-sensitive site in the distal tubule when distal sodium delivery is chronically increased by furosemide.</div><div class=\"graphic_reference\">Data from Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36:682.</div><div id=\"graphicVersion\">Graphic 53198 Version 5.0</div></div></div>"},"53199":{"type":"graphic_picture","displayName":"Candida placentitis","title":"Candida placentitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Candida placentitis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/53199_Candida_placentitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph showing microabscesses on the surface of the umbilical cord in a case of candida placentitis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53199 Version 2.0</div></div></div>"},"53200":{"type":"graphic_figure","displayName":"Tender points fibro PI","title":"Tender points in fibromyalgia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tender points in fibromyalgia</div><div class=\"cntnt\"><img style=\"width:199px; height:281px;\" src=\"images/PI/53200_Tender_points_fibro_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with fibromyalgia usually have many &quot;tender points&quot; on their body that hurt when touched or pressed on. These tender points are bilateral, meaning that they are the same on both the left and right side of the body. Most people with fibromyalgia have tenderness on at least 11 of the 18 points shown in this picture. They usually have also had pain throughout the body for at least three months.</div><div class=\"graphic_reference\">Adapted from: Goldenberg, DL, Hosp Pract (Off Ed) 1989; 24:39.</div><div id=\"graphicVersion\">Graphic 53200 Version 5.0</div></div></div>"},"53202":{"type":"graphic_picture","displayName":"Barbell stud","title":"Barbell stud","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barbell stud</div><div class=\"cntnt\"><img style=\"width:349px; height:293px;\" src=\"images/PEDS/53202_Barbell_stud.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.</div><div id=\"graphicVersion\">Graphic 53202 Version 1.0</div></div></div>"},"53204":{"type":"graphic_figure","displayName":"Glucocorticoid structure","title":"Glucocorticoid structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid structure</div><div class=\"cntnt\"><img style=\"width:444px; height:332px;\" src=\"images/ENDO/53204_Glucocorticoid_structure.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Basic glucocorticoid structure and the chemical modifications (circled) that can be introduced to increase glucocorticoid and/or mineralocorticoid activity. The rings are lettered A through D. A solid line indicates that the group lies in front of the plane of the ring (beta position); a dashed line indicates that the group lies behind the plane of the ring (alpha position). A double bond in a ring (eg, between carbons 4 and 5) is referred to as \"delta\" (in this case, \"delta-4\").</div><div id=\"graphicVersion\">Graphic 53204 Version 2.0</div></div></div>"},"53205":{"type":"graphic_table","displayName":"Secondary hypogonadism male","title":"Causes of secondary hypogonadism in males","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of secondary hypogonadism in males</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Congenital</td> </tr> <tr> <td class=\"subtitle2_single\">Isolated gonadotropin deficiency</td> </tr> <tr> <td class=\"indent1\">Kallmann syndrome</td> </tr> <tr> <td class=\"indent1\"><em>DAX1 </em>mutation</td> </tr> <tr> <td class=\"indent1\"><em>GPR54 </em>mutation</td> </tr> <tr> <td class=\"indent1\">Leptin or leptin receptor mutation</td> </tr> <tr> <td class=\"indent1\">Prader-Willi syndrome</td> </tr> <tr> <td class=\"indent1\">Gonadotropin subunit mutation</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"subtitle2_single\">Deficiencies of multiple pituitary hormones</td> </tr> <tr> <td class=\"indent1\">Pituicyte differentiation gene mutations</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired</td> </tr> <tr> <td class=\"subtitle2_single\">Suppression of gonadotropins</td> </tr> <tr> <td class=\"indent1\">Hyperprolactinemia</td> </tr> <tr> <td class=\"indent1\">Gonadal steroid administration</td> </tr> <tr> <td class=\"indent1\">Glucocorticoid treatment</td> </tr> <tr> <td class=\"indent1\">Critical illness</td> </tr> <tr> <td class=\"indent1\">Chronic systemic illness</td> </tr> <tr> <td class=\"indent1\">Opiates</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Idiopathic</td> </tr> <tr> <td class=\"indent1\">GnRH analogs</td> </tr> <tr> <td class=\"subtitle2_single\">Damage to gonadotroph cells</td> </tr> <tr> <td class=\"indent1\">Benign tumors and cysts</td> </tr> <tr> <td class=\"indent1\">Malignant tumors</td> </tr> <tr> <td class=\"indent1\">Infiltrative diseases</td> </tr> <tr> <td class=\"indent1\">Infections</td> </tr> <tr> <td class=\"indent1\">Pituitary apoplexy</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Surgery in the sellar region</td> </tr> <tr> <td class=\"indent1\">Radiation to the sellar region</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone.</div><div id=\"graphicVersion\">Graphic 53205 Version 3.0</div></div></div>"},"53206":{"type":"graphic_picture","displayName":"Jejunal stricture capsule","title":"Radiation enteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation enteritis</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/GAST/53206_Jejunal_stricture_capsule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Capsule endoscopy showing a jejunal stricture secondary to radiation enteritis.</div><div class=\"graphic_reference\">Courtesy of Ingram Roberts MD.</div><div id=\"graphicVersion\">Graphic 53206 Version 1.0</div></div></div>"},"53207":{"type":"graphic_table","displayName":"Essential clinician tasks","title":"Essential tasks of the contemporary clinician","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Essential tasks of the contemporary clinician</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Comprehend the biomedical and psychosocial knowledge base pertinent to your field of medicine</td> </tr> <tr> <td>Develop a personal strategy to learn continuously and manage the rapid changes in this information</td> </tr> <tr> <td>Connect in a personal, professional manner with each patient who seeks care from you</td> </tr> <tr> <td>Understand the health care delivery system in which you work, and your role in it</td> </tr> <tr> <td>Act in ways that maximize the cost-effectiveness and healing influences of the health care you provide</td> </tr> <tr> <td>Educate and support your patients in the optimal use of the health care system</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53207 Version 3.0</div></div></div>"},"53210":{"type":"graphic_diagnosticimage","displayName":"Fifth metacarpal neck fracture: Lateral","title":"Fifth metacarpal neck fracture: Lateral","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fifth metacarpal neck fracture: Lateral</div><div class=\"cntnt\"><img style=\"width:288px; height:384px;\" src=\"images/SM/53210_Metacarpal_neck_fx_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the hand shows a comminuted fracture of the fifth metacarpal neck with apex dorsal angulation. In addition to the abnormal volar location of the metacarpal head (arrow), a fragment of the shaft can be seen (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 53210 Version 6.0</div></div></div>"},"53211":{"type":"graphic_table","displayName":"SAECG and VT after MI","title":"Incidence of sustained ventricular arrhythmias or sudden cardiac death in patients after myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Incidence of sustained ventricular arrhythmias or sudden cardiac death in patients after myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Test</td> <td class=\"subtitle1\" colspan=\"2\">Percent adverse outcomes</td> </tr> <tr> <td class=\"subtitle2\">For normal test results</td> <td class=\"subtitle2\">For abnormal test results</td> </tr> <tr> <td>SAECG and ejection fraction</td> <td>0-1</td> <td>31-38</td> </tr> <tr> <td>SAECG and Holter monitor</td> <td>0-1</td> <td>27-35</td> </tr> <tr> <td>Ejection fraction and Holter monitor</td> <td>7</td> <td>29</td> </tr> <tr> <td>SAECG, ejection fraction, and Holter monitor</td> <td>0</td> <td>50</td> </tr> <tr> <td>SAECG and programmed stimulation</td> <td>2</td> <td>27</td> </tr> <tr> <td>SAECG and HRV</td> <td>7</td> <td>33</td> </tr> <tr> <td>SAECG, HRV, and Holter monitor</td> <td>4</td> <td>43</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAECG: signal-averaged electrocardiogram; HRV: heart rate variability.</div><div class=\"graphic_reference\">Adapted from Cain, et al. J Am Coll Cardiol 1996; 27:238. </div><div id=\"graphicVersion\">Graphic 53211 Version 2.0</div></div></div>"},"53217":{"type":"graphic_table","displayName":"Contraindications exercise test","title":"Contraindications for exercise testing in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications for exercise testing in children and adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Acute inflammatory cardiac disease (eg, pericarditis, myocarditis, acute rheumatic heart disease)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Uncontrolled heart failure</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute myocardial infarction</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute pulmonary disease (eg, acute asthma, pneumonia)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Severe systemic hypertension (eg, blood pressure greater than 240/120 mmHg)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute renal disease (eg, acute glomerulonephritis)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Acute hepatitis (within three months after onset)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Drug overdose affecting cardiorespiratory response to exercise (eg, digitalis toxicity, salicylism, quinidine toxicity)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Severe aortic stenosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Severe pulmonary stenosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Serious ventricular dysrhythmia, especially when associated with significant cardiac disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Coronary arterial diseases (anomalous left coronary artery, homozygous hypercholesterolemia, Kawasaki disease [acute phase])</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Severe pulmonary vascular disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Metabolic disorders (glycogenolysis types I and V)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hemorrhagic diseases</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Orthostatic hypotension</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Washington RL, Bricker JT, Alpert BS, et al. Guidelines for exercise testing in the pediatric age group. From the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 1994; 90:2166 and James FW. Exercise testing in children and young adults: an overview. Cardiovasc Clin 1978; 9:187.</div><div id=\"graphicVersion\">Graphic 53217 Version 2.0</div></div></div>"},"53218":{"type":"graphic_picture","displayName":"Blepharitis","title":"Blepharitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Blepharitis</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PC/53218_Blepharitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lids demonstrate findings of blepharitis: diffuse eyelid margin thickening and hyperemia with lash crusts.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe, JD. The Eyes Have It: An interactive teaching and assessment program on vision care. WK Kellogg Eye Center, University of Michigan. Copyright &#169; Jonathan D Trobe, MD.</div><div id=\"graphicVersion\">Graphic 53218 Version 1.0</div></div></div>"},"53219":{"type":"graphic_figure","displayName":"Liver flukes life cycle","title":"Liver flukes life cycle","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Liver flukes life cycle</div><div class=\"cntnt\"><img style=\"width:585px; height:469px;\" src=\"images/ID/53219_Liver_flukes_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Embryonated eggs are discharged in the biliary ducts and in the stool <strong>(1)</strong>. Eggs are ingested by a suitable snail intermediate host <strong>(2)</strong>. Each egg releases a miracidia <strong>(2a)</strong>, which go through several developmental stages (sporocysts <strong>(2b)</strong>, rediae <strong>(2c)</strong>, and cercariae <strong>(2d)</strong>). The cercariae are released from the snail and, after a short period of free-swimming time in water, they come in contact and penetrate the flesh of freshwater fish, where they encyst as metacercariae <strong>(3)</strong>. Infection of humans occurs by ingestion of undercooked, salted, pickled, or smoked freshwater fish <strong>(4)</strong>. After ingestion, the metacercariae excyst in the duodenum <strong>(5)</strong> and ascend the biliary tract through the ampulla of Vater <strong>(6)</strong>. Maturation takes approximately one month. The adult flukes (measuring 10 to 25 mm by 3 to 5 mm) reside in small and medium sized biliary ducts. In addition to humans, carnivorous animals can serve as reservoir hosts.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Clonorchiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/clonorchiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/clonorchiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 53219 Version 4.0</div></div></div>"},"53222":{"type":"graphic_figure","displayName":"Principles of polar body biopsy","title":"Principles of polar body biopsy","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Principles of polar body biopsy</div><div class=\"cntnt\"><img style=\"width:581px; height:489px;\" src=\"images/OBGYN/53222_Princip_polar_body_bio_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the absence of crossing-over, analysis of the first polar body (PBI) enables one to deduce the genetic status of the oocyte and, hence, whether the zygote could be affected. If PBI is heterozygous, crossing-over has occurred between homologous chromosomes and PBI analysis is noninformative. However, PB2 analysis enables deduction of the maternal contribution to the zygote. Polar body analysis provides no information about paternal genotype and has the theoretical disadvantage of inefficiency in autosomal recessive disorders. If segregation of a mutant paternal autosomal dominant gene is sought, blastomere analysis rather than polar body analysis is necessary.</div><div class=\"graphic_footnotes\">A: normal allele; a: mutant allele.</div><div class=\"graphic_reference\">Reproduced with permission from: Simpson JL, Elias S. Genetics in Obstetrics and Gynecology, 3rd ed, WB Saunders, Philadelphia 2003. p.416. Copyright &#169; 2003 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 53222 Version 3.0</div></div></div>"},"53224":{"type":"graphic_figure","displayName":"Low atrial isolation","title":"Ablation lesions and lead placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ablation lesions and lead placement</div><div class=\"cntnt\"><img style=\"width:396px; height:293px;\" src=\"images/CARD/53224_Low_atrial_isolation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Isolation of small atrial segment surrounding the atrioventricular node and the His bundle was achieved by sequential radiofrequency ablation. The structures around the Koch triangle in the swine heart are shown here. The relative location of the CS and the IVC is different from that in humans. Please see text for details. The location of the tricuspid annulus is labeled. In this study, the His bundle is mapped first. The atrioventricular node is presumably just proximal and inferior to the His bundle. The small atrial segment surrounding the atrioventricular node and the His bundle is isolated using a series of radiofrequency ablation lesions. The isolation is started with a line crossing the CS-tricuspid isthmus, which is extended superiorly along the anterior edge of the CS. A pacing lead is inserted into the isolated atrial segment surrounded by the ablation lines, the tricuspid annulus, and the atrioventricular node-His bundle. The results of this study are not dependent on the location of the lead implantation (either closer to the AV node or closer to the CS-tricuspid isthmus).</div><div class=\"graphic_footnotes\">The circles labeled as A.B.L.A.T.I.O.N.L.I.N.E. represent the linear ablation lesions.<br>Attain: steerable guiding sheath; AVN: location of the atrioventricular node; CS: coronary sinus; HB: the location of the His bundle; IVC: inferior vena cava.</div><div class=\"graphic_reference\">Reproduced with permission from: Lu F, Laizzo PA, Benditt DG, et al. Isolated atrial segment pacing: an alternative to his bundle pacing after atrioventricular junctional ablation. J Am Coll Cardiol 2007; 49:1443. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 53224 Version 2.0</div></div></div>"},"53227":{"type":"graphic_table","displayName":"Other diagnoses to cardiac ischemia for patients with chest pain","title":"Alternative diagnoses to cardiac ischemia for patients with chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alternative diagnoses to cardiac ischemia for patients with chest pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Nonischemic cardiovascular</td> </tr> <tr> <td>Aortic dissection*</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td>Pericarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Chest wall</td> </tr> <tr> <td>Cervical disc disease</td> </tr> <tr> <td>Costochondritis</td> </tr> <tr> <td>Fibrositis</td> </tr> <tr> <td>Herpes zoster (before the rash)</td> </tr> <tr> <td>Neuropathic pain</td> </tr> <tr> <td>Rib fracture</td> </tr> <tr> <td>Sternoclavicular arthritis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td>Pleuritis</td> </tr> <tr> <td>Pneumonia</td> </tr> <tr> <td>Pulmonary embolus*</td> </tr> <tr> <td>Tension pneumothorax*</td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric</td> </tr> <tr> <td>Affective disorders (eg, depression)</td> </tr> <tr> <td class=\"sublist1_start\">Anxiety disorders</td> </tr> <tr> <td class=\"sublist1\">Hyperventilation</td> </tr> <tr> <td class=\"sublist1\">Panic disorder</td> </tr> <tr> <td class=\"sublist1\">Primary anxiety</td> </tr> <tr> <td class=\"sublist1_start\">Somatoform disorders</td> </tr> <tr> <td class=\"sublist1\">Thought disorders (eg, fixed delusions)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"sublist1_start\">Biliary</td> </tr> <tr> <td class=\"sublist1\">Cholangitis</td> </tr> <tr> <td class=\"sublist1\">Cholecystitis</td> </tr> <tr> <td class=\"sublist1\">Choledocholithiasis</td> </tr> <tr> <td class=\"sublist1\">Colic</td> </tr> <tr> <td class=\"sublist1_start\">Esophageal</td> </tr> <tr> <td class=\"sublist1\">Esophagitis</td> </tr> <tr> <td class=\"sublist1\">Spasm</td> </tr> <tr> <td class=\"sublist1\">Reflux</td> </tr> <tr> <td class=\"sublist1\">Rupture*</td> </tr> <tr> <td>Pancreatitis</td> </tr> <tr> <td class=\"sublist1_start\">Peptic ulcer disease</td> </tr> <tr> <td class=\"sublist1\">Nonperforating</td> </tr> <tr> <td class=\"sublist1\">Perforating*</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Potentially life-threatening conditions.</div><div class=\"graphic_reference\">Adapted with permission from: ACC/AHA/ACP Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 1999; 33:2092. Copyright ©1999 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 53227 Version 3.0</div></div></div>"},"53228":{"type":"graphic_table","displayName":"Corticosteroid drug interact","title":"Major drug interactions with systemic glucocorticoids*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major drug interactions with systemic glucocorticoids*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Interacting class</td> <td class=\"subtitle1\">Sample agents</td> <td class=\"subtitle1\">Effect</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Co-administration of drugs that are strong inducers of CYP 3A may DECREASE glucocorticoid exposure and efficacy<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Anticonvulsants</td> <td>Carbamazepine, fosphenytoin, oxcarbazepine, pentobarbital, phenobarbital, phenytoin, primidone</td> <td class=\"divider_bottom\" rowspan=\"3\">Reduced glucocorticoid effects due to accelerated clearance. Maximal effect of interaction occurs approximately two weeks after initiating a strong CYP inducer. Induction effects may persist for weeks following discontinuation of a strong CYP inducer.</td> <td>Methylprednisolone clearance may be increased by &#62;200 percent by interacting anticonvulsants, significantly decreasing glucocorticoid exposure. Dose alteration of methylprednisolone may be needed. Prednisone and prednisolone are affected considerably less by this interaction.</td> </tr> <tr> <td class=\"indent1\">Anti-infectives</td> <td>Efavirenz, etravirine, nafcillin, nevirapine, rifampin, rifabutin, rifapentine</td> <td>Methylprednisolone, prednisone, and prednisolone exposure may be decreased by as much as 60 percent following rifampin co-administration. Rifampin interacts more significantly than rifabutin or rifapentine.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td>Bosentan, St. John's wort</td> <td>Reduced glucocorticoid exposure is possible. However, no clinical data are available.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Orally administered antacids may decrease bioavailability of orally administered glucocorticoids</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oral antacids</td> <td>Aluminum hydroxide, calcium carbonate, magnesium hydroxide, others</td> <td>Potentially reduced glucocorticoid effects due to decreased oral absorption. Variable effects reported.</td> <td>Separating administration of oral glucocorticoids from antacids by two or more hours may minimize this interaction.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Co-administration of drugs that are strong inhibitors of CYP 3A and/or P-gp may INCREASE glucocorticoid exposure and toxicity<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> <td>Clarithromycin, telithromycin</td> <td rowspan=\"4\">Increased glucocorticoid effects due to decreased clearance.</td> <td rowspan=\"4\"> <p>Methylprednisolone and dexamethasone clearance may be reduced by approximately 30 to 50 percent. Monitor biomarkers for exaggerated glucocorticoid effects.<sup>&#916;</sup> Dose alteration of methylprednisolone and dexamethasone may be needed. No specific recommendation available.</p> <p>Prednisone and prednisolone are not affected to a clinically relevant degree by this interaction.</p> </td> </tr> <tr> <td class=\"indent1\">Antifungals</td> <td>Itraconazole, ketoconazole, posaconazole, voriconazole</td> </tr> <tr> <td class=\"indent1\">Antimycobacterial</td> <td>Isoniazid</td> </tr> <tr> <td class=\"indent1\">Antivirals (including HIV and HCV)</td> <td>Atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, telaprevir</td> </tr> <tr> <td class=\"indent1\">Estrogens</td> <td>Estrogen containing oral contraceptives, conjugated estrogens, esterified estrogens, others</td> <td>Estrogens can significantly increase glucocorticoid exposure and effects. This may be due to alteration of steroid metabolism and protein binding.</td> <td>Monitor biomarkers for exaggerated glucocorticoid effects.<sup>&#916;</sup> Dose alteration of glucocorticoid may be needed. No specific recommendation available.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immunosuppressants</td> <td>Cyclosporine, tacrolimus, everolimus</td> <td>Increased exposure to methylprednisolone, prednisone, and prednisolone. Other effects described include increased and decreased cyclosporine concentrations and decreased everolimus concentrations with dexamethasone.</td> <td> <p>Monitor biomarkers for exaggerated glucocorticoid effects.<sup>&#916;</sup> Dose alteration may be needed. No specific recommendation available.</p> <p>Monitor immunosuppressant concentrations closely. If possible, avoid dexamethasone with everolimus.</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Multiple effects or additive toxicities</td> </tr> <tr> <td class=\"indent1\">Anticoagulants, oral</td> <td>Warfarin</td> <td>Glucocorticoids may increase anticoagulant effect of warfarin by multiple mechanisms.</td> <td>Most patients stabilized on warfarin will require a significant alteration in warfarin dose within three to seven days after initiating glucocorticoid. Monitor INR closely to determine need for dose adjustment.</td> </tr> <tr> <td class=\"indent1\">Diuretics, potassium wasting</td> <td>Furosemide, hydrochlorothiazide, others</td> <td>Glucocorticoids may enhance the kaluretic effects of potassium wasting diuretics.</td> <td>Evaluate serum potassium levels to determine whether alteration of diuretic therapy and/or potassium supplementation is needed.</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolone anti-infectives</td> <td>Ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, others</td> <td>Increased risk of developing tendonitis and rupture.</td> <td>Monitor for new-onset tendon and/or joint pain. Use fluoroquinolones with glucocorticoids cautiously in older adults and children.</td> </tr> <tr> <td class=\"indent1\">Hypoglycemic agents (oral and insulin)</td> <td>Acarbose, glipizide, glyburide, insulins, metformin, pioglitazone, sitagliptin, others</td> <td>Initiation of glucocorticoid treatment may result in glucose dysregulation.</td> <td>Closely monitor blood glucose in patients at risk for glycemic dysregulation. Adjust hypoglycemic agents based on blood glucose results.</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal antiinflammatory drugs (NSAIDs)</td> <td>Ibuprofen, indomethacin, ketorolac, ketoprofen, naproxen, others</td> <td>Increased risk of peptic ulcer disease when glucocorticoids are used in combination with an NSAID, compared with the use of either alone.</td> <td>Refer to UpToDate topics on systemic glucocorticoids.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table does not show all possible interactions. For additional interactions and information including management suggestions, see Lexi-Interact&trade; program included with UpToDate. Interaction data and recommendations refer to systemic drug forms.</div><div class=\"graphic_footnotes\">CYP 3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux membrane transporters; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NSAID: nonsteroidal antiinflammatory drug; INR: international normalized ratio.<br />* No significant interactions with azathioprine, methotrexate, histamine<SUB>2</SUB> antagonists (eg, famotidine, cimetidine, ranitidine), or proton pump inhibitors (eg, omeprazole, pantoprazole, rabeprazole).<br />¶ For a list of CYP 3A4 inducers/inhibitors, see other table: \"Inhibitors and inducers of cytochrome P450 3A4.\"<br />Δ Biomarkers of glucocorticoid toxicity may include neuropsychiatric reactions, fluid and electrolyte disturbances, hypertension, and/or hyperglycemia.</div><div class=\"graphic_reference\">Data from: Czock D, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids; Clin Pharmacokinet 2005; 44:61. Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved; Wynn GH, et al (Eds). Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 53228 Version 11.0</div></div></div>"},"53229":{"type":"graphic_figure","displayName":"Sodium label PI","title":"Food labels can be tricky","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Food labels can be tricky</div><div class=\"cntnt\"><img style=\"width:539px; height:550px;\" src=\"images/PI/53229_Sodium-label-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To figure out how much sodium you are eating, check the label to find out how much sodium is in one serving. If you are having more than one serving, multiply that amount by the number of servings you plan to eat. For instance, if you are going to eat this whole can of soup, you should multiply 850 by 2. That means that you will be having 1700 milligrams of sodium. That's more sodium than many people are supposed to have in one day.</div><div class=\"graphic_footnotes\">%: percent.</div><div id=\"graphicVersion\">Graphic 53229 Version 6.0</div></div></div>"},"53231":{"type":"graphic_table","displayName":"GIST progn criteria","title":"Proposed modification of NIH consensus criteria for risk stratification of GISTs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed modification of NIH consensus criteria for risk stratification of GISTs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n\t<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\t\n\t<tr>\n\t<td class=\"subtitle1\" colspan=\"3\">Original NIH<sup>[1]</sup> criteria</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"subtitle2_left\">Risk group</td>\n\t<td class=\"subtitle2_left\">Size, cm</td>\n\t<td class=\"subtitle2_left\">Mitotic rate, per 50 HPF</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\">Very low risk</td>\n\t<td>&#60;2</td>\n\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\">Low risk</td>\n\t<td>2-5</td>\n\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\" rowspan=\"2\">Intermediate risk</td>\n\t<td>&#60;5</td>\n\t<td>6-10</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>5-10</td>\n\t\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\" rowspan=\"3\">High risk</td>\n\t<td>&#62;5</td>\n\t<td>&#62;5</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>&#62;10</td>\n\t\t<td>Any</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>Any</td>\n\t\t<td>&#62;10</td>\n\t</tr>\n\t\t\n\t</table>\n\t</td>\n\t\n\t<td class=\"container\">\n\t<table cellspacing=\"0\">\n\t\n\t<tr>\n\t<td class=\"subtitle1\" colspan=\"3\">Proposed<sup>[2]</sup> criteria</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"subtitle2_left\">Risk group</td>\n\t<td class=\"subtitle2_left\">Size, cm</td>\n\t<td class=\"subtitle2_left\">Mitotic rate, per 50 HPF</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\">Level I</td>\n\t<td>&#8804;5</td>\n\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\" rowspan=\"2\">Level II</td>\n\t<td>&#60;5</td>\n\t<td>6-10</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>5-10</td>\n\t\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\" rowspan=\"3\">Level III</td>\n\t<td>&#8804;5</td>\n\t<td>&#62;10</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>5-10</td>\n\t\t<td>6-10</td>\n\t</tr>\n\t\n\t<tr>\n\t\t<td>&#62;10</td>\n\t\t<td>&#60;5</td>\n\t</tr>\n\t\n\t<tr>\n\t<td class=\"indent1\">Level IV</td>\n\t<td>&#62;5</td>\n\t<td>&#62;10</td>\n\t</tr>\n\t\n\t</table>\n\t</td>\n\t</tr>\n\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=46280&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>GIST_progn_criteria.htm</title></head></div><div class=\"graphic_footnotes\">GIST: gastrointestinal stromal tumor.</div><div class=\"graphic_reference\">1. Fletcher CD, Berman JJ,&nbsp;Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Path 2002; 10:81.<br />2. Huang HY, Li&nbsp;CF, Huang WW,&nbsp;et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 2007; 141:748.</div><div id=\"graphicVersion\">Graphic 53231 Version 2.0</div></div></div>"},"53232":{"type":"graphic_table","displayName":"Liver injury scale","title":"Liver injury scale (1994 revision)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Liver injury scale (1994 revision)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Injury description</td> </tr> <tr> <td rowspan=\"2\">I</td> <td>Hematoma</td> <td>Subcapsular, &#60;10 percent surface area</td> </tr> <tr> <td>Laceration</td> <td>Capsular tear, &#60;1 cm parenchymal depth</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">II</td> <td rowspan=\"2\">Hematoma</td> <td>Subcapsular, 10-50 percent surface area</td> </tr> <tr> <td>Intraparenchymal, &#60;10 cm in diameter</td> </tr> <tr> <td>Laceration</td> <td>1-3 cm parenchymal depth, &#60;10 cm in length</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">III</td> <td>Hematoma</td> <td>Subcapsular, &#62;50 percent surface area or expanding; ruptured subcapsular or parenchymal hematoma</td> </tr> <tr> <td rowspan=\"2\">Laceration</td> <td>Intraparenchymal hematoma &#62;10 cm or expanding</td> </tr> <tr> <td>&#62;3 cm parenchymal depth</td> </tr> <tr class=\"divider_top\"> <td>IV</td> <td>Laceration</td> <td>Parenchymal disruption involving 25-75 percent of hepatic lobe or 1-3 Couinaud's segments within a single lobe</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">V</td> <td>Laceration</td> <td>Parenchymal disruption involving &#62;75 percent of hepatic lobe or &#62;3 Couinaud's segments within a single lobe</td> </tr> <tr> <td>Vascular</td> <td>Juxtahepatic venous injuries; ie, retrohepatic vena cava/central major hepatic veins</td> </tr> <tr class=\"divider_top\"> <td>VI</td> <td>Vascular</td> <td>Hepatic avulsion</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for multiple injuries, up to grade III.</div><div class=\"graphic_reference\">Adapted from: Moore, EE, Cogbill, TH, Jurkovich, GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38:323.</div><div id=\"graphicVersion\">Graphic 53232 Version 4.0</div></div></div>"},"53233":{"type":"graphic_table","displayName":"Adjusting Rx 12 and up","title":"Assessing asthma control and adjusting therapy in youths greater than or equal to 12 years of age and adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessing asthma control and adjusting therapy in youths greater than or equal to 12 years of age and adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"2\">Components of control</td> <td class=\"subtitle1\" colspan=\"3\">Classification of asthma control (&#8805;12 years of age)</td> </tr> <tr> <td class=\"subtitle2\">Well-controlled</td> <td class=\"subtitle2\">Not-well controlled</td> <td class=\"subtitle2\">Very poorly controlled</td> </tr> <tr> <td rowspan=\"9\">Impairment</td> <td>Symptoms</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Throughout the day</td> </tr> <tr> <td>Nighttime awakenings</td> <td>&#8804;2x/month</td> <td>1 to 3x/week</td> <td>&#8805;4x/week</td> </tr> <tr> <td>Interference with normal activity</td> <td>None</td> <td>Some limitation</td> <td>Extremely limited</td> </tr> <tr> <td>Short-acting beta<sub>2</sub>-agonist use for symptom control (not prevention of EIB)</td> <td>&#8804;2 days/week</td> <td>&#62;2 days/week</td> <td>Several times per day</td> </tr> <tr> <td>FEV<sub>1</sub> or peak flow</td> <td>&#62;80 percent predicted/personal best</td> <td>60 to 80 percent predicted/personal best</td> <td>&#60;60 percent predicted/personal best</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Validated questionnaires</td> </tr> <tr> <td class=\"sublist1\">ATAQ</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">1 to 2</td> <td class=\"sublist_other\">3 to 4</td> </tr> <tr> <td class=\"sublist1\">ACQ</td> <td class=\"sublist_other\">&#8804;0.75*</td> <td class=\"sublist_other\">&#8805;1.5</td> <td class=\"sublist_other\">N/A</td> </tr> <tr> <td class=\"sublist1\">ACT</td> <td class=\"sublist_other\">&#8805;20</td> <td class=\"sublist_other\">16-19</td> <td class=\"sublist_other\">&#8804;15</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Risk</td> <td rowspan=\"2\"><strong>Exacerbations requiring oral systemic glucocorticoids</strong></td> <td><strong>0 to 1/year</strong></td> <td colspan=\"2\"><strong>&#8805;2/year (see footnote)</strong></td> </tr> <tr> <td colspan=\"3\"><strong>Consider severity and interval since last exacerbation</strong></td> </tr> <tr> <td>Progressive loss of lung function</td> <td colspan=\"3\">Evaluation requires long-term followup care</td> </tr> <tr> <td>Treatment-related adverse effects</td> <td colspan=\"3\">Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">Recommended action for treatment</td> <td> <p>&#8226; Maintain current step</p> <p>&#8226; Regular followups every one to six months to maintain control</p> <p>&#8226; Consider step down if well controlled for at least three months</p> </td> <td> <p>&#8226; Step up 1 step and</p> <p>&#8226; Reevaluate in two to six weeks</p> <p>&#8226; For side effects, consider alternative treatment options</p> </td> <td> <p>&#8226; Consider short course of oral systemic glucocorticoids,</p> <p>&#8226; Step up 1 to 2 steps, and</p> <p>&#8226; Reevaluate in two weeks</p> <p>&#8226; For side effects, consider alternative treatment options</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. The level of control is based on the most severe impairment or risk category. Assess impairment domain by patient's recall of previous two to four weeks and by spirometry/or peak flow measures. Symptom assessment for longer periods should reflect a global assessment, such as inquiring whether the patient's asthma is better or worse since the last visit. At present, data are inadequate to correlate frequencies of exacerbations with different levels of asthma control. In general, more frequent and intense exacerbations (eg, requiring urgent, unscheduled care, hospitalization, or ICU admission) indicate poorer disease control. For treatment purposes, patients who had &gt;2 exacerbations requiring oral systemic glucocorticoids in the past year may be considered the same as patients who have not-well-controlled asthma even in the absence of impairment levels consistent with not-well-controlled asthma.<br /><strong>Validated questionnaires for the impairment domain (the questionnaires do not assess lung function or the risk domain):</strong><br />- ATAQ: Asthma Therapy Assessment Questionnaire<br />- ACQ: Asthma Control Questionnaire (user package may be obtained at www.qoltech.co.uk or juniper@qoltech.co.uk)<br />- ACT: Asthma Control Test<br />Minimal important difference: 1.0 for the ATAQ; 0.5 for the ACQ; not determined for the ACT.<br /><strong>Before step up in therapy:</strong><br />- Review adherence to medication, inhaler technique, environmental control, and comorbid conditions.<br />- If an alternative treatment option was used in a step, discontinue and use the preferred treatment for that step.</div><div class=\"graphic_footnotes\">EIB: exercise-induced bronchospasm; FEV<sub>1</sub>: forced expiratory volume in one second; ICU: intensive care unit; N/A: not applicable.<br />* ACQ values of 0.76 to 1.4 are indeterminate regarding well-controlled asthma.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 53233 Version 5.0</div></div></div>"},"53235":{"type":"graphic_picture","displayName":"Perineal degloving injury","title":"Perineal degloving injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perineal degloving injury</div><div class=\"cntnt\"><img style=\"width:380px; height:285px;\" src=\"images/SURG/53235_Perineal_degloving_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complex pelvic fracture with perineal degloving.</div><div id=\"graphicVersion\">Graphic 53235 Version 1.0</div></div></div>"},"53237":{"type":"graphic_picture","displayName":"Hypopyon 3","title":"Hypopyon in a contact wearer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypopyon in a contact wearer</div><div class=\"cntnt\"><img style=\"width:360px; height:316px;\" src=\"images/EM/53237_Hypopyonfromcontacts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal ulcer and hypophion (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Baskin MN. Opthalmic and otolaryngologic emergencies. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53237 Version 15.0</div></div></div>"},"53238":{"type":"graphic_diagnosticimage","displayName":"Orbital floor fracture entrapment","title":"Orbital blow-out fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orbital blow-out fracture</div><div class=\"cntnt\"><img style=\"width:419px; height:426px;\" src=\"images/EM/53238_Orbital_floor_fx_entrapment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal CT demonstrates a fracture in the floor of the right orbit (arrow). Entrapped orbital contents can be seen in the maxillary sinus (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Mark Neuman, MD.</div><div id=\"graphicVersion\">Graphic 53238 Version 5.0</div></div></div>"},"53239":{"type":"graphic_picture","displayName":"Riedels thyroiditis extension","title":"Riedel's thyroiditis: Microscopic section showing extrathyroidal extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Riedel's thyroiditis: Microscopic section showing extrathyroidal extension</div><div class=\"cntnt\"><img style=\"width:320px; height:288px;\" src=\"images/ENDO/53239_Extens_Riedels_thyroiditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic section (hematoxylin and eosin, magnification x 100) of thyroid tissue from a patient with Riedel's thyroiditis shows fibrous tissue extending beyond the thyroid capsule into the perithyroidal fat.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53239 Version 2.0</div></div></div>"},"53240":{"type":"graphic_figure","displayName":"Locations ampullary tumors","title":"Locations ampullary tumors","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Locations ampullary tumors</div><div class=\"cntnt\"><img style=\"width:502px; height:400px;\" src=\"images/GAST/53240_Locations_ampullary_tumors.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53240 Version 1.0</div></div></div>"},"53241":{"type":"graphic_figure","displayName":"Fibroid anatomy","title":"Fibroid locations in the uterus","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Fibroid locations in the uterus</div><div class=\"cntnt\"><img style=\"width:541px; height:298px;\" src=\"images/OBGYN/53241_Fibroid_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict the various types and locations of fibroids. A woman may have one or more types of fibroids.</div><div id=\"graphicVersion\">Graphic 53241 Version 4.0</div></div></div>"},"53242":{"type":"graphic_table","displayName":"Liver tumor study group HCC","title":"American Liver Tumor Study Group modification of the TNM staging for hepatocellular cancer for the purpose of liver transplantation prioritization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Liver Tumor Study Group modification of the TNM staging for hepatocellular cancer for the purpose of liver transplantation prioritization</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>T0</td>\n\n\t\t\t<td>No tumor found</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>T1</td>\n\n\t\t\t<td>One nodule, &#8804;1.9 cm</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>T2</td>\n\n\t\t\t<td>One nodule, 2 to 5 cm; two or three nodules, all &#8804;3 cm</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>T3</td>\n\n\t\t\t<td>One nodule, &#62;5 cm, two or three nodules at least one &#62;3 cm</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>T4a</td>\n\n\t\t\t<td>Four or more nodules of any size</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>T4b</td>\n\n\t\t\t<td>T2, T3, or T4a, plus gross involvement of intrahepatic portal vein or hepatic vein, as indicated by CT, MRI, or ultrasonography</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>N1</td>\n\n\t\t\t<td>Involvement of regional (porta hepatis) lymph nodes</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>M1</td>\n\n\t\t\t<td>Metastatic disease including extrahepatic portal or hepatic vein involvement</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Stage grouping</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage I</td>\n\n\t\t\t<td>T1</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage II</td>\n\n\t\t\t<td>T2</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage III</td>\n\n\t\t\t<td>T3</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage IVA1</td>\n\n\t\t\t<td>T4a</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage IVA2</td>\n\n\t\t\t<td>T4b</td>\n\t\t</tr>\n\n\t\t<tr>\n\t\t\t<td>Stage IVB</td>\n\n\t\t\t<td>Any N1 or M1</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53242 Version 1.0</div></div></div>"},"53243":{"type":"graphic_figure","displayName":"Hormonal response to Na load","title":"Hormonal response to increasing sodium intake","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hormonal response to increasing sodium intake</div><div class=\"cntnt\"><img style=\"width:394px; height:233px;\" src=\"images/NEPH/53243_Hormonal_response_to_Na_loa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Increasing plasma levels of atrial natriuretic peptide (ANP) and falling plasma renin activity in normal subjects given a progressively increasing sodium intake from 10 to 350 meq/day after a 5-day equilibration period. These hormonal responses promote urinary excretion of the excess sodium.</div><div class=\"graphic_reference\">Data from Sagnella GA, Markandu ND, Buckley MG, et al. Am J Physiol 1989; 256:R1171.</div><div id=\"graphicVersion\">Graphic 53243 Version 2.0</div></div></div>"},"53244":{"type":"graphic_diagnosticimage","displayName":"Brain MRI age 12 years juvenile Alexander disease","title":"Contrast-enhanced brain MRI in a patient with presumed juvenile Alexander disease, obtained at the age of 12 years","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contrast-enhanced brain MRI in a patient with presumed juvenile Alexander disease, obtained at the age of 12 years</div><div class=\"cntnt\"><img style=\"width:288px; height:317px;\" src=\"images/NEURO/53244_MRI_juv_12yr_Alex_Dis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note enhancement of the intraparenchymal trajectory of the fifth cranial nerve on both sides.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22:541. Copyright &copy; 2001 American Society of Neuroradiology.</div><div id=\"graphicVersion\">Graphic 53244 Version 4.0</div></div></div>"},"53245":{"type":"graphic_diagnosticimage","displayName":"Pancreatic pseudocyst","title":"Pancreatic pseudocyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic pseudocyst</div><div class=\"cntnt\"><img style=\"width:358px; height:436px;\" src=\"images/PEDS/53245_Pancreatic_pseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) shows a pancreatic pseudocyst with ductal comminucation. A guidewire is introduced into the cystic cavity. A pancreatic stent is placed beyond the stricture.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatrics Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 53245 Version 3.0</div></div></div>"},"53246":{"type":"graphic_table","displayName":"AUDIT-C","title":"AUDIT-C","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AUDIT-C</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Question #1: How often did you have a drink containing alcohol in the past year?</td> </tr> <tr> <td class=\"indent1\">&#8226; Never</td> <td>(0 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Monthly or less</td> <td>(1 point)</td> </tr> <tr> <td class=\"indent1\">&#8226; Two to four times a month</td> <td>(2 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Two to three times per week</td> <td>(3 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Four or more times a week</td> <td>(4 points)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Question #2: How many drinks did you have on a typical day when you were drinking in the past year?</td> </tr> <tr> <td class=\"indent1\">&#8226; 1 or 2</td> <td>(0 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; 3 or 4</td> <td>(1 point)</td> </tr> <tr> <td class=\"indent1\">&#8226; 5 or 6</td> <td>(2 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; 7 to 9</td> <td>(3 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; 10 or more</td> <td>(4 points)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Question #3: How often did you have six or more drinks on one occasion in the past year?</td> </tr> <tr> <td class=\"indent1\">&#8226; Never</td> <td>(0 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Less than monthly</td> <td>(1 point)</td> </tr> <tr> <td class=\"indent1\">&#8226; Monthly</td> <td>(2 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Weekly</td> <td>(3 points)</td> </tr> <tr> <td class=\"indent1\">&#8226; Daily or almost daily</td> <td>(4 points)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=57525&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The AUDIT-C is scored on a scale of 0 to 12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive.</div><div id=\"graphicVersion\">Graphic 53246 Version 4.0</div></div></div>"},"53247":{"type":"graphic_table","displayName":"Five elements","title":"Five elements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five elements</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Fire</td>\n\t\t\t\t\t<td class=\"subtitle1\">Earth</td>\n\t\t\t\t\t<td class=\"subtitle1\">Metal</td>\n\t\t\t\t\t<td class=\"subtitle1\">Water</td>\n\t\t\t\t\t<td class=\"subtitle1\">Wood</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Heart</td>\n\t\t\t\t\t<td>Spleen</td>\n\t\t\t\t\t<td>Lung</td>\n\t\t\t\t\t<td>Kidney</td>\n\t\t\t\t\t<td>Liver</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Pericardium</td>\n\t\t\t\t\t<td>Stomach</td>\n\t\t\t\t\t<td>Large intestine</td>\n\t\t\t\t\t<td>Bladder</td>\n\t\t\t\t\t<td>Gallbladder</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Joy</td>\n\t\t\t\t\t<td>Anxiety</td>\n\t\t\t\t\t<td>Worry, grief</td>\n\t\t\t\t\t<td>Fear, depression</td>\n\t\t\t\t\t<td>Anger</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Summer</td>\n\t\t\t\t\t<td>Late summer</td>\n\t\t\t\t\t<td>Autumn</td>\n\t\t\t\t\t<td>Winter</td>\n\t\t\t\t\t<td>Spring</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Spirit</td>\n\t\t\t\t\t<td>Conscience</td>\n\t\t\t\t\t<td>Health</td>\n\t\t\t\t\t<td>Will</td>\n\t\t\t\t\t<td>Emotion</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53247 Version 1.0</div></div></div>"},"53250":{"type":"graphic_waveform","displayName":"LV RV diastolic pressures","title":"Right and left ventricular end-diastolic pressure tracings","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Right and left ventricular end-diastolic pressure tracings</div><div class=\"cntnt\"><img style=\"width:541px; height:279px;\" src=\"images/CARD/53250_LV_RV_diastolic_pressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous right (RV) and left ventricular (LV) pressures recordings. Panel A: A normal patient who has a junctional rhythm, accounting for the absence of the &quot;a&quot; wave at the end of diastole. Although the diastolic period is relatively flat for the first beat, there is normal filling by the third beat. Panel B: Elevated left ventricular end-diastolic pressure (LVEDP) in patient with impaired LV relaxation and diastolic dysfunction due to chronic mitral regurgitation. Panel C: Recorded at a scale of 0 to 100 mmHg in a patient with decompensated severe heart failure. The LVEDP is significantly elevated and there is also elevation of the right ventricular end diastolic pressure (RVEDP). In addition, the upstroke velocity of LV systole is delayed, consistent with global LV dysfunction. Panel D: Elevations in both RVEDP and LVEDP due to a cardiomyopathy. A ventricular pacemaker is also present, causing a delay and skewing in the RV diastolic relaxation period with overlapping of the LV and RV pressure downslopes. Panel E: A patient with hypertension and heart failure who has a left bundle branch block. The LVEDP is elevated and the LV pressure upslope in systole is more rapid than that of the RV. The LV is noncompliant, resulting in a rapid increase in diastolic pressure which is not seen in the RV. As in panel D, RV diastolic relaxation is delayed and overlaps with that of the LV.</div><div class=\"graphic_reference\">Courtesy of Morton Kern, MD.</div><div id=\"graphicVersion\">Graphic 53250 Version 2.0</div></div></div>"},"53251":{"type":"graphic_diagnosticimage","displayName":"Lung cancer extension MRI I","title":"Transdiaphragmatic extension of lung carcinoma on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transdiaphragmatic extension of lung carcinoma on MRI</div><div class=\"cntnt\"><img style=\"width:334px; height:272px;\" src=\"images/PULM/53251_Lung_cancer_extension_MRI_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T2-weighted section at the same level as the previous CT scan shows high T2-signal intensity in the right hepatic lobe (arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53251 Version 3.0</div></div></div>"},"53253":{"type":"graphic_figure","displayName":"Cell interactions scleroderma","title":"Cellular interactions in the pathogenesis of scleroderma","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Cellular interactions in the pathogenesis of scleroderma</div><div class=\"cntnt\"><img style=\"width:517px; height:282px;\" src=\"images/RHEUM/53253_Cell_interactions_scleroder.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the cellular components implicated in the pathogenesis of scleroderma: the vascular endothelial cells, lymphocytes, and fibroblasts. Interplay between these factors, and between the fibroblasts and noncellular components of the extracellular matrix are likely to play an important role.</div><div id=\"graphicVersion\">Graphic 53253 Version 1.0</div></div></div>"},"53255":{"type":"graphic_picture","displayName":"Central L SC supra needle","title":"Needle insertion for central venous catheter placement using the supraclavicular approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle insertion for central venous catheter placement using the supraclavicular approach</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/53255_Central_L_SC_supra_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When using the supraclavicular approach for central venous catheter placement, it is important that the needle be oriented properly. It should lie 10 to 15 degrees below the coronal plane and oriented to bisect the angle between the clavicle and the sternocleidomastoid. The needle should not be inserted too deeply; the subclavian vein generally lies 1 to 1.5 cm deep to the insertion point.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 53255 Version 2.0</div></div></div>"},"53256":{"type":"graphic_figure","displayName":"Hepatocellular Ca hep C","title":"Hepatocellular carcinoma in cirrhosis due to hepatitis C","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma in cirrhosis due to hepatitis C</div><div class=\"cntnt\"><img style=\"width:502px; height:318px;\" src=\"images/GAST/53256_Hepatocellular_Ca_hep_C.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A study of 384 patients with compensated cirrhosis due to hepatitis C virus infection found that 1.4 percent of patients per year developed hepatocellular carcinoma.</div><div class=\"graphic_reference\">Data from Fattovich, G, Giustina, G, Degos, F, et al, Gastroenterology 1997; 112:463.</div><div id=\"graphicVersion\">Graphic 53256 Version 1.0</div></div></div>"},"53257":{"type":"graphic_figure","displayName":"Aortic regurgitation CW Doppler","title":"Aortic regurgitation as demonstrated by continuous wave Doppler echocardiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic regurgitation as demonstrated by continuous wave Doppler echocardiography</div><div class=\"cntnt\"><img style=\"width:316px; height:255px;\" src=\"images/CARD/53257_Aortic_regurgitation_CW_Dop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous wave Doppler in isolated aortic regurgitation. There is a moderate amount of aortic regurgitation based upon a diastolic deceleration rate that is moderately rapid. The peak velocity across the aortic valve is normal and there is no aortic stenosis.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 53257 Version 2.0</div></div></div>"},"53261":{"type":"graphic_picture","displayName":"Skin abscess","title":"Skin abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin abscess</div><div class=\"cntnt\"><img style=\"width:334px; height:234px;\" src=\"images/ID/53261_Skin_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Larry M Baddour, MD.</div><div id=\"graphicVersion\">Graphic 53261 Version 1.0</div></div></div>"},"53262":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CT IV","title":"Right paratracheal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right paratracheal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/PULM/53262_Med_bronchogen_cyst_CT_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan shows a low attenuation, non-enhancing cyst.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53262 Version 3.0</div></div></div>"},"53263":{"type":"graphic_picture","displayName":"Melanocytic lesions","title":"Dermoscopic structures seen in melanocytic lesions","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures seen in melanocytic lesions</div><div class=\"cntnt\"><img style=\"width:512px; height:398px;\" src=\"images/DERM/53263_Melanocytic_lesions_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopic structures seen in melanocytic lesions.<br> (A) Pigment network.<br> (B) Negative network.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 53263 Version 4.0</div></div></div>"},"53264":{"type":"graphic_diagnosticimage","displayName":"Gastric artery aneurysm associated with pancreatitis","title":"Gastric artery aneurysm associated with pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Gastric artery aneurysm associated with pancreatitis</div><div class=\"cntnt\"><img style=\"width:500px; height:408px;\" src=\"images/SURG/53264_Gastric_artery_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a round collection of iodinated contrast within the area of inflammatory change consistent with a gastric artery aneurysm.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 53264 Version 3.0</div></div></div>"},"53265":{"type":"graphic_figure","displayName":"Cross section of wrist","title":"Cross-sectional anatomy of the wrist","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Cross-sectional anatomy of the wrist</div><div class=\"cntnt\"><img style=\"width:541px; height:450px;\" src=\"images/EM/53265_Cross_section_of_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;figure represents&nbsp;a cross sectional view of&nbsp;the right wrist.&nbsp;Tendons and median nerve may be compressed by inflammation or infection because they are encompassed by synovial sheath and flexor retinaculum.</div><div id=\"graphicVersion\">Graphic 53265 Version 5.0</div></div></div>"},"53266":{"type":"graphic_table","displayName":"ACC AHA indication stopping ETT","title":"ACC/AHA guideline summary: Indications for terminating exercise testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Indications for terminating exercise testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Absolute indications</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Drop in systolic blood pressure &#62;10 mmHg from baseline, despite an increase in workload when accompanied by any other evidence of ischemia</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Moderate-to-severe angina, defined as level 2 angina, approaching level 3; the angina scale is described below</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Increasing nervous system symptoms (eg, ataxia, dizziness, or near syncope)</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Signs of poor perfusion (cyanosis or pallor)</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Technical difficulties monitoring the ECG or systolic blood pressure</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Patient's request to stop</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Sustained ventricular tachycardia</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; ST segment elevation (&#62;1.0 mm) in leads without diagnostic Q waves (other than V1 or aVR)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Relative Indications</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Drop in systolic blood pressure &#8805;10 mmHg from baseline, despite an increase in workload in the absence of other evidence of ischemia</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; ST or QRS changes such as excessive ST depression (&#62;2 mm of horizontal or downsloping of ST segment depression) or marked axis shift</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Arrhythmias other than sustained ventricular tachycardia, including multifocal ventricular premature beats, ventricular triplets, supraventricular tachycardia, heart block, or bradyarrhythmias</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Fatigue, shortness of breath, wheezing, leg cramps, or claudication</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Development of bundle branch block or intraventricular conduction delay that cannot be distinguished from ventricular tachycardia</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Increasing chest pain</td> </tr> <tr> <td colspan=\"2\">&#8226;&nbsp; Hypertensive response (systolic blood pressure &#62;250 mmHg and/or diastolic blood pressure &#62;115 mmHg)</td> </tr> <tr> <td class=\"subtitle1\">Four-level angina scale for exercise tolerance testing</td> <td class=\"subtitle1\">Level</td> </tr> <tr> <td>Onset of angina, mild but recognized as the usual angina-of-effort pain or discomfort with which the patient is familiar</td> <td>1</td> </tr> <tr> <td>Same pain, moderately severe and definitely uncomfortable but still tolerable</td> <td>2</td> </tr> <tr> <td>Severe anginal pain at a level that the subject will wish to stop exercising</td> <td>3</td> </tr> <tr> <td>Unbearable chest pain; the most severe pain the patient has felt</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Gibbons, RJ, Balady, GJ, Bricker, JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.</div><div id=\"graphicVersion\">Graphic 53266 Version 2.0</div></div></div>"},"53268":{"type":"graphic_figure","displayName":"Treatment of membranous lupus","title":"Cumulative probability of remission of proteinuria in patients with membranous lupus treated with cyclosporine, intravenous cyclophosphamide, or prednisone","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Cumulative probability of remission of proteinuria in patients with membranous lupus treated with cyclosporine, intravenous cyclophosphamide, or prednisone</div><div class=\"cntnt\"><img style=\"width:500px; height:442px;\" src=\"images/NEPH/53268_Treatment_membranous_lupus.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSA: cyclosporine; IVCY: intravenous cyclophosphamide; Pred: prednisone.</div><div class=\"graphic_reference\">Reproduced with permission from: Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901. Copyright &copy; 2009 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 53268 Version 4.0</div></div></div>"},"53269":{"type":"graphic_table","displayName":"Nonoral Rx sexual dysfunction","title":"Suppositories, injections, and devices for treatment of male sexual dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suppositories, injections, and devices for treatment of male sexual dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">US trade name</td> <td class=\"subtitle1\">Method of use and effect</td> <td class=\"subtitle1\">Advantages and limitations</td> <td class=\"subtitle1\">Usage pattern</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Suppository</td> </tr> <tr> <td class=\"indent1\">Alprostadil intraurethral pellet</td> <td>Muse</td> <td> <p>Alprostadil (prostaglandin E1) in gel form delivered by applicator into meatus of penis.</p> Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.</td> <td> <p>Less invasive than intracavernosal injections, but also less effective. Can be used twice daily.</p> Not recommended with pregnant partners.</td> <td>Inserted 5 to 10 minutes before sex. Effects last up to 1 hour.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Penile injection</td> </tr> <tr> <td class=\"indent1\">Alprostadil</td> <td> <p>Caverject</p> Edex</td> <td>Prostaglandin E1 injected into base of penis. Causes smooth muscle relaxation in corpus cavernosae.</td> <td> <p>Effective in 50 to 85 percent of cases.</p> Disadvantages include dislike of penile self-injection, pain at injection site, requires reconstitution and sterile technique, not for use more than three times per week or more than once per 24 hours. Bleeding risk with anticoagulants. Priapism occurs uncommonly.</td> <td>Inject 10 to 20 minutes before sex. Erections may last over an hour.</td> </tr> <tr> <td class=\"indent1\">Vasoactive intestinal peptide (VIP, aviptadil) and phentolamine</td> <td>Invicorp (not available in US)</td> <td>Causes vasodilation by direct vascular smooth muscle relaxation allowing blood flow and entrapment in penis.</td> <td>Possibly more effective than alprostadil. Causes less pain. Priapism rare.</td> <td>Inject 10 to 20 minutes before sex. Requires stimulation to have erection.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Device</td> </tr> <tr> <td class=\"indent1\">Vacuum pump</td> <td>Various</td> <td>Removes air from chamber over penis, creating a vacuum and drawing blood into penile cavernosae. Elastic tourniquet at base holds blood in penis.</td> <td>One-time expense. Safe if erection not maintained more than one hour. May not be acceptable to partner. Penis is hinged at base. May interfere with ejaculation. Can cause bruising of penis.</td> <td>Inflated just before sexual activity. Erection lasts until elastic ring removed.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53269 Version 4.0</div></div></div>"},"53270":{"type":"graphic_table","displayName":"Risk of BRCA1 mutation","title":"Relationship between family history of breast and ovarian cancer and likelihood of BRCA1 mutation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relationship between family history of breast and ovarian cancer and likelihood of BRCA1 mutation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Chance of BRCA1 mutation, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Single affected patient</td>\n\n      <td>In individual</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Breast cancer, &#60;age 30</td>\n\n      <td>12</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Breast cancer, ages 30-39</td>\n\n      <td>6</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Breast cancer, ages 40-49</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Ovarian cancer, &#60;age 50</td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Sisters</td>\n\n      <td>In family</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2 breast cancers, &#60;age 40</td>\n\n      <td>37</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2  breast cancers, ages 40-49</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Breast cancer &#60;age 50, ovarian cancer&nbsp;&#60;age 50</td>\n\n      <td>46</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2 ovarian cancers, &#60;age 50</td>\n\n      <td>61</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">Families</td>\n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#8805;3 breast cancers, all before age 50</td>\n\n      <td>40</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#8805;2 breast cancers, &#8805;1 ovarian cancer </td>\n\n      <td>82</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">&#8805;2 breast cancers, &#8805;2 ovarian cancers</td>\n\n      <td>92</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Greene, MH, Mayo Clin Proc 1997; 72:54.</div><div id=\"graphicVersion\">Graphic 53270 Version 1.0</div></div></div>"},"53271":{"type":"graphic_picture","displayName":"Tinea corporis on leg","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:319px; height:396px;\" src=\"images/PC/53271_Tinea_corporis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This annular lesion with central clearing and a scaly border was consistent with tinea corporis.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53271 Version 3.0</div></div></div>"},"53273":{"type":"graphic_table","displayName":"Treatment CDI adults","title":"Antibiotic regimens for the treatment of <em>Clostridium difficile</em> infection in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotic regimens for the treatment of <em>Clostridium difficile</em> infection in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical definition</td> <td class=\"subtitle1\">Treatment*</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <p><strong>Nonsevere disease</strong></p> Supportive clinical data: White blood cell count &#8804;15,000 cells/mL and serum creatinine &#60;1.5 mg/dL</td> </tr> <tr> <td class=\"indent1\">Initial episode</td> <td> <ul> <li>Vancomycin 125 mg orally four times daily for 10 days, <strong>OR</strong> </li> <li>Fidaxomicin 200 mg orally twice daily for 10 days </li> <li>If above agents are unavailable: Metronidazole 500 mg orally three times daily for 10 days<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">First recurrence</td> <td> <ul> <li>If vancomycin was used for the initial episode: <ul> <li>Vancomycin pulsed-tapered regimen: <ul> <li>125 mg orally four times daily for 10 to 14 days, then </li> <li>125 mg orally twice daily for 7 days, then </li> <li>125 mg orally once daily for 7 days, then </li> <li>125 mg orally every 2 or 3 days for 2 to 8 weeks, <strong>OR</strong> </li> </ul> </li> <li>Fidaxomicin 200 mg orally twice daily for 10 days </li> </ul> </li> <li>If fidaxomicin or metronidazole was used for the initial episode: Vancomycin 125 mg orally four times daily for 10 days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Second or subsequent recurrence</td> <td> <ul> <li>Vancomycin pulsed-tapered regimen (outlined above), <strong>OR</strong> </li> <li>Fidaxomicin 200 mg orally twice daily for 10 days, <strong>OR</strong> </li> <li>Vancomycin followed by rifaximin: <ul> <li>Vancomycin 125 mg orally four times per day for 10 days, then </li> <li>Rifaximin 400 mg three times daily for 20 days, <strong>OR</strong> </li> </ul> </li> <li>Fecal microbiota transplantation<sup>&#916;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Severe disease</strong><sup>&#9674;</sup></p> Supportive clinical data: White blood cell count &#62;15,000 cells/mL and/or serum creatinine &#8805;1.5 mg/dL</td> <td> <ul> <li>Vancomycin 125 mg orally four times daily for 10 days, <strong>OR</strong> </li> <li>Fidaxomicin 200 mg orally twice daily for 10 days </li> </ul> </td> </tr> <tr> <td> <p><strong>Fulminant disease </strong>(previously referred to as severe, complicated <em>C. difficile </em>infection)<sup>&#9674;</sup></p> Supportive clinical data: Hypotension or shock, ileus, megacolon</td> <td> <ul> <li>Enteric vancomycin plus parenteral metronidazole: <ul> <li>Vancomycin 500 mg orally or via nasogastric tube four times daily, <strong>AND</strong> </li> <li>Metronidazole 500 mg intravenously every 8 hours </li> </ul> </li> <li>If ileus is present, rectal vancomycin may be administered as a retention enema (500 mg in 100 mL normal saline per rectum; retained for as long as possible and readministered every 6 hours)<sup>&#167;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CDI: <EM>Clostridium difficile </EM>infection.<br />* All randomized trials have compared 10-day treatment courses, but some patients (particularly those treated with metronidazole) may have delayed response to treatment; in such circumstances, extending treatment duration to 14 days is reasonable.<br />¶ Metronidazole should be avoided in patients who are very elderly or infirm or who develop CDI in association with inflammatory bowel disease.<br />Δ Where available, fecal microbiota transplantation (FMT) is the preferred management approach for patients with third or subsequent recurrence. Appropriate antibiotic treatment for at least two recurrences (ie, three CDI episodes) should be attempted prior to offering FMT.<br /><FONT class=lozenge>◊</FONT> The criteria proposed for defining severe or fulminant CDI are based on expert opinion and may need to be reviewed upon publication of prospectively validated severity scores for patients with CDI.<br />§ Administration of intracolonic vancomycin is associated with risk of colonic perforation. Therefore, this approach should be restricted to patients who are not responsive to oral therapy, and the procedure should be performed by personnel with expertise in administering enemas.</div><div class=\"graphic_reference\">Adapted from: McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018, by permission of Oxford University Press on behalf of IDSA and SHEA. Copyright &copy; 2018. <a href=\"http://www.idsociety.org/PracticeGuidelines/\" target=\"_blank\">http://www.idsociety.org/PracticeGuidelines/</a>.</div><div id=\"graphicVersion\">Graphic 53273 Version 23.0</div></div></div>"},"53274":{"type":"graphic_movie","displayName":"Arm and hand atrophy in ALS","title":"Arm and intrinsic hand muscle atrophy in a patient with amyotrophic lateral sclerosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arm and intrinsic hand muscle atrophy in a patient with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/53274_alsaratrconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:241px;\" src=\"images/NEURO/53274_alsaratr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arm and intrinsic hand muscle atrophy with a &quot;claw hand&quot; appearance is noted. Fasciculations causing intermittent movement of the left fingers are apparent.</div><div class=\"graphic_reference\">Courtesy of Nestor Galvez-Jimenez, MD, FACP.</div><div id=\"graphicVersion\">Graphic 53274 Version 3.0</div></div></div>"},"53277":{"type":"graphic_figure","displayName":"Jaw thrust maneuver","title":"Jaw thrust maneuver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jaw thrust maneuver</div><div class=\"cntnt\"><img style=\"width:406px; height:168px;\" src=\"images/EM/53277_Jaw_thrust.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rescuer uses two or three fingers of each hand to lift the jaw upward and outward so that the lower central incisors are anterior to the upper central incisors. In children with traumatic injuries, the cervical spine must be maintained in a neutral position during this maneuver.</div><div id=\"graphicVersion\">Graphic 53277 Version 2.0</div></div></div>"},"53279":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD with LV to RA shunt still frame","title":"Membranous VSD with LV to RA shunt still frame","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Membranous VSD with LV to RA shunt still frame</div><div class=\"cntnt\"><img style=\"width:504px; height:417px;\" src=\"images/CARD/53279_Membr_VSD_LV_RA_shunt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal coronal still frame with color flow mapping showing the LV-RA shunt. This communication is between the LVOT and the RA. The defect (arrow) directs blood into the RA directly from the LVOT, entering just above the septal leaflet of the tricuspid valve.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; LV: left ventricle; RV: right ventricle; IVS: intraventricular septum; LVOT: left ventricular outflow tract; TV: tricuspid valve; VSD: ventricular septal defect (arrow).</div><div id=\"graphicVersion\">Graphic 53279 Version 4.0</div></div></div>"},"53280":{"type":"graphic_figure","displayName":"Vitamin C and CHD","title":"Role of ascorbic acid (vitamin C) in coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Role of ascorbic acid (vitamin C) in coronary heart disease</div><div class=\"cntnt\"><img style=\"width:366px; height:324px;\" src=\"images/CARD/53280_Vitamin_C_and_CHD.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53280 Version 1.0</div></div></div>"},"53281":{"type":"graphic_table","displayName":"Cytogenetic abnormalities AMM","title":"Cytogenic abnormalties in agnogenic myeloid metaplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytogenic abnormalties in agnogenic myeloid metaplasia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Abnormality</td>\n\n      <td class=\"subtitle1\">Frequency, percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>20q-</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td>13q-</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>abn chromosome 1</td>\n\n      <td>17</td>\n\n    </tr>\n\n    <tr>\n\n      <td>+8</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td>+9</td>\n\n      <td>13</td>\n\n    </tr>\n\n    <tr>\n\n      <td>-7</td>\n\n      <td>11</td>\n\n    </tr>\n\n    <tr>\n\n      <td>abn chromosome 12</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>-5</td>\n\n      <td>6</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Includes patients with post-polycythemia and post-thrombocythemia myeloid metaplasia.</div><div class=\"graphic_reference\">Data from: Tefferi, A, et al. Br J Haematol 2001; 113:763.</div><div id=\"graphicVersion\">Graphic 53281 Version 1.0</div></div></div>"},"53282":{"type":"graphic_picture","displayName":"Richters transformation","title":"Richter's transformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Richter's transformation</div><div class=\"cntnt\"><img style=\"width:303px; height:287px;\" src=\"images/HEME/53282_Richters_transformation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymph node from a patient with chronic lymphocytic leukemia (CLL) undergoing Richter's transformation. The monotonous infiltrate of small lymphocytes on the left side, representing the pre-existing CLL, contrasts with the large B cells on the right, representing transformation to a diffuse large B cell lymphoma.</div><div class=\"graphic_reference\">From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 53282 Version 3.0</div></div></div>"},"53284":{"type":"graphic_table","displayName":"Geriatric weight chart","title":"Weight charts for older persons","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weight charts for older persons</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Height (inches)</td>\n\n      <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Weight (pounds)</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">60-69 years</td>\n\n\n      <td class=\"subtitle2\">70-79 years</td>\n\n      <td class=\"subtitle2\">80-89 years&nbsp;&nbsp;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>61</td>\n\n      <td>127-151&nbsp;</td>\n\n\n      <td>121-153</td>\n\n      <td>-</td>\n\n    </tr>\n\n    <tr>\n\n      <td>62</td>\n\n      <td>131-163</td>\n\n\n      <td>125-155</td>\n\n      <td>119-148</td>\n\n    </tr>\n\n    <tr>\n\n      <td>63</td>\n\n      <td>135-163</td>\n\n\n      <td>127-157 </td>\n\n      <td>120-150</td>\n\n    </tr>\n\n    <tr>\n\n      <td>64</td>\n\n      <td>140-173</td>\n\n\n      <td>129-161</td>\n\n      <td>128-152</td>\n\n    </tr>\n\n    <tr>\n\n      <td>65</td>\n\n      <td>144-179</td>\n\n\n      <td>130-164</td>\n\n      <td>125-155</td>\n\n    </tr>\n\n    <tr>\n\n      <td>66</td>\n\n      <td>148-184</td>\n\n\n      <td>133-167</td>\n\n      <td>128-158</td>\n\n    </tr>\n\n    <tr>\n\n      <td>67</td>\n\n      <td>153-190</td>\n\n\n      <td>136-170</td>\n\n      <td>130-162</td>\n\n    </tr>\n\n    <tr>\n\n      <td>68</td>\n\n      <td>158-196</td>\n\n\n      <td>139-174</td>\n\n      <td>133-165</td>\n\n    </tr>\n\n    <tr>\n\n      <td>69</td>\n\n      <td>162-201</td>\n\n\n      <td>142-178</td>\n\n      <td>137-169</td>\n\n    </tr>\n\n    <tr>\n\n      <td>70</td>\n\n      <td>167-207</td>\n\n\n      <td>146-182 </td>\n\n      <td>140-175</td>\n\n    </tr>\n\n    <tr>\n\n      <td>71</td>\n\n      <td>172-213</td>\n\n\n      <td>149-186</td>\n\n      <td>144-180</td>\n\n    </tr>\n\n    <tr>\n\n      <td>72</td>\n\n      <td>177-219</td>\n\n\n      <td>154-190</td>\n\n      <td>148-187</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Any patient falling below these weights should be considered nutritionally at risk; multiply height by 2.54 to convert to cm, and divide weight by 2.2 to convert to kg.</div><div id=\"graphicVersion\">Graphic 53284 Version 1.0</div></div></div>"},"53287":{"type":"graphic_diagnosticimage","displayName":"PVOD CXR PA","title":"Chest radiographs in pulmonary veno-occlusive disease (PVOD)","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Chest radiographs in pulmonary veno-occlusive disease (PVOD)</div><div class=\"cntnt\"><img style=\"width:494px; height:207px;\" src=\"images/PULM/53287_PVOD_CXR_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) reveals a normal sized cardiac silhouette with thickened septal lines in both lower lobes, which are more easily seen on the magnified view of the lower lobe (arrows in B).</div><div class=\"graphic_reference\">Reproduced with permission from: Mandel J, Mark E, Hales C. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society © American Lung Association.</div><div id=\"graphicVersion\">Graphic 53287 Version 3.0</div></div></div>"},"53288":{"type":"graphic_waveform","displayName":"Pulse wave Doppler COPD constr","title":"Pulse-wave Doppler distinguishes between constrictive pericarditis and chronic obstructive pulmonary disease","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Pulse-wave Doppler distinguishes between constrictive pericarditis and chronic obstructive pulmonary disease</div><div class=\"cntnt\"><img style=\"width:509px; height:222px;\" src=\"images/CARD/53288_Pulse_wave_Doppler_COPD_con.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with chronic obstructive pulmonary disease (COPD) the pulse-wave Doppler echocardiogram shows pronounced respiratory variation in superior vena caval (SVC) blood flow velocity (red arrows, panel A), which is not seen in constrictive pericarditis. In contrast, the mitral flow velocity (panel B) shows a similar respiratory variation (E wave, black arrows) in COPD and constrictive pericarditis. Recording SVC blood flow velocity is therefore a simple way to distinguish pulsus paradoxus due to constrictive pericarditis from that due to COPD.</div><div class=\"graphic_footnotes\">S: systole; D: diastole.; ins: inspiration; exp: expiration.</div><div class=\"graphic_reference\">Reproduced with permission from: Boonyaratevej, S, Oh, JK, Tajik, AJ, et al. J Am Coll Cardiol 1998; 32:2043. Copyright © 1998 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 53288 Version 2.0</div></div></div>"},"53289":{"type":"graphic_table","displayName":"GI bleeding after TIPS","title":"Causes of gastrointestinal bleeding after TIPS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of gastrointestinal bleeding after TIPS</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Continued variceal hemorrhage</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Persistent gastric varices</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Associated with spontaneous splenorenal collaterals </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Associated with massive splenomegaly</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Stent dysfunction</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Thrombosis</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Retractions</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Kinking</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Displacement</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Stenosis</td>\n    </tr>\n    <tr>\n\n      <td>Hemobilia</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">TIPS: transjugular intrahepatic portosystemic shunt.</div><div class=\"graphic_reference\">Adapted from: Sanyal AJ. Semin Gastrointest Dis 1997; 8:188.</div><div id=\"graphicVersion\">Graphic 53289 Version 2.0</div></div></div>"},"53291":{"type":"graphic_table","displayName":"Features of malaria species","title":"Comparing the malaria species","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparing the malaria species</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>P. falciparum</em></td> <td class=\"subtitle1\"><em>P. vivax </em></td> <td class=\"subtitle1\"><em>P. ovale </em></td> <td class=\"subtitle1\"><em>P. malariae </em></td> <td class=\"subtitle1\"><em>P. knowlesi</em><sup>[1-7]</sup></td> </tr> <tr> <td>Geography</td> <td>Tropical, temperate zones</td> <td>Tropical, temperate zones, absent from West Africa</td> <td>Tropical, endemic in West Africa, present in Philippines, Indonesia, and Papua New Guinea</td> <td>Tropical, isolated pockets</td> <td>Southeast Asia</td> </tr> <tr> <td>RBC preference</td> <td>RBCs of all ages</td> <td>Young RBCs (reticulocytes)</td> <td>Young RBCs (reticulocytes)</td> <td>Older RBCs</td> <td>RBCs of all ages</td> </tr> <tr> <td>Infected RBC diameter</td> <td>Normal</td> <td>Larger than normal</td> <td>Larger than normal</td> <td>Normal or smaller than normal</td> <td>Normal</td> </tr> <tr> <td>Ameboid trophozoites</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Band forms</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Schizont*</td> <td>16 to 20 merozoites; very rare in peripheral circulation</td> <td>20 to 24 merozoites</td> <td>4 to 16 merozoites (8 typical)</td> <td>6 to 12 merozoites (8 or 10 typical)</td> <td>8 to 16 (10 typical)</td> </tr> <tr> <td>Parasitemia</td> <td>Can be very high</td> <td>Usually &#60;2 percent</td> <td>Usually &#60;2 percent</td> <td>Usually very low</td> <td>Can be high</td> </tr> <tr> <td>Disease severity</td> <td>End organ damage and death can occur</td> <td>End organ damage and death less common than <em>P. falciparum</em> but can occur</td> <td>Severe disease uncommon</td> <td>Severe disease rare</td> <td>Severe disease can occur</td> </tr> <tr> <td>Chloroquine resistance</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>Rare</td> <td>No</td> </tr> <tr> <td>Relapses from liver</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Incubation period</td> <td>12 days (8 to 25)</td> <td>14 days (10 to 30; occasionally months)</td> <td>15 days (10 to 20)</td> <td>18 days (15 to 35; occasionally months to years)</td> <td>11 days (9 to 12)</td> </tr> <tr> <td>Prepatent period<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><sup>&#182;</sup></span></td> <td>11 days</td> <td>12 days<sup>&#916;</sup></td> <td>12 days</td> <td>32 days</td> <td>Uncertain in naturally infected humans</td> </tr> <tr> <td>Cycle in red cell</td> <td>48 hours</td> <td>48 hours</td> <td>48 hours</td> <td>72 hours</td> <td>24 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cell.<br />* Identification of a schizont with &gt;12 merozoites in the peripheral circulation is an important diagnostic clue for <EM>P. vivax</EM>. In general, schizonts of<EM> P. falciparum</EM> are very rarely seen in blood films; they occur only in the setting of severe disease with hyperparasitemia.<br />¶ The prepatent period is the time from mosquito bite to the first appearance of parasites in the peripheral blood (as detected by microscopy).<br />Δ The latency period of vivax is typically longer than falciparum (refer to UpToDate table summarizing time to symptoms for each species).<br /></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Shearer FM, Huang Z, Weiss DJ, et al. Estimating geographical variation in the risk of zoonotic Plasmodium knowlesi infection in countries eliminating malaria. PLoS Negl Trop Dis 2016; 10:e0004915.</LI>&#xD;&#xA;<LI>Lim C, Hansen E, DeSimone TM, et al. Expansion of host cellular niche can drive adaptation of a zoonotic malaria parasite to humans. Nat Commun 2013; 4:1638.</LI>&#xD;&#xA;<LI>Lee KS, Cox-Singh J, Singh B. Morphological features and differential counts of Plasmodium knowlesi parasites in naturally acquired human infections. Malar J 2009; 8:73.</LI>&#xD;&#xA;<LI>William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011; 17:1248.</LI>&#xD;&#xA;<LI>Grigg MJ, William T, Menon J, et al. Artesunate-mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): An open-label, randomised controlled trial. Lancet Infect Dis 2016; 16:180.</LI>&#xD;&#xA;<LI>Chin W, Contacos PG, Collins WE, et al. Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey. Am J Trop Med Hyg 1968; 17:355. </LI>&#xD;&#xA;<LI>Coatney GR, Collins WE, Contacos PG. The Primate malarias.&nbsp;Division of Parasitic Diseases, Atlanta, GA 1971.</LI></OL></div><div id=\"graphicVersion\">Graphic 53291 Version 9.0</div></div></div>"},"53292":{"type":"graphic_picture","displayName":"Mucoid phenotype K pneu","title":"Mucoid phenotype of Klebsiella pneumoniae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucoid phenotype of Klebsiella pneumoniae</div><div class=\"cntnt\"><img style=\"width:360px; height:315px;\" src=\"images/ID/53292_Mucoid_phenotype_K_pneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When colonies were touched with a loop and the loop lifted vertically from the surface of the agar plate, mucoid isolates adhered to the loop as it was lifted from the plate. (Figure first presented at the 36th annual conference of the Infectious Diseases Society of America, Denver, Colorado, USA, 1998.)</div><div class=\"graphic_reference\">Reproduced from: Yu, VL, Hansen, DS, Chien Ko, W, et al. Virulence characteristics of Klebsiella and clinical manifestations of K. pnemoniae bloodstream infections. Emerg Infect Dis 2007; 13:986. Available online at <a href=\"http://www.cdc.gov/EID/content/13/7/986.htm\">http://www.cdc.gov/EID/content/13/7/986.htm</a> (Accessed on August 29, 2007).</div><div id=\"graphicVersion\">Graphic 53292 Version 3.0</div></div></div>"},"53295":{"type":"graphic_picture","displayName":"MDI in-line spacer","title":"Inline metered dose inhaler spacing device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inline metered dose inhaler spacing device</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PULM/53295_MDI_in-line_spacer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using a chamber results in a four- to six-fold greater delivery of aerosol than actuation into a connector attached directly to the endotracheal tube, or into an inline device that lacks a chamber.</div><div id=\"graphicVersion\">Graphic 53295 Version 2.0</div></div></div>"},"53297":{"type":"graphic_picture","displayName":"Incontinentia pigmenti 3","title":"Incontinentia pigmenti","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Incontinentia pigmenti</div><div class=\"cntnt\"><img style=\"width:504px; height:376px;\" src=\"images/DERM/53297_Incontpigmenti3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Verrucous, hyperkeratotic, linear plaques in a female infant with incontinentia pigmenti.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53297 Version 5.0</div></div></div>"},"53298":{"type":"graphic_table","displayName":"Fatal and near-fatal anaphylactic reaction to SCIT injections","title":"Factors contributing to fatal and near-fatal anaphylactic reaction to SCIT injections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors contributing to fatal and near-fatal anaphylactic reaction to SCIT injections</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Fatal reactions<sup>[1,2]</sup></td> <td class=\"subtitle1\">Near-fatal reactions<sup>[3]</sup></td> </tr> <tr> <td class=\"subtitle2\">(n = 34*)</td> <td class=\"subtitle2\">(n = 68)</td> </tr> <tr> <td>1. Uncontrolled asthma</td> <td>62%</td> <td>10%</td> </tr> <tr> <td>2. Prior systemic reaction</td> <td>53%</td> <td>9%</td> </tr> <tr> <td>3. Pollen season</td> <td>47%</td> <td>46%</td> </tr> <tr> <td>4. Epinephrine delayed or not given</td> <td>43%</td> <td>6%</td> </tr> <tr> <td>5. Reaction in allergist's office</td> <td>59%</td> <td>93%</td> </tr> <tr> <td>6. Dosing/administration errors (3 of 17 given IM)</td> <td>35%</td> <td>25%</td> </tr> <tr> <td>7. None reported</td> <td>17%<sup>&#182;</sup></td> <td>&ndash;</td> </tr> <tr> <td>8. Inadequate waiting period</td> <td>12%</td> <td>3%</td> </tr> <tr> <td>9. Home administration</td> <td>9%</td> <td>0%</td> </tr> <tr> <td>10. Beta-blockers/ACE inhibitors</td> <td>2% each</td> <td>3%/1.5%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCIT: subcutaneous immunotherapy; IM: intramuscularly; ACE-inhibitors: angiotensin-converting enzyme inhibitors.<br />* Data combined from two SCIT fatality studies<SUP>[1,2]</SUP>.<br />¶ Reference [2] only.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Reid MJ, et al. Survey of fatalities from skin testing and immunotherapy 1985 to 1989. J Allergy Clin Immunol 1993; 92:6.</li>&#xD;&#xA;    <li>Bernstein DI, et al. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990 to 2001. J Allergy Clin Immunol 2004; 113:1129.</li>&#xD;&#xA;    <li>Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53298 Version 8.0</div></div></div>"},"53302":{"type":"graphic_figure","displayName":"Mortality with syncope by cause","title":"Overall survival of patients with syncope","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Overall survival of patients with syncope</div><div class=\"cntnt\"><img style=\"width:463px; height:324px;\" src=\"images/CARD/53302_Mortality_with_syncope_by_c.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival was worst for patients with a cardiovascular cause of syncope. P &lt;0.001 for the comparison between participants with and those without syncope. The category \"Vasovagal and other causes\" includes vasovagal, orthostatic, medication-induced, and other, infrequent cause of syncope.</div><div class=\"graphic_reference\">Sorteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.</div><div id=\"graphicVersion\">Graphic 53302 Version 3.0</div></div></div>"},"53303":{"type":"graphic_table","displayName":"Diagnosis of COPD I","title":"Diagnosis of chronic obstructive pulmonary disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnosis of chronic obstructive pulmonary disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History </td> </tr> <tr> <td class=\"subtitle2_single\">Risk factors </td> </tr> <tr> <td class=\"indent2\">Family history </td> </tr> <tr> <td class=\"sublist3_start\">Smoking history </td> </tr> <tr> <td class=\"sublist3\">Age at initiation </td> </tr> <tr> <td class=\"sublist3\">Average amount smoked per day since initiation </td> </tr> <tr> <td class=\"sublist3\">Date when stopped smoking or a current smoker </td> </tr> <tr> <td class=\"sublist3_start\">Environmental history </td> </tr> <tr> <td class=\"sublist3\">The chronologically taken environmental history may disclose important risk factors for COPD</td> </tr> <tr> <td class=\"indent2\">Asthma</td> </tr> <tr> <td class=\"subtitle2_single\">Symptoms </td> </tr> <tr> <td class=\"subtitle3_single\">Dyspnea </td> </tr> <tr> <td class=\"indent2\">Ask about the amount of effort required to induce uncomfortable breathing. Many individuals will deny symptoms of dyspnea, but will have reduced their activity levels substantially.</td> </tr> <tr> <td class=\"subtitle3_single\">Cough </td> </tr> <tr> <td class=\"indent2\">Cough with or without sputum production should be an indication for spirometric testing. The presence of chronic cough and sputum has been used to define chronic bronchitis.</td> </tr> <tr> <td class=\"subtitle3_single\">Wheezing </td> </tr> <tr> <td class=\"indent2\">Wheezing or squeaky noises occurring during breathing indicate the presence of airflow obstruction</td> </tr> <tr> <td class=\"subtitle3_single\">Acute chest illnesses </td> </tr> <tr> <td class=\"indent2\">Inquire about occurrence and frequency of episodes of increased cough and sputum with wheezing, dyspnea, or fever </td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination </td> </tr> <tr> <td>All physical findings are generally present only with severe disease</td> </tr> <tr> <td class=\"subtitle2_single\">Chest </td> </tr> <tr> <td class=\"indent1\">The presence of emphysema (only when severe) is indicated by: overdistention of the lungs in the stable state (chest held near full inspiratory position at end of normal expiration, low diaphragmatic position), decreased intensity of breath and heart sounds, and prolonged expiratory phase</td> </tr> <tr> <td class=\"indent1\">Evidence of airflow obstruction: wheezes during auscultation on slow or forced breathing and prolongation of forced expiratory time</td> </tr> <tr> <td class=\"indent1\">Frequently observed with severe disease (characteristic, but not diagnostic): pursed-lip breathing, use of accessory respiratory muscles, retraction of lower interspaces</td> </tr> <tr> <td class=\"subtitle2_single\">Other </td> </tr> <tr> <td class=\"indent1\">Unusual positions to relieve dyspnea at rest</td> </tr> <tr> <td class=\"indent1\">Digital clubbing is NOT typical in COPD (even with associated hypoxemia) and suggests other diagnoses (eg, lung cancer, bronchiectasis, pulmonary fibrosis)</td> </tr> <tr> <td class=\"indent1\">Mild dependent edema may be seen in the absence of right heart failure</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53303 Version 3.0</div></div></div>"},"53306":{"type":"graphic_picture","displayName":"Chagas myocarditis ","title":"Chagas myocarditis light micrographs","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Chagas myocarditis light micrographs</div><div class=\"cntnt\"><img style=\"width:551px; height:237px;\" src=\"images/CARD/53306_ChagasmyocarditisLight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chagas heart disease showing severe myocarditis. (Left panel) Light micrograph of the myocardium in the acute phase: intense parasitism of muscle fibers by amastigote forms of <EM>Trypanosoma cruzi</EM> has led to the formation of pseudocysts (arrow). (Right panel) High-power view more clearly shows <EM>T. cruzi </EM>pseudocysts.</div><div class=\"graphic_reference\">Courtesy of João Samuel Meira Oliveira, MD and Harriet Provine.</div><div id=\"graphicVersion\">Graphic 53306 Version 2.0</div></div></div>"},"53309":{"type":"graphic_diagnosticimage","displayName":"Macular edema secondary to BRVO","title":"Optical coherence tomograph depicting macular edema secondary to branch retinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Optical coherence tomograph depicting macular edema secondary to branch retinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:514px; height:174px;\" src=\"images/PC/53309_Optical_coherence_tomograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Used to assess progression of retinal vein occlusion or response to treatment.</div><div id=\"graphicVersion\">Graphic 53309 Version 6.0</div></div></div>"},"53315":{"type":"graphic_table","displayName":"Conditions provoking or exacerbating ischemia","title":"Conditions provoking or exacerbating ischemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions provoking or exacerbating ischemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased oxygen demand</td> </tr> <tr> <td class=\"subtitle2_single\">Noncardiac</td> </tr> <tr> <td class=\"indent1\">Hyperthermia</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Sympathomimetic toxicity (eg, cocaine use)</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Anxiety</td> </tr> <tr> <td class=\"indent1\">Arteriovenous fistulae</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Aortic stenosis</td> </tr> <tr> <td class=\"indent1\">Dilated cardiomyopathy</td> </tr> <tr> <td class=\"sublist2_start\">Tachycardia</td> </tr> <tr> <td class=\"sublist2\">Ventricular</td> </tr> <tr> <td class=\"sublist2\">Supraventricular</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Decreased oxygen supply</td> </tr> <tr> <td class=\"subtitle2_single\">Noncardiac</td> </tr> <tr> <td class=\"indent1\">Anemia</td> </tr> <tr> <td class=\"sublist2_start\">Hypoxemia </td> </tr> <tr> <td class=\"sublist2\">Pneumonia</td> </tr> <tr> <td class=\"sublist2\">Asthma</td> </tr> <tr> <td class=\"sublist2\">Chronic obstructive pulmonary disease</td> </tr> <tr> <td class=\"sublist2\">Pulmonary hypertension</td> </tr> <tr> <td class=\"sublist2\">Interstitial pulmonary fibrosis</td> </tr> <tr> <td class=\"sublist2\">Obstructive sleep apnea</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease</td> </tr> <tr> <td class=\"indent1\">Sympathomimetic toxicity (eg, cocaine use)</td> </tr> <tr> <td class=\"sublist2_start\">Hyperviscosity</td> </tr> <tr> <td class=\"sublist2\">Polycythemia</td> </tr> <tr> <td class=\"sublist2\">Leukemia</td> </tr> <tr> <td class=\"sublist2\">Thrombocytosis</td> </tr> <tr> <td class=\"sublist2\">Hypergammaglobulinemia</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Aortic stenosis</td> </tr> <tr> <td class=\"indent1\">Hypertrophic cardiomyopathy</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: ACC/AHA/ACP Guidelines for the Management of Patients with Chronic Stable Angina. J Am Coll Cardiol 1999; 33:2092. Copyright ©1999 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 53315 Version 2.0</div></div></div>"},"53316":{"type":"graphic_figure","displayName":"Heart conduction WPW PI","title":"Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><img style=\"width:540px; height:380px;\" src=\"images/PI/53316_Heart_conduction_WPW_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with WPW syndrome have an extra electrical pathway between the atria and the ventricles, known as an accessory pathway. The abnormal pathway directly connects the atria and ventricles and bypasses the AV node, which is the slowest conducting part of the heart's electrical system. As a result, the normal sinus impulse can travel down the normal pathway through the AV node, as well as the more rapidly conducting accessory pathway. This allows the impulse traveling through the accessory pathway to reach the ventricle earlier, causing what is termed \"preexcitation.\"</div><div id=\"graphicVersion\">Graphic 53316 Version 4.0</div></div></div>"},"53317":{"type":"graphic_picture","displayName":"Mediastinal lymphoma","title":"Mediastinal diffuse large B cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal diffuse large B cell lymphoma</div><div class=\"cntnt\"><img style=\"width:313px; height:324px;\" src=\"images/HEME/53317_Mediastinal_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interstitial thick bands of fibrosis separate tumor cells into lobules of varying size, giving the lymphoma a pseudo- carcinomatous appearance.</div><div class=\"graphic_reference\">From: Warnke RA, Weiss LM, Chan JK, et al. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 53317 Version 2.0</div></div></div>"},"53321":{"type":"graphic_diagnosticimage","displayName":"Bone scan of Paget affecting both femurs","title":"Bone scan of Paget affecting both femurs","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Bone scan of Paget affecting both femurs</div><div class=\"cntnt\"><img style=\"width:550px; height:488px;\" src=\"images/RHEUM/53321_Bone_scan_Paget_femurs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone scan in a patient with Paget disease affecting both femurs. Note the intense uptake, beginning in subchondral bone and moving in one direction through that bone. There is a suggestion by this bone scan of&nbsp;Paget disease&nbsp;in the R tibia as well.</div><div class=\"graphic_reference\">Courtesy of Margaret Seton, MD.</div><div id=\"graphicVersion\">Graphic 53321 Version 2.0</div></div></div>"},"53322":{"type":"graphic_algorithm","displayName":"Treatment of severe alcohol withdrawal without diazepam*","title":"Treatment of severe alcohol withdrawal when IV diazepam is not available*","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Treatment of severe alcohol withdrawal when IV diazepam is not available*</div><div class=\"cntnt\"><img style=\"width:582px; height:596px;\" src=\"images/EM/53322_Sev_alch_wdraw_WO_diazepam.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AWS: alcohol withdrawal syndrome; CIWA: clinical institute withdrawal assessment for alcohol scale; RASS: richmond agitation sedation scale.<br />* Doses are for adults. Medications and doses may need adjustment based upon comorbities (eg, liver disease), patient age, or other factors (eg, coadministered medications).<br />&para; Lorazepam infusion is titrated to effect, and additional symptom-based bolus doses, 2-4 mg IV, are given when titrating the infusion up.</div><div class=\"graphic_reference\">Courtesy of Robert S. Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 53322 Version 2.0</div></div></div>"},"53324":{"type":"graphic_table","displayName":"Risk factors macrosomia","title":"Risk factors for fetal macrosomia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for fetal macrosomia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Diabetes</td>\n</tr>\n<tr>\n<td>Obesity</td>\n</tr>\n<tr>\n<td>Multiparity</td>\n</tr>\n<tr>\n<td>Prolonged gestation</td>\n</tr>\n<tr>\n<td>Male fetus</td>\n</tr>\n<tr>\n<td>Previous delivery of an infant weighing more than 4000 g</td>\n</tr>\n<tr>\n<td>Race and ethnicity</td>\n</tr>\n<tr>\n<td>Genetic syndromes</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of George T Mandy, MD.</div><div id=\"graphicVersion\">Graphic 53324 Version 1.0</div></div></div>"},"53325":{"type":"graphic_figure","displayName":"CDC weight for age girls 2 to 20 years","title":"Weight-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Weight-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:534px; height:689px;\" src=\"images/PEDS/53325_Weight_age_girls_more_2_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 53325 Version 5.0</div></div></div>"},"53326":{"type":"graphic_diagnosticimage","displayName":"Dilated vein in superotemporal BRVO","title":"Fluorescein angiogram frame depicts dilated vein in superotemporal branch retinal vein occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fluorescein angiogram frame depicts dilated vein in superotemporal branch retinal vein occlusion</div><div class=\"cntnt\"><img style=\"width:424px; height:340px;\" src=\"images/PC/53326_Dilated_vein.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53326 Version 4.0</div></div></div>"},"53330":{"type":"graphic_algorithm","displayName":"Anticoagulation algorithm in HD","title":"Guidelines for anticoagulation in dialysis patients at high risk for bleeding","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Guidelines for anticoagulation in dialysis patients at high risk for bleeding</div><div class=\"cntnt\"><img style=\"width:460px; height:204px;\" src=\"images/NEPH/53330_Anticoagulation_algorithm_i.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Guidelines for treatment of patients with renal failure requiring dialysis but at high risk for bleeding.</div><div class=\"graphic_footnotes\">dDAVP: desmopressin; CAVH/D: continuous arteriovenous hemofiltration or hemodialysis; RCA: regional citrate administration.</div><div id=\"graphicVersion\">Graphic 53330 Version 4.0</div></div></div>"},"53331":{"type":"graphic_picture","displayName":"Fusobacterium chorioamnionitis","title":"Fusobacterium chorioamnionitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fusobacterium chorioamnionitis</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/OBGYN/53331_Fusobacterium_chorioamnioni.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fusobacterium chorioamnionitis with severe, necrotizing infiltrate (arrow).&nbsp;Bacilli are not visualized at this low power.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53331 Version 3.0</div></div></div>"},"53332":{"type":"graphic_table","displayName":"TTP HUS HELLP","title":"Comparison of frequency of signs, symptoms, and laboratory findings in TTP, HUS, and HELLP","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of frequency of signs, symptoms, and laboratory findings in TTP, HUS, and HELLP</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">TTP</td> <td class=\"subtitle1\">HUS</td> <td class=\"subtitle1\">HELLP</td> <td class=\"subtitle1\">AFLP</td> </tr> <tr> <td><strong>Abdominal pain</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td><strong>Low ADAMST13 activity</strong></td> <td class=\"centered\">+/++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">?</td> </tr> <tr> <td><strong>Anemia</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Elevated lactic dehydrogenase</strong></td> <td class=\"centered\">++ very high values</td> <td class=\"centered\">++ very high values</td> <td class=\"centered\">++</td> <td class=\"centered\">+/++</td> </tr> <tr> <td><strong>Elevated transaminases</strong></td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td><strong>Fever</strong></td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Headache or visual disturbance</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;/+</td> </tr> <tr> <td><strong>Hypertension</strong></td> <td class=\"centered\">+/++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Jaundice</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>Nausea and vomiting</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td><strong>Proteinuria</strong></td> <td class=\"centered\">+ and hematuria</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Thrombocytopenia</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> </tr> <tr> <td><strong>von Willebrand factor</strong></td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">?</td> </tr> <tr> <td><strong>Hypoglycemia</strong></td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">++</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome; HELLP: hemolysis, elevated liver function tests, low platelets; AFLP: acute fatty liver of pregnancy; +: prevalence of finding in affected patients.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Stella CL, Dacus J, Guzman E, et al. The diagnostic dilemma of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the obstetric triage and emergency department: lessons from 4 tertiary hospitals. Am J Obstet Gynecol 2009; 200:381. Original Table 4.</li>&#xD;&#xA;    <li>Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol 2015;189:68. Table 1.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53332 Version 7.0</div></div></div>"},"53333":{"type":"graphic_algorithm","displayName":"Epidemiologic algorithm neglect","title":"Hot water burns: epidemiologic algorithm","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Hot water burns: epidemiologic algorithm</div><div class=\"cntnt\"><img style=\"width:484px; height:468px;\" src=\"images/PEDS/53333_Epidemiologic_algorithm_neg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm uses the example of a child who has sustained significant hot water burns to illustrate the relationships between individuals who may identify the manifestations of a child at risk, caretakers and agencies who have responsibility for the child's well-being, and targeted prevention strategies. These strategies include the following: A) Parents/sitter must be educated regarding the risk and outcomes of hot water burns. B) Legal consequences for the parents/sitter may include education or other constructive strategies. C and D) Public health officials must establish standards for safe hot water heater temperatures that can be enforced by housing inspectors. E) Social service agencies must designate state and federal funds to support compliance with public health regulations. F) State and/or federal legislation must establish standards for hot water heater manufacturers regarding settings that adjust water temperature.</div><div class=\"graphic_reference\">Reproduced with permission from: Helfer, RE. The Neglect of Our Children. Pediatr Clin North Am 1990; 37:923. Copyright ©1990 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 53333 Version 2.0</div></div></div>"},"53334":{"type":"graphic_picture","displayName":"Postauricular lymph node","title":"Postauricular lymphadenopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postauricular lymphadenopathy</div><div class=\"cntnt\"><img style=\"width:280px; height:391px;\" src=\"images/PEDS/53334_Postauricular_lymph_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postauricular lymph node in a child with tinea capitus and kerion.</div><div class=\"graphic_reference\">Reproduced with permission from: Gorbach SL, Bartlett JG, et al. Infectious Diseases. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53334 Version 2.0</div></div></div>"},"53335":{"type":"graphic_figure","displayName":"Arrangement of T cell receptor","title":"Somatic rearrangements of the T cell receptor b chain germline DNA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Somatic rearrangements of the T cell receptor b chain germline DNA</div><div class=\"cntnt\"><img style=\"width:431px; height:407px;\" src=\"images/PULM/53335_Arrangement_of_T_cell_recep.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The B chain of the T cell antigen receptor is composed of variable (V), diversity (D), and joining (J) segments. Somatic rearrangements occur with D-J joining followed by V-D-J joining. The random addition and/or deletion of nucleotides (N) forming the NDbN account for the tremendous diversity of the variable region of the b chain.</div><div class=\"graphic_reference\">Adapted from T cell maturation in the thymus. In: Cellular and Molecular Immunology, Abbas, AK, Lithtman, AH, Pober, JS, (Eds), Philadelphia, WB Saunders 1994. p.172.</div><div id=\"graphicVersion\">Graphic 53335 Version 1.0</div></div></div>"},"53336":{"type":"graphic_figure","displayName":"Lateral condyle elbow fracture mechanism of injury","title":"Lateral condyle elbow fracture mechanism of injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral condyle elbow fracture mechanism of injury</div><div class=\"cntnt\"><img style=\"width:398px; height:598px;\" src=\"images/EM/53336_Mech_lat_condyle_elbow_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most common mechanism of injury is believed to occur when the elbow is forced into varus (bottom left), which, along with the extensor muscles and lateral collateral ligaments, applies an avulsion force to the lateral condyle. When the fracture line extends to the trochlear notch (bottom right), the elbow becomes unstable.</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001.&nbsp;Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53336 Version 12.0</div></div></div>"},"53337":{"type":"graphic_algorithm","displayName":"NASPGHN evaluation CVS","title":"Evaluation of cyclic vomiting pattern in children older than 2 years","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Evaluation of cyclic vomiting pattern in children older than 2 years</div><div class=\"cntnt\"><img style=\"width:566px; height:762px;\" src=\"images/GAST/53337_NASPGHN_evaluation_CVS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* May not need metabolic evaluation.</div><div class=\"graphic_reference\">Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53337 Version 8.0</div></div></div>"},"53338":{"type":"graphic_figure","displayName":"Arcuate uterus","title":"Uterus bicornuate: arcuate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus bicornuate: arcuate</div><div class=\"cntnt\"><img style=\"width:406px; height:228px;\" src=\"images/OBGYN/53338_Arcuateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53338 Version 13.0</div></div></div>"},"53339":{"type":"graphic_diagnosticimage","displayName":"Post traumatic lung cyst CT","title":"Post-traumatic lung cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Post-traumatic lung cyst</div><div class=\"cntnt\"><img style=\"width:363px; height:350px;\" src=\"images/PULM/53339_Post_traumatic_lung_cyst_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Motor vehicle accident with paraspinal laceration (so-called Type II laceration) of the right lower lobe lung parenchyma. CT scan shows a thin-walled cavity with a gas liquid level resulting from bleeding into the posttraumatic cyst.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53339 Version 3.0</div></div></div>"},"53340":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa draining inflammatory nodule","title":"Hidradenitis suppurativa draining inflammatory nodule","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa draining inflammatory nodule</div><div class=\"cntnt\"><img style=\"width:379px; height:283px;\" src=\"images/SURG/53340_Draininflammnoduleedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient was diagnosed with hidradenitis suppurativa in the groin. This photograph shows an inflammatory draining nodule just&nbsp;medial to the left inguinal crease.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 53340 Version 6.0</div></div></div>"},"53342":{"type":"graphic_figure","displayName":"Hormonal changes during adrenarche","title":"Hormonal changes during adrenarche","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Hormonal changes during adrenarche</div><div class=\"cntnt\"><img style=\"width:532px; height:294px;\" src=\"images/PEDS/53342_hormon_adrenarche_5.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changing pattern of adrenal steroidogenic response to adrenocorticotropic hormone with maturation. Shown are plasma steroid levels before (basal, 8:00 AM after dexamethasone 1 mg/m<SUP>2</SUP> given eight hours before) and the rise (Δ) 30 minutes after cosyntropin (ACTH) administration (10 mcg/m<SUP>2</SUP>) in healthy prepubertal children, children with premature adrenarche, and follicular phase adult women. Note that 17-hydroxypregnenolone (17PREG) and dehydroepiandrosterone (DHEA) responses of children with premature adrenarche are intermediate between prepubertal and adult responses.<br />These changes underlie the characteristic maturational rise in serum DHEA sulfate (DHEAS). DHEAS&nbsp;mean norms are 11 mcg/dL in prepubertal girls, 105 mcg/dL in girls with&nbsp;premature adrenarche, and 208 mcg/dL in adult&nbsp;follicular phase females.&nbsp;&nbsp;&nbsp;</div><div class=\"graphic_footnotes\">17PROG: 17-hydroxyprogesterone; ADNE: androstenedione; CMPD S: compound S (11-deoxycortisol).</div><div class=\"graphic_reference\">From: Rosenfield RL, Cooke DW, Radovick S. Puberty and its disorders in the female. In: Pediatric Endocrinology, 3rd Edition, Sperling M (Ed). Elsevier, Philadelphia, 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.<br />Data from: Rich BH, Rosenfield RL, Lucky AW, Helke JC, Otto P. Adrenarche: changing adrenal response to adrenocorticotropin. J Clin Endocrinol Metab. 1981;52:1129-34.</div><div id=\"graphicVersion\">Graphic 53342 Version 3.0</div></div></div>"},"53343":{"type":"graphic_table","displayName":"Terminology of preexcitation pathways","title":"Terminology and anatomic connections of preexcitation pathways","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology and anatomic connections of preexcitation pathways</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Old terminology</td> <td class=\"subtitle1\">Proposed or commonly used terminology</td> <td class=\"subtitle1\">Anatomic connections</td> </tr> <tr> <td>Kent bundle*</td> <td>Accessory AV connection or AV bypass tract</td> <td>Atrium to ventricle</td> </tr> <tr> <td rowspan=\"2\">James fiber<sup>&#182;</sup></td> <td>Atrionodal bypass tract</td> <td>Atrium to low AV node</td> </tr> <tr> <td>Atriofascicular bypass tract</td> <td>Atrium to bundle of His</td> </tr> <tr> <td rowspan=\"4\">Mahaim fiber</td> <td>Atriofascicular bypass tract</td> <td>Atrium to bundle branch</td> </tr> <tr> <td>Nodofascicular bypass tract</td> <td>AV node to bundle branch</td> </tr> <tr> <td>Nodoventricular bypass tract</td> <td>AV node to ventricular tissue</td> </tr> <tr> <td>Fasciculoventricular bypass tract</td> <td>Bundle branch to ventricular tissue</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AV: atrioventricular.<br />* These bypass tracts result in delta waves and the Wolff-Parkinson-White syndrome.<br />¶ These bypass tracts result in the Lown-Ganong-Levine syndrome and enhanced AV nodal conduction.</div><div id=\"graphicVersion\">Graphic 53343 Version 6.0</div></div></div>"},"53344":{"type":"graphic_table","displayName":"Diagnostic criteria for leukocyte-adhesion defect type I","title":"Diagnostic criteria for leukocyte-adhesion defect type I","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for leukocyte-adhesion defect type I</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis* </td> </tr> <tr> <td class=\"sublist1_start\">A male or female patient with decreased intensity of expression of CD18 on neutrophils (less than 5% of normal) and at least one of the following: </td> </tr> <tr> <td class=\"sublist1\">1. Mutation in the beta-2 integrin gene. </td> </tr> <tr> <td class=\"sublist1\">2. Absence of beta-2 integrin mRNA in leukocytes. </td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis* </td> </tr> <tr> <td class=\"sublist1_start\">A male or female patient with defective expression of CD18 on leukocytes (less than 5% of normal) and all of the following: </td> </tr> <tr> <td class=\"sublist1\">1. Recurrent or persistent bacterial or fungal infections. </td> </tr> <tr> <td class=\"sublist1\">2. Leukocytosis (WBC greater than 25,000/mm<sup>3</sup>). </td> </tr> <tr> <td class=\"sublist1\">3. Delayed separation of the umbilical cord and/or defective wound healing. </td> </tr> <tr> <td class=\"subtitle1_single\">Possible diagnosis* </td> </tr> <tr> <td class=\"sublist1_start\">Infant with marked leukocytosis (WBC greater than 25,000/mm<sup>3</sup>) and one of the following: </td> </tr> <tr> <td class=\"sublist1\">1. Recurrent bacterial infections. </td> </tr> <tr> <td class=\"sublist1\">2. Severe deep-seated infection. </td> </tr> <tr> <td class=\"sublist1\">3. Absence of pus at sites of infection. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CD18: common beta-2 subunit of the beta-2 leukocyte integrins; WBC: white blood cell.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis. Patients with a possible diagnosis are those that have some but not all of the characteristic clinical or laboratory findings of a particular disorder.</div><div class=\"graphic_reference\">From Conley ME, Notarangelo LD, Etzioni A. Clin Immunol 1999; 93:190.</div><div id=\"graphicVersion\">Graphic 53344 Version 3.0</div></div></div>"},"53347":{"type":"graphic_table","displayName":"Electrophysiologic characteristics of different types of SVT","title":"Electrophysiologic characteristics of the different types of supraventricular tachycardia (SVT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrophysiologic characteristics of the different types of supraventricular tachycardia (SVT)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Characteristic</td>\n<td class=\"subtitle1\">Reentrant</td>\n<td class=\"subtitle1\">Triggered</td>\n<td class=\"subtitle1\">Automatic</td>\n</tr>\n<tr>\n<td>Initiation by extrastimuli and/or continuous pacing</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Initiation by continuous pacing depends upon the rate and number of stimuli</td>\n<td>No</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Termination by extrastimuli</td>\n<td>Yes</td>\n<td>No</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Termination by continuous pacing (overdrive)</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Overdrive suppression of tachycardia</td>\n<td>No</td>\n<td>No</td>\n<td>Yes</td>\n</tr>\n<tr>\n<td>Overdrive enhancement of tachycardia</td>\n<td>Yes</td>\n<td>Yes</td>\n<td>No</td>\n</tr>\n<tr>\n<td>Entrainment possible</td>\n<td>Yes</td>\n<td>No</td>\n<td>No</td>\n</tr>\n<tr>\n<td>First P wave identical to P waves in arrhythmia</td>\n<td>No</td>\n<td>Sometimes</td>\n<td>Yes</td>\n</tr>\n<tr>\n<td>Warm-up or acceleration of pacemaker after onset</td>\n<td>No</td>\n<td>Sometimes</td>\n<td>Yes</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53347 Version 2.0</div></div></div>"},"53349":{"type":"graphic_picture","displayName":"Alagille facies","title":"Typical facies in Alagille syndrome","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Typical facies in Alagille syndrome</div><div class=\"cntnt\"><img style=\"width:514px; height:350px;\" src=\"images/PEDS/53349_Alagille_facies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The typical facial features of Alagille syndrome are triangular, with a prominent forehead, deep-set eyes, a pointed chin, and a straight nose with a bulbous tip. The facial features change over time, with a more triangular shape during childhood and prominence of the jaw as patients reach adulthood.</div><div class=\"graphic_reference\">Reproduced with permission from: Kamath BM, Loomes KM, Piccoli DA. Medical Management of Alagille Syndrome. J Pediatr Gastroenterol Nutr 2010; 50:580. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53349 Version 12.0</div></div></div>"},"53350":{"type":"graphic_figure","displayName":"Anterior drawer test2","title":"Anterior drawer test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior drawer test</div><div class=\"cntnt\"><img style=\"width:396px; height:287px;\" src=\"images/PEDS/53350_Anterior_drawer_test2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior drawer test is used to assess the integrity of the anterior cruciate ligament. With the knee flexed to 90 degrees&nbsp;and the foot stabilized, the proximal tibia is grasped firmly with both hands, and the tibia is forcibly pulled anteriorly, noting any pain, laxity, or abnormal movement compared with the opposite side.</div><div id=\"graphicVersion\">Graphic 53350 Version 3.0</div></div></div>"},"53351":{"type":"graphic_picture","displayName":"Closed reduction of a nasal fracture","title":"Closed reduction of a nasal fracture in a teenager","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closed reduction of a nasal fracture in a teenager</div><div class=\"cntnt\"><img style=\"width:405px; height:514px;\" src=\"images/EM/53351_Closed_reduct_nasal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Note the obvious nasal bridge deformity sustained during wrestling.<br> (B) Asch forceps are used to elevate the fractured cartilage.<br> (C) Nasal bridge appearance after reduction.<br> (D) Splinting bandage.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 53351 Version 2.0</div></div></div>"},"53352":{"type":"graphic_figure","displayName":"Lund and Browder","title":"Lund and Browder chart","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Lund and Browder chart</div><div class=\"cntnt\"><img style=\"width:606px; height:766px;\" src=\"images/EM/53352_Lund_and_Browder_edit1.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53352 Version 3.0</div></div></div>"},"53353":{"type":"graphic_diagnosticimage","displayName":"Extramed hematopoiesis","title":"Extramedullary hematopoiesis (paraspinal masses) on CT scan in thalassemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramedullary hematopoiesis (paraspinal masses) on CT scan in thalassemia</div><div class=\"cntnt\"><img style=\"width:371px; height:276px;\" src=\"images/HEME/53353_Extramed_hematopoiesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an axial contrast-enhanced CT scan through the level of the chest in a 23-year-old thalassemic woman, showing uniformly enhancing paraspinal hematopoietic masses with no bony erosion (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">From: Georgiades CS, Neyman EG, Francis IR, et al. Typical and atypical presentations of extramedullary hemopoiesis. AJR Am J Roentgenol 2002; 179:1239. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 53353 Version 13.0</div></div></div>"},"53354":{"type":"graphic_table","displayName":"Homesickness prevention for planned separation","title":"Homesickness-prevention strategies for parents to use with children around planned separations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Homesickness-prevention strategies for parents to use with children around planned separations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Discuss the upcoming separation with your child. Young people should be told, \"Almost everyone misses something about home when they are away. Homesickness is normal. And the good news is that there are lots of things you can think and do to help make things better if homesickness bothers you.\"</td> </tr> <tr> <td>2. Involve your child in the decision to spend time away from home. Prepare and pack as a family. Taking part in even the smallest decisions will increase perceptions of control. By contrast, feeling forced to leave home often increases the severity of homesickness.</td> </tr> <tr> <td class=\"sublist1_start\">3. Discuss coping strategies with your child. Using some of these strategies during practice time away from home will boost your child's confidence about the separation. </td> </tr> <tr> <td class=\"sublist1\">a. Do something fun, like play with friends, to forget about homesick feelings. </td> </tr> <tr> <td class=\"sublist1\">b. Do something (write a letter, look at a family picture) to feel closer to home. </td> </tr> <tr> <td class=\"sublist1\">c. Go see someone who can talk with you to help you feel better. </td> </tr> <tr> <td class=\"sublist1\">d. Think about the good side of things (activities, friends) to feel better. </td> </tr> <tr> <td class=\"sublist1\">e. Think that time away is actually pretty short to make time go by faster. </td> </tr> <tr> <td class=\"sublist1\">f. Try not to think about home and loved ones to forget about homesickness. </td> </tr> <tr> <td class=\"sublist1\">g. Think about loved ones to figure out what they would say to help. </td> </tr> <tr> <td>4. Arrange for practice time away from home, such as a weekend at a friend's or relative's house. Ideally, these two or three days do not include telephone calls but do include opportunities for writing a letter or postcard home. After the practice time away, discuss with your child how things went and which coping strategies worked best.</td> </tr> <tr> <td>5. Practice correspondence. Ensuring that children know how to write traditional letters increases the likelihood that they will maintain some contact with home. Give children prestamped, preaddressed envelopes and notebook paper.</td> </tr> <tr> <td>6. Work together with your child to learn about their new environment, be it a hospital, school, new neighborhood, or summer camp. The more young people know about the new place to which they are going, the more at home they will feel when they arrive. Websites, orientation booklets, and current participants, alumni, or staff members are excellent resources.</td> </tr> <tr> <td>7. Help your child get to know some of the people in the new environment. Having at least one familiar face, be it an adult or a peer, in a new place can diminish feelings of homesickness by increasing feelings of social support and connection.</td> </tr> <tr> <td>8. Encourage your child to make new friends and seek the support of trusted adults. Both kinds of connections ease the transition to a new environment.</td> </tr> <tr> <td>9. Avoid expressing anxious or ambivalent feelings about time away from home to your child. Instead, express enthusiasm and optimism about the fun your child is going to have in the new environment.</td> </tr> <tr> <td>10. Use a wall calendar to show your child the time between today and the day of the separation. Highlight which days or weeks they will be away so that he or she can see that it is a discrete period, not an eternity. During the separation, a calendar might be a way for your child to keep perspective on the separation.</td> </tr> <tr> <td>11. Do not make a \"pick-up deal\" with your son or daughter. Promising that \"if you don't like it, I'll come pick you up\" decreases your child's likelihood of success in the new environment; this will give the impression to your child that you have so little confidence in his or her ability to cope with the separation that the only solution is to be rescued. Also, such deals create difficulties for staff members, who after enthusiastic support and coaching may be faced with a child who says, \"My parents said that if I didn't like it here, they would come to get me.\" It also puts you in the position of either (1) fulfilling your promise to pick up your child, robbing him or her of a wonderful opportunity to grow and develop, or (2) reneging on your promise, causing an erosion of trust in your relationship with your child. Respond to the query, \"What if I feel homesick?\" with a statement such as, \"You probably will feel a little homesick, but your practice time away has taught you what to think or do in case any homesickness bothers you. Plus, staff members will be there to talk with you and help you make it through. You'll have a great time.\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 119, Pages 192-201, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 53354 Version 15.0</div></div></div>"},"53355":{"type":"graphic_diagnosticimage","displayName":"M mode aorta cardiomyopathy","title":"M-mode echocardiogram of aortic root in cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of aortic root in cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:276px; height:310px;\" src=\"images/CARD/53355_Mmodeaortacardiomyopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In cardiomyopathy with reduced stroke volume, the systolic anterior excursion of the aortic (Ao) root is greatly reduced in comparison&nbsp;with the normal pattern. Additionally, the aortic valve (AoV) opening is greatly reduced, and its duration abbreviated. Just after achieving their maximum separation, the AoV leaflets immediately begin drifting closed, with a loss of the normal box-like configuration.</div><div class=\"graphic_footnotes\">RVOT: right ventricular outflow tract; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 53355 Version 5.0</div></div></div>"},"53359":{"type":"graphic_picture","displayName":"Sweet syndrome","title":"Sweet syndrome","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Sweet syndrome</div><div class=\"cntnt\"><img style=\"width:556px; height:279px;\" src=\"images/RHEUM/53359_Sweets_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous annular plaque lesions on the neck of a patient (left panel). Vesicular and pustular lesions of Sweet syndrome involving the buttocks (right panel).</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 53359 Version 2.0</div></div></div>"},"53360":{"type":"graphic_picture","displayName":"Cord hemangioma","title":"Cord hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cord hemangioma</div><div class=\"cntnt\"><img style=\"width:415px; height:432px;\" src=\"images/OBGYN/53360_Cord_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53360 Version 1.0</div></div></div>"},"53361":{"type":"graphic_diagnosticimage","displayName":"Endomyocard fibros RA echo","title":"Endomyocardial fibrosis","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Endomyocardial fibrosis</div><div class=\"cntnt\"><img style=\"width:519px; height:217px;\" src=\"images/CARD/53361_Endomyocard_fibros_RA_echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Surface echocardiogram with right ventricular apical fibrosis and severe right atrial enlargement.<br />(B) Left ventriculogram with severe mitral regurgitation and apical obliteration.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: Salemi VM, Rochitte CE, Barbosa MM, Mady C. Images in cardiology. Clinical and echocardiographic dissociation in a patient with right ventricular endomyocardial fibrosis. Heart 2005; 91:1399. Copyright © 2005 BMJ Publishing Group.<br />(B) Reproduced with permission from: Joshi R, Abraham S, Kumar AS. New approach for complete endocardiectomy in left ventricular endomyocardial fibrosis. J Thorac Cardiovasc Surg 2003; 125:40. Copyright © 2003 American Association for Thoracic Surgery.</div><div id=\"graphicVersion\">Graphic 53361 Version 4.0</div></div></div>"},"53362":{"type":"graphic_diagnosticimage","displayName":"Subcutaneous met melanoma","title":"Subcutaneous melanoma metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcutaneous melanoma metastases</div><div class=\"cntnt\"><img style=\"width:354px; height:273px;\" src=\"images/ONC/53362_Subcutaneous_met_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image demonstrating a subcutaneous metastasis from melanoma involving the left anterior upper chest wall. These lesions are particularly conspicuous on CT scans because of the density of the metastatic nodules relative to the low attenuation of the surrounding subcutaneous fat.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 53362 Version 3.0</div></div></div>"},"53364":{"type":"graphic_figure","displayName":"Recurrent nerve variation","title":"Recurrent laryngeal nerve variation","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Recurrent laryngeal nerve variation</div><div class=\"cntnt\"><img style=\"width:497px; height:251px;\" src=\"images/SURG/53364_Recurrent_nerve_variation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The uncommon, but high-risk anatomic variation where the recurrent laryngeal nerve (RLN) courses lateral to the tubercle of Zuckerkandl, which is often enlarged. The nerve is encountered much earlier in the dissection required for thyroidectomy and is at risk of being misidentified as a vascular structure.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53364 Version 2.0</div></div></div>"},"53365":{"type":"graphic_waveform","displayName":"ECG - Dilated cardiomyopathy in 13 yo boy","title":"Electrocardiogram of 13-year-old boy with dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of 13-year-old boy with dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:586px; height:313px;\" src=\"images/PEDS/53365_ECG_dilated_cardiomyo_13b.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram demonstrating increased QRS voltage with ST segment and T wave abnormalities in a 13-year-old boy with dilated cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 53365 Version 2.0</div></div></div>"},"53366":{"type":"graphic_picture","displayName":"AIP infiltrate Light LP","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/GAST/53366_AIP_infiltrate_Light_LP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a pancreas biopsy in a patient with autoimmune pancreatitis. The acinar parenchyma is atrophic and fibrotic and contains a lymphoplasmacytic infiltrate.</div><div class=\"graphic_reference\">Courtesy of Russell Dorer, MD.</div><div id=\"graphicVersion\">Graphic 53366 Version 1.0</div></div></div>"},"53367":{"type":"graphic_table","displayName":"Comparative approach to hysterectomy","title":"Comparison of three approaches to hysterectomy for benign gynecological disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of three approaches to hysterectomy for benign gynecological disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vaginal hysterectomy compared&nbsp;with abdominal hysterectomy</td> </tr> <tr> <td>Shorter hospitalization (mean difference -1.07 days, 95% CI -1.22 to 0.92)</td> </tr> <tr> <td>Speedier return to normal activities (mean difference -9.47 days, 95% CI -12.57 to&nbsp;-6.37)</td> </tr> <tr> <td>Fewer infections or fevers (odds ratio&nbsp;0.42, 95% CI 0.21-0.83)</td> </tr> <tr> <td class=\"subtitle1_single\">Laparoscopic hysterectomy compared&nbsp;with abdominal hysterectomy</td> </tr> <tr> <td>Less blood loss (mean difference 45.26 mL, 95% CI 17.85-72.68)</td> </tr> <tr> <td>Shorter hospital stay (mean difference 2.01 days, 95% CI 1.86-2.17)</td> </tr> <tr> <td>Speedier return to normal activities (mean difference 13.63 days, 95% CI 11.84-15.42)</td> </tr> <tr> <td>Fewer wound infections or fevers (odds ratio&nbsp;0.31, 95% CI 0.12-0.77)</td> </tr> <tr> <td>Longer operating time (mean difference&nbsp;20.27 minutes, 95% CI 3.95-36.59)</td> </tr> <tr> <td>More urinary tract injuries (OR 2.41, 95% CI 1.21-4.82)</td> </tr> <tr> <td class=\"subtitle1_single\">Laparoscopic hysterectomy compared&nbsp;with vaginal hysterectomy</td> </tr> <tr> <td>Similar outcomes except longer operating time (mean difference&nbsp;39.29 minutes, 95% CI 38.72-39.86)</td> </tr> <tr> <td class=\"subtitle1_single\">Total laparoscopic hysterectomy compared&nbsp;with laparoscopically-assisted vaginal hysterectomy</td> </tr> <tr> <td>Similar outcomes except longer operating time (mean difference 25.3 minutes, 95% CI 10-40.6)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Nieboer TE, Johnson N, Lethaby A, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev 2009; 3:CD003677.</div><div id=\"graphicVersion\">Graphic 53367 Version 5.0</div></div></div>"},"53369":{"type":"graphic_picture","displayName":"Budding Candida cells","title":"Budding cells of <EM>Candida</EM> species","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Budding cells of <EM>Candida</EM> species</div><div class=\"cntnt\"><img style=\"width:390px; height:252px;\" src=\"images/ID/53369_BuddingCandidacells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Candida albicans</EM>, <EM>C. krusei</EM>, <EM>C. parapsilosis </EM>and <EM>C. tropicalis </EM>all form elliptical budding cells that typically are larger in size than those of <EM>C. glabrata</EM>. Elaborate multicellular filaments, particularly when in contact with a solid substrate such as mucosal membranes or agar culture media.</div><div class=\"graphic_reference\">Courtesy of Wiley Schell, MS.</div><div id=\"graphicVersion\">Graphic 53369 Version 4.0</div></div></div>"},"53370":{"type":"graphic_picture","displayName":"Gram-positive cocci chains","title":"<em>Streptococcus pyogenes</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Streptococcus pyogenes</em></div><div class=\"cntnt\"><img style=\"width:371px; height:240px;\" src=\"images/ID/53370_Gramposcoccichains.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of an aspirate from a neck abscess (x1000) shows gram-positive cocci in long chains. <EM>Streptococcus pyogenes </EM>(group A <EM>Streptococcus</EM>) grew from this specimen on blood agar and tested negative by catalase.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 53370 Version 4.0</div></div></div>"},"53371":{"type":"graphic_picture","displayName":"Ear canal exostoses","title":"Ear canal exostoses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ear canal exostoses</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/53371_Ear_canal_exostoses.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ear canal exostoses (outgrowths of bone into the external ear canal).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 53371 Version 2.0</div></div></div>"},"53373":{"type":"graphic_table","displayName":"Patients who should be asked about intimate partner violence","title":"Patients who should be asked about intimate partner violence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patients who should be asked about intimate partner violence</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Women with injuries</td> </tr> <tr> <td>Women with chronic unexplained abdominal pain</td> </tr> <tr> <td>Women with chronic unexplained headaches</td> </tr> <tr> <td>Women with sexually transmitted diseases</td> </tr> <tr> <td>Older adults&nbsp;with evidence of neglect</td> </tr> <tr> <td>Older adults&nbsp;with injuries</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53373 Version 4.0</div></div></div>"},"53374":{"type":"graphic_figure","displayName":"Mortality and time to reperfusion in MI","title":"Time to thrombolysis and 35-day mortality","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time to thrombolysis and 35-day mortality</div><div class=\"cntnt\"><img style=\"width:377px; height:282px;\" src=\"images/CARD/53374_Time_to_reperfusion_in_MI.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The importance of time to thrombolysis in acute myocardial infarction and the absolute reduction in 35-day mortality in a meta-analysis of over 50,000 patients. The benefit from thrombolytic therapy is greatest when it is administered within two hours of symptom onset. The survival benefit is progressively reduced as the delay in therapy increases; after two hours, the benefit from thrombolytic therapy fits a linear function (black line) in which the benefit falls by approximately 1.6 lives per 1000 patients per hour of treatment delay.</div><div class=\"graphic_reference\">Data from Boersma E, Maas ACP, Simoon ML. Lancet 1996; 348:771.</div><div id=\"graphicVersion\">Graphic 53374 Version 5.0</div></div></div>"},"53375":{"type":"graphic_table","displayName":"Emergency medical kit for commercial airlines","title":"Emergency medical kit for commercial airlines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergency medical kit for commercial airlines</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td>Epinephrine 1:1000</td> </tr> <tr> <td>Epinephrine 1:10000 (can be dilution of epinephrine 1:1000)&nbsp;</td> </tr> <tr> <td>Antihistamine*</td> </tr> <tr> <td>Dextrose 50%&nbsp;50 mL (or equivalent)</td> </tr> <tr> <td>Nitroglycerin tablets or spray</td> </tr> <tr> <td>Major analgesic, injectable or oral</td> </tr> <tr> <td>Sedative anticonvulsant*</td> </tr> <tr> <td>Antipsychotic&nbsp;(eg, haloperidol)</td> </tr> <tr> <td>Antiemetic, injectable or oral dissolvable (eg, ondansetron)</td> </tr> <tr> <td>Bronchial dilator inhaler with spacer</td> </tr> <tr> <td>Atropine*</td> </tr> <tr> <td>Adrenocortical steroid, injectable or oral absorption equivalent*</td> </tr> <tr> <td>Diuretic*</td> </tr> <tr> <td>Sodium chloride 0.9% (1000 mL recommended)</td> </tr> <tr> <td>Acetylsalicylic acid for oral use</td> </tr> <tr> <td>Oral beta blocker</td> </tr> <tr> <td>List of medications - generic name, plus trade name if indicated on the item</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Equipment</td> </tr> <tr> <td>Stethoscope</td> </tr> <tr> <td>Sphygmomanometer (electronic preferred)</td> </tr> <tr> <td>Airways, oropharyngeal (appropriate range of sizes)</td> </tr> <tr> <td>Syringes (appropriate range of sizes)</td> </tr> <tr> <td>Needles (appropriate range of sizes)</td> </tr> <tr> <td>IV catheters (appropriate range of sizes)</td> </tr> <tr> <td>Antiseptic wipes</td> </tr> <tr> <td>Gloves (disposable)</td> </tr> <tr> <td>Sharps disposal box</td> </tr> <tr> <td>Urinary catheter with sterile lubricating gel</td> </tr> <tr> <td>System for delivering intravenous fluid</td> </tr> <tr> <td>Venous tourniquet</td> </tr> <tr> <td>Sponge gauze</td> </tr> <tr> <td>Tape adhesive</td> </tr> <tr> <td>Surgical mask</td> </tr> <tr> <td>Flashlight and batteries (operator may decide to have one per aircraft in an easily accessible location)</td> </tr> <tr> <td>Thermometer (non-mercury)</td> </tr> <tr> <td>Emergency tracheal catheter (or large gauge intravenous cannula)</td> </tr> <tr> <td>Umbilical cord clamp</td> </tr> <tr> <td>Bag-valve mask</td> </tr> <tr> <td>List of equipment</td> </tr> <tr> <td>Basic and Advanced Life Support cards</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Some kits may include: epinephrine auto-injector, glucagon, naloxone, ondansetron (oral), and/or injectable diazepam.<br /><br />When available, auto-injectors can be used by the cabin crew of some airlines under order from a ground medical advisor if there are no health professionals on board.&nbsp;<br /><br />Alternative methods of administration (eg, nasal spray, sub-lingual spray, oral-dissolving tablet) may replace injections in order to facilitate treatment by a volunteer, including personnel who are not trained to use this method (eg, cabin crew), under direction from a ground medical&nbsp;advisor or based upon a standing order from the airline.</div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Injectable.</div><div class=\"graphic_reference\">Reproduced with permission from: Medical Emergencies: Managing In-flight Medical Events. Aerospace Medical Association 2016. Available at: <A href=\"https://www.asma.org/asma/media/AsMA/Travel-Publications/Medical%20Guidelines/In-flight-medical-events-guidance-document-revised-July-2016.pdf\">https://www.asma.org/asma/media/AsMA/Travel-Publications/Medical%20Guidelines/In-flight-medical-events-guidance-document-revised-July-2016.pdf</A>&nbsp;(Accessed on February 1, 2017).</div><div id=\"graphicVersion\">Graphic 53375 Version 9.0</div></div></div>"},"53376":{"type":"graphic_figure","displayName":"Conization vaporization","title":"Cervical (uterine cervix) conization-vaporization procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical (uterine cervix) conization-vaporization procedure</div><div class=\"cntnt\"><img style=\"width:379px; height:325px;\" src=\"images/OBGYN/53376_Conization_vaporization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Areas planned for vaporization-conization are marked in quadrants. One quadrant is vaporized at a time.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr.</div><div id=\"graphicVersion\">Graphic 53376 Version 2.0</div></div></div>"},"53377":{"type":"graphic_table","displayName":"Heparin nomogram for stroke","title":"Heparin-adjusted nomogram for stroke","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heparin-adjusted nomogram for stroke</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">Initial dosing for continuous intravenous heparin infusion</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Weight (kg)</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle2\">Initial infusion (U/hour)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&#60;50</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">500</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">50 to 59</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">600</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">60 to 69</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">700</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">70 to 79</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">800</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">80 to 89</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">900</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">90 to 99</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">1000</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">100 to 109</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">1100</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">110 to 119</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">1200</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"2\" rowspan=\"1\">&#62;119</td>\n\n\n      <td colspan=\"2\" rowspan=\"1\">1400</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_left\" colspan=\"4\" rowspan=\"1\">Heparin adjustment based upon aPTT drawn six hours after initiation of therapy</td>\n\n\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2\">aPTT (seconds)</td>\n\n      <td class=\"subtitle2\">Stop infusion</td>\n\n      <td class=\"subtitle2\">Rate change</td>\n\n      <td class=\"subtitle2\">Repeat aPTT</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#60;40</td>\n\n      <td>No</td>\n\n      <td>Increase by 250 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>40 to 49</td>\n\n      <td>No</td>\n\n      <td>Increase by 150 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>50 to 59</td>\n\n      <td>No</td>\n\n      <td>Increase by 100 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>60 to 90</td>\n\n      <td>No</td>\n\n      <td>No change</td>\n\n      <td>Next morning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>91 to 100</td>\n\n      <td>No</td>\n\n      <td>Decrease by 100 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>101 to 120</td>\n\n      <td>No</td>\n\n      <td>Decrease by 150 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>&#62;120</td>\n\n      <td>No</td>\n\n      <td>Decrease by 250 U/hour</td>\n      <td>6 hours</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">No bolus is administered in patients with acute stroke.</div><div class=\"graphic_reference\">Data from: Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke 2002; 33:670.</div><div id=\"graphicVersion\">Graphic 53377 Version 2.0</div></div></div>"},"53378":{"type":"graphic_picture","displayName":"HGPUC","title":"Non-invasive high-grade papillary urothelial carcinoma (HGPUC)","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Non-invasive high-grade papillary urothelial carcinoma (HGPUC)</div><div class=\"cntnt\"><img style=\"width:578px; height:178px;\" src=\"images/ONC/53378_HGPUC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (A, 20x) HGPUC shows a pattern of disorder with easily recognizable architectural and cytologic variation. The papillae are frequently fused and branching. At high power (B-C, 40x) there is moderate to marked pleomorphism. The chromatin tends to be clumped, the nucleoli may be prominent, the thickness of the urothelium may vary considerably, and mitoses are often present.</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53378 Version 1.0</div></div></div>"},"53379":{"type":"graphic_figure","displayName":"Lung ca I PI","title":"Stage I lung cancer","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Stage I lung cancer</div><div class=\"cntnt\"><img style=\"width:544px; height:398px;\" src=\"images/PI/53379_Lung_ca_I_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a stage I cancer. In stage I lung cancer, the tumor is small and has not spread to any of the lymph nodes or other structures in the chest.</div><div id=\"graphicVersion\">Graphic 53379 Version 5.0</div></div></div>"},"53380":{"type":"graphic_picture","displayName":"CRPS child foot","title":"Complex regional pain syndrome of the foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complex regional pain syndrome of the foot</div><div class=\"cntnt\"><img style=\"width:355px; height:432px;\" src=\"images/PEDS/53380_CRPS_child_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: David D Sherry, MD.</div><div id=\"graphicVersion\">Graphic 53380 Version 2.0</div></div></div>"},"53381":{"type":"graphic_picture","displayName":"Hirschsprung histology","title":"Hirschsprung disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hirschsprung disease</div><div class=\"cntnt\"><img style=\"width:358px; height:513px;\" src=\"images/PEDS/53381_Hirschsprung_histology_edt1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Normal: Hematoxylin and eosin (H&amp;E) staining section of rectal tissue shows a normal myenteric ganglion containing many neurons that are easily identified as large cells with nucleus containing prominent nucleoli and amphophilic cytoplasm due with Nissl granules.<br />(B) Hirschsprung disease: A rectal biopsy specimen from a patient with Hirschsprung disease shows a hypertrophic nerve in the myenteric plexus and an absence of ganglion cells.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: Small and large bowel structure: Development and mechanical disorders. In: Lewin, Weinstein and Riddell's Gastrointestinal Pathology and its Clinical Implications, 2nd ed, Riddell R, Jain D (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright © Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.<br />(B) Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53381 Version 3.0</div></div></div>"},"53382":{"type":"graphic_diagnosticimage","displayName":"Scimitar syndrome III","title":"Scimitar syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scimitar syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:306px;\" src=\"images/PULM/53382_Scimitar_syndrome_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angiogram (venous phase) demonstrates the aberrant right pulmonary vein draining part of the right lung to the inferior vena cava.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53382 Version 2.0</div></div></div>"},"53383":{"type":"graphic_algorithm","displayName":"Emergent evaluation of pediatric syncope","title":"Emergent evaluation of syncope in children and adolescents","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Emergent evaluation of syncope in children and adolescents</div><div class=\"cntnt\"><img style=\"width:606px; height:795px;\" src=\"images/EM/53383_Emergent_eval_syncope_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LOC: loss of consciousness; CNS: central nervous system; HCG: human chorionic gonadotropin.</div><div id=\"graphicVersion\">Graphic 53383 Version 7.0</div></div></div>"},"53384":{"type":"graphic_diagnosticimage","displayName":"Sesamoid under fifth metatarsophalangeal joint - Anteroposterior","title":"Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small sesamoid underlying the fifth metatarsophalangeal joint (arrow)</div><div class=\"cntnt\"><img style=\"width:324px; height:414px;\" src=\"images/EM/53384_Sesamoid_under_5th_mcp_AP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior (AP) view also shows a midshaft, nondisplaced fracture of the proximal phalanx of the little toe (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 53384 Version 4.0</div></div></div>"},"53386":{"type":"graphic_picture","displayName":"ER HGIN Barretts Endosc","title":"Endoscopic images of a multi-band mucosectomy (MBM) in a patient with Barrett's esophagus with a focal lesion with HGIN","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Endoscopic images of a multi-band mucosectomy (MBM) in a patient with Barrett's esophagus with a focal lesion with HGIN</div><div class=\"cntnt\"><img style=\"width:550px; height:241px;\" src=\"images/GAST/53386_EMR_HGIN_Barretts_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Overview of a 3 cm long segment of Barrett's esophagus.<br />(B) There is a subtle lesion in the center of the endoscopic image.<br />(C) View after placement of electrocoagulation markers to delineate the lesion.<br />(D) A transparent cap with six rubber bands at its outside (identical to a variceal six-shooter) has been attached to the distal tip of the endoscope (Wilson-Cook Medical, Limerick, Ireland). The two wires to which the rubber bands are connected pass through the working channel of the endoscope and are connected to the handle that allows release of the bands.<br />(E) The area of interest is suctioned into the cap, without prior submucosal injection, followed by the release of one of the black rubber bands.<br />(F) The modified handle of the MBM device allows passage of a hexagonal polypectomy snare alongside the wires of the ligator. The snare is closed either above or below the rubber band followed by cutting using electrocoagulation.<br />(G) The wound after resection.<br />(H) The specimen is retrieved for histological assessment. Histology showed HGIN. The lateral and deep resection margins were free of dysplasia.</div><div class=\"graphic_footnotes\">HGIN: high-grade intraepithelial dysplasia.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &copy; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 53386 Version 4.0</div></div></div>"},"53387":{"type":"graphic_figure","displayName":"Skinning vulvectomy incision","title":"Skinning vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skinning vulvectomy</div><div class=\"cntnt\"><img style=\"width:284px; height:358px;\" src=\"images/OBGYN/53387_Skinning_vulvectomy_incisio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incision.</div><div id=\"graphicVersion\">Graphic 53387 Version 1.0</div></div></div>"},"53388":{"type":"graphic_figure","displayName":"Peritonsillar space","title":"Peritonsillar space anatomy","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Peritonsillar space anatomy</div><div class=\"cntnt\"><img style=\"width:461px; height:516px;\" src=\"images/ID/53388_Peritonsillar-space.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53388 Version 1.0</div></div></div>"},"53389":{"type":"graphic_table","displayName":"Major PRRs in humans: Secreted and circulating","title":"Major pattern recognition receptors (PRRs) in humans: Secreted and circulating*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major&nbsp;pattern recognition receptors (PRRs) in humans: Secreted and circulating*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PRR</td> <td class=\"subtitle1\">Recognize</td> <td class=\"subtitle1\">Functions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antimicrobial peptides</td> </tr> <tr> <td class=\"indent1\">Defensins</td> <td rowspan=\"2\">Microbial membranes</td> <td rowspan=\"2\"> <p>Microbial cell lysis</p> <p>Opsonization</p> <p>Chemoattraction</p> Link to adaptive immunity</td> </tr> <tr> <td class=\"indent1\">Cathelicidin (LL-37)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Collectins</td> </tr> <tr> <td class=\"indent1\">Clq</td> <td> <p>Microbe-fixed antibody</p> <p>Microbial and DAMPs membranes</p> </td> <td>Complement activation, opsonization, efferocytosis<sup>&#182;</sup>, embryonic tissue development</td> </tr> <tr> <td class=\"indent1\">MBL</td> <td>Microbial mannan</td> <td>Complement activation, microbial lysis, and opsonization</td> </tr> <tr> <td class=\"indent1\">Surfactant proteins A and D</td> <td>Microbial membranes</td> <td>Opsonization, lysis of bacteria and fungi, efferocytosis<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lectins</td> </tr> <tr> <td class=\"indent1\">MBL</td> <td rowspan=\"3\">Microbial carbohydrates</td> <td rowspan=\"3\">Activation of lectin pathway of complement with microbial lysis and opsonization</td> </tr> <tr> <td class=\"indent1\">Ficolins 1, 2, 3</td> </tr> <tr> <td class=\"indent1\">Galectins</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pentraxins</td> </tr> <tr> <td class=\"indent1\">C-reactive protein (CRP)</td> <td rowspan=\"2\">Bacterial carbohydrate</td> <td rowspan=\"2\">Activation of classical pathway of complement with microbial lysis and opsonization</td> </tr> <tr> <td class=\"indent1\">Pentraxin 3 (PTX3)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>PRR: pattern recognition receptor; Clq: first component of the C1 complex; DAMPs: damage-associated molecular patterns; MBL: mannose-binding lectin.</FONT><br />* This table includes&nbsp;major examples but is not exhaustive. <br />¶ Efferocytosis (Latin for \"to take to the grave, to bury\") refers to the process by which apoptotic cells are removed by phagocytosis.</div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Liu AH, Zasloff MA, Johnston RB Jr. Innate immunity. In: Middleton's Allergy: Principles and Practice, 7th ed, Adkinson NF Jr, Busse WW, Bochner BS, et al (Eds), Elsevier 2008. Illustration used with the permission of Elsevier, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53389 Version 10.0</div></div></div>"},"53390":{"type":"graphic_diagnosticimage","displayName":"VCUG Grade V reflux","title":"Voiding cystourethrogram (VCUG) demonstrating bilateral Grade V vesicoureteral reflux","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Voiding cystourethrogram (VCUG) demonstrating bilateral Grade V vesicoureteral reflux</div><div class=\"cntnt\"><img style=\"width:756px; height:628px;\" src=\"images/PEDS/53390_VCUG_grade_V_reflux.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53390 Version 3.0</div></div></div>"},"53391":{"type":"graphic_table","displayName":"Observed signs of catatonia","title":"Observed signs of catatonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Observed signs of catatonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Description and examples</td> </tr> <tr> <td>Immobility</td> <td>Hypokinetic or akinetic behavior that is not influenced by external stimuli.</td> </tr> <tr> <td>Stupor</td> <td>Decreased alertness, hypoactivity, and diminished responses to voice and painful stimuli.</td> </tr> <tr> <td>Excitement</td> <td>Impulsive, frantic, and stereotypic behavior that may include sudden outbursts of talking, singing, dancing, and tearing of clothes. Patients may be irritable and damage objects or injure themselves or others. Excitement may suddenly alternate with stupor.</td> </tr> <tr> <td>Mutism</td> <td>Patients are awake but verbally unresponsive. Mutism is not always associated with immobility and may appear elective. Less severe forms of mutism include lack of spontaneous speech, sluggish responses to questions with automatic answers such as \"I don't know\" (speech-prompt), and speaking with progressively less volume until speech is an inaudible mumble (prosectic speech).</td> </tr> <tr> <td>Posturing (catalepsy)</td> <td>Voluntarily maintaining a position of the body or a body part for a long time; eg, standing or lying down in the same position, an exaggerated pucker, lying in bed with the head elevated and unsupported as if on a pillow, holding arms above the head or raised in a prayer-like manner, and holding fingers and hands in odd positions.</td> </tr> <tr> <td>Echophenomena</td> <td>Echolalia (senseless repetition of another person's utterances) and echopraxia (senseless repetition of another person's movements).</td> </tr> <tr> <td>Speech mannerisms</td> <td>Robotic speech, feigned foreign accent, palilalia or verbigeration (involuntary repetition of words or phrases).</td> </tr> <tr> <td>Behavioral mannerisms</td> <td>Odd, purposeful movements, such as holding hands as if they were handguns or saluting passersby, or exaggerated or stilted caricatures of mundane movements.</td> </tr> <tr> <td>Stereotypy</td> <td>Non-goal-directed, repetitive movements that often are awkward or stiff; examples include grimacing, teeth/tongue clicking, rocking, sniffing, biting, or automatically touching or tapping.</td> </tr> <tr> <td>Staring</td> <td>Fixed gaze with little or no scanning of the environment and decreased blinking.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br> <ol> <li>Fink M, Taylor MA. The catatonia syndrome: Forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173. </li> <li>American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000. </li> <li>Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129. </li> <li>Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 2005; 9:1. </li> </ol></div><div id=\"graphicVersion\">Graphic 53391 Version 3.0</div></div></div>"},"53392":{"type":"graphic_algorithm","displayName":"Administering cephalosporins to a historically allergic patient","title":"Administration of a cephalosporin to a patient with a history of an immediate allergic reaction to another cephalosporin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Administration of a cephalosporin to a patient with a history of an immediate allergic reaction to another cephalosporin</div><div class=\"cntnt\"><img style=\"width:380px; height:296px;\" src=\"images/ALLRG/53392_Admin_ceph_pt_hx_ceph.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Figure 1 in Ann Allergy Asthma Immunol 1999; 83: Suppl. Copyright &#169; 1999 American College of Allergy, Asthma and Immunology.</div><div id=\"graphicVersion\">Graphic 53392 Version 4.0</div></div></div>"},"53393":{"type":"graphic_figure","displayName":"Pelvic organ prolapse PI","title":"Pelvic organ prolapse","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Pelvic organ prolapse</div><div class=\"cntnt\"><img style=\"width:530px; height:622px;\" src=\"images/PI/53393_PelvicorganprolapsePI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the tissues that support the organs in a woman's pelvis relax, organs can drop down and bulge into the vagina. In each picture, the black arrow shows how the organs move. In picture A, the organs are normal.&nbsp;Picture&nbsp;B shows prolapse of the bladder (called a \"cystocele\" or \"anterior vaginal wall prolapse\"). Picture&nbsp;C shows prolapse of the rectum&nbsp;(called a \"rectocele\" or \"posterior vaginal wall prolapse\"). Picture&nbsp;D shows prolapse of the uterus (called uterine prolapse).</div><div id=\"graphicVersion\">Graphic 53393 Version 2.0</div></div></div>"},"53394":{"type":"graphic_picture","displayName":"Light microscopy Sertoli tumor","title":"Sertoli cell tumor","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Sertoli cell tumor</div><div class=\"cntnt\"><img style=\"width:714px; height:534px;\" src=\"images/ONC/53394_Lght_mcrscpy_srtl_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a Sertoli cell tumor of the testis. The tumor contains bland cuboidal cells with a tubular to nested growth pattern and associated hyalinized stroma. No mitoses or necrosis are identified.&nbsp;Tumor cells would be immunoreactive for inhibin and WT1.</div><div class=\"graphic_reference\">Courtesy of Dr. Michelle S. Hirsch, Department of Pathology, Brigham and Womens Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 53394 Version 2.0</div></div></div>"},"53396":{"type":"graphic_picture","displayName":"Cutis marmorata","title":"Cutis marmorata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis marmorata</div><div class=\"cntnt\"><img style=\"width:432px; height:278px;\" src=\"images/PEDS/53396_Cutis_marmorata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutis marmorata is a normal reticulated mottling of the skin caused by vascular response to cold.</div><div class=\"graphic_reference\">Reproduced with permission from: Kenneth Greer,MD.</div><div id=\"graphicVersion\">Graphic 53396 Version 1.0</div></div></div>"},"53397":{"type":"graphic_figure","displayName":"Tetanus epidemiology US","title":"Tetanus cases in the United States","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tetanus cases in the United States</div><div class=\"cntnt\"><img style=\"width:410px; height:678px;\" src=\"images/PEDS/53397_TetanusepidemiologyUS.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Tetanus. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12<SUP>th</SUP> ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington, DC 2011. Available at:&nbsp;<A href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf\">www.cdc.gov/vaccines/pubs/pinkbook/downloads/tetanus.pdf</A> (Accessed on September 12, 2011).</div><div id=\"graphicVersion\">Graphic 53397 Version 5.0</div></div></div>"},"53399":{"type":"graphic_table","displayName":"Normal range fetal hemoglobin","title":"Normal mean and <2 SD values for fetal hemoglobin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal mean and &lt;2&nbsp;SD values for fetal hemoglobin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gestational age, weeks</td> <td class=\"subtitle1\">Mean hemoglobin, gm/dL</td> <td class=\"subtitle1\">&#60;2 SD hemoglobin from the mean, gm/dL</td> </tr> <tr> <td>18</td> <td>11.3</td> <td>9.3</td> </tr> <tr> <td>19</td> <td>11.5</td> <td>9.5</td> </tr> <tr> <td>20</td> <td>11.7</td> <td>9.7</td> </tr> <tr> <td>21</td> <td>11.9</td> <td>9.9</td> </tr> <tr> <td>22</td> <td>12.1</td> <td>10.1</td> </tr> <tr> <td>23</td> <td>12.3</td> <td>10.3</td> </tr> <tr> <td>24</td> <td>12.5</td> <td>10.5</td> </tr> <tr> <td>25</td> <td>12.7</td> <td>10.7</td> </tr> <tr> <td>26</td> <td>12.8</td> <td>10.8</td> </tr> <tr> <td>27</td> <td>13.0</td> <td>11.0</td> </tr> <tr> <td>28</td> <td>13.2</td> <td>11.2</td> </tr> <tr> <td>29</td> <td>13.4</td> <td>11.4</td> </tr> <tr> <td>30</td> <td>13.6</td> <td>11.6</td> </tr> <tr> <td>31</td> <td>13.8</td> <td>11.8</td> </tr> <tr> <td>32</td> <td>14.0</td> <td>12.0</td> </tr> <tr> <td>33</td> <td>14.2</td> <td>12.2</td> </tr> <tr> <td>34</td> <td>14.4</td> <td>12.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Two&nbsp;standard deviations&nbsp;below the mean&nbsp;is approximately&nbsp;2 g/dL below the mean hemoglobin for gestational age.</div><div class=\"graphic_footnotes\">SD: standard deviations; gm/L: grams/liter.</div><div class=\"graphic_reference\">Data from: Nicolaides KH, Soothill PW, Clewell WH, et al. Fetal haemoglobin measurement in the assessent of red cell isoimmunization. Lancet 1988; 8594:1073.</div><div id=\"graphicVersion\">Graphic 53399 Version 3.0</div></div></div>"},"53402":{"type":"graphic_picture","displayName":"MRCP biliary tract post LT","title":"Biliary anastomotic stricture following liver transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biliary anastomotic stricture following liver transplantation</div><div class=\"cntnt\"><img style=\"width:396px; height:374px;\" src=\"images/GAST/53402_MRCP_biliary_tract_post_LT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRCP image of the biliary tract of a patient who developed pruritus and jaundice 12 months after liver transplantation. The MRCP showed complex biliary strictures in the anastomotic site and at the hilum (a nonanastomotic stricture).</div><div class=\"graphic_reference\">Courtesy of Andres Cárdenas, MD, MMSc.</div><div id=\"graphicVersion\">Graphic 53402 Version 2.0</div></div></div>"},"53404":{"type":"graphic_picture","displayName":"Intravascular hemolysis","title":"Intravascular hemolysis due to <EM>Clostridium perfringens </EM>sepsis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravascular hemolysis due to <EM>Clostridium perfringens </EM>sepsis</div><div class=\"cntnt\"><img style=\"width:432px; height:319px;\" src=\"images/HEME/53404_Intravascular_hemolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a peripheral blood smear from a patient with severe intravascular hemolysis due to sepsis with <EM>Clostridium perfringens</EM>. Neutrophils show toxic changes, including toxic granulation and vacuoles. There is an increased number of spherocytes (blue arrows) and polychromatophilic red cells (ie, reticulocytes [red arrow]). The major finding on this slide is the large number of red blood cell ghosts (black arrows), due to the intravascular lysis of red cells from the phospholipase and other lytic enzymes elaborated by the clostridial organisms.</div><div class=\"graphic_reference\">Kindly provided by Dr. German Pihan, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 53404 Version 5.0</div></div></div>"},"53406":{"type":"graphic_picture","displayName":"Unstable spiral metacarpal shaft fracture","title":"Unstable spiral metacarpal shaft fracture ","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Unstable spiral metacarpal shaft fracture </div><div class=\"cntnt\"><img style=\"width:514px; height:324px;\" src=\"images/SURG/53406_Unsta_spir_meta_shaft_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most displaced metacarpal shaft fractures require open reduction and fixation. This series of figures depicts an unstable spiral metacarpal shaft finger fracture with rotation and shortening that was treated with fixation using lag screws.</div><div id=\"graphicVersion\">Graphic 53406 Version 4.0</div></div></div>"},"53407":{"type":"graphic_picture","displayName":"Seborrheic dermatitis axilla","title":"Intertriginous seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intertriginous seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53407_Seborrheicdermaxilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intertriginous seborrheic dermatitis of the axilla in an HIV-positive patient with secondary folliculitis.&nbsp;</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53407 Version 7.0</div></div></div>"},"53408":{"type":"graphic_picture","displayName":"Diphtheria cutaneous lesion 1","title":"Diphtheria skin lesion on the neck","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diphtheria skin lesion on the neck</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/53408_Diphth_cutan_lesion_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention Public Health Image Library. Available at:http://phil.cdc.gov/phil/home.asp./u003c/div/u003e/u003cdiv id/u003d\"graphicVersion\">Graphic 53408 Version 2.0</div></div></div>"},"53409":{"type":"graphic_table","displayName":"Mood disorder questionnaire","title":"Mood disorder questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mood disorder questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td colspan=\"3\"><strong>1. Has there ever been a period of time when you were not your usual self and...</strong></td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" colspan=\"3\">...you felt so good or so hyper that other people thought you were not your normal self or you were so hyper that you got into trouble?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were so irritable that you shouted at people or started fights or arguments?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you felt much more self-confident than usual?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you got much less sleep than usual and found you didn't really miss it?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were much more talkative or spoke faster than usual?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...thoughts raced through your head or you couldn't slow your mind down?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were so easily distracted by things around you that you had trouble concentrating or staying on track?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you had much more energy than usual?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were much more active or did many more things than usual?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were much more social or outgoing than usual, for example, you telephoned friends in the middle of the night?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you were much more interested in sex than usual?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...you did things that were unusual for you or that other people might have thought were excessive, foolish, or risky?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">...spending money got you or your family into trouble?</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td colspan=\"3\"><strong>2. If you checked YES to more than one of the above, have several of these ever happened during the same period of time? <em>Please circle one response only.</em></strong></td> <td class=\"centered\"><strong>Yes</strong></td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr class=\"divider_top\"> <td><strong>3. How much of a problem did any of these cause you - like being unable to work; having family, money, or legal troubles; getting into arguments or fights? <em>Please circle one response only.</em></strong></td> <td class=\"centered\"><strong>No problem</strong></td> <td class=\"centered\"><strong>Minor problem</strong></td> <td class=\"centered\"><strong>Moderate problem</strong></td> <td class=\"centered\"><strong>Serious problem</strong></td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=100837&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Patients screen positively for bipolar disorder if they answer &quot;yes&quot; to seven or more items in section 1, &quot;yes&quot; in section 2, and &quot;moderate problem&quot; or &quot;serious problem&quot; in section 3.<br> The mood disorder questionnaire should not be used to diagnose bipolar disorder. Patients who screen positive should be interviewed to establish the diagnosis; including family members is often helpful.</div><div class=\"graphic_reference\">Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873. Reprinted with permission from the American Journal of Psychiatry (Copyright 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 53409 Version 4.0</div></div></div>"},"53412":{"type":"graphic_figure","displayName":"Superior pontine syndrome","title":"Superior pontine syndrome","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Superior pontine syndrome</div><div class=\"cntnt\"><img style=\"width:493px; height:620px;\" src=\"images/NEURO/53412_Superior_pontine_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 53412 Version 1.0</div></div></div>"},"53413":{"type":"graphic_figure","displayName":"Friedman labor curve","title":"Friedman labor curve","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Friedman labor curve</div><div class=\"cntnt\"><img style=\"width:501px; height:401px;\" src=\"images/OBGYN/53413_Labor_curve.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">First stage = A + B + C + D, where A = latent phase, B = acceleration phase, C = phase of maximum slope, and D = deceleration phase.<br />Second stage = E.</div><div class=\"graphic_reference\">Data&nbsp;from: Friedman EA. Labor: Clinical evaluation and management, 2nd ed, Appleton-Century-Crofts, New York 1978.</div><div id=\"graphicVersion\">Graphic 53413 Version 4.0</div></div></div>"},"53414":{"type":"graphic_table","displayName":"Rx pneumonia pregnancy","title":"Summary of treatment of pregnant women with pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of treatment of pregnant women with pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. The indications for chest&nbsp;radiograph are the same in pregnant as in nonpregnant patients.</td> </tr> <tr> <td>2. Provide supplemental O2 to maintain oxygen saturation &#8805;95 percent or to maintain maternal pO2 &#62;70 mmHg. Maintain frequent or continuous evaluations of oxygen saturation.</td> </tr> <tr> <td>3. Obtain blood gas, especially if there is concern for CO2 retention, and remember that the normal PCO2 in pregnancy is 25 to 33 mmHg. Thus, a pCO2 of 35 mmHg already represents CO2 retention and possible impending respiratory failure.</td> </tr> <tr> <td>4. Treat fever with acetaminophen.</td> </tr> <tr> <td>5. Consult the obstetricis service for fetal well-being assessment (such as fetal heart rate monitoring, obstetric ultrasound). This may require the presence of obstetric nurses who are comfortable with fetal heart rate monitoring.</td> </tr> <tr> <td>6. Monitor fluid status carefully as these patients are prone to the development of pulmonary edema.</td> </tr> <tr> <td>7. Obtain blood cultures and sputum for gram stain and culture.</td> </tr> <tr> <td> <p>8. The choice of antibiotics for treatment is similar to those used in nonpregnant patients but because of an increase in renal clearance, higher and more frequent doses may be indicated. However, the use of tetracyclines, clarithromycin, and the fluoroquinolones should be avoided.</p> <ul> <li> <p>For pregnant women with community acquired pneumonia and no features of severe disease, we suggest combination therapy with an antipneumococcal beta-lactam (ceftriaxone, cefotaxime, ampicillin-sulbactam) plus azithromycin.</p> </li> <li> <p>Patients with past allergic reactions to cephalosporins can be treated with clindamycin plus aztreonam, unless they have severe pneumonia. For patients with severe pneumonia and past reactions to cephalosporins, we suggest vancomycin plus azithromycin plus aztreonam. </p> </li> </ul> </td> </tr> <tr> <td>9. If indicated, obtain serology for mycoplasma, urine for&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\"><em>Streptococcus</em> pneumonia and</span>&nbsp;<em>Legionella</em> antigen, and <em>Legionella</em> culture of respiratory specimen. The FilmArray molecular test is the best test to detect <em>M. pneumoniae</em>, <em>C. pneumoniae</em>, <em>Legionella</em> and <em>B. pertussis</em>. Results are available within 60 minutes; sensitivity and specificity are &#62;95 percent. However, it is not universally available.</td> </tr> <tr> <td>10. Try to anticipate intubation well in advance so appropriate equipment and experienced personnel are readily available.</td> </tr> <tr> <td>11. Try to position the patient so that the gravid uterus does not obstruct venous return (ie, on left side or with right hip elevated, if necessary).</td> </tr> <tr> <td>12. Bronchoscopy can be performed safely in pregnant women and should not be withheld if the information obtained will be important for the management of the patient.</td> </tr> <tr> <td>13. Ill pregnant woman confined to bed are likely to benefit from prophylaxis for venous thromboembolic disease.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53414 Version 6.0</div></div></div>"},"53415":{"type":"graphic_table","displayName":"Energy preservation methods","title":"Ways to preserve energy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ways to preserve energy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Basic activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Bathing and grooming</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Wash your hair in the shower rather than over a sink.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use a terry robe instead of towels to dry off.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use organizers to keep things within reach.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use a chair in the shower or tub.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use a long-handled sponge or brush to reach your back and feet.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Rest elbows on counter or dressing table to avoid leaning unsupported.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use long handled brushes or combs to avoid holding your arms overhead.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use liquid soap or soap on a rope.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use an elevated toilet seat.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Dressing</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Wear loose clothes that are easier to put on and take off.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bring your foot to your knee to put on socks and shoes so you won't have to lean over.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Wear slip-on shoes or shoes with Velcro closures or elastic shoelaces.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use a long handled shoe horn or sock aid.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Fasten your bra in front and then turn it around.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Wear clothes that button in front rather than pullovers or clothes that button in the back.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use a reacher or dressing stick to help with zippers in back.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Advanced activities</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Housework</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Spread tasks out over the week or month.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hire help.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use long-handled dusters, mops, dust pans.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use automatic washer and dryer if possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use lightweight iron.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Shopping</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Make a list.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Organize your shopping list by store aisle.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Request assistance in stores.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Have groceries delivered if possible.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Use canned, frozen, or other prepared foods, or try ordering out.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">On days when you feel well, cook extra food and freeze in small containers. Reheat frozen food on days when you're tired.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Ask your doctor, nurse, or social worker about community resources that deliver prepared meals.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Eat small, frequent meals rather than several large meals each day.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Have snack foods readily available.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">If you're really exhausted, put some favorite foods and beverages in a cooler with ice next to you as you rest.</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"indent1\">Make quick meals with a microwave or blender.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53415 Version 1.0</div></div></div>"},"53418":{"type":"graphic_table","displayName":"Thyroid hormone preparations","title":"Characteristics of oral thyroid hormone preparations available in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of oral thyroid hormone preparations available in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Composition</td> <td class=\"subtitle1\">Brand names*</td> <td class=\"subtitle1\">Average adult dose/day (oral)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Levothyroxine<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">T4</td> <td>Tablets<sup>&#916;</sup>: Levoxyl, Synthroid, Unithroid, Unithroid Direct</td> <td class=\"divider_bottom\" rowspan=\"3\">112 to 125 mcg</td> </tr> <tr> <td>Soft gel capsules<sup>&#9674;</sup>: Tirosint </td> </tr> <tr class=\"divider_bottom\"> <td>Oral solution: Tirosint-Sol</td> </tr> <tr class=\"divider_bottom\"> <td>Liothyronine</td> <td>T3</td> <td>Cytomel<sup>&#167;</sup></td> <td>37.5 mcg</td> </tr> <tr class=\"divider_bottom\"> <td>Liotrix</td> <td>4:1 mixture of T4 and T3</td> <td>Thyrolar</td> <td>T4 (75 mcg)/T3 (18.75 mcg)</td> </tr> <tr> <td rowspan=\"3\">Desiccated thyroid extract<br /> (Thyroid USP)</td> <td>4:1 mixture of T4 and T3 (approximately)</td> <td rowspan=\"3\"> <p>Armour Thyroid, Nature-Throid, NP Thyroid, WP Thyroid</p> </td> <td rowspan=\"3\">90 mg</td> </tr> <tr> <td>1 grain of desiccated thyroid extract (60 mg) should contain approximately 38 mcg T4 and 9 mcg T3</td> </tr> <tr> <td>Pork or beef origin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine.<br />* Generic preparations of levothyroxine and liothyronine are also available.<br />¶ Best preparation.<br />Δ Available in tablet strengths from 25 to 300 mcg.<br />◊ Available in capsule strengths from&nbsp;13 to 150 mcg.<br />§&nbsp;Available in tablet strengths of 5, 25, and 50 mcg.</div><div id=\"graphicVersion\">Graphic 53418 Version 4.0</div></div></div>"},"53419":{"type":"graphic_table","displayName":"Causes of protein-losing gastroenteropathy","title":"Causes of protein-losing gastroenteropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of protein-losing gastroenteropathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inflammatory exudation due to mucosal erosions or ulcerations</td> </tr> <tr> <td class=\"sublist1_start\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"sublist1\">Crohn's disease</td> </tr> <tr> <td class=\"sublist1\">Ulcerative colitis</td> </tr> <tr> <td class=\"sublist1_start\">Gastrointestinal malignancy</td> </tr> <tr> <td class=\"sublist1\">Gastric cancer</td> </tr> <tr> <td class=\"sublist1\">Lymphoma</td> </tr> <tr> <td class=\"sublist1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"sublist1\">Alpha chain disease</td> </tr> <tr> <td>Pseudomembranous colitis due to <em>Clostridium difficile</em></td> </tr> <tr> <td>Erosive gastritis and multiple gastric ulcers</td> </tr> <tr> <td>Nonsteroidal antiinflammatory drug (NSAID) enteropathy</td> </tr> <tr> <td>Post-chemotherapy</td> </tr> <tr> <td>Cap polyposis</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> <tr> <td class=\"subtitle1_single\">Intestinal loss of lymphatic fluid due to lymphatic obstruction</td> </tr> <tr> <td>Primary intestinal lymphangiectasia</td> </tr> <tr> <td class=\"sublist1_start\">Right-sided heart failure</td> </tr> <tr> <td class=\"sublist1\">Heart failure</td> </tr> <tr> <td class=\"sublist1\">Constrictive pericarditis</td> </tr> <tr> <td class=\"sublist1\">Congenital heart diseases</td> </tr> <tr> <td class=\"sublist1\">Fontan procedure for single ventricle</td> </tr> <tr> <td>Retroperitoneal lymph node enlargement (eg, due to chemotherapy, infection, or toxin exposure)</td> </tr> <tr> <td>Cirrhosis/portal hypertensive gastropathy</td> </tr> <tr> <td>Hepatic venous outflow obstruction</td> </tr> <tr> <td>Enteric-lymphatic fistula</td> </tr> <tr> <td>Mesenteric venous thrombosis</td> </tr> <tr> <td>Mesenteric tuberculosis or sarcoidosis</td> </tr> <tr> <td>Sclerosing mesenteritis</td> </tr> <tr> <td>Neoplasia involving the mesenteric lymph nodes or lymphatics</td> </tr> <tr> <td>Chronic pancreatitis with pseudocysts</td> </tr> <tr> <td>Crohn's disease</td> </tr> <tr> <td>Whipple disease</td> </tr> <tr> <td>Thoracic duct obstruction</td> </tr> <tr> <td>Congenital malformations of lymphatics</td> </tr> <tr> <td>Retroperitoneal fibrosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Increased permeability due to mucosal disease without erosions or ulcerations</td> </tr> <tr> <td>Celiac disease</td> </tr> <tr> <td>Tropical sprue</td> </tr> <tr> <td class=\"sublist1_start\">Giant hypertrophic gastritis (M&#233;n&#233;trier's disease)</td> </tr> <tr> <td class=\"sublist1\">Possible relation to <em>Helicobacter pylori</em> infection</td> </tr> <tr> <td>Lymphocytic gastritis</td> </tr> <tr> <td>Secretory hypertrophic gastropathy</td> </tr> <tr> <td>Amyloidosis</td> </tr> <tr> <td class=\"sublist1_start\">Infections</td> </tr> <tr> <td class=\"sublist1\">Bacterial overgrowth</td> </tr> <tr> <td class=\"sublist1\">Acute viral infection</td> </tr> <tr> <td class=\"sublist1\">Parasitic infection</td> </tr> <tr> <td class=\"sublist1\">Whipple disease</td> </tr> <tr> <td class=\"sublist1_start\">Rheumatic diseases</td> </tr> <tr> <td class=\"sublist1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"sublist1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"sublist1\">Mixed connective tissue disease</td> </tr> <tr> <td class=\"sublist1\">Intestinal vasculitis</td> </tr> <tr> <td>Allergic gastroenteropathy</td> </tr> <tr> <td>Eosinophilic gastroenteritis</td> </tr> <tr> <td>Collagenous colitis</td> </tr> <tr> <td>Congenital disorders of glycosylation</td> </tr> <tr> <td>Congenital enterocyte heparin sulfate deficiency</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53419 Version 8.0</div></div></div>"},"53422":{"type":"graphic_figure","displayName":"Maylard incision","title":"Maylard incision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maylard incision</div><div class=\"cntnt\"><img style=\"width:447px; height:590px;\" src=\"images/SURG/53422_Maylard_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse muscle-cutting incision. (A) Incision of rectus sheath is extended laterally to iliac spine to expose rectus muscle. Rectus muscles are cut transversly. (B) Cut edges of muscles are sutured to the rectus sheath. Ligated epigastric vessels and exposed transversalis fascia are shown. Transversalis fascia and peritoneum are incised transversely. Urachus is ligated.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 53422 Version 3.0</div></div></div>"},"53423":{"type":"graphic_picture","displayName":"Hand-foot-and-mouth disease - foot","title":"Hand-foot-and-mouth disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-foot-and-mouth disease</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53423_Hand_foot_mouth_dis_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple vesicular lesions on an erythematous base are present on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53423 Version 5.0</div></div></div>"},"53424":{"type":"graphic_picture","displayName":"Plantar warts close view","title":"Plantar warts","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Plantar warts</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/DERM/53424_Plantar_warts_close_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperkeratotic papules are present on the sole of the foot. Note the presence of thrombosed capillaries and the interruption of dermatoglyphics (skin lines).</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53424 Version 5.0</div></div></div>"},"53425":{"type":"graphic_picture","displayName":"Pemphigus vulgaris bullae and erosions","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53425_Pemphvulgarisbullaeeros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flaccid bullae and erosions on the skin of a patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53425 Version 6.0</div></div></div>"},"53426":{"type":"graphic_figure","displayName":"Rey-Osterrieth complex figure","title":"Rey-Osterrieth complex figure","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Rey-Osterrieth complex figure</div><div class=\"cntnt\"><img style=\"width:531px; height:419px;\" src=\"images/NEURO/53426_ReyOsterriethcomplexfig.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subjects are asked to draw this diagram, first as a copy, then from memory.</div><div class=\"graphic_reference\">Reproduced with permission from: Schiffer RB, Lajara-Nanson WA. Neuropsychiatric examination. In: Neuropsychiatry, 2nd ed, Schiffer RB, Rao SM, Fogel BS (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53426 Version 8.0</div></div></div>"},"53427":{"type":"graphic_diagnosticimage","displayName":"Avulsionfracture of lateral malleolus ","title":"Avulsion fracture of the lateral malleolus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture of the lateral malleolus</div><div class=\"cntnt\"><img style=\"width:399px; height:426px;\" src=\"images/EM/53427_Avulsion_distal_lat_malleol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seen on this x-ray is a transverse avulsion fracture of the lateral malleolus (yellow arrow)&nbsp;distal to the joint line.&nbsp;The fracture fragment is larger than those typically associated with an avulsion fracture, suggesting the possibility of additional injuries and ankle instability.</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 53427 Version 3.0</div></div></div>"},"53428":{"type":"graphic_diagnosticimage","displayName":"Pneumothorax","title":"Pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Pneumothorax</div><div class=\"cntnt\"><img style=\"width:468px; height:422px;\" src=\"images/EM/53428_Pneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This posterior-anterior (PA) radiograph of the chest reveals a left pneumothorax. The lateral border of the lung (arrows) no longer lies adjacent to the chest wall and the lung parynchema is contracted accounting for the lung's abnormal appearance. Note the air and absence of lung markings along the left lateral border of the heart (small arrowheads) and the inferior and medial displacement of the left mainstem bronchus. The border of the scapula (large arrowheads) is sometimes mistaken for a pneumothorax.</div><div id=\"graphicVersion\">Graphic 53428 Version 3.0</div></div></div>"},"53429":{"type":"graphic_figure","displayName":"Anatomy of lacrimal system","title":"Anatomy of the lacrimal system","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the lacrimal system</div><div class=\"cntnt\"><img style=\"width:428px; height:411px;\" src=\"images/PEDS/53429_Anatomy_of_lacrimal_system.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53429 Version 1.0</div></div></div>"},"53432":{"type":"graphic_figure","displayName":"Glucocorticoid side effects time dose","title":"Time course of glucocorticoid side effects","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of glucocorticoid side effects</div><div class=\"cntnt\"><img style=\"width:349px; height:235px;\" src=\"images/RHEUM/53432_Steroidsideeffectstimed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival curves demonstrating the time to development of the first serious adverse event (ie, the probability of remaining free of an adverse event) in patients with rheumatoid arthritis treated with no or different doses of prednisone. There is a clear dose-dependence of side effects: odds ratio 4.5 for 5 to 10 mg/day and 32.3 for 10 to 15 mg/day.</div><div class=\"graphic_reference\">Data from Saag, KG, Koehnke, R, Caldwell, JR, et al. Am J Med 1994; 96:115.</div><div id=\"graphicVersion\">Graphic 53432 Version 3.0</div></div></div>"},"53436":{"type":"graphic_figure","displayName":"Proportional hazard analysis","title":"Comparison of renal transplant recipient survival according to months on dialysis","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Comparison of renal transplant recipient survival according to months on dialysis</div><div class=\"cntnt\"><img style=\"width:481px; height:408px;\" src=\"images/NEPH/53436_proportional_hazard_analysi.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes:&nbsp;A paired donor kidney analysis. Transplantation 2002; 74:1377.</div><div id=\"graphicVersion\">Graphic 53436 Version 3.0</div></div></div>"},"53437":{"type":"graphic_figure","displayName":"Internuclear ophthalmoplegia","title":"Internuclear ophthalmoplegia (INO)","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Internuclear ophthalmoplegia (INO)</div><div class=\"cntnt\"><img style=\"width:453px; height:469px;\" src=\"images/NEURO/53437_Internuclearophthalmoplegi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient exhibits a left INO characterized by adduction slowing without ocular limitation. The top picture (A) depicts the patient in a primary gaze position, while the bottom picture (B) depicts the point at which the right eye reaches a 20 degree target while saccading to the right. Note that the right eye reaches the target prior to the left eye, as demonstrated with the midpupillary markers shown. (Note that the left eye has not changed position off of the midpupillary marker.) At saccade end, both eyes achieve target fixation (as shown in the oculogram).</div><div class=\"graphic_reference\">Reproduced with permission from: Frohman EM, O'Suilleabhain P, Dewey RB, et al. A new measure of dysconjugacy in INO: the first-pass amplitude. J Neurol Sci 2003; 210:65. Copyright ©2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 53437 Version 5.0</div></div></div>"},"53438":{"type":"graphic_picture","displayName":"Intervillous thrombus","title":"Intervillous thrombus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intervillous thrombus</div><div class=\"cntnt\"><img style=\"width:432px; height:294px;\" src=\"images/OBGYN/53438_Intervillousthrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cut section of placental parenchyma with a dark red, laminated,&nbsp;space-occupying lesion grossly consistent with an intervillous thrombus.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53438 Version 2.0</div></div></div>"},"53439":{"type":"graphic_table","displayName":"Total fetal loss rate TC-CVS compared with TA-CVS","title":"Total fetal loss rate: Randomized trials of TC-CVS compared with TA-CVS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Total fetal loss rate: Randomized trials of TC-CVS compared with TA-CVS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study, year</td> <td class=\"subtitle1\" colspan=\"2\">Total loss rate, percent</td> <td class=\"subtitle1\" rowspan=\"2\">Difference, percentage</td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk (95% CI)</td> </tr> <tr> <td class=\"subtitle2\">TC-CVS</td> <td class=\"subtitle2\">TA-CVS</td> </tr> <tr> <td>Brambati (1991)</td> <td>16.0 (95/592)</td> <td>17.3 (102/591)</td> <td>-1.2</td> <td>0.9 (0.7-1.2)</td> </tr> <tr> <td>Smidt-Jensen (1992)</td> <td>12.4 (188/1514)</td> <td>7.4 (113/1527)</td> <td>5.0</td> <td>1.7 (1.3-2.1)</td> </tr> <tr> <td>Jackson (1992)</td> <td>4.0 (74/1846)</td> <td>4.1 (72/1744)</td> <td>-0.1</td> <td>1.0 (0.8-1.7)</td> </tr> <tr> <td>Overall</td> <td>9.03&nbsp;</td> <td>7.43&nbsp;</td> <td>1.6</td> <td>1.2 (1.1-1.4)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Total fetal loss rate&nbsp;during the time&nbsp;from randomizaton&nbsp;to the end of pregnancy.</div><div class=\"graphic_footnotes\">TC-CVS: transcervical chorionic villus sampling; TA-CVS: transabdominal chorionic villus sampling; CI: confidence interval.</div><div id=\"graphicVersion\">Graphic 53439 Version 6.0</div></div></div>"},"53440":{"type":"graphic_table","displayName":"Differential diagnosis of leptomeningeal metastases","title":"Differential diagnosis of leptomeningeal metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of leptomeningeal metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Neoplasms</td> </tr> <tr> <td class=\"indent1\">Skull base metastases</td> </tr> <tr> <td class=\"indent1\">Dural metastases</td> </tr> <tr> <td class=\"indent1\">Parenchymal brain metastases</td> </tr> <tr> <td class=\"indent1\">Primary leptomeningeal melanomatosis</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Opportunistic (tuberculosis, cryptococcus)</td> </tr> <tr> <td class=\"indent1\">Meningitis (bacterial or viral)</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">West Nile virus</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune</td> </tr> <tr> <td class=\"indent1\">Vasculitis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Bell's palsy</td> </tr> <tr> <td class=\"subtitle1_single\">Artifact</td> </tr> <tr> <td class=\"indent1\">Post-radiotherapy nerve root thickening and/or enhancement</td> </tr> <tr> <td class=\"indent1\">Post-lumbar puncture</td> </tr> <tr> <td class=\"indent1\">Intracranial hypovolemia</td> </tr> <tr> <td class=\"indent1\">Intracranial hypotension</td> </tr> <tr> <td class=\"indent1\">Enhancing meningeal blood vessels</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53440 Version 4.0</div></div></div>"},"53441":{"type":"graphic_diagnosticimage","displayName":"Adenomyosis 6a","title":"35-year-old woman with menorrhagia and dysmenorrhea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">35-year-old woman with menorrhagia and dysmenorrhea</div><div class=\"cntnt\"><img style=\"width:348px; height:288px;\" src=\"images/OBGYN/53441_Adenomyosis_6a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal fast spin-echo T2-weighted MR image obtained before embolization shows global uterine enlargement and diffuse adenomyosis. Junctional zone thickness (arrow) is 14 mm.</div><div id=\"graphicVersion\">Graphic 53441 Version 2.0</div></div></div>"},"53442":{"type":"graphic_figure","displayName":"Locations transverse vag septa","title":"Schematic drawing of possible locations of a transverse vaginal septum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic drawing of possible locations of a transverse vaginal septum</div><div class=\"cntnt\"><img style=\"width:278px; height:386px;\" src=\"images/OBGYN/53442_Locationstransversevagse.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53442 Version 10.0</div></div></div>"},"53443":{"type":"graphic_picture","displayName":"Anterior rhinoscopy with septal deviation","title":"Anterior rhinoscopy with septal deviation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior rhinoscopy with septal deviation</div><div class=\"cntnt\"><img style=\"width:400px; height:376px;\" src=\"images/PC/53443_Ant_rhino.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53443 Version 1.0</div></div></div>"},"53444":{"type":"graphic_picture","displayName":"Normal endoscopic view of closed eustachian tube","title":"Normal endoscopic view of closed eustachian tube","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Normal endoscopic view of closed eustachian tube</div><div class=\"cntnt\"><img style=\"width:480px; height:325px;\" src=\"images/PC/53444_Normal_endo_ET.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal left eustachian tube, in the resting (closed) position. Adenoid pad (yellow arrow); medial cartilaginous lamina also known as posterior cushion (black arrow); eustachian tube orifice with closed valve (white arrow); lateral cartilaginous lamina (green arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Poe DS, Gopen Q. Eustachian Tube Dysfunction. In Wackym PA: Ballenger's Textbook of Otolaryngology. Toronto: BC Decker, 2008. Copyright &#169; 2008 PMPH-USA.</div><div id=\"graphicVersion\">Graphic 53444 Version 3.0</div></div></div>"},"53445":{"type":"graphic_picture","displayName":"Scapular strength L PI","title":"Scapular strengthening exercise - \"L\"","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scapular strengthening exercise - \"L\"</div><div class=\"cntnt\"><img style=\"width:346px; height:440px;\" src=\"images/PI/53445_Scapular_strength_L_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Position the arms to form an \"L.\" Hold arms bent with upper arms and forearms parallel to the floor.<br />(B) Rotate the arms so that the hands are pointed toward the floor. Hold for a second or two, then return to the starting position; repeat 10 to 15 times.</div><div id=\"graphicVersion\">Graphic 53445 Version 5.0</div></div></div>"},"53446":{"type":"graphic_table","displayName":"Definition metabolic syndrome","title":"Five definitions of the metabolic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Five definitions of the metabolic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameters</td> <td class=\"subtitle1\">NCEP ATP3 2005*</td> <td class=\"subtitle1\">IDF 2006</td> <td class=\"subtitle1\">EGIR 1999</td> <td class=\"subtitle1\">WHO 1999</td> <td class=\"subtitle1\">AACE 2003</td> </tr> <tr class=\"divider_bottom\"> <td>Required</td> <td>&nbsp;</td> <td>Waist &#8805;94 cm (men) or &#8805;80 cm (women)<sup>&#182;</sup></td> <td>Insulin resistance or fasting hyperinsulinemia in top 25 percent</td> <td>Insulin resistance in top 25 percent<sup>&#916;</sup>; glucose &#8805;6.1 mmol/L (110 mg/dL); 2-hour glucose &#8805;7.8 mmol/L (140 mg/dL)</td> <td>High risk of insulin resistance<sup>&#9674;</sup> or BMI &#8805;25 kg/m<sup>2</sup> or waist &#8805;102 cm (men) or &#8805;88 cm (women)</td> </tr> <tr class=\"divider_bottom\"> <td>Number of abnormalities</td> <td>&#8805;3 of:</td> <td>And &#8805;2 of:</td> <td>And &#8805;2 of:</td> <td>And &#8805;2 of:</td> <td>And &#8805;2 of:</td> </tr> <tr class=\"divider_bottom\"> <td>Glucose</td> <td>&#8805;5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose</td> <td>&#8805;5.6 mmol/L (100 mg/dL) or diagnosed diabetes</td> <td>6.1-6.9 mmol/ (110-125 mg/dL)</td> <td>&nbsp;</td> <td>&#8805;6.1 mmol/L (110 mg/dL); &#8805;2-hour glucose 7.8 mmol/L (140 mg/dL)</td> </tr> <tr class=\"divider_bottom\"> <td>HDL cholesterol</td> <td>&#60;1.0 mmol/L (40 mg/dL) (men); &#60;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C<sup>&#167;</sup></td> <td>&#60;1.0 mmol/L (40 mg/dL) (men); &#60;1.3 mmol/L (50 mg/dL) (women) or drug treatment for low HDL-C</td> <td>&#60;1.0 mmol/L (40 mg/dL)</td> <td>&#60;0.9 mmol/L (35 mg/dL) (men); &#60;1.0 mmol/L (40 mg/dL) (women)</td> <td>&#60;1.0 mmol/L (40 mg/dL) (men); &#60;1.3 mmol/L (50 mg/dL) (women)</td> </tr> <tr class=\"divider_bottom\"> <td>Triglycerides</td> <td>&#8805;1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides<sup>&#167;</sup></td> <td>&#8805;1.7 mmol/L (150 mg/dL) or drug treatment for high triglycerides</td> <td>or &#8805;2.0 mmol/L (180 mg/dL) or drug treatment for dyslipidemia</td> <td>or &#8805;1.7 mmol/L (150 mg/dL)</td> <td>&#8805;1.7 mmol/L (150 mg/dL)</td> </tr> <tr class=\"divider_bottom\"> <td>Obesity</td> <td>Waist &#8805;102 cm (men) or &#8805;88 cm (women)<sup>&#165;</sup></td> <td>&nbsp;</td> <td>Waist &#8805;94 cm (men) or &#8805;80 cm (women)</td> <td>Waist/hip ratio &#62;0.9 (men) or &#62;0.85 (women) or BMI &#8805;30 kg/m<sup>2</sup></td> <td>&nbsp;</td> </tr> <tr> <td>Hypertension</td> <td>&#8805;130/85 mmHg or drug treatment for hypertension</td> <td>&#8805;130/85 mmHg or drug treatment for hypertension</td> <td>&#8805;140/90 mmHg or drug treatment for hypertension</td> <td>&#8805;140/90 mmHg</td> <td>&#8805;130/85 mmHg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NCEP: National Cholesterol Education Program; IDF: International Diabetes Federation; EGIR: Group for the Study of Insulin Resistance; WHO: World Health Organization; AACE: American Association of Clinical Endocrinologists; HDL: high density lipoprotein; BMI: body mass index.<br />* Most commonly agreed upon criteria for metabolic syndrome (any three of five risk factors).<br />¶ For South Asia and Chinese patients, waist ≥90 cm (men) or ≥80 cm (women); for Japanese patients, waist ≥90 cm (men) or ≥80 cm (women).<br />Δ Insulin resistance measured using insulin clamp.<br /><FONT class=lozenge>◊</FONT> High risk of being insulin resistant is indicated by the presence of at least one of the following: diagnosis of CVD, hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease or acanthosis nigricans; family history of type 2 diabetes, hypertension of CVD; history of gestational diabetes or glucose intolerance; nonwhite ethnicity; sedentary lifestyle; BMI 25 kb/m<SUP>2</SUP> or waist circumference 94 cm for men and 80 cm for women; and age 40 years.<br />§ Treatment with one or more of fibrates or niacin.<br />¥ In Asian patients, waist ≥90 cm (men) or ≥80 cm (women).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640.</LI>&#xD;&#xA;<LI>Meigs J. Metabolic syndrome and risk for type 2 diabetes. Expert Rev Endocrin Metab 2006; 1:57. Table 1. Updated data from the International Diabetes Federation, 2006.</LI></OL></div><div id=\"graphicVersion\">Graphic 53446 Version 10.0</div></div></div>"},"53448":{"type":"graphic_figure","displayName":"Pancreatograms AIP","title":"Pancreatograms either by MRCP or ERCP in autoimmune chronic pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Pancreatograms either by MRCP or ERCP in autoimmune chronic pancreatitis</div><div class=\"cntnt\"><img style=\"width:532px; height:542px;\" src=\"images/GAST/53448_Pancreatograms_AIP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRCP: magnetic resonance cholangiopancreatography. ERCP: endoscopic retrograde cholangiopancreatography.</div><div class=\"graphic_reference\">Redrawn by permission from Macmillan Publishers, Ltd: Kim KP, Kim MH, Song MH, et al. Autoimmune chronic pancreatitis. Am J Gastroenterol 2004; 99:1605. Copyright © 2004.</div><div id=\"graphicVersion\">Graphic 53448 Version 4.0</div></div></div>"},"53449":{"type":"graphic_diagnosticimage","displayName":"Sequestration aortogram II","title":"Right lower lobe intralobar sequestration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right lower lobe intralobar sequestration</div><div class=\"cntnt\"><img style=\"width:360px; height:352px;\" src=\"images/PULM/53449_Sequestration_aortogram_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An aortogram demonstrates a splanchnic artery originating from the upper abdominal aorta, which supplies a large basal sequestration.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53449 Version 3.0</div></div></div>"},"53450":{"type":"graphic_figure","displayName":"Aspiration shoulder effusion","title":"Aspiration of shoulder effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration of shoulder effusion</div><div class=\"cntnt\"><img style=\"width:387px; height:315px;\" src=\"images/RHEUM/53450_Aspiration_shoulder_effusio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the anterior approach to aspiration of a shoulder effusion.</div><div id=\"graphicVersion\">Graphic 53450 Version 1.0</div></div></div>"},"53451":{"type":"graphic_figure","displayName":"Identification of the long thoracic nerve","title":"Identification of the long thoracic nerve","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Identification of the long thoracic nerve</div><div class=\"cntnt\"><img style=\"width:454px; height:358px;\" src=\"images/SURG/53451_Ident_thoracic_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both index fingers are used to spread along the chest wall to expose the long thoracic nerve.</div><div class=\"graphic_reference\">Reproduced with permission from: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53451 Version 2.0</div></div></div>"},"53452":{"type":"graphic_picture","displayName":"Periungual desquamation in Kawasaki disease","title":"Characteristic periungual desquamation of the hands and feet seen in Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Characteristic periungual desquamation of the hands and feet seen in Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:251px; height:573px;\" src=\"images/ALLRG/53452_Periungular_both.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin peeling usually begins under the nails during the second week of illness. Peeling of large sheets of skin progresses proximally over the next several days.</div><div id=\"graphicVersion\">Graphic 53452 Version 1.0</div></div></div>"},"53453":{"type":"graphic_figure","displayName":"Breast cancer development","title":"Breast cancer development","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Breast cancer development</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/PI/53453_BreastcancerPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The earliest breast cancers are called \"in situ\" cancers. In situ means the tumor has stayed inside the place where it first formed and has not spread to nearby tissues.<br />The most common form of in situ cancer is called \"ductal carcinoma in situ,\" or DCIS. DCIS forms inside the ducts of the breast, which are tubes that carry milk to the nipple when a woman is breastfeeding.<br />Lobular carcinoma in situ, or LCIS has a similar name but is not considered a true cancer. Instead, it is considered a risk factor for developing cancer in the future. LCIS refers to abnormal cells in the lobules of the breast, which is where milk is made.<br />When breast cancers spread beyond the ducts or lobules of the breast into the nearby tissue, they are called \"locally invasive cancers.\"<br />When tumors spread to areas outside the breast through the blood and lymph vessels, they are called \"metastatic cancers.\"</div><div id=\"graphicVersion\">Graphic 53453 Version 9.0</div></div></div>"},"53455":{"type":"graphic_table","displayName":"Histopathology report melanoma","title":"Histopathology report of melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathology report of melanoma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Essential data\n   </td>\n   </tr>\n   <tr>\n   <td>Diagnosis: Malignant melanoma, in situ or invasive</td>\n   </tr>\n   <tr>\n   <td>Breslow thickness: mm</td>\n   </tr>\n   <tr>\n   <td>Ulceration: present or absent</td>\n   </tr>\n   <tr>\n   <td>Mitoses: number/mm<sup>2</sup></td>\n   </tr>\n   <tr>\n   <td>Microscopic satellites: Present or absent</td>\n   </tr>\n   <tr>\n   <td>Vascular invasion: Present or absent</td>\n   </tr>\n   <tr>\n   <td>Surgical margins: Adequacy</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Other prognostic data\n   </td>\n   </tr>\n   <tr>\n   <td>Clark Level: I, II, III, IV, V</td>\n   </tr>\n   <tr>\n   <td>Growth phase: Radial or vertical</td>\n   </tr>\n   <tr>\n   <td>Regression: Present or absent</td>\n   </tr>\n   <tr>\n   <td>TIL's: Present (brisk or non-brisk) or absent</td>\n   </tr>\n   <tr>\n   <td>Histologic type: eg, Superficial spreading, desmoplastic</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Courtesy of Roy King, MD.</div><div id=\"graphicVersion\">Graphic 53455 Version 1.0</div></div></div>"},"53457":{"type":"graphic_table","displayName":"Developmental issues diabetes","title":"Major developmental issues and their effect on diabetes in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major developmental issues and their effect on diabetes in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Developmental stage<br /> (approximate ages)</td> <td class=\"subtitle1\">Normal developmental tasks</td> <td class=\"subtitle1\">Type 1 diabetes management priorities</td> <td class=\"subtitle1\">Family issues in type 1 diabetes management</td> </tr> <tr class=\"divider_bottom\"> <td>Infancy<br /> (0-12 months)</td> <td>Developing a trusting relationship/\"bonding\" with primary caregiver(s)</td> <td> <p>Preventing and treating hypoglycemia</p> Avoiding extreme fluctuations in blood glucose levels</td> <td> <p>Coping with stress</p> Sharing the \"burden of care\" to avoid parent burnout</td> </tr> <tr class=\"divider_bottom\"> <td>Toddler<br /> (13-36 months)</td> <td>Developing a sense of mastery and autonomy</td> <td> <p>Preventing and treating hypoglycemia</p> Avoiding extreme fluctuations in blood glucose levels due to irregular food intake</td> <td> <p>Establishing a schedule</p> <p>Managing the \"picky eater\"</p> <p>Setting limits and coping with toddler's lack of cooperation with regimen</p> Sharing the burden of care</td> </tr> <tr class=\"divider_bottom\"> <td>Preschooler and early elementary school-age<br /> (3-7 years)</td> <td>Developing initiative in activities and confidence in self</td> <td> <p>Preventing and treating hypoglycemia</p> <p>Coping with unpredictable appetite and activity</p> <p>Positively reinforcing cooperation with regimen</p> Trusting other caregivers with diabetes management</td> <td> <p>Reassuring child that diabetes is no one's fault</p> Educating other caregivers about diabetes management</td> </tr> <tr class=\"divider_bottom\"> <td>Older elementary school-age<br /> (8-11 years)</td> <td> <p>Developing skills in athletic, cognitive, artistic, social areas</p> Consolidating self-esteem with respect to the peer group</td> <td> <p>Making diabetes regimen flexible to allow for participation in school or peer activities</p> Child learning short- and long-term benefits of optimal control</td> <td> <p>Maintaining parental involvement in insulin and blood glucose monitoring tasks, while allowing for independent self-care for \"special occasions\"</p> Continuing to educate school and other caregivers</td> </tr> <tr class=\"divider_bottom\"> <td>Early adolescence<br /> (12-15 years)</td> <td> <p>Managing body changes</p> Developing a strong sense of self-identity</td> <td> <p>Managing increased insulin requirements during puberty</p> <p>Diabetes management and blood glucose control becoming more difficult</p> Weight and body image concerns</td> <td> <p>Renegotiating parents and teen's roles in diabetes management to be acceptable to both</p> <p>Learning coping skills to enhance ability to self-manage</p> <p>Preventing and intervening with diabetes-related family conflict</p> Monitoring for signs of depression, eating disorders, and risky behaviors</td> </tr> <tr> <td>Later adolescence<br /> (16-19 years)</td> <td>Establishing a sense of identity after high school (decision about location, social issues, work, education)</td> <td> <p>Discussion of transition to a new diabetes team (discussion may begin in earlier adolescent years)</p> Integrating diabetes into new lifestyle</td> <td> <p>Supporting the transition to independence</p> <p>Learning coping skills to enhance ability to self-manage</p> <p>Preventing and intervening with diabetes-related family conflict</p> Monitoring for signs of depression, eating disorders and risky behaviors</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted from: Silverstein J, Klingensmith G, Copeland K. Care of Children and Adolescents with Type 1 Diabetes. Diabetes Care 2005; 28:186. Copyright &copy; 2005 The American Diabetes Association. (Reaffirmed in Chiang JL et al, Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.)</div><div id=\"graphicVersion\">Graphic 53457 Version 3.0</div></div></div>"},"53458":{"type":"graphic_figure","displayName":"HIE outcome","title":"Outcome following neonatal hypoxic-ischemic encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Outcome following neonatal hypoxic-ischemic encephalopathy</div><div class=\"cntnt\"><img style=\"width:566px; height:354px;\" src=\"images/PEDS/53458_HIE_outcome.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 53458 Version 2.0</div></div></div>"},"53459":{"type":"graphic_picture","displayName":"Oblit bronchiolitis BMT I","title":"Bronchiolitis obliterans following allogeneic bone marrow transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans following allogeneic bone marrow transplantation</div><div class=\"cntnt\"><img style=\"width:375px; height:256px;\" src=\"images/PULM/53459_Oblit_bronchiolitis_BMT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrographs of a partially obliterated bronchiole in a patient who has received an allogeneic bone marrow transplant. Left: Hematoxylin and eosin stained section shows a largely obliterated bronchiole with peribronchiolar fibrosis and an associated infiltrate of mononuclear inflammatory cells. Right: An elastic tissue stain outlines the elastic layer of the same bronchiole pictured on the left and shows a compressed but patent lumen (arrow).</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 53459 Version 2.0</div></div></div>"},"53463":{"type":"graphic_table","displayName":"Valproate interactions with other antiseizure drugs","title":"Some interactions between valproate and other antiseizure drugs*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some interactions between valproate and other antiseizure drugs*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Interacting drugs</td> <td class=\"subtitle1\">Effects (probable mechanism)</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Valproate, with:</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Carbamazepine</td> <td>Decreased valproate effect and possible increased toxicity (increased metabolism by CYP 2C9, 2C19, glucuronidation, and formation of toxic metabolite)</td> <td>Monitor clinical status and valproate concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Carbamazepine toxicity (increased concentration of active epoxide metabolite<sup>&#182;</sup> and displacement from binding sites)</td> <td>Monitor clinical status and carbamazepine and carbamazepine epoxide concentrations; carbamazepine dose may need to be adjusted</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Ethosuximide</td> <td>Possible ethosuximide toxicity (decreased metabolism)</td> <td>Monitor clinical status and ethosuximide concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Possible decreased valproate effect (mechanism not established)</td> <td>Monitor clinical status and valproate concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Felbamate</td> <td>Possible decreased felbamate effect (mechanism unknown)</td> <td>Monitor clinical status</td> </tr> <tr class=\"divider_bottom\"> <td>Possible valproate toxicity (decreased metabolism by CYP2C19)</td> <td>Monitor clinical status and valproate concentrations. A reduction in valproate dose is recommended when initiating felbamate. Specific dose adjustment recommendations are provided in the Lexicomp monograph.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lamotrigine</td> <td>Lamotrigine toxicity (decreased metabolism; glucuronidation)</td> <td>Decrease lamotrigine dose by approximately 50 percent; monitor clinical status and lamotrigine concentrations. Specific lamotrigine dose adjustment recommendations for use with valproate are provided in the Lexicomp monograph.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxcarbazepine</td> <td>Possible decreased oxcarbazepine effect (increased metabolism)</td> <td>Monitor clinical status and oxcarbazepine concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Phenobarbital</td> <td>Possible phenobarbital toxicity (decreased metabolism by CYP2C9 and glucuronidation)</td> <td>Monitor clinical status and phenobarbital concentrations</td> </tr> <tr class=\"divider_bottom\"> <td>Possible decreased valproate effect (increased metabolism by glucuronidation and CYP oxidation)</td> <td>Monitor clinical status and valproate concentrations</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Phenytoin</td> <td>Possible phenytoin toxicity (displacement from binding sites and decreased metabolism; complex time course)</td> <td>Monitor clinical status and phenytoin concentrations (unbound concentrations may be more helpful than total)</td> </tr> <tr class=\"divider_bottom\"> <td>Possible decreased valproate effect and increased toxicity (increased metabolism and formation of toxic valproate metabolites)</td> <td>Monitor clinical status and valproate serum concentrations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rufinamide</td> <td>Possible increased rufinamide toxicity (decreased metabolism)</td> <td>Monitor clinical status; a decrease in initial rufinamide dose is recommended. Specific rufinamide dose adjustment recommendations for use with valproate are provided in the Lexicomp monograph.</td> </tr> <tr> <td class=\"indent1\">Topiramate</td> <td>Possible increased hepatotoxic effect of valproate and increased risk for hypothermia (mechanism not established)</td> <td>Monitor clinical status</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>Valproate is highly bound to plasma proteins and undergoes complex hepatic metabolism including glucuronidation (30 to 50 percent); the unbound fraction of valproate increases as valproate serum concentrations rise, causing wide inter-individual variability in the observed effect(s) of drug interactions.</li>&#xD;&#xA;    <li>Valproate effects can be altered by other antiseizure drugs via multiple mechanisms, eg, altered protein binding and competitive inhibition at sites of hepatic drug metabolism (ie, glucuronidation).</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">CYP: cytochrome P450.<br />* <strong>Not all potential interactions are listed.</strong> Additional interactions of antiepileptic drugs and management suggestions may be determined using the drug interactions tool (Lexi-Interact) included within UpToDate.<br />&para; Routine carbamazepine serum measurements do not assess for accumulation of the active carbamazepine-epoxide metabolite, but this metabolite can be measured as a separate test; refer to accompanying text.</div><div class=\"graphic_reference\">Adapted from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70):37-46. Copyright © 2008 The Medical Letter. Additional data from: Lexicomp Online. Copyright © 1978-2017 Lexicomp, Inc. All Rights Reserved and Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2013; 11(126):9-11. Copyright © 2013 The Medical Letter.</div><div id=\"graphicVersion\">Graphic 53463 Version 10.0</div></div></div>"},"53465":{"type":"graphic_figure","displayName":"Joints of the wrist","title":"Joints of the wrist","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Joints of the wrist</div><div class=\"cntnt\"><img style=\"width:536px; height:433px;\" src=\"images/PEDS/53465_Wrist_joints.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53465 Version 3.0</div></div></div>"},"53466":{"type":"graphic_picture","displayName":"Bullous pemphigoid DIF","title":"Direct immunofluorescence of bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Direct immunofluorescence of bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:380px; height:396px;\" src=\"images/PC/53466_Bullous_pemphigoid_DIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct immunofluorescence discloses linear deposits of IgG and C3 along the dermoepidermal junction. Ultrastructurally, these antibodies and complement are present in the lamina lucida.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright ©1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53466 Version 3.0</div></div></div>"},"53467":{"type":"graphic_figure","displayName":"Summary of the healing process","title":"Summary of the healing process","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Summary of the healing process</div><div class=\"cntnt\"><img style=\"width:318px; height:656px;\" src=\"images/SURG/53467_Summary_healing_process_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Summary of the healing process. Intermediate phase of the repair reaction.<br> (A) As a new extracellular matrix is deposited at the wound site, the initial fibrin clot is lysed by a combination of extracellular proteolytic enzymes and phagocytosis.<br> (B) Concurrent with fibrin removal, there is deposition of a temporary matrix formed by proteoglycans, glycoproteins, and type III collagen.<br> (C) Final phase of the repair reaction. Eventually the temporary matrix is removed by a combination of extracellular and intracellular digestion, and the definitive matrix, rich in type I collagen, is deposited.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53467 Version 1.0</div></div></div>"},"53468":{"type":"graphic_table","displayName":"Causes of gynecomastia","title":"Conditions associated with gynecomastia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with gynecomastia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Physiological</td> </tr> <tr> <td>Infancy</td> </tr> <tr> <td>Puberty</td> </tr> <tr> <td>Aging</td> </tr> <tr> <td class=\"subtitle1_single\">Pathologic</td> </tr> <tr> <td>Drugs</td> </tr> <tr> <td>Cirrhosis or malnutrition</td> </tr> <tr> <td>Male hypogonadism - primary or secondary</td> </tr> <tr> <td class=\"sublist1_start\">Tumors</td> </tr> <tr> <td class=\"sublist1\">Testicular - germ cell, Leydig cell, Sertoli cell, sex cord</td> </tr> <tr> <td class=\"sublist1\">Adrenal - adenoma or carcinoma </td> </tr> <tr> <td class=\"sublist1\">Ectopic production of human chorionic gonadotropin</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Chronic kidney&nbsp;disease and dialysis</td> </tr> <tr> <td class=\"sublist1_start\">Rare causes</td> </tr> <tr> <td class=\"sublist1\">Enzymatic defects of testosterone production*</td> </tr> <tr> <td class=\"sublist1\">Androgen-insensitivity syndromes*</td> </tr> <tr> <td class=\"sublist1\">True hermaphroditism*</td> </tr> <tr> <td class=\"sublist1\">Aromatase excess syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These conditions are usually associated with ambiguity of genitalia or deficient virilization.</div><div id=\"graphicVersion\">Graphic 53468 Version 3.0</div></div></div>"},"53471":{"type":"graphic_diagnosticimage","displayName":"Bronchiectasis CF CT","title":"CT scan of the lungs in a patient with cystic fibrosis, demonstrating bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of the lungs in a patient with cystic fibrosis, demonstrating bronchiectasis</div><div class=\"cntnt\"><img style=\"width:347px; height:292px;\" src=\"images/PULM/53471_Bronchiectasis_CF_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computerized tomography (CT)&nbsp;of the chest in a patient with cystic fibrosis demonstrates mild cylindrical bronchiectasis, with thickened bronchial walls involving the upper lobes and the superior segments of the lower lobes. Note the subsegmental atelectasis in the posterior segment of the right upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53471 Version 4.0</div></div></div>"},"53472":{"type":"graphic_figure","displayName":"Lack of restenosis with sirolimus stent","title":"Lack of restenosis with sirolimus stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lack of restenosis with sirolimus stent</div><div class=\"cntnt\"><img style=\"width:418px; height:307px;\" src=\"images/CARD/53472_No_restenosis_sirolimus_ste.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative frequency of stenosis immediately after stenting and at six months in patients who received sirolimus-eluting stents and standard stents. At six months, restenosis, defined as luminal narrowing of 50 percent or more (dashed line), occurred in no patient with a sirolimus stent compared to 23 percent of those with standard stents. The percentage of stenosis at six months with sirolimus stents was essentially the same as that immediately after the procedure and in all cases was less than 35 percent.</div><div class=\"graphic_reference\">Data from Morice MC, Serruys PW, Sousa JE, et al. N Engl J Med 2002; 346:1773.</div><div id=\"graphicVersion\">Graphic 53472 Version 3.0</div></div></div>"},"53473":{"type":"graphic_picture","displayName":"Erythema migrans Biopsy II","title":"Erythema migrans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema migrans</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/RHEUM/53473_Erythema_migrans_Biopsy_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy from within 1 cm of the peripheral border of an erythema migrans plaque showing increased mucin deposition. These findings may be the sequelae of ischemia due to endothelialitis.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 53473 Version 1.0</div></div></div>"},"53474":{"type":"graphic_figure","displayName":"WHO weight for length boys 0 to 24 months","title":"Weight-for-length percentiles, boys 0 to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Weight-for-length percentiles, boys 0 to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:563px; height:508px;\" src=\"images/PEDS/53474_WHO_wt_leng_boys_0_24_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 53474 Version 5.0</div></div></div>"},"53475":{"type":"graphic_picture","displayName":"Prurigo nodularis 1","title":"Prurigo nodularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prurigo nodularis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53475_Prurigo_nodularis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete, excoriated nodules on the leg of a patient with nodular prurigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53475 Version 5.0</div></div></div>"},"53478":{"type":"graphic_table","displayName":"Urine chloride concentration in metabolic alkalosis","title":"Urine chloride concentration in the diagnosis of metabolic alkalosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urine chloride concentration in the diagnosis of metabolic alkalosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Less than 25 meq/L</td> </tr> <tr> <td>Vomiting or nasogastric suction</td> </tr> <tr> <td>Diuretics (late)</td> </tr> <tr> <td>Factitious diarrhea</td> </tr> <tr> <td>Posthypercapnia</td> </tr> <tr> <td>Cystic fibrosis</td> </tr> <tr> <td>Low chloride intake</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Greater than 40 meq/L</td> </tr> <tr> <td>Primary mineralocorticoid excess</td> </tr> <tr> <td>Diuretics (early)</td> </tr> <tr> <td>Alkali load (bicarbonate or other organic anion)</td> </tr> <tr> <td>Bartter or Gitelman syndrome</td> </tr> <tr> <td>Severe hypokalemia (plasma [K+] &#60; 2.0 meq/L)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53478 Version 2.0</div></div></div>"},"53479":{"type":"graphic_figure","displayName":"Shoulder anat lateral PI","title":"Lateral view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Lateral view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:508px; height:510px;\" src=\"images/PI/53479_Shoulder_anat_lateral_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53479 Version 2.0</div></div></div>"},"53480":{"type":"graphic_picture","displayName":"Fibrosis after myocarditis","title":"Scarring after acute myocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scarring after acute myocarditis</div><div class=\"cntnt\"><img style=\"width:360px; height:220px;\" src=\"images/CARD/53480_Fibrosis_after_myocarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endomyocardial biopsy obtained one year after biopsy-proven acute myocarditis. There is now considerable fibrosis with disruption of the normal myocardial architecture.</div><div class=\"graphic_reference\">Courtesy of Walter Abelmann, MD.</div><div id=\"graphicVersion\">Graphic 53480 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial byopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/CARD/80914_Normal_myocardium_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy from a normal endomyocardial biopsy.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80914 Version 1.0</div></div></div>"},"53481":{"type":"graphic_table","displayName":"Learning disability exam","title":"Important aspects of the examination of a child with learning difficulty*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the examination of a child with learning difficulty*<SUP>¶</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination feature</td> <td class=\"subtitle1\">Potential clinical implication<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General observations and appearance</td> </tr> <tr> <td class=\"indent1\">Sadness, anxiety, attention span, impulsivity, activity</td> <td>Emotional or behavioral problems may affect learning</td> </tr> <tr> <td class=\"indent1\">Ability to communicate and respond to instructions</td> <td>Measure of language skills other than phonologic processing</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Stigmata of genetic syndromes (eg, Klinefelter, Turner, fragile X)</td> <td>Klinefelter syndrome: Tall stature, small testes</td> </tr> <tr> <td>Turner syndrome: Short stature, webbed neck, micrognathia, short metacarpals, nail dysplasia, widely spaced nipples</td> </tr> <tr class=\"divider_bottom\"> <td>Fragile X syndrome: Narrow face, large jaw, long, prominent ears, large testes (after puberty)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Growth parameters</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Head circumference</td> <td>Head circumference &#60;10<sup>th</sup> percentile may suggest fetal alcohol syndrome</td> </tr> <tr> <td>Children with fragile X syndrome usually have head circumference &#62;50<sup>th</sup> percentile</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"3\">Height and weight</td> <td>Height and weight &#60;10<sup>th</sup> percentile may suggest fetal alcohol syndrome</td> </tr> <tr> <td>Short stature is a feature of Turner syndrome</td> </tr> <tr class=\"divider_bottom\"> <td>Tall stature is a feature of Klinefelter syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Caf&#233;-au-lait spots, ash leaf spots, adenoma sebaceum</td> <td>Neurocutaneous disorders (eg, neurofibromatosis, tuberous sclerosis) are associated with learning problems</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Genitalia</td> </tr> <tr> <td class=\"indent1\">Delayed sexual maturation</td> <td>May be associated with Turner syndrome, Klinefelter syndrome</td> </tr> <tr> <td class=\"indent1\">Small testes</td> <td>Suggestive of Klinefelter syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Large testes (after puberty)</td> <td>Suggestive of fragile X syndrome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sensory screening</td> </tr> <tr> <td class=\"indent1\">Hearing assessment</td> <td>Hearing impairment may affect learning</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vision assessment</td> <td>Vision impairment may affect learning</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic examination</td> </tr> <tr> <td class=\"indent1\">Asymmetry, increased or decreased muscle tone </td> <td>Cerebral palsy</td> </tr> <tr> <td class=\"indent1\">Coordination problems</td> <td>Developmental coordination disorder</td> </tr> <tr> <td class=\"indent1\">Weakness</td> <td>Muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">Tics</td> <td>Tourette syndrome</td> </tr> <tr> <td class=\"indent1\">Staring episodes</td> <td>Seizure disorder</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* In this table, \"learning disability\" refers to a heterogeneous group of disorders characterized by the unexpected failure of an individual to acquire, retrieve, and use information competently, rather than intellectual disability (mental retardation).<br />&para; Most children with learning disability have a normal physical examination.<br />&Delta; Learning disability is rarely the first manifestation of these disorders.</div><div id=\"graphicVersion\">Graphic 53481 Version 4.0</div></div></div>"},"53482":{"type":"graphic_diagnosticimage","displayName":"Thyroid ultrasound enlarged lymph node metastatic thyroid cancer","title":"Thyroid ultrasound of an enlarged lymph node due to metastatic thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound of an enlarged lymph node due to metastatic thyroid cancer</div><div class=\"cntnt\"><img style=\"width:359px; height:185px;\" src=\"images/ENDO/53482_Lymph_node_vascularity_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Left panel) Sonogram of the neck that shows an enlarged lymph node (N) due to metastatic thyroid cancer.<br />(Right panel) Doppler image that shows its intense vascularity.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 53482 Version 4.0</div></div></div>"},"53483":{"type":"graphic_picture","displayName":"Los Angeles grade C esophagitis","title":"Los Angeles grade C esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Los Angeles grade C esophagitis</div><div class=\"cntnt\"><img style=\"width:300px; height:306px;\" src=\"images/GAST/53483_LA_grade_C_esophagitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Los Angeles grade C esophagitis: One or more mucosal breaks bridging the tops of mucosal folds involving less than 75 percent of the circumference of the lumen.</div><div id=\"graphicVersion\">Graphic 53483 Version 3.0</div></div></div>"},"53486":{"type":"graphic_diagnosticimage","displayName":"Acute interstitial pneumCXR","title":"Radiograph of acute interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph of acute interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:350px; height:263px;\" src=\"images/PULM/53486_Acute_interstitial_pneumCXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior chest radiograph showing extensive bilateral areas of airspace opacities involving all lobes.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 53486 Version 3.0</div></div></div>"},"53489":{"type":"graphic_figure","displayName":"Percentage of donor oocyte","title":"Percentage of ART cycles using donor eggs, by age of woman, 2012","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Percentage of ART cycles using donor eggs, by age of woman, 2012</div><div class=\"cntnt\"><img style=\"width:688px; height:386px;\" src=\"images/ENDO/53489_Percentage_of_donor_oocyte.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ART: assisted reproductive technology.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. 2012 Assisted Reproductive Technology National Summary Report. Section 4: ART Cycles using donor eggs. Available at: <a href=\"http://www.cdc.gov/art/pdf/2012-report/slides/art-2012-graphs-charts-figure-38.pdf\" target=\"_blank\">www.cdc.gov/art/pdf/2012-report/slides/art-2012-graphs-charts-figure-38.pdf</a> (Accessed May 26, 2015).</div><div id=\"graphicVersion\">Graphic 53489 Version 4.0</div></div></div>"},"53490":{"type":"graphic_figure","displayName":"PIT scores for EATL survival","title":"Survival of patients with enteropathy associated T-cell lymphoma according to Prognostic Index for PTCL, unspecified (PIT) score","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Survival of patients with enteropathy associated T-cell lymphoma according to Prognostic Index for PTCL, unspecified (PIT) score</div><div class=\"cntnt\"><img style=\"width:555px; height:614px;\" src=\"images/HEME/53490_PIT_scores_EATL_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PIT: prognostic index for peripheral T-cell lymphoma; EATL: enteropathy-associated T-cell lymphoma.</div><div class=\"graphic_reference\">This research was originally published in Blood. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood 2011; 118:148. Copyright &#169; 2011 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 53490 Version 2.0</div></div></div>"},"53492":{"type":"graphic_table","displayName":"High-potassium foods","title":"High-potassium content foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High-potassium content foods</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Highest content (&#62;25 mEq/100 g)</td> </tr> <tr> <td>Dried figs</td> </tr> <tr> <td>Molasses</td> </tr> <tr> <td>Seaweed</td> </tr> <tr> <td class=\"subtitle1_single\">Very high content (&#62;12.5 mEq/100 g)</td> </tr> <tr> <td>Dried fruits (dates, prunes)</td> </tr> <tr> <td>Nuts</td> </tr> <tr> <td>Avocados</td> </tr> <tr> <td>Bran cereals</td> </tr> <tr> <td>Wheat germ</td> </tr> <tr> <td>Lima beans</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">High content (&#62;6.2 mEq/100 g)</td> </tr> <tr> <td class=\"subtitle2_single\">Vegetables</td> </tr> <tr> <td class=\"indent1\">Spinach</td> </tr> <tr> <td class=\"indent1\">Tomatoes</td> </tr> <tr> <td class=\"indent1\">Broccoli</td> </tr> <tr> <td class=\"indent1\">Winter squash</td> </tr> <tr> <td class=\"indent1\">Beets</td> </tr> <tr> <td class=\"indent1\">Carrots</td> </tr> <tr> <td class=\"indent1\">Cauliflower</td> </tr> <tr> <td class=\"indent1\">Potatoes</td> </tr> <tr> <td class=\"subtitle2_single\">Fruits</td> </tr> <tr> <td class=\"indent1\">Bananas</td> </tr> <tr> <td class=\"indent1\">Cantaloupe</td> </tr> <tr> <td class=\"indent1\">Kiwis</td> </tr> <tr> <td class=\"indent1\">Oranges</td> </tr> <tr> <td class=\"indent1\">Mangos</td> </tr> <tr> <td class=\"subtitle2_single\">Meats</td> </tr> <tr> <td class=\"indent1\">Ground beef</td> </tr> <tr> <td class=\"indent1\">Steak</td> </tr> <tr> <td class=\"indent1\">Pork</td> </tr> <tr> <td class=\"indent1\">Veal</td> </tr> <tr> <td class=\"indent1\">Lamb</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Gennari FJ. Hypokalemia. N Engl J Med 1998; 339:451.</div><div id=\"graphicVersion\">Graphic 53492 Version 4.0</div></div></div>"},"53493":{"type":"graphic_table","displayName":"Arm volumeter instructions","title":"Home arm volumeter instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Home arm volumeter instructions</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">I. How to construct a home arm volumeter</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">A. Parts. All parts are made of common polyvinyl chloride (PVC) piping used in plumbing. All parts are unthreaded. (Note: Phrases set in quotation marks in this section indicate the phrase to use when purchasing materials at the hardware store.)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">one 6-inch (15-cm) internal diameter PVC pipe of approximately 1/4-inch (6-mm) standard thickness (called \"6-inch Pipe\"); length equal to arm length</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">one 4-inch (10-cm) internal diameter PVC pipe (called \"4-inch Pipe\"), 9 inches (23 cm) long</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">one asymmetric \"Y\" PVC all female connector (called \"Asymmetric Y connector\"; also called \"Wye\" in some plumbing catalogs), designed to connect two 6-inch and one 4-inch pipes</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">one PVC 45-degree elbow (called \"Elbow\") with one male and one female connecter end, designed to connect two 4-inch-diameter PVC pipes, also called a \"45-degree 4-inch male-female PVC angle\"</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">one 6-inch PVC cap (called \"6 inch Cap\")</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">PVC solvent glue</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">B. Assembly instructions.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle3_single\">1. Arm length</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">Determine arm length by measuring the arm from the inner fold of the armpit (anterior axillary fold; Point A) along the inside (anterior aspect) of the arm to the tip of the middle finger when the hand is outstretched in a taut position (Point B).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle3_single\">2. Cutting and gluing</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">Warning: It is dangerous to cut PVC pipe with a power saw and to handle PVC glue, which emits toxic vapors; these tasks should be left to a properly trained person.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">Reference for metric equivalents: Conversion factor: 1 inch = 2.5 cm. Approximate equivalents: 1/4 inch = 6 mm; 4 inches = 10 cm; 5 inches = 13 cm; 6 inches = 15 cm; 9 inches = 23 cm.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">a. Cut the 6-inch pipe to a length equal the length of the arm.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">b. Cut the 4-inch pipe to a length of 9 inches (23 cm).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">c. Cut the asymmetric Y-connector. Stand the asymmetric Y-connector with the 4-inch connector end facing down. Measure 5 inches (13 cm) up from the bottom of the 6-inch connector end and mark point A. Mark point B just above the ridge of the 4-inch connector end (Step 1). Cut across the asymmetric Y-connector in a straight line spanning from point A to point B (Step 2). File and sand the newly cut top edge to make a smooth, curved lip (Step 3).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">d. Glue the 6-inch cap to one end of the 6-inch pipe to seal the bottom of the volumeter.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">e. Glue the asymmetric Y-connector to the other end of the 6-inch pipe.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle3_single\">3. Fitting</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent2\">Attach the 4-inch pipe to one end of the elbow and attach the elbow to the asymmetric Y-connector. The volumeter's spout is now in place. The spout also serves as a handle to lift, drag, or carry the volumeter.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">C. Filing, sanding, cleaning, and disinfecting. Clean all parts before assembly. Carefully check the assembled volumeter, inside and out. File and sand any sharp edges or points. Clean and disinfect the volumeter using a bleach solution. Rinse thoroughly with water to remove any trace of bleach.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">II. How to measure arm volume</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">A. Equipment</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Home arm volumeter</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Beverage pitcher (the pitcher does not need to have volume gradations because the water volume is measured by weighing)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Digital gram kitchen scale or postal scale (the scale should read up to 5000 grams, be accurate to 1 gram, and have a platform large enough to hold the pitcher. The display must be in grams [not ounces] because water weight in grams is equivalent to water volume in milliliters, which is the only way the water volume can be determined through weighing. The author strongly recommends that patients weigh the water and not use graduated containers, which are too imprecise and yield misleading volumetric readings.)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">B. Measurement procedure. </td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">1. Weigh the empty pitcher and record its empty weight (Step 1). This will be a constant that you always subtract from the weight of the pitcher of water.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">2. Place the volumeter on a level-surfaced floor. To achieve comparable measurements, try to place the volumeter in the same location each time.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">3. Prepare a comfortable seat beside the volumeter, for example, a stool or low chair. A closed toilet seat may also be convenient with the volumeter placed beside the toilet.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">4. Place the pitcher under the volumeter spout. Under the pitcher, place any type of flat base, such as a plastic food storage container, to raise the pitcher up to the edge of the spout. This base is necessary so that no drops of water splash outside of the pitcher (Step 2).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">5. Fill the volumeter with lukewarm water until it overflows into the pitcher. Wait for all air bubbles to settle. Top off the water level with a bit more water and wait for the overflow to completely stop dripping into the pitcher (Step 3).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">6. Empty the water out of the pitcher (Step 4). Dry the pitcher with a towel. Return the dry pitcher to its original spot under the spout of the volumeter.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">7. You are now ready to measure your arm volume. Sit beside the volumeter. Slowly and gently lower your arm into the volumeter. Water will rush out through the spout into the pitcher. Continue lowering your arm until your middle finger touches the bottom of the volumeter, while keeping your fingers, wrist, and elbow in a fully extended and taut position (Step 5).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">8. Hold this position until the water stops dripping into the pitcher. You can best see this by watching when the water in the pitcher becomes still.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">9. Remove your arm and dry it with a towel.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">10. Place the pitcher filled with the overflow water on the scale (Step 6).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">11. Record the gram output showing on the scale. From this number, subtract the weight of the empty pitcher (Step 1). The difference equals the volume in grams of the water in the pitcher. This amount equals the volume in millilitres of your arm.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">12. We recommend that you do at least two consecutive measurements, and preferably&nbsp;three (see Helpful Hints).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">13. When you have finished measuring, the volumeter can be dragged or lifted by the spout and tipped into the bathtub or shower to empty.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">III. Helpful hints</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>The most important procedure in measuring arm volume is Procedure 8: holding the arm immobile in the volumeter until the water stops dripping. This may take up to&nbsp;one minute. It is therefore important to be comfortable and relaxed when you take your arm measurement. Your seat should be comfortable. To avoid straining your back, try to bend from the waist and keep your back straight.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Measuring in the bathtub: since the floor of the bathtub is not a level surface, it may not be an ideal location for the volumeter. Also, sitting on the side of a bathtub (in a straddle or side-saddle position) is not usually comfortable.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>We recommend that you take three measurements in a row and calculate the average, in case of an erratic measurement. By comparing three measurements, you can judge your skill at measurement. With practice, your measurements may vary by less than 10 mililiters, which is highly precise.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>If you discover that the six-inch pipe has been cut too long and your middle finger does not touch bottom before the top of the volumeter hits your armpit, you can use a \"landmark,\" such as a freckle on your upper arm, and stop immersion at that landmark. You can also add a \"false bottom\" to your volumeter by filling a plastic container with vase gems, marbles, or polished stones and placing the weighted container in the volumeter.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>To lower costs of making the volumeter, patients can group together to have several made at one time.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>We recommend that you not modify the design of the home use volumeter. It is the result of trial and error and numerous prototypes over&nbsp;two years. Even a minor design change may change the volume and shape of the water meniscus at the top of the cylinder of water and result in unreliable measurements.</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Reproduced with permission from: Lette J. A simple and innovative device to measure arm volume at home for patients with lymphedema after breast cancer. J Clin Oncol 2006; 24:5434. Copyright &#169;2006 The American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 53493 Version 2.0</div></div></div>"},"53496":{"type":"graphic_picture","displayName":"Caustic stricture esophagus","title":"Caustic strictures of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Caustic strictures of the esophagus</div><div class=\"cntnt\"><img style=\"width:357px; height:359px;\" src=\"images/EM/53496_Caustic_stricture_esophagus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 17-year-old patient presented with recurrent dysphagia after ingesting an unknown quantity of pine oil solvent and sodium hydroxide six weeks prior. Endoscopic evaluation noted multiple strictures and edema. Inital direct laryngoscopy one day after ingestion&nbsp;had been&nbsp;unremarkable.</div><div class=\"graphic_reference\">Courtesy of Karen Murray, MD.</div><div id=\"graphicVersion\">Graphic 53496 Version 2.0</div></div></div>"},"53497":{"type":"graphic_figure","displayName":"Wrap technique","title":"Ribbon gauze method of ring removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ribbon gauze method of ring removal</div><div class=\"cntnt\"><img style=\"width:271px; height:587px;\" src=\"images/EM/53497_Wraptechnique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The success of this technique depends upon tight, close wrapping of the digit or penis. Do not attempt this technique if the patient has ischemia of the digit or penis or an open wound, fracture, or dislocation distal to the ring. <br />(A) After appropriate analgesia, place one end of a 2.0 or 3.0 suture, Penrose drain, or umbilical tape 20 to 25 inches (0.5 to 0.6 m) in length under the ring from the proximal to the distal side with 5 inches (12.5 cm) of material remaining proximally.<br />(B) Wrap the suture material, drain, or tape tightly around the digit or penis beginning at the distal aspect of the ring. Overlap the wrappings so that no tissue is visible. Continue wrapping beyond the proximal interphalangeal joint of the digit or beyond the coronal sulcus of the penis. <br />(C) Once the wrapping is complete, pull on the proximal end of the wrapping material so that the ring is removed from the finger or penis.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53497 Version 11.0</div></div></div>"},"53498":{"type":"graphic_figure","displayName":"Assessment of TLR4 pathway by flow cytometry","title":"Assessment of TLR4 pathway by flow cytometry","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Assessment of TLR4 pathway by flow cytometry</div><div class=\"cntnt\"><img style=\"width:470px; height:304px;\" src=\"images/ALLRG/53498_TLR_pathway_anal.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal individuals show induction of TNF-alpha in monocytes upon LPS stimulation. Individuals with IRAK-4 deficiency do not show optimal TNF-alpha expression.</div><div class=\"graphic_footnotes\">TLR4: Toll-like receptor 4; IRAK-4: interleukin-1 receptor associated kinase-4; TNF-alpha: tumor necrosis factor-alpha; LPS: lipopolysaccharide.</div><div id=\"graphicVersion\">Graphic 53498 Version 3.0</div></div></div>"},"53499":{"type":"graphic_table","displayName":"Antiarrhythmic drugs to maintain sinus rhythm in AF","title":"Pooled results of randomized controlled trials of antiarrhythmic drugs for maintenance of sinus rhythm after conversion of atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pooled results of randomized controlled trials of antiarrhythmic drugs for maintenance of sinus rhythm after conversion of atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td colspan=\"1\" rowspan=\"2\" class=\"subtitle1\">Drug</td>\n\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Odds ratio versus control (95% CI, number of trials)</td>\n\n      <td class=\"subtitle1\" rowspan=\"1\" colspan=\"2\">Trials reporting side effect</td>\n\n\n\n\n    </tr>\n\n\n    <tr>\n\n\n      \n\n\n      \n\n\n      <td class=\"subtitle2\"> Sustained ventricular, arrhythmia, percent</td>\n\n\n      <td class=\"subtitle2\">Cessation or decreased dose, percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Amiodarone</td>\n\n\n      <td>6.8 (4.0 to 11.4, 2 trials)</td>\n\n\n      <td>0</td>\n\n\n      <td>0 to 9</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Propafenone</td>\n\n\n      <td>3.0 (2.0 to 4, 7, 4 trials)</td>\n\n\n      <td>0 to 3</td>\n\n\n      <td>3 to 25</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Disopyramide</td>\n\n\n      <td>2.9 (1.4 to 6.1, 2 trials)</td>\n\n\n      <td>0</td>\n\n\n      <td>0 to 55</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Sotalol</td>\n\n\n      <td>2.5 (1.7 to 3.7, 4 trials)</td>\n\n\n      <td>0 to 5</td>\n\n\n      <td>5 to 13</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Flecainide</td>\n\n\n      <td>4.3 (1.3 to 14.1, 3 trials)</td>\n\n\n      <td>0</td>\n\n\n      <td>0 to 20 percent</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Quinidine</td>\n\n\n      <td>2.7 (1.1 to 6.8, 4 trials)</td>\n\n\n      <td>0 to 12</td>\n\n\n      <td>4 to 58</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Azimilide</td>\n\n\n      <td>1.6 (1.2 to 2.2, 1 trial)</td>\n\n\n      <td>1</td>\n\n\n      <td>5</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_lgnd\">NOTE: The data in this table cannot be directly applied to clinical practice since the choice of drug will vary with a number of factors including the presence or absence of coronary disease or heart failure.</div><div class=\"graphic_reference\">Adapted from McNamara RL, Tamariz LJ, Segal JB, Bass EB. Ann Intern Med 2004; 139:1018.</div><div id=\"graphicVersion\">Graphic 53499 Version 6.0</div></div></div>"},"53503":{"type":"graphic_picture","displayName":"Parotid gland swelling","title":"Parotid gland swelling in a young child","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Parotid gland swelling in a young child</div><div class=\"cntnt\"><img style=\"width:808px; height:482px;\" src=\"images/ID/53503_Parotid_gland_swell.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is swelling of the parotid gland anterior and inferior to the auricle, obscuring the angle of the mandible.</div><div class=\"graphic_reference\">Reprinted with permission from Salivary Gland Disorders, June 1, 2014, Vol 89, No 11, American Family Physician Copyright &copy; 2014 American Academy of Family physicians. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 53503 Version 4.0</div></div></div>"},"53504":{"type":"graphic_table","displayName":"Risk factors for MRSA colonization","title":"Risk factors for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) colonization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) colonization</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Health care-associated risk factors include:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recent hospitalization </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Residence in a long-term care facility </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Recent surgery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Hemodialysis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Additional risk factors for MRSA infection include:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Human immunodeficiency virus (HIV) infection </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Injection drug use </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Prior antibiotic use </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Factors associated with MRSA outbreaks include:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Incarceration </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Military service </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sharing sports equipment </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Sharing needles, razors, or other sharp objects </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53504 Version 9.0</div></div></div>"},"53506":{"type":"graphic_picture","displayName":"Necrotizing GN","title":"Necrotizing glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Necrotizing glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/53506_Necrotizing_GN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing fresh segmental necrotizing lesions with bright red fibrin deposition (arrows). A necrotizing glomerulonephritis can be seen in a variety of inflammatory disorders including vasculitis and lupus nephritis. The latter has prominent immune complex deposition which is generally absent in vasculitis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 53506 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"53508":{"type":"graphic_waveform","displayName":"12-lead ECG WPW concertina effect","title":"12-lead electrocardiogram (ECG) showing concertina effect in Wolff-Parkinson-White syndrome","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing concertina effect in Wolff-Parkinson-White syndrome</div><div class=\"cntnt\"><img style=\"width:541px; height:304px;\" src=\"images/CARD/53508_WPW_concertina_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG and rhythm strip during sinus rhythm show a short PR interval and QRS complex which is aberrated and has a delta wave. After the fifth complex on the rhythm strip, there is a sinus pause after which the QRS compex is still aberrated but the PR interval is somewhat longer. Subsequently, the PR interval becomes progressively shorter. This variability in the PR interval during sinus rhythm is known as the \"concertina effect.\"</div><div id=\"graphicVersion\">Graphic 53508 Version 6.0</div></div></div>"},"53509":{"type":"graphic_picture","displayName":"Nail psoriasis hyperkeratosis","title":"Nail psoriasis with subungual hyperkeratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nail psoriasis with subungual hyperkeratosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53509_Nail_psoriasis_hyperker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marked subungual hyperkeratosis is present on several nails of this patient with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53509 Version 6.0</div></div></div>"},"53510":{"type":"graphic_table","displayName":"Indications test hypothyroidism","title":"Indications to test for hypothyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications to test for hypothyroidism</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_left\">Clinical symptoms and signs</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Fatigue</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Cold intolerance</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Constipation</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Impaired memory</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Slowed mental processing</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Depression</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Nerve entrapment syndromes</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Ataxia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Muscle weakness</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Muscle cramps</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Menstrual disturbance</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Infertility</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Bradycardia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Diastolic hypertension</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hoarseness</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Goitre</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Periorbital oedema</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Weight gain</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Galactorrhoea</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_left\">Laboratory test abnormalities</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hypercholesterolaemia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hyponatraemia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hyperprolactinaemia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Hyperhomocysteinaemia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Anemia</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Creatine phosphokinase elevation</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_left\">Radiological abnormalities</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pericardial and pleural effusions</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td>Pituitary gland enlargement</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_left\">Risk factors for hypothyroidism</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_left\">Autoimmune thyroiditis</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Established serological or tissue diagnosis</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Diffuse goitre</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Previous Graves' disease, de Quervain's thyroiditis, or painless (postpartum) thyroiditis</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Family history of autoimmune thyroid disease</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Down's syndrome</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Turner's syndrome</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Personal\nor family history of associated autoimmune disorders (eg, vitiligo,\npernicious anaemia, adrenal insufficiency, diabetes mellitus type 1,\novarian failure, coeliac disease, Sj&#246;gren's syndrome)</td>\n\t\t\t\t\t\t</tr>\n\n\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Primary pulmonary hypertension</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Multiple Sclerosis</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_left\">Previous thyroid injury</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Thyroidectomy or other neck surgery</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Radioactive iodine therapy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">External radiotherapy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Exposure to polybrominated and polychlorinated biphenyls, and resorcinol</td>\n\t\t\t\t\t\t</tr>\n\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle1_left\">Postpartum status</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_left\">Drugs impairing thyroid function</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Lithium carbonate</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Amiodarone</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Aminoglutethimide</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Interferon &#945;</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Thalidomide</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Betaroxine</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Stavudine</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_left\">Hypothalamic disorders</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Hypothalamic or suprasellar mass</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">History of hypothalamic radiotherapy or surgery</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Disorders causing hypothalamic dysfunction-- eg, sarcoidosis, haemochromatosis, Langerhans' cell histiocytosis</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"subtitle2_left\">Pituitary disorders</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Known pituitary tumour</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Other elements of hypopituitarism</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">Manifestations of a sellar mass (eg, headache, bitemporal haemianopsia, or diplopia)</td>\n\t\t\t\t\t\t</tr>\n\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">History of pituitary surgery of radiotherapy</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">History of head trauma</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">History of pituitary apoplexy, including Sheehan's syndrome</td>\n\t\t\t\t\t\t</tr>\n\n\t\t\t\t\t\t<tr>\n\t\t\t\t\t\t\t<td class=\"indent1\">History of other disorders causing hypopituitarism - eg, metastatic cancer and lymphocytic hypophysitis</td>\n\t\t\t\t\t\t</tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Roberts, CG, Ladenson, PW. Hypothyroidism. Lancet 2004; 363:793. Copyright &#169; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 53510 Version 1.0</div></div></div>"},"53512":{"type":"graphic_figure","displayName":"HLA TCR complex","title":"Interaction of the major histocompatibility complex and the T cell antigen receptor complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interaction of the major histocompatibility complex and the T cell antigen receptor complex</div><div class=\"cntnt\"><img style=\"width:416px; height:536px;\" src=\"images/PULM/53512_HLA_TCR_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The TCR is composed of an alpha and a beta chain, which are linked by disulfide bonds (S-S)&nbsp;forming a heterodimer. The TCR recognizes and interacts with processed peptide antigen presented in the context of the&nbsp;MHC (HLA class I, which binds to CD8,&nbsp;or HLA class II, which binds to CD4).</div><div class=\"graphic_footnotes\">APC: antigen-presenting cell; MHC: major histocompatibility complex;&nbsp;HLA: human leukocyte antigen; TCR: T cell antigen receptor; P: phosphate.</div><div class=\"graphic_reference\">Adapted from: Krensky AM, Weiss A, Crabtree G, et al. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990; 322:510.</div><div id=\"graphicVersion\">Graphic 53512 Version 3.0</div></div></div>"},"53513":{"type":"graphic_figure","displayName":"Longitudinal relaxation in MRI","title":"Longitudinal relaxation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal relaxation</div><div class=\"cntnt\"><img style=\"width:321px; height:199px;\" src=\"images/PULM/53513_Longitudinal_relaxation_in.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evolution of magnetization after a 180&#176; radiofrequency excitation. Magnetization is flipped 180&#176; at time zero (t=0). Magnetization relaxes toward equilibrium as energy is lost. Magnetization recovery is 63 percent complete at time t=T1 and 100 percent complete at time t&gt;&gt;T1.</div><div id=\"graphicVersion\">Graphic 53513 Version 1.0</div></div></div>"},"53514":{"type":"graphic_picture","displayName":"Outward rotation PI","title":"Outward rotation exercise","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Outward rotation exercise</div><div class=\"cntnt\"><img style=\"width:526px; height:350px;\" src=\"images/PI/53514_Outward_rotation_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold your elbows at 90 degrees, close to your sides; holding a towel between your torso and the inside of your elbow will cue you to keep your elbow by your side. Hold one end of a rubber band in each hand and rotate the affected forearm outward two or three inches, holding for five seconds.</div><div id=\"graphicVersion\">Graphic 53514 Version 4.0</div></div></div>"},"53515":{"type":"graphic_waveform","displayName":"Decremental response with RNS","title":"Repetitive nerve stimulation: Decremental response","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Repetitive nerve stimulation: Decremental response</div><div class=\"cntnt\"><img style=\"width:525px; height:204px;\" src=\"images/NEURO/53515_Decremental_response_RNS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repetitive nerve stimulation at 3 Hz in a patient with myasthenia gravis. Stimulating the nerve at the wrist recording at the first dorsal interousseous. Maximal decrement is noted to the right of the trace.</div><div class=\"graphic_reference\">Reproduced from: Preston DC, Shapiro BE. Neuromuscular junction disorders. In: Electromyography and neuromuscular disorders: Clinical-electrophysiologic correlations, 2nd edition, Butterworth-Heinemann, 2005. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53515 Version 2.0</div></div></div>"},"53516":{"type":"graphic_table","displayName":"Massive transfusion protocol","title":"Massive transfusion protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Massive transfusion protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"11%\"></colgroup><colgroup width=\"89%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">University of Minnesota medical center, Fairview department of trauma services</td> </tr> <tr> <td><strong>Category:</strong></td> <td>Provision of care, treatment and services department of trauma services</td> </tr> <tr class=\"divider_top\"> <td><strong>Subject:</strong></td> <td>Massive transfusion protocol</td> </tr> <tr class=\"divider_top\"> <td><strong>Purpose:</strong></td> <td>To ensure timely and appropriate treatment of or anticipation of massive transfusion episodes. To maximize the availability of blood and blood components, and to utilize resources efficiently.</td> </tr> <tr class=\"divider_top\"> <td><strong>Policy:</strong></td> <td>The massive transfusion protocol (MTP) is a multidisciplinary process whereby blood and blood components are obtained rapidly for an exsanguinating patient. Initiation of the MTP is reported to the transfusion service physician (BB MD) on-call as soon as possible by the blood bank staff. The BB MD serves as a consultant in the evaluation and management of the patient's transfusion therapy during the massive transfusion episode.</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"52\"><strong>Procedure:</strong></td> <td class=\"sublist1_start\"><strong>Example reasons for initiation:</strong></td> </tr> <tr> <td class=\"indent1\">1. Replacement of at least one blood volume (8 to 10 red blood cell units in a 70 kg adult) within 24 hours or at least one half blood volume within 2 hours</td> </tr> <tr> <td class=\"indent1\">2. Life-threatening trauma presenting to the emergency department</td> </tr> <tr> <td class=\"indent1\">3. Unexpected or anticipated surgical blood emergencies</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Trauma service responsibilities:</strong></td> </tr> <tr> <td class=\"indent1\">1. The massive transfusion protocol (MTP) is initiated by the patient's staff physician or the staff anesthesiologist by calling the blood bank (this phone call may be delegated to another individual)</td> </tr> <tr> <td class=\"indent2\">a. Clearly state to the blood bank: \"Initiate the massive transfusion protocol\". Indicate whether it is an adult MTP or pediatric MTP (for patient's less than 35 kg).</td> </tr> <tr> <td class=\"indent2\">b. Give the patient's name and medical record number</td> </tr> <tr> <td class=\"indent2\">c. Provide the patient's current location and a phone number that can be used to reach the patient's care team</td> </tr> <tr> <td class=\"indent2\">d. Determine if patient requires emergency release of two uncrossmatched and untagged O Neg red blood cells for immediate transfusion. Note: Average time for first MTP set is 15 to 20 minutes.</td> </tr> <tr> <td class=\"indent1\">2. Send a properly labeled specimen (3 mL purple tube) to the blood bank for a type and screen if not done in last three days. The specimen label must contain the patient's name, medical record number, date, and the initials of the collector written on the tube.</td> </tr> <tr> <td class=\"indent1\">3. Record initiation of protocol in patient's chart</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Blood bank responsibilities:</strong></td> </tr> <tr> <td class=\"indent1\">1. Release two emergency O Neg red blood cells (RBCs) if requested</td> </tr> <tr> <td class=\"indent1\">2. Prepare 4 RBCs, 4 plasma, and 1 dose of platelets for adult MTP or 2 RBCs, 2 plasma, and &#189; platelet apheresis for pediatric MTP. Note: Group \"O\" uncrossmatched RBCs will be issued, if necessary, until type specific and later crossmatched becomes available.</td> </tr> <tr> <td class=\"indent1\">3. Provide a cooler with ice for each set of RBC and plasma components</td> </tr> <tr> <td class=\"indent1\">4. Notify the patient's care team when a set of components is ready for pickup</td> </tr> <tr> <td class=\"indent1\">5. Notify BB MD on-call</td> </tr> <tr> <td class=\"indent1\">6. Stay 1 MTP set ahead (prepare each set immediately following pickup of previous set)</td> </tr> <tr> <td class=\"indent1\">7. Continue process until notified to discontinue the protocol</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Nursing responsibilities:</strong></td> </tr> <tr> <td class=\"indent1\">1. Assign personnel to obtain the set of components from the blood bank</td> </tr> <tr> <td class=\"indent2\">a. Blood bank will call when each set is ready for pickup</td> </tr> <tr> <td class=\"indent2\">b. Send a completed release form with the personnel picking up the components</td> </tr> <tr> <td class=\"indent1\">2. Order labs as directed by the trauma team</td> </tr> <tr> <td class=\"indent1\">3. Communicate the lab results to the trauma team and the blood bank</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Attending physician, surgeon, or anesthesiologist responsibilities:</strong></td> </tr> <tr> <td class=\"indent1\">1. Obtain baseline CBC and coagulation studies</td> </tr> <tr> <td class=\"indent1\">2. Determine if rFVIIa is required (see section below for guidelines)</td> </tr> <tr> <td class=\"indent1\">3. Monitor CBC, ABG, potassium, ionized calcium, and coag tests frequently</td> </tr> <tr> <td class=\"indent1\">4. If a coagulopathy is suspected measure the fibrinogen test and other coagulations studies</td> </tr> <tr> <td class=\"indent1\">5. Determine when the protocol should be discontinued</td> </tr> <tr> <td class=\"indent2\">a. Call the blood bank (this phone call may be delegated to another individual)</td> </tr> <tr> <td class=\"indent2\">b. Document discontinuation in the patient's chart</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Use of rFVIIa (Novaseven) in surgery and trauma:</strong></td> </tr> <tr> <td class=\"indent1\">1. Indication of the use of rFVIIa</td> </tr> <tr> <td class=\"indent2\">a. Active bleeding following administration of 6 to 8 units of red blood cells, 6 to 8 units of plasma, and one dose of platelets</td> </tr> <tr> <td class=\"indent2\">b. Administer 10 units of cryoprecipitate if the fibrinogen is &#60;100 mg/dL</td> </tr> <tr> <td class=\"indent1\">2. Contraindications for the use of rFVIIa</td> </tr> <tr> <td class=\"indent2\">a. pH &#60;7.00</td> </tr> <tr> <td class=\"indent2\">b. Immediately following cardiac arrest</td> </tr> <tr> <td class=\"indent2\">c. Patient considered \"unsalvageable\" by staff surgeon</td> </tr> <tr> <td class=\"indent2\">d. Pregnancy</td> </tr> <tr> <td class=\"indent2\">e. Recent thrombotic event, MI, or stroke</td> </tr> <tr> <td class=\"indent1\">3. Dosing of rFVIIa</td> </tr> <tr> <td class=\"indent2\">a. If the patient has been on warfarin and arrives with an elevated INR and rapid bleeding, consider using one small vial of rFVII or 1.2 mg. This is usually a 15 micrograms/kg dose for adults.</td> </tr> <tr> <td class=\"indent2\">b. If the patient is not on warfarin, consider using 45 micrograms/kg as a half dose and repeat this dose in 30 to 60 minutes</td> </tr> <tr> <td class=\"indent2\">c. Always round down to the nearest full vial for doses of rFVIIa</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Review of massive transfusion protocol events by transfusion services:</strong></td> </tr> <tr> <td class=\"indent1\">1. Each event is summarized by blood bank staff</td> </tr> <tr> <td class=\"indent1\">2. Review is performed by blood bank supervisor and transfusion service physicians</td> </tr> <tr> <td class=\"indent1\">3. The events are reported to the transfusion committee</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>References:</strong></td> <td>1. Technical Manual, American Association of Blood Banks. Bethesda, MD.</td> </tr> <tr> <td>2. Guidelines for Massive Transfusion, American Association of Blood Banks. Bethesda, MD.</td> </tr> <tr class=\"divider_top\"> <td><strong>Approved by:</strong></td> <td> <p>Dr. Matthew Byrnes<br /> Director of the Trauma Service<br /> Department of General Surgery<br /> University of Minnesota Medical Center, Fairview</p> <p>Dr. Donovan Hess<br /> Director of the Pediatric Trauma Service<br /> University of Minnesota Medical Center, Fairview</p> Transfusion Committee<br /> University of Minnesota Medical Center, Fairview</td> </tr> <tr class=\"divider_top\"> <td><strong>Date effective:</strong></td> <td>10/01/2007</td> </tr> <tr class=\"divider_top\"> <td><strong>Date revised:</strong></td> <td>May 16, 2008; April 6, 2010</td> </tr> <tr class=\"divider_top\"> <td><strong>Date reviewed:</strong></td> <td>April 6, 2010</td> </tr> <tr class=\"divider_top\"> <td><strong>Original authors:</strong></td> <td> <p>James Harmon, MD<br /> Department of General Surgery<br /> Trauma Service<br /> University of Minnesota Medical Center, Fairview</p> Julie Welbig<br /> Blood Bank Technical Supervisor<br /> University of Minnesota Medical Center, Fairview</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Bracey A. Guidelines for Massive Transfusion, American Association of Blood Banks, Bethesda, MD 2005.</li>&#xD;&#xA;    <li>Technical Manual, 16th ed, American Association of Blood Banks, Bethesda, MD 2008.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Data reproduced with permission from: the American Association of Blood Banks (AABB).</div><div id=\"graphicVersion\">Graphic 53516 Version 1.0</div></div></div>"},"53517":{"type":"graphic_table","displayName":"Outcome delayed rx","title":"Reported experience with deliberate delay of therapy for patients with invasive cervical cancer to allow for time for fetal maturity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported experience with deliberate delay of therapy for patients with invasive cervical cancer to allow for time for fetal maturity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">EGA at diagnosis</td> <td class=\"subtitle1\">EGA at delivery</td> <td class=\"subtitle1\">Delay in treatment (weeks)</td> <td class=\"subtitle1\">Disease progression</td> <td class=\"subtitle1\">Follow-up (month; mean/range)</td> <td class=\"subtitle1\">Maternal outcome</td> </tr> <tr> <td>Prem, 1966</td> <td>4</td> <td>I</td> <td>&#8805;28</td> <td>35-36</td> <td>6 (average)</td> <td>-</td> <td>All &#62;60 months</td> <td>All NED</td> </tr> <tr> <td>Prem, 1966</td> <td>5</td> <td>I</td> <td>20-34</td> <td>34-38</td> <td>11-17</td> <td>-</td> <td>34-64</td> <td>All NED</td> </tr> <tr> <td>Boutselis, 1972</td> <td>5</td> <td>IA1</td> <td>8-24</td> <td>3rd trimester</td> <td>-</td> <td>-</td> <td>72-180</td> <td>All NED</td> </tr> <tr> <td>Dudan, 1973</td> <td>2</td> <td>IB</td> <td>-</td> <td>-</td> <td>8-24</td> <td>2</td> <td>-</td> <td>&#8805;1 DOD</td> </tr> <tr> <td>Thompson, 1975</td> <td>7</td> <td>IA</td> <td>-</td> <td>3rd trimester</td> <td>5-28</td> <td>-</td> <td>50 (3-120)</td> <td>All NED</td> </tr> <tr> <td>Lee, 1981</td> <td>9</td> <td>IA-II</td> <td>&#8805;24</td> <td>3rd trimester</td> <td>&#60;12</td> <td>No</td> <td>-</td> <td>All NED</td> </tr> <tr> <td>Nisker, 1983</td> <td>1</td> <td>IB</td> <td>-</td> <td>3rd trimester</td> <td>24</td> <td>1</td> <td>-</td> <td>DOD</td> </tr> <tr> <td>Greer, 1989</td> <td>5</td> <td>IB</td> <td>20-24</td> <td>28-37</td> <td>6-17</td> <td>No</td> <td>23 (13-35)</td> <td> <p>4 NED</p> <p>1 DOD</p> </td> </tr> <tr> <td>Monk, 1992</td> <td>4</td> <td>IA2-IB</td> <td>10-23</td> <td>3rd trimester</td> <td>10-23</td> <td>No</td> <td>40 (2-228)</td> <td>All NED</td> </tr> <tr> <td>Duggan, 1993</td> <td>8</td> <td>IA1-IB1</td> <td>11-31</td> <td>31-40</td> <td>8-30</td> <td>No</td> <td>33 (3-124)</td> <td>All NED</td> </tr> <tr> <td>Sorosky, 1995</td> <td>8</td> <td>IB1</td> <td>0-34*</td> <td>33-38</td> <td>3-40</td> <td>No</td> <td>33 (13-68)</td> <td>All NED</td> </tr> <tr> <td>Sorosky, 1996</td> <td>4<sup>&#182;</sup></td> <td>IB1-IB2</td> <td>18-32</td> <td>35-36</td> <td>4-15</td> <td>-</td> <td>51 (12-120)</td> <td> <p>3 NED</p> <p>1 DOD</p> </td> </tr> <tr> <td>Sood, 1996</td> <td>11</td> <td>IA1-IB1</td> <td>-</td> <td>3rd trimester</td> <td>3-32</td> <td>-</td> <td>118 (12-360)</td> <td>All NED</td> </tr> <tr> <td>Van Vliet, 1998</td> <td>4</td> <td>IB</td> <td>23-32</td> <td>32-35</td> <td>3-10</td> <td>-</td> <td>67 (16-106)</td> <td>All NED</td> </tr> <tr> <td>Takushi, 2002</td> <td>12</td> <td>IA1-IB2</td> <td>12-27</td> <td>30 - term</td> <td>6-25</td> <td>No</td> <td>70-156</td> <td>All NED</td> </tr> <tr> <td>Taen, 2006</td> <td>1</td> <td>IB1</td> <td>14</td> <td>31</td> <td>17</td> <td>No</td> <td>17</td> <td>NED</td> </tr> <tr> <td>Germann, 2005</td> <td>9</td> <td>IB1</td> <td>1st and 2nd trimester</td> <td>3rd trimester</td> <td>4-24 (16)</td> <td>No</td> <td>63 (2-168)</td> <td>All NED</td> </tr> <tr> <td>Lee, 2007</td> <td>11</td> <td>IA1-IIA</td> <td>6-31</td> <td>-</td> <td>4-34</td> <td>-</td> <td>-</td> <td> <p>9 NED</p> 2 DOD</td> </tr> <tr class=\"divider_bottom\"> <td>Yahata, 2008</td> <td>4</td> <td>IA1<sup>&#916;</sup></td> <td>16-23</td> <td>37-41</td> <td>&#62;16-25</td> <td>No</td> <td>24-155</td> <td>All NED</td> </tr> <tr> <td><strong>TOTAL</strong></td> <td><strong>98</strong></td> <td><strong>IA1-II</strong></td> <td><strong>0-34</strong></td> <td><strong>3rd trimester</strong></td> <td><strong>3-40</strong></td> <td><strong>3</strong></td> <td><strong>2-360</strong></td> <td> <p><strong>93 NED</strong></p> <strong>4 DOD</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In some cases treatment delay was greater than the time difference of diagnosis to delivery as post-delivery irradiation may not have started for several weeks postpartum.</div><div class=\"graphic_footnotes\">EGA: estimated gestational age; NED: no evidence of disease; DOD: dead of disease.<br />* One patient was diagnosed in the cycle prior to conception and followed through pregnancy.<br />¶ Excluded 3 cases that were doubly reported in Sorosky's 1995 and 1996 series.<br />Δ All adenocarcinoma.</div><div class=\"graphic_reference\">Reproduced and modified with permission from: Nature Reviews. Karam A, Feldman N, Holschneider CH. Neoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancy. Nat Clin Pract Oncol 2007; 4:375. Copyright &copy;2007 Macmillan Magazines Ltd.</div><div class=\"contractual\"><br/><a href=\"http://www.nature.com/\">http://www.nature.com</a></div><div id=\"graphicVersion\">Graphic 53517 Version 3.0</div></div></div>"},"53518":{"type":"graphic_table","displayName":"Nonmotor features PD PI","title":"Nonmotor symptoms of Parkinson disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nonmotor symptoms of Parkinson disease</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td>Cognitive dysfunction</td>\n   </tr>\n   <tr>\n   <td>Psychosis</td>\n   </tr>\n   <tr>\n   <td>Mood disorders (depression, anxiety, apathy/abulia)</td>\n   </tr>\n   <tr>\n   <td>Sleep disturbances</td>\n   </tr>\n   <tr>\n   <td>Fatigue</td>\n   </tr>\n   <tr>\n   <td>Autonomic dysfunction (urinary urgency/frequency, constipation, orthostasis, erectile dysfunction)</td>\n   </tr>\n   <tr>\n   <td>Olfactory dysfunction</td>\n   </tr>\n   <tr>\n   <td>Pain and sensory disturbances</td>\n   </tr>\n   <tr>\n   <td>Dermatologic findings (seborrhea)</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 53518 Version 1.0</div></div></div>"},"53519":{"type":"graphic_picture","displayName":"Neonatal HSV liver","title":"Liver pathology in disseminated neonatal herpes simplex virus (HSV) infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Liver pathology in disseminated neonatal herpes simplex virus (HSV) infection</div><div class=\"cntnt\"><img style=\"width:331px; height:444px;\" src=\"images/PEDS/53519_Neonatal_HSV_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross section of liver from a neonate who died of disseminated HSV disease. Liver tissue on gross inspection showed extensive areas of hemorrhage and focal pale areas of necrosis (Panel A). Histopathologic slide (magnification 20X) of liver of a neonate who died of disseminated HSV, showing hepatic necrosis (Panel B). Immunoperoxidase stain specific for HSV antigens shows area of HSV-associated necrosis in reddish brown.</div><div class=\"graphic_reference\">Courtesy of Edwina Popek, DO, Department of Pathology, Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 53519 Version 1.0</div></div></div>"},"53520":{"type":"graphic_picture","displayName":"Penile glans amputation","title":"Penile glans amputation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile glans amputation</div><div class=\"cntnt\"><img style=\"width:444px; height:160px;\" src=\"images/PEDS/53520_Penile_glans_amputation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn penile glans amputation during circumcision and successful reattachment. <BR>(A) Glans and foreskin amputated specimen.<BR>(B) Graft anastomosis with stent.<BR>(C) Three-month follow-up with good cosmesis and function.</div><div class=\"graphic_reference\">Reproduced from: Gluckman G, Stoller M, Jacobs M, Kogan B. Pediatric urology: newborn penile glans amputation during circumcision and successful reattachment. J Urol 1995; 153:778. Copyright © 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53520 Version 3.0</div></div></div>"},"53522":{"type":"graphic_picture","displayName":"Pilar cyst","title":"Pilar cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pilar cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PC/53522_Pilar_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pilar cysts (trichilemmal cysts) resemble epidermal inclusion cysts. They are firm, slow-growing subcutaneous nodules most commonly located on the scalp.</div><div class=\"graphic_reference\">Courtesy of Vaibhav Parekh, MD, MBA.</div><div id=\"graphicVersion\">Graphic 53522 Version 2.0</div></div></div>"},"53523":{"type":"graphic_picture","displayName":"Warm reactive AIHA","title":"Peripheral blood smear in autoimmune hemolytic anemia (AIHA)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral blood smear in autoimmune hemolytic anemia (AIHA)</div><div class=\"cntnt\"><img style=\"width:379px; height:265px;\" src=\"images/HEME/53523_Warm_reactive_AIHA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This peripheral blood smear from a patient with AIHA due to a warm-reactive immunoglobulin G (IgG) antibody demonstrates the presence of many dark red, small microspherocytes (red arrows) and larger spherocytes (black arrow) (x1000). Many large, irregular, blue-tinted red cells are also present, representing reticulocytes (blue arrows).</div><div class=\"graphic_reference\">Reproduced from:&nbsp;Ware RE. Autoimmune hemolytic anemia. In: Nathan and Oski's Hematology of Infancy and Childhood, 7th Ed, Orkin S, Nathan DG, Ginsburg D, et al (Eds), Saunders, Philadelphia 2009. Illustration used with the permission of Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 53523 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"53524":{"type":"graphic_table","displayName":"Immunosuppressive rx infections","title":"Infections associated with specific immunosuppressive regimens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections associated with specific immunosuppressive regimens</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antilymphocyte globulins</td> </tr> <tr> <td>T cell depleting antibodies - activation of latent (herpes) viruses, fever, cytokine release</td> </tr> <tr> <td class=\"subtitle1_single\">Glucocorticoids</td> </tr> <tr> <td>Bacteria, <em>Pneumocystis pneumonia</em>, activation of hepatitis C and hepatitis B</td> </tr> <tr> <td class=\"subtitle1_single\">Azathioprine</td> </tr> <tr> <td>Neutropenia, possible role in human papillomavirus infection</td> </tr> <tr> <td class=\"subtitle1_single\">Mycophenolate mofetil</td> </tr> <tr> <td>Early bacterial infection B cell depression, possible role in late-onset cytomegalovirus (CMV)</td> </tr> <tr> <td class=\"subtitle1_single\">Cyclosporine/tacrolimus</td> </tr> <tr> <td>Increased viral replication, B cell depression, gingival infection, intracellular pathogens</td> </tr> <tr> <td class=\"subtitle1_single\">Rapamycin (sirolimus)</td> </tr> <tr> <td>Excess infections in combination with current agents, idiosyncratic pulmonary syndrome, often with concomitant respiratory pathogens</td> </tr> <tr> <td class=\"subtitle1_single\">Plasmapheresis</td> </tr> <tr> <td>Encapsulated bacteria</td> </tr> <tr> <td class=\"subtitle1_single\">Costimulatory blockade</td> </tr> <tr> <td>Unknown so far (possible role in posttransplant lymphoproliferative disorder [PTLD])</td> </tr> <tr> <td class=\"subtitle1_single\">Rituximab</td> </tr> <tr> <td>B cell depletion, bacterial and viral infections</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53524 Version 5.0</div></div></div>"},"53529":{"type":"graphic_picture","displayName":"Chronic paronychia 1","title":"Chronic paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic paronychia</div><div class=\"cntnt\"><img style=\"width:360px; height:389px;\" src=\"images/DERM/53529_Chronic_paronychia_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic paronychia. Note the swelling of the proximal nail fold, the loss of the cuticle, and the dystrophy of the nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53529 Version 1.0</div></div></div>"},"53530":{"type":"graphic_table","displayName":"ACC AHA preoperative ECG","title":"ACC/AHA guideline summary: Preoperative 12-lead rest electrocardiogram (ECG) prior to noncardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Preoperative 12-lead rest electrocardiogram (ECG) prior to noncardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1_single\">\r\n \r\n  Class I - There is evidence and/or general agreement that a preoperative rest ECG should be obtained in the following setting\r\n \r\n  </td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>&#8226; Patients with a least one clinical risk factor who require vascular surgical procedures</td>\r\n \r\n  </tr>\r\n\r\n<tr>\r\n\r\n  <td>&#8226; Patients with atherosclerotic cardiovascular disease scheduled for intermediate-risk procedures</td>\r\n\r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1_single\">\r\n \r\n  Class IIa - The evidence or opinion is in favor of usefulness of a preoperative rest ECG in the following setting\r\n \r\n  </td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>&#8226; Patients with no clinical risk factors who require vascular surgical procedures</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1_single\">\r\n \r\n  Class IIb - The evidence or opinion is less well established for the usefulness of a preoperative rest ECG in the following settings\r\n \r\n  </td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>&#8226; Patients with at least one clinical risk factor scheduled to undergo intermediate-risk procedures</td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td class=\"subtitle1_single\">\r\n \r\n  Class III - There is evidence and/or general agreement that preoperative rest and postoperative ECGs are not useful in the following setting\r\n \r\n  </td>\r\n \r\n  </tr>\r\n \r\n  <tr>\r\n \r\n  <td>&#8226; Asymptomatic patients who are scheduled for a low-risk operative procedures.</td>\r\n \r\n  </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">2.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=1982&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>ACC_AHA_preoperative_ECG.htm</title></head></div><div class=\"graphic_reference\">Data from: Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.</div><div id=\"graphicVersion\">Graphic 53530 Version 3.0</div></div></div>"},"53533":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor III CT","title":"Fibrous tumor of pleura","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of pleura</div><div class=\"cntnt\"><img style=\"width:741px; height:248px;\" src=\"images/PULM/53533_FbrsplrltmrIIICT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">65-year-old man in cardiac failure with history of prior asbestos exposure. Chest mass was detected, as incidental finding, on CT angiogram and subsequently proven to be solitary fibrous tumor of pleura.<br />(A-C) Unenhanced axial CT images in lung windows completed at yearly intervals from 2006 through 2010 (images from 2007 and 2009 not shown). Dominant left lower lobe nodule (arrow) shows significant side-to-side motion and change in position from posterior costophrenic sulcus to lateral costophrenic sulcus. Initial axial PET/CT images (not shown) revealed minimal 18F-FDG uptake within nodule with maximal standardized uptake value less than mediastinal blood uptake. Although bilateral calcified pleural plaques are present, solitary fibrous tumors are unrelated to asbestos exposure.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography; 18F-FDG: fluorine-18-fluorodeoxyglucose.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Chick JF, Chauhan NR, Madan R. Solitary fibrous tumors of the thorax: nomenclature, epidemiology, radiologic and pathologic findings, differential diagnoses, and management. AJR Am J Roentgenol 2013; 200:W238. Copyright &copy; 2013 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 53533 Version 3.0</div></div></div>"},"53534":{"type":"graphic_figure","displayName":"Mediastinal compartments","title":"Mediastinal compartments","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Mediastinal compartments</div><div class=\"cntnt\"><img style=\"width:527px; height:403px;\" src=\"images/PULM/53534_Mediastinal_compartments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure demonstrates the boundaries of the mediastinal compartments based upon the three-compartment ITMIG classification<SUP>[1]</SUP>.</div><div class=\"graphic_footnotes\">ITMIG: International Thymic Malignancy Interest Group. </div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Carter BW, Benveniste MF, Madan R, et al. ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses. Radiographics 2017; 37:413.</LI></OL></div><div id=\"graphicVersion\">Graphic 53534 Version 3.0</div></div></div>"},"53535":{"type":"graphic_picture","displayName":"Discoid lupus erythematosus of the scalp","title":"Discoid lupus of the scalp","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Discoid lupus of the scalp</div><div class=\"cntnt\"><img style=\"width:504px; height:488px;\" src=\"images/RHEUM/53535_Discoid_LE_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discoid lupus erythematosus affecting the scalp and face. There are discoid plaques over eyebrows, forehead, and scalp, with postinflammatory peripheral hyperpigmentation, central depigmentation,&nbsp;scarring, and alopecia.</div><div class=\"graphic_reference\">Copyright © 2017 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 53535 Version 15.0</div></div></div>"},"53536":{"type":"graphic_table","displayName":"Stages of chronic AR","title":"Stages of chronic aortic regurgitation in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of chronic aortic regurgitation in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics</td> <td class=\"subtitle1\">Hemodynamic consequences</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>A</strong></td> <td><strong>At risk of AR</strong></td> <td> <ul> <li>Bicuspid aortic valve (or other congenital valve anomaly) </li> <li>Aortic valve sclerosis </li> <li>Diseases of the aortic sinuses or ascending aorta </li> <li>History of rheumatic fever or known rheumatic heart disease </li> <li>IE </li> </ul> </td> <td> <ul> <li>AR severity: None or trace </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>B</strong></td> <td><strong>Progressive AR</strong></td> <td> <ul> <li>Mild-to-moderate calcification of a trileaflet valve bicuspid aortic valve (or other congenital valve anomaly) </li> <li>Dilated aortic sinuses </li> <li>Rheumatic valve changes </li> <li>Previous IE </li> </ul> </td> <td> <ul> <li>Mild AR: <ul> <li>Jet width &#60;25% of LVOT; </li> <li>Vena contracta &#60;0.3 cm; </li> <li>RVol &#60;30 mL/beat; </li> <li>RF &#60;30%; </li> <li>ERO &#60;0.10 cm<sup>2</sup>; </li> <li>Angiography grade 1+ </li> </ul> </li> <li>Moderate AR: <ul> <li>Jet width 25 to 64% of LVOT; </li> <li>Vena contracta 0.3 to 0.6 cm; </li> <li>RVol 30 to 59 mL/beat; </li> <li>RF 30 to 49%; </li> <li>ERO 0.10 to 0.29 cm<sup>2</sup>; </li> <li>Angiography grade 2+ </li> </ul> </li> </ul> </td> <td> <ul> <li>Normal LV systolic function </li> <li>Normal LV volume or mild LV dilation </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"><strong>C</strong></td> <td><strong>Asymptomatic severe AR</strong></td> <td> <ul> <li>Calcific aortic valve disease </li> <li>Bicuspid valve (or other congenital abnormality) </li> <li>Dilated aortic sinuses or ascending aorta </li> <li>Rheumatic valve changes </li> <li>IE with abnormal leaflet closure or perforation </li> </ul> </td> <td> <ul> <li>Severe AR: <ul> <li>Jet width &#8805;65% of LVOT; </li> <li>Vena contracta &#62;0.6 cm; </li> <li>Holodiastolic flow reversal in the proximal abdominal aorta </li> <li>RVol &#8805;60 mL/beat; </li> <li>RF &#8805;50%; </li> <li>ERO &#8805;0.3 cm<sup>2</sup>; </li> <li>Angiography grade 3+ to 4+; </li> <li>In addition, diagnosis of chronic severe AR requires evidence of LV dilation </li> </ul> </li> </ul> </td> <td> <ul> <li>C1: Normal LVEF (&#8805;50%) and LVESD &#8804;50 mm </li> <li>C2: Abnormal LV systolic function with depressed LVEF (&#60;50%) or&nbsp; LVESD &#62;50 mm or indexed LVESD &#62;25 mm/m<sup>2</sup> </li> </ul> </td> <td> <ul> <li>None; exercise testing is reasonable to confirm symptom status </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>D</strong></td> <td><strong>Symptomatic severe AR</strong></td> <td> <ul> <li>Calcific valve disease </li> <li>Bicuspid valve (or other congenital abnormality) </li> <li>Dilated aortic sinuses or ascending aorta </li> <li>Rheumatic valve changes </li> <li>Previous IE with abnormal leaflet closure or perforation </li> </ul> </td> <td> <ul> <li>Severe AR: <ul> <li>Doppler jet width &#8805;65% of LVOT; </li> <li>Vena contracta &#62;0.6 cm; </li> <li>Holodiastolic flow reversal in the proximal abdominal aorta; </li> <li>RVol &#8805;60 mL/beat; </li> <li>RF &#8805;50%; </li> <li>ERO &#8805;0.3 cm<sup>2</sup>; </li> <li>Angiography grade 3+ to 4+; </li> <li>In addition, diagnosis of chronic severe AR requires evidence of LV dilation </li> </ul> </li> </ul> </td> <td> <ul> <li>Symptomatic severe AR may occur with normal systolic function (LVEF &#8805;50%), mild-to-moderate LV dysfunction (LVEF 40 to 50%), or severe LV dysfunction (LVEF &#60;40%); </li> <li>Moderate-to-severe LV dilation is present </li> </ul> </td> <td> <ul> <li>Exertional dyspnea or angina or more severe HF symptoms </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">%: percent; AR: aortic regurgitation; ERO: effective regurgitant orifice; HF: heart failure; IE: infective endocarditis; LV: left ventricular; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic dimension; LVOT: left ventricular outflow tract; RF: regurgitant fraction; RVol: regurgitant volume.</div><div class=\"graphic_reference\">Original figure modified for this publication. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; e82. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53536 Version 6.0</div></div></div>"},"53537":{"type":"graphic_algorithm","displayName":"Exacerbation COPD inpatient","title":"Antibiotic treatment of exacerbations of COPD in hospitalized patients","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Antibiotic treatment of exacerbations of COPD in hospitalized patients</div><div class=\"cntnt\"><img style=\"width:528px; height:462px;\" src=\"images/ID/53537_AECOPD_abx_inpatient.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The doses recommended above are intended for patients with normal renal function; the doses must be adjusted in patients with renal insufficiency.</div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.<br />* <EM>Pseudomonas</EM> risk factors: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Advanced COPD</LI>&#xD;&#xA;<LI>Previous isolation of <EM>Pseudomonas </EM>from sputum</LI>&#xD;&#xA;<LI>Concomitant bronchiectasis</LI>&#xD;&#xA;<LI>Frequent administration of antibiotics</LI>&#xD;&#xA;<LI>Frequent hospital admissions</LI>&#xD;&#xA;<LI>Systemic glucocorticoid use</LI></UL></div><div id=\"graphicVersion\">Graphic 53537 Version 9.0</div></div></div>"},"53539":{"type":"graphic_movie","displayName":"Left atrial myxoma 4 chamber view","title":"Left atrial myxoma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53539_4chlamyxconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:287px; height:429px;\" src=\"images/CARD/53539_4chlamyx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber view from a two-dimensional echocardiogram shows a large atrial myxoma within the left atrium behind the posterior leaflet of the mitral valve.</div><div id=\"graphicVersion\">Graphic 53539 Version 3.0</div></div></div>"},"53541":{"type":"graphic_table","displayName":"Boston criteria CAA","title":"Boston criteria for CAA-related hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Boston criteria for CAA-related hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Classic Boston criteria</td> </tr> <tr> <td rowspan=\"4\"><strong>Definite CAA</strong></td> <td class=\"subtitle2_left\">Full postmortem examination demonstrating:</td> </tr> <tr> <td class=\"indent1\">Lobar, cortical, or corticosubcortical hemorrhage</td> </tr> <tr> <td class=\"indent1\">Severe CAA with vasculopathy</td> </tr> <tr> <td class=\"indent1\">Absence of other diagnostic lesion</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Probable CAA with supporting pathology</strong></td> <td class=\"subtitle2_left\">Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy) demonstrating:</td> </tr> <tr> <td class=\"indent1\">Lobar, cortical, or corticosubcortical hemorrhage</td> </tr> <tr> <td class=\"indent1\">Some degree of CAA in specimen</td> </tr> <tr> <td class=\"indent1\">Absence of other diagnostic lesion</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Probable CAA</strong></td> <td class=\"subtitle2_left\">Clinical data and MRI or CT demonstrating:</td> </tr> <tr> <td class=\"indent1\">Multiple hemorrhages restricted to lobar, cortical, or corticosubcortical regions (cerebellar hemorrhage allowed)</td> </tr> <tr> <td class=\"indent1\">Age &#8805;55 y</td> </tr> <tr> <td class=\"indent1\">Absence of other cause of hemorrhage</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Possible CAA</strong></td> <td class=\"subtitle2_left\">Clinical data and MRI or CT demonstrating:</td> </tr> <tr> <td class=\"indent1\">Single lobar, cortical, or corticosubcortical hemorrhage</td> </tr> <tr> <td class=\"indent1\">Age &#8805;55 y</td> </tr> <tr> <td class=\"indent1\">Absence of other cause of hemorrhage</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">5/27/2010--Requested permission (JD). 6/11/2010--Permission granted; figure to Terrence (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40271&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">CAA: cerebral amyloid angiopathy.</div><div class=\"graphic_reference\">Reproduced with permission from: Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74:1346. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53541 Version 10.0</div></div></div>"},"53542":{"type":"graphic_table","displayName":"HCG postmiscarriage","title":"Percent decline in HCG levels following spontaneous pregnancy loss, based on the initial measured level","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percent decline in HCG levels following spontaneous pregnancy loss, based on the initial measured level</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Initial HCG level (milli-int. units/mL) </td> <td class=\"subtitle1\" colspan=\"3\">Percent decline in HCG* </td> <td class=\"subtitle1\" rowspan=\"2\">Mean days until HCG &#60;5 </td> </tr> <tr> <td class=\"subtitle2\">Day 2 </td> <td class=\"subtitle2\">Day 7 </td> <td class=\"subtitle2\">Day 14 </td> </tr> <tr> <td>250</td> <td>70 (36, 21)</td> <td>93 (72, 60)</td> <td>100 (87, 75)</td> <td>12</td> </tr> <tr> <td>500</td> <td>71 (39, 24)</td> <td>94 (77, 68)</td> <td>100 (92, 94)</td> <td>13</td> </tr> <tr> <td>1000</td> <td>72 (42, 28)</td> <td>95 (82, 74)</td> <td>100 (95, 90)</td> <td>14</td> </tr> <tr> <td>1500</td> <td>73 (43, 30)</td> <td>96 (84, 77)</td> <td>100 (96, 92)</td> <td>15</td> </tr> <tr> <td>2000</td> <td>74 (44, 31)</td> <td>96 (85, 79)</td> <td>100 (97, 93)</td> <td>15</td> </tr> <tr> <td>2500</td> <td>74 (45, 32)</td> <td>96 (86, 80)</td> <td>100 (97, 94)</td> <td>15</td> </tr> <tr> <td>3000</td> <td>74 (46, 33)</td> <td>96 (87, 81)</td> <td>100 (97, 95)</td> <td>15</td> </tr> <tr> <td>4000</td> <td>75 (47, 34)</td> <td>97 (88, 83)</td> <td>100 (98, 96)</td> <td>15</td> </tr> <tr> <td>5000</td> <td>75 (47, 35)</td> <td>97 (89, 84)</td> <td>100 (98, 96)</td> <td>16</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Expressed as mean percent decline with 90<sup>th</sup> and 95<sup>th</sup> percentiles in parentheses.</div><div class=\"graphic_reference\">Reproduced with permission from: Barnhart K, Sammel MD, Chung K, et al. Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol 2004; 104:975. Copyright © 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53542 Version 10.0</div></div></div>"},"53544":{"type":"graphic_picture","displayName":"Ecthyma gangrenosum purpura","title":"Ecthyma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Ecthyma gangrenosum</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53544_Ecthyma_gangrenosum_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpuric lesions in a patient with ecthyma gangrenosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53544 Version 3.0</div></div></div>"},"53545":{"type":"graphic_figure","displayName":"Hymenolepis nana life cycle","title":"<EM>Hymenolepis nana</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\"><EM>Hymenolepis nana</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:548px; height:435px;\" src=\"images/ID/53545_Hymenolepis_nana_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eggs of <EM>Hymenolepis nana</EM> are immediately infective when passed with the stool and cannot survive more than 10 days in the external environment <STRONG>(1)</STRONG>. When eggs are ingested by an arthropod intermediate host <STRONG>(2)</STRONG> (various species of beetles and fleas may serve as intermediate hosts), they develop into cysticercoids, which can infect humans or rodents upon ingestion <STRONG>(3)</STRONG> and develop into adults in the small intestine. A morphologically identical variant, <EM>H. nana</EM> var. <EM>fraterna</EM>, infects rodents and uses arthropods as intermediate hosts. When eggs are ingested <STRONG>(4)</STRONG> (in contaminated food or water or from hands contaminated with feces), the oncospheres contained in the eggs are released. The oncospheres (hexacanth larvae) penetrate the intestinal villus and develop into cysticercoid larvae <STRONG>(5)</STRONG>. Upon rupture of the villus, the cysticercoids return to the intestinal lumen, evaginate their scoleces <STRONG>(6)</STRONG>, attach to the intestinal mucosa, and develop into adults that reside in the ileal portion of the small intestine producing gravid proglottids <STRONG>(7)</STRONG>. Eggs are passed in the stool when released from proglottids through its genital atrium or when proglottids disintegrate in the small intestine <STRONG>(8)</STRONG>. An alternate mode of infection consists of internal autoinfection, in which the eggs release their hexacanth embryo, which penetrates the villus continuing the infective cycle without passage through the external environment <STRONG>(9)</STRONG>. The life span of adult worms is four to six weeks, but internal autoinfection allows the infection to persist for years.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Hymenolepiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/hymenolepiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/hymenolepiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 53545 Version 6.0</div></div></div>"},"53546":{"type":"graphic_figure","displayName":"Blood supply and lymph nodes of the rectum and upper anal canal","title":"Blood supply and lymph nodes of the rectum and upper anal canal","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Blood supply and lymph nodes of the rectum and upper anal canal</div><div class=\"cntnt\"><img style=\"width:508px; height:539px;\" src=\"images/SURG/53546_Blood-lymph-rectum-anus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the lymph nodes and blood supply to the rectum and upper anal canal.</div><div id=\"graphicVersion\">Graphic 53546 Version 1.0</div></div></div>"},"53547":{"type":"graphic_picture","displayName":"Endotracheal tube hockey stick in children","title":"Hockey stick configuration for endotracheal tube versus gentle curve","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hockey stick configuration for endotracheal tube versus gentle curve</div><div class=\"cntnt\"><img style=\"width:468px; height:246px;\" src=\"images/EM/53547_ETT_hockey_stick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bending the styletted endotracheal tube into a hockey stick configuration as opposed to a gentle curve allows for the tube to be directed anteriorly through the glottis in children.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 53547 Version 3.0</div></div></div>"},"53548":{"type":"graphic_waveform","displayName":"Advanced case 5","title":"Advanced case 5","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 5</div><div class=\"cntnt\"><img style=\"width:540px; height:142px;\" src=\"images/CARD/53548_Advanced_case_5.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53548 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"53549":{"type":"graphic_picture","displayName":"Grasping the vas during vasectomy","title":"Grasping the vas during vasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Grasping the vas during vasectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:381px;\" src=\"images/PC/53549_Grasping_the_vas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vas is elevated through the incision.</div><div class=\"graphic_reference\">Reproduced with permission from: Clenney, TL, Higgins, JC. Vasectomy Techniques. American Family Physician 1999; 60:137. Copyright &#169;1999 Timothy Clenney, MD, MPH.</div><div id=\"graphicVersion\">Graphic 53549 Version 2.0</div></div></div>"},"53550":{"type":"graphic_table","displayName":"Major causes of edema by primary mechanism","title":"Major causes of edema by primary mechanism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of edema by primary mechanism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increased capillary hydraulic pressure</td> </tr> <tr> <td class=\"indent1\"><strong>Increased plasma volume due to renal sodium retention</strong></td> </tr> <tr> <td class=\"indent2\">Heart failure, including cor pulmonale</td> </tr> <tr> <td class=\"indent2\">Primary renal sodium retention</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Renal disease, including the nephrotic syndrome </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Drugs:* Nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, fludrocortisone, thiazolidinediones (glitazones), insulins, estrogens, progestins, androgens, testosterone, aromatase inhibitors, tamoxifen; and by multiple mechanisms: vasodilators (hydralazine, minoxidil, diazoxide) and calcium channel blockers (particularly dihydropyridines, ie, amlodipine, nifedipine); also refer to \"Arteriolar vasodilation\" below </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Refeeding edema </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Early hepatic cirrhosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Pregnancy and premenstrual edema</td> </tr> <tr> <td class=\"indent2\">Idiopathic edema, when diuretic induced</td> </tr> <tr> <td class=\"indent2\">Sodium or fluid overload: Parenteral antibiotics or other drugs with large amounts of sodium, sodium bicarbonate, or excessive or overly rapid fluid replacement</td> </tr> <tr> <td class=\"indent1\"><strong>Venous obstruction or insufficiency</strong></td> </tr> <tr> <td class=\"indent2\">Cirrhosis or hepatic venous obstruction</td> </tr> <tr> <td class=\"indent2\">Acute pulmonary edema</td> </tr> <tr> <td class=\"indent2\">Local venous obstruction</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Venous thrombosis </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Venous stenosis </li> </ul> </td> </tr> <tr> <td class=\"indent2\">Chronic venous insufficiency - post-thrombotic syndrome</td> </tr> <tr> <td class=\"indent1\"><strong>Arteriolar vasodilation</strong></td> </tr> <tr> <td class=\"indent2\">Drugs:* Frequent - vasodilators (hydralazine, minoxidil, diazoxide), dihydropyridine calcium channel blockers; less frequent - alpha1 blockers, sympatholytics (ie, methyldopa), nondihydropyridine calcium channel blockers<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Idiopathic edema (?)</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoalbuminemia</td> </tr> <tr> <td class=\"indent1\"><strong>Protein loss</strong></td> </tr> <tr> <td class=\"indent2\">Nephrotic syndrome</td> </tr> <tr> <td class=\"indent2\">Protein-losing enteropathy</td> </tr> <tr> <td class=\"indent1\"><strong>Reduced albumin synthesis</strong></td> </tr> <tr> <td class=\"indent2\">Liver disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Malnutrition</td> </tr> <tr> <td class=\"subtitle1_single\">Increased capillary permeability</td> </tr> <tr> <td class=\"indent1\">Idiopathic edema (?)</td> </tr> <tr> <td class=\"indent1\">Burns</td> </tr> <tr> <td class=\"indent1\">Trauma</td> </tr> <tr> <td class=\"indent1\">Inflammation or sepsis</td> </tr> <tr> <td class=\"indent1\">Allergic reactions, including certain forms of angioedema</td> </tr> <tr> <td class=\"indent1\">Adult respiratory distress syndrome</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Interleukin-2 therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Malignant ascites</td> </tr> <tr> <td class=\"subtitle1_single\">Lymphatic obstruction or increased interstitial oncotic pressure</td> </tr> <tr> <td class=\"indent1\">Lymph node dissection</td> </tr> <tr> <td class=\"indent1\">Nodal enlargement due to malignancy</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Malignant ascites</td> </tr> <tr> <td class=\"subtitle1_single\">Other drugs* (uncertain mechanism)</td> </tr> <tr> <td class=\"indent1\">Anticonvulsant: Gabapentin, pregabalin</td> </tr> <tr> <td class=\"indent1\">Antineoplastic: Docetaxel, cisplatin</td> </tr> <tr> <td class=\"indent1\">Antiparkinson: Pramipexole, ropinirole</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with decreased cardiac output, preexisting renal insufficiency, and/or receiving higher doses are more likely to experience edema and edema-associated adverse events. This is not a complete list of drugs associated with edema. For additional information, refer to the Lexicomp individual drug monographs included with UpToDate.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Messerli FH. Vasodilatory edema: A common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4(6):479.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53550 Version 9.0</div></div></div>"},"53551":{"type":"graphic_table","displayName":"Society and expert recommendations for mammographic screening","title":"Society and expert recommendations for routine mammographic screening in women at average risk","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Society and expert&nbsp;recommendations for routine mammographic screening in women at average risk</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Group (date)</td> <td class=\"subtitle1\" rowspan=\"2\">Frequency of screening (years)</td> <td class=\"subtitle1\" colspan=\"3\">Initiation of screening</td> </tr> <tr> <td class=\"subtitle2\">40 to 49 years of age</td> <td class=\"subtitle2\">50 to 69 years of age</td> <td class=\"subtitle2\">&#8805;70 years of age</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Government-sponsored groups</td> </tr> <tr> <td class=\"indent1\">US Preventive Services Task Force (2016)<sup>[1]</sup></td> <td>Two</td> <td>Individualize*</td> <td>Yes</td> <td>Yes, to age 74</td> </tr> <tr> <td class=\"indent1\">Canadian Task Force on Preventive Health Care (2011)<sup>[2]</sup></td> <td>Two to three</td> <td>Recommend against*</td> <td>Yes</td> <td>Yes, to age 74</td> </tr> <tr> <td class=\"indent1\">National Health Service, United Kingdom (2013)<sup>[3]</sup></td> <td>Three</td> <td>Yes, start age 47</td> <td>Yes</td> <td>Yes, to age 73</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Royal Australian College of General Practitioners (2012)<sup>[4]</sup></td> <td>Two</td> <td>No (eligible but not targeted)</td> <td>Yes</td> <td>No (eligible but not targeted)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Medical societies</td> </tr> <tr> <td class=\"indent1\">American College of Obstetricians and Gynecologists (2016)<sup>[5]</sup></td> <td>One to two<sup>*</sup></td> <td>Individualize*</td> <td>Yes</td> <td>Yes, to at least age 75<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">American College of Physicians (2015)<sup>[6]</sup></td> <td>One to two</td> <td>Individualize*</td> <td>Yes</td> <td>Yes, to age 74</td> </tr> <tr> <td class=\"indent1\">American Academy of Family Physicians (2016)<sup>[7]</sup></td> <td>Two</td> <td>Individualize*</td> <td>Yes</td> <td>Yes, to age 74</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">American Cancer Society (2015)<sup>[8]</sup></td> <td>One&nbsp;year age 45 to 54</td> <td rowspan=\"2\"> <p><span style=\"color: black;\">Individualize* through age 44</span></p> <p>Yes, start age 45</p> </td> <td rowspan=\"2\">Yes</td> <td rowspan=\"2\">Yes<sup>&#916;</sup></td> </tr> <tr> <td> <p><span style=\"color: black;\">One to two years</span> age &#8805;55</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">American College of Radiology (2013)<sup>[9]</sup></td> <td>One</td> <td>Yes</td> <td>Yes</td> <td>Yes<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Coalitions</td> </tr> <tr> <td class=\"indent1\">National Comprehensive Cancer Network (2014)<sup>[10]</sup></td> <td>One</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Women should be counseled about the harms and benefits of mammography; individualized&nbsp;decisions should&nbsp;include shared decision-making&nbsp;based on risks, benefits, patient values and preferences.<br />¶ <FONT color=black>Decision to discontinue screening mammography should be based on a shared decision-making process informed by the woman's health status and longevity. <br /></FONT><FONT color=black>Δ If in good health and life expectancy &gt;10 years.</FONT><br />◊ Individualize to current health and life expectancy; if a woman is in reasonably good health and would be a candidate for treatment, then should continue screening.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US Preventive Services Task Force. Screening for Breast Cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2016; 164:279.</LI>&#xD;&#xA;<LI>Canadian Task Force on Preventive Health Care, Tonelli M, Connor Gorber S, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ 2011; 183:1991.</LI>&#xD;&#xA;<LI>NHS England Department of Health. Public health functions to be exercised by NHS England. Public Health Policy and Strategy Unit, Department of Health 2013. <A href=\"http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/192971/S7A_VARIATION_2013-14_FINAL_130417.pdf\" target=_blank>www.gov.uk/government/uploads/system/uploads/attachment_data/file/192971/S7A_VARIATION_2013-14_FINAL_130417.pdf</A> (Accessed August 17, 2015).</LI>&#xD;&#xA;<LI>RACGP. Guidelines for preventive activities in general practice, breast cancer. <A spellcheck=true href=\"http://www.racgp.org.au/your-practice/guidelines/redbook/9-early-detection-of-cancers/93-breast-cancer/\">www.racgp.org.au/your-practice/guidelines/redbook/9-early-detection-of-cancers/93-breast-cancer/</A>.</LI>&#xD;&#xA;<LI><FONT color=blue><FONT color=black>American College of Obstetricians-Gynecologists. Practice bulletin no.</FONT><FONT color=black> 179: Breast cancer risk assessment and screening in average-risk women. Obstet Gynecol 2017;130:e1-16&nbsp;&nbsp;</FONT></FONT></LI>&#xD;&#xA;<LI><FONT color=blue><FONT color=red><FONT color=blue><FONT color=red><FONT color=blue><FONT color=red><FONT color=black>Wilt TJ, Harris RP, Qaseem A, High Value Care Task Force of the American College of Physicians. Screening for Cancer: advice for high-value care from the American College of Physicians. Ann Intern Med 2015; 162:718.</FONT></FONT></FONT></FONT></FONT></FONT></FONT></LI>&#xD;&#xA;<LI><FONT color=red><FONT color=black>American Academy of Family Physicians. Clinical Preventive Service Recommendation: Breast Cancer. <A href=\"http://www.aafp.org/patient-care/clinical-recommendations/all/breast-cancer.html\" target=_blank>www.aafp.org/patient-care/clinical-recommendations/all/breast-cancer.html</A>.</FONT></FONT></LI>&#xD;&#xA;<LI>Oeffinger KC, Fontham ETH, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 2015; 314:1599.</LI>&#xD;&#xA;<LI>Mainiero MB, Lourenco A, Mahoney MC, et al. ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol 2013; 10:11.</LI>&#xD;&#xA;<LI>NCCN. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Fort Washington, PA 2014.</LI></OL></div><div id=\"graphicVersion\">Graphic 53551 Version 26.0</div></div></div>"},"53552":{"type":"graphic_picture","displayName":"Valgus stress testing thumb","title":"Valgus stress testing of the thumb","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Valgus stress testing of the thumb</div><div class=\"cntnt\"><img style=\"width:373px; height:273px;\" src=\"images/EM/53552_Valgus_stress_testing_thumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The carpometacarpal (CMC) joint and the metacarpal bone of the thumb are securely grasped by one hand while the distal thumb is firmly grasped by the other. Using the thumbs for leverage, stress is applied across the metacarpophalangeal (MP) joint to the collateral ligament located on the ulnar side of the thumb (ie, the thumb is pulled away from the palm while the MP joint is braced).</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 53552 Version 3.0</div></div></div>"},"53554":{"type":"graphic_picture","displayName":"Plasmacytoid dendritic cells anti-BDCA-2 in DM","title":"Plasmacytoid dendritic cells anti-BDCA-2 in DM","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Plasmacytoid dendritic cells anti-BDCA-2 in DM</div><div class=\"cntnt\"><img style=\"width:480px; height:341px;\" src=\"images/RHEUM/53554_Plas_dendritic_DM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plasmacytoid dendritic cells identified by immunoreactivity to anti-BDCA-2 antibody in a perimysial and perivascular location in dermatomyositis muscle.</div><div class=\"graphic_reference\">Courtesy of Steven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 53554 Version 1.0</div></div></div>"},"53555":{"type":"graphic_diagnosticimage","displayName":"CF atelectasis1","title":"Right upper lobe atelectasis in a newborn with cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right upper lobe atelectasis in a newborn with cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:432px; height:351px;\" src=\"images/PEDS/53555_CF_atelectasis1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a newborn male with cystic fibrosis and&nbsp;right upper lobe&nbsp;atelectasis.</div><div class=\"graphic_reference\">Courtesy of Jonathan D Finder, MD.</div><div id=\"graphicVersion\">Graphic 53555 Version 3.0</div></div></div>"},"53558":{"type":"graphic_picture","displayName":"RTT prior to developmental arrest","title":"Rett syndrome prior to developmental arrest","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome prior to developmental arrest</div><div class=\"cntnt\"><img style=\"width:378px; height:252px;\" src=\"images/PEDS/53558_RS_stage_I_develop_arrest_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At six months of age, this girl with RTT appears normal and has animated facial expression.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 53558 Version 4.0</div></div></div>"},"53559":{"type":"graphic_table","displayName":"Pediatric supraventricular tachycardia rapid overview","title":"Rapid overview: Emergency management of supraventricular tachycardia (SVT) in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergency management of supraventricular tachycardia (SVT) in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Evaluation</td> </tr> <tr> <td colspan=\"2\">Provide oxygen and ventilation immediately as needed.</td> </tr> <tr> <td colspan=\"2\">Goals: Identify the unstable patient; distinguish SVT from sinus tachycardia.</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Clinical assessment</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Potential causes of sinus tachycardia (dehydration, fever, pain, drugs).</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Signs of poor perfusion (poor capillary refill, hypotension, pallor, diminished mental status).</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Signs of heart failure (increased work of breathing, rales, hepatomegaly).</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">12-lead ECG</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">The following are consistent with SVT:</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><span class=\"indent2\"></span>Rate: Infants 220 to 280 bpm; children&nbsp;and adolescents 180 to 240 bpm.</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Relentlessly regular rhythm without variation with respiration or activity.</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Abnormal P waves (absent or negative in II, III, and aVF).</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">For wide QRS complex, assume the origin is ventricular (although in children, most are SVT with aberrant conduction).*</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Management<br /> </td> </tr> <tr> <td colspan=\"2\">Goal: Terminate the abnormal rhythm. Consult pediatric cardiology early.</td> </tr> <tr> <td class=\"subtitle2_single\">Stable</td> <td class=\"subtitle2_single\">Unstable</td> </tr> <tr> <td> <ul> <li>Children with SVT who are stable are unlikely to deteriorate suddenly. </li> <li>Begin treatment with vagal maneuvers and/or adenosine and consult pediatric cardiology. </li> </ul> </td> <td> <ul> <li>For unstable patients (depressed mental status, hypotension, signs of shock), begin treatment to convert to sinus rhythm immediately. </li> <li>Continue oxygen and ventilation as needed. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong><span class=\"indent1\"></span><span class=\"indent1\"></span>Vagal maneuvers:</strong> For infants, apply bag containing ice water to the face above the nose and mouth for 15 to 30 seconds. Do not obstruct ventilation. In older children, bearing down or blowing into an occluded straw for 15 to 20 seconds provides vagal stimulation. Do not use carotid massage or orbital pressure.</td> <td class=\"indent1\"><strong>Vagal maneuvers:</strong> Do not delay treatment to administer vagal maneuvers in unstable patients. Attempt while preparing for cardioversion or drug therapy.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><strong><span class=\"subtitle2_left\">Adenosine</span>:</strong> With continuous ECG monitoring, administer rapidly through IV closest to the central circulation. Initial dose: 0.1 mg/kg (max 6 mg); if no response in two minutes, repeat dose 0.2 mg/kg (max 12 mg). Follow each dose immediately with a saline flush of 5 mL.<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif;\"><strong><sup>&#182;</sup></strong></span></td> <td class=\"indent1\"> <p><span class=\"subtitle2_left\"><strong>Without IV/IO in place</strong></span><span class=\"subtitle2_left\">: </span></p> <p><span class=\"subtitle2_left\"><strong>Synchronized cardioversion:</strong> Cardiovert immediately all unstable patients without IV access. Use 0.5 to 1 J/kg. If not effective, increase to 2 J/kg.</span></p> </td> </tr> <tr> <td class=\"indent1\"> <p><strong>With IV/IO in place:</strong><sup><span style=\"font-size: 13px;\">&#916;</span></sup><span style=\"font-size: 13px;\"></span></p> <ul> <li><span style=\"font-size: 13px;\"><strong>Adenosine:</strong> If immediately available, adenosine may be given to unstable patients with narrow complex SVT with IV access&nbsp;while preparing to cardiovert. Initial dose: 0.1 mg/kg (max 6 mg); if no response in two minutes, repeat dose 0.2 mg/kg (max 12 mg). Follow each dose immediately with a saline flush of 5 mL.<sup>&#182;</sup></span> </li> </ul> <p><span style=\"font-size: 13px;\"><sup></sup></span>&nbsp;</p> <ul> <li><span style=\"font-size: 13px;\"><strong>Synchronized cardioversion:</strong> If adenosine is not immediately available or if there is no response to adenosine, synchronized cardioversion should be performed in all unstable patients with IV access. Use 0.5 to 1 J/kg. If not effective, increase to 2 J/kg.</span> </li> </ul> <p>&nbsp;</p> <p><span style=\"font-size: 13px;\"></span></p> <ul> <li><span style=\"font-size: 13px;\"><strong>IV antiarrhythmic options for refractory SVT</strong>:<sup>&#9674;</sup></span> <ul> <li><span style=\"font-size: 13px;\"><sup></sup></span><strong>Procainamide:</strong><sup>&#167;</sup> Procainamide is an option for SVT that is refractory to adenosine and cardioversion. Dose: Neonates receive a loading dose of 7 to 10 mg/kg over 30 to 45 minutes; for infants and older children the loading dose is 10 to 15 mg/kg over 30 to 45 minutes (maximum adult dose range 1000 to 1500 mg). Follow with a continuous infusion starting at 20 mcg/kg per minute (maximum 2000 mg/day). </li> </ul> </li> </ul> <p>&nbsp;</p> <p class=\"indent2\">&nbsp;OR</p> <p class=\"indent2\">&nbsp;</p> <ul> <ul> <li><strong>Amiodarone:</strong><sup><span style=\"font-size: 13px;\">&#167;</span></sup> Amiodarone is an option for SVT that is refractory to adenosine and cardioversion. Dose: 5 mg/kg IV over 20 to 60 minutes. If no response, repeat the bolus dose up to a total of 15 mg/kg. If the patient responds, then follow bolus with a continuous infusion of 10 to 15 mg/kg per 24 hours (0.4 to 0.6 mg/kg per hour). </li> </ul> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; bpm: beats per minute; IV: intravenous; IO: intraosseous.<br />* Refer to separate UpToDate content for details of evaluation and management of wide QRS complex tachyarrhythmias in children.<br />¶ The use of two syringes (one with adenosine and the other with normal saline flush) connected to a stopcock is a useful way of ensuring rapid and effective drug delivery.<br />Δ IV access is preferred over IO for administration of adenosine and antiarrhythmic drugs. An IO can be used for these agents, but conversion to sinus rhythm with adenosine may not be successful when using IO access.<br />◊ The agents listed here are supported by the American Heart Association guidelines for pediatric cardiopulmonary resuscitation. Other options that may be used for termination of SVT include IV verapamil (in children &gt;1 year only) and IV esmolol. Consultation with a pediatric cardiologist is advised. Refer to UpToDate topics on management of tachyarrhythmias in children for further details.<br />§&nbsp;These drugs have potential for serious adverse effects and, therefore, consultation with a pediatric cardiologist is advised&nbsp;whenever possible. Both amiodarone and procainamide can prolong the QT interval and they should not be administered together. Refer to UpToDate content on SVT in children for additional details.</div><div id=\"graphicVersion\">Graphic 53559 Version 11.0</div></div></div>"},"53561":{"type":"graphic_picture","displayName":"HCV hepatitis Light","title":"Mild hepatitis in chronic HCV","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild hepatitis in chronic HCV</div><div class=\"cntnt\"><img style=\"width:440px; height:288px;\" src=\"images/GAST/53561_HCV_hepatitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a liver biopsy shows mild inflammation primarily limited to the portal area with focal periportal (piecemeal) necrosis in a patient with chronic hepatitis C virus (HCV) infection.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 53561 Version 1.0</div></div></div>"},"53562":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber TV prolapse","title":"Tricuspid valve prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid valve prolapse</div><div class=\"cntnt\"><img style=\"width:242px; height:216px;\" src=\"images/CARD/53562_Apical_4_chamber_TV_prolaps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four chamber view of a two dimensional echocardiogram shows a prolapse of the tricuspid valve; the arrows denote the superior displacement of the septal and anterior leaflets of the tricuspid valve. There is also mitral valve (MV) prolapse; tricuspid prolapse almost never occurs in the absence of mitral prolapse.</div><div id=\"graphicVersion\">Graphic 53562 Version 2.0</div></div></div>"},"53563":{"type":"graphic_table","displayName":"Adverse effects - TB and HIV medicines","title":"Common side effects shared by antiretrovirals and antituberculosis medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common side effects shared by antiretrovirals and antituberculosis medications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Antiretrovirals</td> <td class=\"subtitle1\">Antituberculosis medications</td> </tr> <tr> <td>Hepatitis</td> <td> <p>Nevirapine</p> <p>Ritonavir-boosted protease inhibitors</p> </td> <td> <p>Isoniazid</p> <p>Rifampin*</p> <p>Pyrazinamide</p> </td> </tr> <tr> <td>Gastrointestinal distress</td> <td>All antiretrovirals (less common with lamivudine and emtricitabine)</td> <td> <p>Fluoroquinolones</p> <p>Ethionamide (associated with taste alteration)</p> <p>Para-amniosalicylic acid</p> </td> </tr> <tr> <td>Nephrotoxicity </td> <td> <p>Tenofovir (renal tubular disfunction)</p> <p>Idinavir-ritonavir</p> </td> <td> <p>Aminoglycosides (nephrotoxic TB agents carry particular risk of potentiating lactic acidosis common to the NRTIs used in antiretroviral rollout regimens)</p> </td> </tr> <tr> <td>Neuropsychiatric disorders</td> <td>Efavirenz (insomnia, drowsiness, vivid dreams)</td> <td> <p>Cycloserine (headaches, tremor, seizure)</p> <p>Terizidone (mainly headache and seizures)</p> </td> </tr> <tr> <td>Peripheral neuropathy</td> <td> <p>Stavudine</p> <p>Didanosine</p> <p>Zidovudine</p> </td> <td> <p>Cycloserine</p> <p>Streptomycin</p> <p>Amnioglycosides</p> <p>Isoniazid (overcome with pyridoxine administration)</p> <p>Linezolid</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Stavudine, didanosine, tenofovir, lamivudine, and emtricitabine are NRTIs. Nevirapine and efavirenz are NNRTIs. Idinavir and ritonovir are protease inhibitors. Common global rollout antiretroviral regimens: (stavudine or zidovidine) + (lamivudine or emtricitabine) + (nevirapine or efavirenz) or (tenofovir or abacavir) + (lamivudine or emtricitabine) + (nevirapine or efavirenz).</div><div class=\"graphic_footnotes\">MDR: multidrug resistant; NNRTIs: nonnuceloside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; TB: tuberculosis; XDR: extensively drug resistant.<br />* Rifampin induction of cytochrome P450 reduces serum levels of NNRTIs and protease inhibitors but is not therapeutically relevant for MDR/XDR TB.<br /></div><div class=\"graphic_reference\">Modified with permission from: Shenoi S, Heysell SK, Moll AP, Friedland G. Multi-drug Resistant and Extensively Drug-Resistant Tuberculosis: Consequences for the Global HIV Community. Curr Opin Infect Dis 2009; 22:11. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53563 Version 13.0</div></div></div>"},"53565":{"type":"graphic_diagnosticimage","displayName":"Miliary infiltrates in histo","title":"Miliary infiltrates in disseminated histoplasmosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Miliary infiltrates in disseminated histoplasmosis</div><div class=\"cntnt\"><img style=\"width:278px; height:338px;\" src=\"images/ID/53565_Miliary_infiltrates_in_hist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph with a miliary pattern in a patient with fever, weight loss, and a bone marrow positive for granulomas and organisms resembling <EM>H. capsulatum</EM>.</div><div id=\"graphicVersion\">Graphic 53565 Version 3.0</div></div></div>"},"53566":{"type":"graphic_picture","displayName":"Severe herpes zoster in cancer","title":"Disseminated herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated herpes zoster</div><div class=\"cntnt\"><img style=\"width:257px; height:397px;\" src=\"images/ID/53566_Severe_herpes_zoster_in_can.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe vesiculopustular lesions on erythematous bases present in multiple dermatomes in this patient with squamous cell carcinoma of the vocal cord.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders, MD.</div><div id=\"graphicVersion\">Graphic 53566 Version 1.0</div></div></div>"},"53570":{"type":"graphic_table","displayName":"Phases radiation injury","title":"Phases of radiation injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phases of radiation injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Dose (Gy)</td> <td class=\"subtitle1\" colspan=\"4\">Symptoms</td> <td class=\"subtitle1\" rowspan=\"2\">Prognosis</td> </tr> <tr> <td class=\"subtitle2\">Prodrome</td> <td class=\"subtitle2\">Hematologic</td> <td class=\"subtitle2\">GI</td> <td class=\"subtitle2\">Cerebrovascular</td> </tr> <tr> <td>0.5 to 1</td> <td>+</td> <td>+</td> <td>0</td> <td>0</td> <td>Survival almost certain</td> </tr> <tr> <td>1 to 2</td> <td>+/++</td> <td>+</td> <td>0</td> <td>0</td> <td>Survival &#62;90 percent</td> </tr> <tr> <td>2 to 3.5</td> <td>++</td> <td>++</td> <td>0</td> <td>0</td> <td>Probable survival</td> </tr> <tr> <td>3.5 to 5.5</td> <td>+++</td> <td>+++</td> <td>+</td> <td>0</td> <td>Death in 50 percent&nbsp;at 3.5 to 6 weeks</td> </tr> <tr> <td>5.5 to 7.5</td> <td>+++</td> <td>+++</td> <td>++</td> <td>0</td> <td>Death probable in 2 to 3 weeks</td> </tr> <tr> <td>7.5 to 10</td> <td>+++</td> <td>+++</td> <td>+++</td> <td>0*</td> <td>Death probable in 1 to 2.5 weeks</td> </tr> <tr> <td>10 to 20</td> <td>+++</td> <td>+++</td> <td>+++</td> <td>+++</td> <td>Death certain in 5 to 12 days</td> </tr> <tr> <td>&#62;20</td> <td>+++</td> <td>+++</td> <td>+++</td> <td>+++<sup>&#182;</sup></td> <td>Death certain in 2 to 5 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Gy: dose in Gray; GI: gastrointestinal side effects; 0: no effects; +: mild; ++: moderate; +++: severe or marked.<br />* Hypotension.<br />¶ Also cardiovascular collapse, fever, shock.</div><div class=\"graphic_reference\">Modified from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Intern Med 2004; 140:1037.</div><div id=\"graphicVersion\">Graphic 53570 Version 6.0</div></div></div>"},"53571":{"type":"graphic_table","displayName":"Differential diagnosis of hyperthermia*","title":"Differential diagnosis of hyperthermia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hyperthermia*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Meningitis</td> </tr> <tr> <td class=\"indent1\">Encephalitis</td> </tr> <tr> <td class=\"indent1\">Brain abscess</td> </tr> <tr> <td class=\"indent1\">Tetanus</td> </tr> <tr> <td class=\"indent1\">Typhoid fever</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Drug or toxin related</td> </tr> <tr> <td class=\"indent1\">Malignant hyperthermia</td> </tr> <tr> <td class=\"indent1\">Neuroleptic malignant syndrome</td> </tr> <tr> <td class=\"indent1\">Withdrawal syndromes (eg, alcohol, sedative hypnotic)</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Sympathomimetic poisoning (eg, amphetamines)</td> </tr> <tr> <td class=\"indent1\">Anticholinergic poisoning (eg, antihistamine)</td> </tr> <tr> <td class=\"indent1\">Serotonin syndrome</td> </tr> <tr> <td class=\"indent1\">Stimulant-containing dietary drugs</td> </tr> <tr> <td class=\"indent1\">Salicylate poisoning</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Hypothalamic stroke</td> </tr> <tr> <td class=\"indent1\">Status epilepticus</td> </tr> <tr> <td class=\"indent1\">Cerebral hemorrhage</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Environmental</td> </tr> <tr> <td class=\"indent1\">High temperature and humidity</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Thyroid storm</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"indent1\">Diabetic ketoacidosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Oncologic</td> </tr> <tr> <td class=\"indent1\">Lymphoma</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*While cardiovascular disease does not directly cause heat illness, compromised cardiovascular function from underlying disease (eg, heart failure) or medication (eg, beta or calcium channel blocker) impairs a patient's ability to respond to increased environmental heat and humidity, and can contribute to heat illness. </div><div class=\"graphic_reference\">Adapted from: Lanken PN, Manaker S, Hanson CW III. (Eds), The Intensive Care Unit Manual, 1st ed, Elsevier 2000 and Danzl D. Heat Related Illness. In: Harrison's Principles of Internal Medicine, 19th ed, McGraw Hill (In press).</div><div id=\"graphicVersion\">Graphic 53571 Version 5.0</div></div></div>"},"53575":{"type":"graphic_figure","displayName":"Resection of right colon mesentery","title":"Resection of right colon mesentery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resection of right colon mesentery</div><div class=\"cntnt\"><img style=\"width:365px; height:482px;\" src=\"images/SURG/53575_Resect_mesentery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the incision of the peritoneal surface of the mesentery and ligation of the mesenteric vessels.</div><div id=\"graphicVersion\">Graphic 53575 Version 2.0</div></div></div>"},"53576":{"type":"graphic_picture","displayName":"Photoaging arm","title":"Photoaging","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Photoaging</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53576_Photoaging_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photodamage signs (elastosis, hyperpigmented macules, actinic keratoses) superimposed on intrinsic aging.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53576 Version 4.0</div></div></div>"},"53579":{"type":"graphic_picture","displayName":"Endstage corneal scarring","title":"End-stage corneal scarring and neovascularization after infectious ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">End-stage corneal scarring and neovascularization after infectious ulcer</div><div class=\"cntnt\"><img style=\"width:324px; height:220px;\" src=\"images/PC/53579_Endstage_corneal_scarring.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53579 Version 1.0</div></div></div>"},"53580":{"type":"graphic_figure","displayName":"Number needed to treat","title":"Number needed to treat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Number needed to treat</div><div class=\"cntnt\"><img style=\"width:346px; height:282px;\" src=\"images/PEDS/53580_Nmbr_ndd_trt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depiction of the results of two hypothetical placebo controlled trials involving 100 patients. The number needed to treat (NNT) is sensitive to the control rate (ie, the frequency that events such as death occur at baseline). The NNT decreases as the number of events (such as deaths) in the control arm (placebo arm) increases. The relative risk in these studies (the death rate in those receiving drug divided by the death rate in those receiving placebo) is equal; both demonstrate a 50 percent reduction in the risk of death in patients who received the drug. However, the number needed to treat (the reciprocal of the death rate in the placebo minus the death rate in the drug group) is different (5 versus 2.5). This difference reflects the higher death rate (ie, the control rate) in the second study.</div><div id=\"graphicVersion\">Graphic 53580 Version 4.0</div></div></div>"},"53583":{"type":"graphic_movie","displayName":"Robot-assisted rad hyst 3","title":"Closure of the vaginal cuff","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Closure of the vaginal cuff</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53583_Closurevaginalcuffconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:396px; height:304px;\" src=\"images/CARD/53583_Closurevaginalcuff.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Colleen M Feltmate, MD.</div><div id=\"graphicVersion\">Graphic 53583 Version 4.0</div></div></div>"},"53587":{"type":"graphic_table","displayName":"Nutrition assessment VLBW infant","title":"Nutritional assessment of the VLBW infant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional assessment of the VLBW infant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Assessment</td> <td class=\"subtitle1\">Frequency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fluid intake</td> </tr> <tr> <td class=\"indent1\">Parenteral</td> <td>Daily</td> </tr> <tr> <td class=\"indent1\">Enteral</td> <td>Daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nutrient intake</td> </tr> <tr> <td class=\"indent1\">Energy</td> <td>Daily</td> </tr> <tr> <td class=\"indent1\">Protein</td> <td>Daily</td> </tr> <tr> <td class=\"indent1\">Specific nutrient</td> <td>Daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Anthropomorphic measurements</td> </tr> <tr> <td class=\"indent1\">Body weight</td> <td>Daily at same time</td> </tr> <tr> <td class=\"indent1\">Length</td> <td>Weekly</td> </tr> <tr> <td class=\"indent1\">Head circumference</td> <td>Weekly</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Laboratory values</td> </tr> <tr> <td class=\"indent1\">Hemoglobin, hematocrit</td> <td>After full feeds are achieved, measure every 2 to 3 weeks until it is clear that the results are stable.</td> </tr> <tr> <td class=\"indent1\">Calcium, phosphorus</td> <td>As above</td> </tr> <tr> <td class=\"indent1\">Alkaline phosphatase</td> <td>As above</td> </tr> <tr> <td class=\"indent1\">Blood urea nitrogen (BUN)&nbsp;</td> <td>As above. If values are abnormal, also measure prealbumin&nbsp;</td> </tr> <tr> <td class=\"indent1\">Serum electrolytes&nbsp;</td> <td>In selected infants (receiving diuretics, or feeds of unfortified human milk, or&nbsp;limited intake, or slow growth)&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VLBW: very low birthweight (birthweight ≤1500 g).</div><div class=\"graphic_reference\">Adapted from: Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. p.387.</div><div id=\"graphicVersion\">Graphic 53587 Version 5.0</div></div></div>"},"53588":{"type":"graphic_table","displayName":"SIDS resources","title":"Sudden unexpected infant death/Sudden infant death syndrome resources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sudden unexpected infant death/Sudden infant death syndrome resources</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First Candle/SIDS Alliance </td> </tr> <tr> <td>(a national network of SIDS support groups)</td> </tr> <tr> <td>1314 Bedford Avenue</td> </tr> <tr> <td>Suite 210 Baltimore, MD 21208</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-221-7437<a href=\"#\" title=\"Call: 1-800-221-7437\"><img alt=\"\" title=\"Call: 1-800-221-7437\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-410-653-8226<a href=\"#\" title=\"Call: 1-410-653-8226\"><img alt=\"\" title=\"Call: 1-410-653-8226\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span></td> </tr> <tr> <td>email: <a href=\"mailto:info&#64;firstcandle.org\"><span style=\"color: #0000ff;\">info&#64;firstcandle.org</span></a></td> </tr> <tr> <td>website: <a href=\"http://www.firstcandle.org/\">www.firstcandle.org</a> </td> </tr> <tr> <td class=\"subtitle1_single\">The Lullaby Trust</td> </tr> <tr> <td>11 Belgrave Road</td> </tr> <tr> <td>London, SW1V 1RB</td> </tr> <tr> <td>020 7802 3200</td> </tr> <tr> <td>email: <a href=\"mailto:office&#64;lullabytrust.org.uk\" spellcheck=\"true\">office&#64;lullabytrust.org.uk</a></td> </tr> <tr> <td>website: <a href=\"http://www.lullabytrust.org.uk/\" spellcheck=\"true\">www.lullabytrust.org.uk</a></td> </tr> <tr> <td class=\"subtitle1_single\">Canadian Foundation for the Study of Infant Deaths (CFSID) </td> </tr> <tr> <td>586 Eglinton Avenue East</td> </tr> <tr> <td>Suite 308</td> </tr> <tr> <td>Toronto, Ontario, Canada M4P 1P2</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-363-7437<a href=\"#\" title=\"Call: 1-800-363-7437\"><img alt=\"\" title=\"Call: 1-800-363-7437\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (toll-free) or</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-416-488-3260<a href=\"#\" title=\"Call: 1-416-488-3260\"><img alt=\"\" title=\"Call: 1-416-488-3260\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> or</td> </tr> <tr> <td><span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-416-488-3864<a href=\"#\" title=\"Call: 1-416-488-3864\"><img alt=\"\" title=\"Call: 1-416-488-3864\" style=\"overflow: hidden; cursor: hand; height: 16px; width: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span> (fax)</td> </tr> <tr> <td>email: <a href=\"mailto:sidsinfo&#64;sidscanada.org\">sidsinfo&#64;sidscanada.org</a> &nbsp;</td> </tr> <tr> <td>website: <a href=\"http://www.sidscanada.org/\">www.sidscanada.org</a> </td> </tr> <tr> <td class=\"subtitle1_single\">Red Nose (formerly National SIDS Council of Australia) </td> </tr> <tr> <td>17/75 Lorimer Street</td> </tr> <tr> <td>Docklands, VIC 3008, Australia</td> </tr> <tr> <td>1300 308 307 or</td> </tr> <tr> <td>03 9818 4596 (fax)</td> </tr> <tr> <td>email: <a href=\"mailto:support&#64;rednose.com.au\">support&#64;rednose.com.au</a></td> </tr> <tr> <td>website: <a href=\"https://rednosegriefandloss.com.au/\" spellcheck=\"true\">rednosegriefandloss.com.au</a></td> </tr> <tr> <td class=\"subtitle1_single\">SIDS Family Association Japan (SIDSFAJ) </td> </tr> <tr> <td>email: <a href=\"mailto:englishcontact&#64;sids.gr.jp\">englishcontact&#64;sids.gr.jp</a> </td> </tr> <tr> <td>website: <a href=\"http://www.sids.gr.jp/\">www.sids.gr.jp</a> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: the National Institute of Child Health &amp; Human Development Fact Sheet: Sudden infant death syndrome (www.nichd.nih.gov/publications/pubs/sidsfact.htm).</div><div id=\"graphicVersion\">Graphic 53588 Version 5.0</div></div></div>"},"53589":{"type":"graphic_table","displayName":"Hantavirus worldwide prevalence","title":"Worldwide prevalence of hantaviruses that cause disease in humans","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Worldwide prevalence of hantaviruses that cause disease in humans</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Virus</td> <td class=\"subtitle1\">Reservoir hosts</td> <td class=\"subtitle1\">Countries where disease has been reported</td> <td class=\"subtitle1\">Distribution of reservoir host</td> <td class=\"subtitle1\">Disease</td> </tr> <tr> <td>Hantaan</td> <td><em>Apodemus agrarius</em></td> <td>China, Korea, Russia</td> <td>Central Europe south to Thrace, Caucasus, and Tien Shan Mountains; Amur River through Korea to eastern Xizang and eastern Yunnan, western Sichuan, Fujiau, and Taiwan</td> <td>HFRS</td> </tr> <tr> <td>Seoul</td> <td><em>Rattus norvegicus</em>, <em>Rattus rattus</em></td> <td>China, Korea, United Kingdom (rare), United States (rare)</td> <td>Worldwide; commensal rat hosts</td> <td>HFRS</td> </tr> <tr> <td>Dobrava/Belgrade</td> <td><em>Apodemus flavicollis</em></td> <td>Widespread throughout central and western Europe</td> <td>England and Wales; from northwestern Spain, France, southern Scandinavia through Russia to Urals, southern Italy, the Balkans, Syria, Lebanon, and Israel</td> <td>HFRS</td> </tr> <tr> <td>Puumala</td> <td><em>Myodes glareolus</em></td> <td>Scandinavia, western Europe, Russia</td> <td>Western Palaearctic from France and Scandinavia to Lake Baikal, south to northern Spain, northern Italy, Balkans, western Turkey, northern Khazakhstan, Altai and Sayan Mountains, Britain, and southwestern Ireland</td> <td>HFRS</td> </tr> <tr> <td>Sin Nombre</td> <td><em>Peromyscus maniculatus</em></td> <td>United States, Canada</td> <td>Alaska panhandle across northern and western Canada, south through most of the continental United States excluding southeastern and eastern seaboard, to southernmost Baja California Sur, and to north central Oaxaca, Mexico</td> <td>HCPS</td> </tr> <tr> <td>Black Creek Canal</td> <td><em>Sigmodon hispidus</em></td> <td>United States (only reported in Florida)</td> <td>United States, from southern Nebraska to central Virginia, south to southeastern Arizona and peninsular Florida; interior and eastern Mexico through Middle America to central Panama; in South America to northern Colombia and northern Venezuela</td> <td>HCPS</td> </tr> <tr> <td>New York</td> <td><em>Peromyscus leucopus</em></td> <td>United States (may be restricted to Long Island, New York)</td> <td>Central and eastern United States to southern Alberta and southern Ontario, Quebec and Nova Scotia, Canada; to northern Durango and along Caribbean coast to isthmus of Tehuantepec and Yucatan peninsula, Mexico</td> <td>HCPS</td> </tr> <tr> <td>Bayou</td> <td><em>Oryzomys palustris</em></td> <td>United States</td> <td>Southeastern United States, southeastern Kansas to eastern Texas, eastward to southern New Jersey and peninsular Florida</td> <td>HCPS</td> </tr> <tr> <td>Andes</td> <td><em>Oligoryzomys longicaudatus</em></td> <td>Brazil, Chile, Argentina</td> <td>North central to southern Andes, approximately to 50&#188;S latitude, of Chile and Argentina</td> <td>HCPS</td> </tr> <tr> <td>Laguna Negra</td> <td><em>Calomys laucha</em></td> <td>Paraguay, Bolivia</td> <td>Northern Argentina and Uruguay, southeastern Bolivia, western Paraguay, and west central Brazil</td> <td>HCPS</td> </tr> <tr> <td>Choclo</td> <td><em>Oligoryzomys fulvescens</em></td> <td>Panama</td> <td>Southern Mexico, through Mesoamerica, to Ecuador, northernmost Brazil, and Guineas in South America</td> <td>HCPS</td> </tr> <tr> <td>Rio Mamore</td> <td><em>Oligoryzomys microtis</em></td> <td>Peru</td> <td>Bolivia, Peru, Brazil, Paraguay, and French Guiana</td> <td>HCPS</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HFRS: hemorrhagic fever with renal syndrome;&nbsp;HCPS: hantavirus cardiopulmonary syndrome.</div><div id=\"graphicVersion\">Graphic 53589 Version 8.0</div></div></div>"},"53590":{"type":"graphic_picture","displayName":"Cholinergic urticaria","title":"Cholinergic urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholinergic urticaria</div><div class=\"cntnt\"><img style=\"width:432px; height:336px;\" src=\"images/ALLRG/53590_Cholinergic_urticaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small urticarial papules on red skin (axon reflex erythema) occurring on the neck within 30 minutes of vigorous exercise.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright © 1997 McGraw Hill.</div><div id=\"graphicVersion\">Graphic 53590 Version 2.0</div></div></div>"},"53591":{"type":"graphic_picture","displayName":"Streptobacillus moniliformis","title":"Streptobacillus moniliformis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Streptobacillus moniliformis</div><div class=\"cntnt\"><img style=\"width:230px; height:335px;\" src=\"images/ID/53591_Streptobacillus_moniliformi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pleomorphic filamentous bacilli with characteristic bulbous swelling arranged in chains and tangled clumps on Gram's stain (x 1000).</div><div class=\"graphic_reference\">Reproduced with permission from Torres, A, Cuende, E, De Pablos, M, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with subcutaneous streptobacillus moniliformis abscess. J Rheumatol 2001; 28:1696. Copyright &#169; 2001 Journal of Rheumatology.</div><div id=\"graphicVersion\">Graphic 53591 Version 1.0</div></div></div>"},"53593":{"type":"graphic_table","displayName":"Seizure diary PI","title":"Seizure diary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seizure diary</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">After your child has a seizure, try to answer the following questions.</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did the seizure occur at night or when the child was asleep, falling asleep, or upon awakening? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Was the child taking medication (prescription or over-the-counter) or herbs before the seizure? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did the child have facial or arm/leg twitching before the seizure? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Does the child always cry before a seizure? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Are there any seizure triggers? (examples, strong emotions, intense exercise, certain sounds or music, and flashing lights) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Do one or both arms or legs move during the seizure, and if so, which side? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Were the child's eyes and mouth open or closed during the seizure? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Could the child respond to your voice? To being pinched? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did the child's color change (eg, pale or blue) during the seizure? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>How long did the episode last? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>How did the child behave after the seizure? Did he or she recover immediately, or was there confusion or sleepiness? Did the child speak normally? Was the child able to move normally after the seizure? Did the child have any difficulty moving the arms or legs on one or both sides? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Did the child remember having the seizure or the events that occurred during it? </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53593 Version 3.0</div></div></div>"},"53594":{"type":"graphic_figure","displayName":"Placenta and membranes in twin pregnancies","title":"Placenta and membranes in twin pregnancies","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Placenta and membranes in twin pregnancies</div><div class=\"cntnt\"><img style=\"width:542px; height:222px;\" src=\"images/OBGYN/53594_Placenta_membranes_twins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Two placentas, two amnions, two chorions (from either dizygotic twins or monozygotic twins with cleavage of zygote during first&nbsp;three days after fertilization).<br />(B) One placenta, one chorion, two amnions (monozygotic twins with cleavage of zygote from the fourth to the eighth day after fertilization).<br />(C) One placenta, one chorion, one amnion (monozygotic twins with cleavage of zygote from the&nbsp;8<SUP>th</SUP> to the&nbsp;12<SUP innerHtml>th </SUP>day after fertilization).</div><div id=\"graphicVersion\">Graphic 53594 Version 6.0</div></div></div>"},"53596":{"type":"graphic_picture","displayName":"Erythema induratum","title":"Erythema induratum (nodular vasculitis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Erythema induratum (nodular vasculitis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53596_Eryth_induratum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules are present on the posterior lower legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53596 Version 3.0</div></div></div>"},"53598":{"type":"graphic_picture","displayName":"Nabothian cyst2","title":"Nabothian cyst","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Nabothian cyst</div><div class=\"cntnt\"><img style=\"width:540px; height:348px;\" src=\"images/OBGYN/53598_Nabothian_cyst2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Marc Steben, MD, Institut National de Sant&#233; Publique du Qu&#233;bec.</div><div id=\"graphicVersion\">Graphic 53598 Version 1.0</div></div></div>"},"53599":{"type":"graphic_figure","displayName":"Methemoglobin reduction","title":"Metabolic pathways for reduction of methemoglobin","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Metabolic pathways for reduction of methemoglobin</div><div class=\"cntnt\"><img style=\"width:524px; height:471px;\" src=\"images/HEME/53599_Methemoglobin_reduction.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major pathway for methemoglobin reduction is via cytochrome b5 reductase (thick arrows). An alternative pathway, which requires an exogenous electron acceptor such as methylene blue, is via NADPH methemoglobin reductase.</div><div id=\"graphicVersion\">Graphic 53599 Version 3.0</div></div></div>"},"53600":{"type":"graphic_table","displayName":"Hereditary RCC syndromes","title":"Clinical and molecular characteristics of the most common hereditary kidney cancer syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and molecular characteristics of the most common hereditary kidney cancer syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene/protein</td> <td class=\"subtitle1\">Chromosomal locus</td> <td class=\"subtitle1\">Potential pathway</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Hereditary papillary renal cancer</td> <td>c-MET</td> <td>7q31</td> <td>HGFR</td> <td>Papillary type I renal cell carcinoma</td> </tr> <tr> <td>Hereditary leiomyomatosis renal cell carcinoma</td> <td>Fumarate hydratase</td> <td>1q42</td> <td>Krebs cycle/HIF1</td> <td>Papillary type II renal cell carcinoma/skin carcinoma, and uterine leiomyoma</td> </tr> <tr> <td>Birt-Hogg-Dube</td> <td>Folliculin</td> <td>17p11</td> <td>mTOR</td> <td>Chromophobe, oncocytic, hybrid, and clear cell renal cell carcinoma, fibrofolliculoma, pulmonary cysts, pneumothorax</td> </tr> <tr> <td>Hereditary paraganglioma and pheochromocytoma</td> <td>Succinate dehydrogenase</td> <td>5p15</td> <td>Krebs cycle/hypoxia</td> <td>Clear cell, chromophobe renal cell carcinoma, pheochromocytoma, paragangliomas</td> </tr> <tr> <td>Tuberous sclerosis complex (TSC)</td> <td> <p>TSC1</p> TSC2</td> <td> <p>9q34</p> 16p13</td> <td>mTOR</td> <td>Clear cell renal cell carcinoma, angiomyolipoma</td> </tr> <tr> <td>von Hippel-Lindau (VHL)</td> <td>VHL gene</td> <td>3p25</td> <td>HIF-1</td> <td>Clear cell renal cell carcinoma, hemangioblastomas, retinal angiomas, pheochromocytomas, endolymphatic sac tumors of the middle ear</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HGFR: hepatocyte growth factor receptor (also known as c-MET); HIF-1: hypoxia-inducible factor 1; mTOR: mammalian target of rapamycin.</div><div id=\"graphicVersion\">Graphic 53600 Version 5.0</div></div></div>"},"53602":{"type":"graphic_picture","displayName":"Irritant asthma Early","title":"Irritant-induced asthma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Irritant-induced asthma</div><div class=\"cntnt\"><img style=\"width:370px; height:246px;\" src=\"images/PULM/53602_Irritant_asthma_Early.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchial biopsy taken three days after acute accidental inhalation of high concentration of chlorine showing almost complete desquamation of bronchial mucosa (upper part) with fibrinohemorrhagic deposits (dark pink) and inflammatory influx of neutrophils (dark purple spots in the middle and upper portions). Normal smooth muscle is shown in the lower portion. Weigert-Masson stain.</div><div class=\"graphic_reference\">Courtesy of Lemiere, C, Malo, JL, Boulet, M.</div><div id=\"graphicVersion\">Graphic 53602 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"53603":{"type":"graphic_picture","displayName":"Rigid bronchoscope","title":"Rigid bronchoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid bronchoscopy</div><div class=\"cntnt\"><img style=\"width:332px; height:383px;\" src=\"images/PULM/53603_Rigid_bronchoscope.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Efer-Dumon rigid bronchoscope with external port for ventilation, free moving telescope with attached C-mount for video, and external side port for suction catheter and laser fiber.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD.</div><div id=\"graphicVersion\">Graphic 53603 Version 2.0</div></div></div>"},"53605":{"type":"graphic_algorithm","displayName":"Algorithm for Diagnosis of OA","title":"Occupational asthma diagnosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occupational asthma diagnosis</div><div class=\"cntnt\"><img style=\"width:349px; height:287px;\" src=\"images/PULM/53605_AlgorithmdiagnosisOA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PEFR: peak expiratory flow rate.</div><div id=\"graphicVersion\">Graphic 53605 Version 2.0</div></div></div>"},"53609":{"type":"graphic_figure","displayName":"Risk vascular events after TIA or minor stroke","title":"Mean yearly risk of vascular events, mortality, and stroke over time after TIA or minor ischemic stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mean yearly risk of vascular events, mortality, and stroke over time after TIA or minor ischemic stroke</div><div class=\"cntnt\"><img style=\"width:405px; height:272px;\" src=\"images/NEURO/53609_Risk_after_TIA_minor_stroke.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: van Wijk I, Kappelle LJ, van Gign J, et al. Long-term survival and vascular events risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 2005; 365: 2098. Copyright © 2005 Elsevier.</div><div id=\"graphicVersion\">Graphic 53609 Version 2.0</div></div></div>"},"53610":{"type":"graphic_diagnosticimage","displayName":"MRI ependymoma","title":"Magnetic resonance (MRI) image of an ependymoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance (MRI)&nbsp;image of an ependymoma</div><div class=\"cntnt\"><img style=\"width:540px; height:345px;\" src=\"images/PEDS/53610_MRI_ependymoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) A sagittal T1 image with contrast of an ependymoma that arises in the 4<SUP>th</SUP> ventricle causing obstruction and hydrocephalus.<br />(Panel B) An axial T1 image of the same lesion.</div><div class=\"graphic_reference\">Courtesy of Susan Blaney, MD.</div><div id=\"graphicVersion\">Graphic 53610 Version 5.0</div></div></div>"},"53611":{"type":"graphic_picture","displayName":"Tube in middle ear","title":"Medial displacement of a tympanostomy tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medial displacement of a tympanostomy tube</div><div class=\"cntnt\"><img style=\"width:288px; height:321px;\" src=\"images/PEDS/53611_Tube_in_middle_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tube has migrated deep to the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD.</div><div id=\"graphicVersion\">Graphic 53611 Version 1.0</div></div></div>"},"53612":{"type":"graphic_figure","displayName":"Dipylidium caninum life cycle","title":"<EM>Dipylidium caninum</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\"><EM>Dipylidium caninum</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:610px; height:460px;\" src=\"images/ID/53612_Dypylidium_caninum_life_cyc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gravid proglottids are passed intact in the feces or emerge from the perianal region of the host <STRONG>(1)</STRONG>. Subsequently, they release typical egg packets <STRONG>(2)</STRONG>. On rare occasions, proglottids rupture and egg packets are seen in stool samples. Following ingestion of an egg by the intermediate host (larval stages of the dog or cat flea <EM>Ctenocephalides</EM> spp), an oncosphere is released into the flea's intestine. The oncosphere penetrates the intestinal wall, invades the insect's hemocoel (body cavity), and develops into a cysticercoid larva <STRONG>(3)</STRONG>. The larva develops into an adult, and the adult flea harbors the infective cysticercoid <STRONG>(4)</STRONG>. The vertebrate host becomes infected by ingesting the adult flea containing the cysticercoid <STRONG>(5)</STRONG>. The dog is the principal definitive host for <EM>Dipylidium caninum</EM>. Other potential hosts include cats, foxes, and humans (mostly children) <STRONG>(6,7)</STRONG>. Humans acquire infection by ingesting the cysticercoid contaminated flea. This can be promulgated by close contact between children and their infected pets. In the small intestine of the vertebrate host, the cysticercoid develops into the adult tapeworm, which reaches maturity about one month after infection <STRONG>(8)</STRONG>. The adult tapeworms (measuring up to 60 cm in length and 3 mm in width) reside in the small intestine of the host, where they each attach by their scolex. They produce proglottids (or segments) that have two genital pores (hence the name \"double-pored\" tapeworm). The proglottids mature, become gravid, detach from the tapeworm, and migrate to the anus or are passed in the stool <STRONG>(1)</STRONG>.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Dipylidium caninum infection. Available at: <A href=\"http://www.cdc.gov/dpdx/dipylidium/index.html\">http://www.cdc.gov/dpdx/dipylidium/index.html</A>.</div><div id=\"graphicVersion\">Graphic 53612 Version 5.0</div></div></div>"},"53613":{"type":"graphic_figure","displayName":"Anal abscess and fistula PI","title":"Anal abscess and fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anal abscess and fistula</div><div class=\"cntnt\"><img style=\"width:430px; height:453px;\" src=\"images/PI/53613_Anal-abscess-and-fistula-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anal abscess is a mass filled with pus that forms when a gland inside the anus gets infected and clogged. Doctors can find abscesses by inserting a gloved finger into the rectum and feeling for lumps. Some abscesses form fistulas, tunnels that connect the abscess to the outside of the body.</div><div id=\"graphicVersion\">Graphic 53613 Version 1.0</div></div></div>"},"53614":{"type":"graphic_picture","displayName":"DIP basic splint","title":"Standard splint for DIP joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard splint for DIP joint</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/53614_DIP_basic_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 53614 Version 2.0</div></div></div>"},"53615":{"type":"graphic_picture","displayName":"Diversion colitis histology","title":"Diversion colitis histology","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Diversion colitis histology</div><div class=\"cntnt\"><img style=\"width:473px; height:355px;\" src=\"images/GAST/53615_Diversion_colitis_Light_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology of diversion colitis characterized by reactive lymphoid hyperplasia, as well as crypt atrophy.</div><div class=\"graphic_reference\">From: Wu XR, Liu XL, Katz S, Shen B. Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. Inflamm Bowel Dis 2015; 21:703. DOI: <a href=\"http://journals.lww.com/ibdjournal/Abstract/2015/03000/Pathogenesis,_Diagnosis,_and_Management_of.23.aspx\" target=\"_blank\">10.1097/MIB.0000000000000227</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 53615 Version 2.0</div></div></div>"},"53616":{"type":"graphic_table","displayName":"PPI drug interactions","title":"Comparison of drug interactions with proton pump inhibitors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of drug interactions with proton pump inhibitors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Concomitant drug</td> <td class=\"subtitle1\">Omeprazole</td> <td class=\"subtitle1\">Lansoprazole</td> <td class=\"subtitle1\">Rabeprazole</td> <td class=\"subtitle1\">Pantoprazole</td> <td class=\"subtitle1\">Esomeprazole</td> </tr> <tr> <td>Warfarin</td> <td>PT decreased by 10 percent</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Diazepam</td> <td>T1/2 increased by 130 percent</td> <td>-</td> <td>-</td> <td>-</td> <td>Decreased clearance</td> </tr> <tr> <td>Phenytoin</td> <td>T1/2 increased by 27 percent</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Theophylline</td> <td>-</td> <td>AUC increased by 10 percent</td> <td>-</td> <td>-</td> <td>Unknown</td> </tr> <tr> <td>Digoxin</td> <td>AUC increased by 10 percent</td> <td>-</td> <td>AUC, Cmax, T1/2 increased</td> <td>-</td> <td>Unknown</td> </tr> <tr> <td>Carbamazepine</td> <td>AUC increased by 75 percent</td> <td>-</td> <td>-</td> <td>-</td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PT: prothrombin time; Cmax: maximum plasma concentration; AUC: area under the curve.</div><div class=\"graphic_reference\">Adapted from: Gugler R, Jensen JC, Gastroenterology 1985; 89:1235; Diaz D, Fabre I, Daujat M, et al, Gastroenterology 1990; 99:737; Meyer UA, Eur J Gastroenterol Hepatol 1996; 8(Suppl 1):S21; Parsons ME, Eur J Gastroenterol Hepatol 1996; 8(Suppl 1):S15; Lew EA, Aliment Pharmacol Ther 1999; 13(Suppl 5):11; Lorf T, et al, Eur J Clin Pharmacol 2000; 55:733.</div><div id=\"graphicVersion\">Graphic 53616 Version 3.0</div></div></div>"},"53619":{"type":"graphic_figure","displayName":"COP vs IPF duration","title":"Duration of COP and IPF prior to diagnosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duration of COP and IPF prior to diagnosis</div><div class=\"cntnt\"><img style=\"width:416px; height:279px;\" src=\"images/PULM/53619_BOOP_vs_IPF_duration.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comparison of the duration of illness prior to diagnosis in patients with COP and IPF. Seventy-two percent of patients with COP (n = 92) had the diagnosis established within three months of the onset of symptoms versus only 24 percent of those (n = 25) with IPF.</div><div class=\"graphic_footnotes\">COP: cryptogenic organizing pneumonia, also known as bronchiolitis obliterans organizing pneumonia (BOOP); IPF: idiopathic pulmonary fibrosis.</div><div class=\"graphic_reference\">Redrawn from: King TE Jr, Mortenson RL, Immunol Allergy Clin North Am 1992; 12:461.</div><div id=\"graphicVersion\">Graphic 53619 Version 2.0</div></div></div>"},"53620":{"type":"graphic_table","displayName":"Interpretation of PAW and LVEDP","title":"Disorders in which pulmonary artery wedge pressure and left ventricular end-diastolic pressure may be discordant","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders in which pulmonary artery wedge pressure and left ventricular end-diastolic pressure may be discordant</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Conditions in which PAW&#62;LVEDP</td> </tr> <tr> <td>Mitral stenosis</td> </tr> <tr> <td>Left atrial myxoma</td> </tr> <tr> <td>Pulmonary embolus</td> </tr> <tr> <td>Mitral valve regurgitation</td> </tr> <tr> <td>Pulmonary venocclusive disease</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions in which PAW&#60;LVEDP</td> </tr> <tr> <td>Decreased LV compliance</td> </tr> <tr> <td>High (&#62;25 mmHg) LVEDP</td> </tr> <tr> <td>Aortic valve regurgitation</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions in which PAW does not approximate PCWP</td> </tr> <tr> <td>(More than 1-4 mmHg difference)</td> </tr> <tr> <td>Increased pulmonary vascular resistance</td> </tr> <tr> <td>Pulmonary hypertension</td> </tr> <tr> <td>Cor pulmonale</td> </tr> <tr> <td>Pulmonary embolus</td> </tr> <tr> <td>Eisenmenger's syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53620 Version 4.0</div></div></div>"},"53621":{"type":"graphic_table","displayName":"Medication effects on fracture healing","title":"Drugs that may affect fracture healing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that may affect fracture healing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Medication class</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Purported effect</td> </tr> <tr> <td>Chemotherapy</td> <td> <p>Doxorubicin</p> <p>Cyclophosphamide</p> <p>Adriamycin</p> <p>Methotrexate</p> </td> <td>Decreased callus formation</td> </tr> <tr class=\"divider_top\"> <td>Glucocorticoids</td> <td> <p>Dexamethasone</p> <p>Prednisone</p> <p>Methylprednisolone</p> </td> <td>Evidence is inconsistent; may decrease bone mineralization</td> </tr> <tr class=\"divider_top\"> <td>Antibiotics</td> <td> <p>Fluoroquinolones (eg, Levofloxacin)</p> <p>Gentamicin</p> <p>Tetracycline</p> </td> <td>Fluoroquinolones have adverse effects upon cartilage regrowth and bone healing. Evidence concerning other antibiotics is inconsistent.</td> </tr> <tr class=\"divider_top\"> <td>NSAIDs</td> <td>Multiple nonspecific and COX-2 inhibitors</td> <td>Animal studies suggest decreased healing; human studies are inconsistent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53621 Version 1.0</div></div></div>"},"53622":{"type":"graphic_picture","displayName":"Eclipse nevus 2","title":"Eclipse nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eclipse nevus</div><div class=\"cntnt\"><img style=\"width:432px; height:329px;\" src=\"images/DERM/53622_Eclipse_nevus_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A compound nevus on the scalp of a child showing a light brown center and a more intensely pigmented rim.</div><div id=\"graphicVersion\">Graphic 53622 Version 1.0</div></div></div>"},"53623":{"type":"graphic_picture","displayName":"2-hand chest method PI","title":"Child CPR: 2-handed chest compressions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Child CPR: 2-handed chest compressions</div><div class=\"cntnt\"><img style=\"width:305px; height:430px;\" src=\"images/PI/53623_Two_hand_chest_method_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressing on the chest for CPR is called doing &quot;compressions.&quot; To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim's chest with the heel of your bottom hand. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches (5 centimeters) under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.</div><div id=\"graphicVersion\">Graphic 53623 Version 2.0</div></div></div>"},"53626":{"type":"graphic_waveform","displayName":"Basic case 14 with answer","title":"Typical left bundle branch block","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Typical left bundle branch block</div><div class=\"cntnt\"><img style=\"width:462px; height:309px;\" src=\"images/CARD/53626_Basic_case_14_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in typical complete LBBB. The asynchronous activation of the two ventricles increases the QRS duration (0.14 sec). The abnormal initial vector results in loss of normal septal forces as manifested by absence of physiologic q waves in leads I, aVL, and V6. The late activation of the left ventricle prolongs the dominant leftward progression of the middle and later depolarization forces, leading to a positive and widened R wave in the lateral leads. Both the ST segment and T wave vectors are opposite in direction from the QRS, a &quot;secondary&quot; repolarization abnormality.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 53626 Version 2.0</div></div></div>"},"53628":{"type":"graphic_table","displayName":"Infant hypoallergenic formula PI","title":"Formula options for infants with dietary protein-induced conditions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Formula options for infants with dietary protein-induced conditions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Extensively hydrolyzed casein-based formulas</td> </tr> <tr> <td class=\"indent1\">Enfamil&nbsp;Nutramigen</td> <td>(Mead Johnson Nutrition)</td> </tr> <tr> <td class=\"indent1\">Enfamil Nutramigen with Enflora LGG</td> <td>(Mead Johnson Nutrition)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pregestimil DHA and ARA</td> <td>(Mead Johnson Nutrition)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Similac Expert Care Alimentum*</td> <td>(Abbott Nutrition)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Extensively hydrolyzed whey-based formulas</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&nbsp;Gerber Extensive HA</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Amino acid-based formulas&nbsp;</td> </tr> <tr> <td class=\"indent1\">Elecare for infants</td> <td>(Abbott Nutrition)</td> </tr> <tr> <td class=\"indent1\">Neocate Infant DHA and ARA</td> <td>(Nutricia)</td> </tr> <tr> <td class=\"indent1\">PurAmino DHA and ARA</td> <td>(Mead Johnson Nutrition)</td> </tr> <tr> <td class=\"indent1\">Alfamino Infant</td> <td>(Nestle)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Extensively hydrolyzed or amino acid-based formulas are sometimes called \"hypoallergenic.\"</div><div class=\"graphic_footnotes\">LGG: Lactobacillus rhamnosus GG; DHA: docosahexaenoic acid; ARA: arachidonic acid.<br />*&nbsp;The ready-to-feed (liquid) form of Similac Alimentum is corn-free. All of the other formulas listed contain corn, including the powder form of Simiac Alimentum. &nbsp;</div><div id=\"graphicVersion\">Graphic 53628 Version 6.0</div></div></div>"},"53629":{"type":"graphic_table","displayName":"Medication doses for pediatric acute asthma","title":"Recommended doses of medications to treat children with an acute asthma exacerbation<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses of medications to treat children with an acute asthma exacerbation<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inhaled short-acting bronchodilators (beta<sub>2</sub>agonists)</td> </tr> <tr> <td class=\"indent1\">Albuterol (salbutamol) by nebulizer</td> <td>0.15 mg/kg per dose (minimum 2.5 mg, maximum 5 mg/dose) every 20 to 30 minutes for three doses, then 0.15 to 0.3 mg/kg (maximum 10 mg) every 30 minutes to four hours as needed or switch to continuous therapy.</td> </tr> <tr> <td class=\"indent1\">Continuous albuterol (salbutamol) by nebulizer</td> <td> <p>0.5 mg/kg per hour (maximum 20 mg per hour) by large volume nebulizer. Dose may also be determined based upon body weight as follows:</p> <p>5 to 10 kg - 7.5 mg per hour</p> <p>10 to 20 kg - 11.25 mg per hour</p> &#62;20 kg - 15 mg per hour</td> </tr> <tr> <td class=\"indent1\"> <p>Albuterol by MDI with spacer (VHC)</p> (90 micrograms/puff)</td> <td>One-fourth to one-third puff/kg or four to eight puffs every 20 to 30 minutes for three doses, then every one to four hours as needed (minimum two puffs/dose, maximum eight puffs/dose). Use VHC spacer. Add mask in children less than four years.</td> </tr> <tr> <td class=\"indent1\">Levalbuterol (levosalbutamol)</td> <td>One-half the recommended dose for racemic albuterol.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Inhaled bronchodilator (anticholinergic)</td> </tr> <tr> <td class=\"indent1\">Ipratropium bromide nebulizer solution (250 micrograms/mL)</td> <td> <p>&#60;20 kg - 250 mcg/dose</p> <p>&#8805;20 kg - 500 mcg/dose</p> Every 20 minutes for three doses, then as needed. May combine with albuterol for intermittent or continuous nebulizer treatment.</td> </tr> <tr> <td class=\"indent1\">Ipratropium bromide MDI with spacer (18 micrograms/puff)</td> <td>Four to eight puffs every 20 minutes as needed for up to three hours. Use VHC spacer; add mask in children less than four years. May give as combined MDI (18 micrograms ipratropium with 90 micrograms albuterol per puff).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Prednisone or prednisolone*</td> <td>1 to 2 mg/kg (maximum 60 mg/day) by mouth for the first dose, and then 0.5 to 1 mg/kg twice daily for subsequent doses starting the following day.&nbsp;A 3- to 10-day course is generally given.</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> <td>1 to 2 mg/kg (maximum 125 mg/day) IV</td> </tr> <tr> <td class=\"indent1\">Dexamethasone</td> <td>0.6 mg/kg (maximum 16 mg/day) by mouth, IM, or IV</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic beta<sub>2</sub>agonists<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Epinephrine 1 mg/mL (also labeled 1:1000)</td> <td>0.01 mg/kg IM or SC if no evidence of anaphylaxis (maximum 0.4 mg/dose = 0.4 mL of 1 mg/mL solution). May be repeated every 10 to 20 minutes for three doses.</td> </tr> <tr> <td class=\"indent1\">Terbutaline (1 mg/mL)</td> <td> <p>0.01 mg/kg SC or IM (maximum 0.25 mg/dose). May be repeated every 20 minutes for three doses, then every two to six hours as needed.</p> May give terbutaline <strong>OR</strong> epineprhine, but not both.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other treatment</td> </tr> <tr> <td class=\"indent1\">Magnesium sulfate</td> <td>25 to 75 mg/kg IV (0.1 to 0.3 mmol/kg) over 20 minutes (up to 2 grams approximately equal to 8 mmol)<sup>&#916;</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDI: metered-dose inhaler; VHC: valved holding chamber; IV: intravenous; IM: intramuscular; SC: subcutaneous.<br />* Useful formulations of prednisolone include concentrated oral liquids and orally disintegrating tablets (ODTs). For detail, refer to Lexicomp drug specific monograph included with UpToDate.<br />¶&nbsp;The use of systemic epinephrine or terbutaline is reserved for patients with poor inspiratory flow or who cannot cooperate with inhaled therapy. Systemic beta<SUB>2</SUB>agonist treatment requires noninvasive cardiopulmonary monitoring, such as that available in a critical care setting. Orally administered systemic beta<SUB>2</SUB>agonists are not recommended.<br />Δ Maximum dose of magnesium sulfate of up to 2.5 grams IV (approximately equal to 10 mmol) may be considered. Refer to UpToDate topics on emergency department management of&nbsp;acute asthma exacerbations in children, inpatient management of acute asthma exacerbations in children, and intensive care unit management of&nbsp;acute severe asthma exacerbations in children.<SUP>[2]</SUP></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.</LI>&#xD;&#xA;<LI>Scarfone RJ, Loiselle JM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 2000; 36:572.</LI></OL>Courtesy of Richard Scarfone, MD, FAAP.<br />Additional data from: US Department of Health and Human Services. Expert panel report 3: Guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. August 2007 available at&nbsp;<A href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</A>&nbsp;(accessed July 27, 2015).</div><div id=\"graphicVersion\">Graphic 53629 Version 14.0</div></div></div>"},"53630":{"type":"graphic_picture","displayName":"Polypectomy short stalk Endosc","title":"Resection of a pedunculated colonic polyp with a short stalk","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Resection of a pedunculated colonic polyp with a short stalk</div><div class=\"cntnt\"><img style=\"width:528px; height:126px;\" src=\"images/GAST/53630_Polypectomy_short_stalk_End.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) 2 cm polyp in the descending colon, note the short stalk; (B) prophylactic injection of epinephrine solution 1:20.000; (C) polypectomy in toto; (D) resection site after polypectomy: a non-bleeding vessel is visible; (E) prophylactic placement of hemoclips.</div><div class=\"graphic_reference\">Courtesy of Uwe Seitz, MD, Sabine Bohnacker, MD, and Nib Soehendra, MD.</div><div id=\"graphicVersion\">Graphic 53630 Version 1.0</div></div></div>"},"53631":{"type":"graphic_algorithm","displayName":"Management bacterial arthritis","title":"Clinical approach to evaluation and management of suspected septic arthritis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Clinical approach to evaluation and management of suspected septic arthritis</div><div class=\"cntnt\"><img style=\"width:712px; height:436px;\" src=\"images/ID/53631_Managem_bacterial_arthritis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Add aminoglycoside if <em>Pseudomonas</em> is suspected.<br />&para; The clinical approach in the setting of a positive Gram stain and negative culture depends on individual circumstances. It is advisable to seek consultation with an infectious disease specialist if possible, repeat cultures if applicable, and assess the evidence for the presence of an alternate diagnosis (such as crystal-induced arthritis).</div><div id=\"graphicVersion\">Graphic 53631 Version 7.0</div></div></div>"},"53632":{"type":"graphic_figure","displayName":"Trypanosoma cruzi life cycle","title":"Life cycle of <em>Trypanosoma cruzi</em>","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Life cycle of <em>Trypanosoma cruzi</em></div><div class=\"cntnt\"><img style=\"width:610px; height:475px;\" src=\"images/ID/53632_Trypanosoma_cruzi_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An infected triatomine insect vector (or \"kissing\" bug) takes a blood meal and releases trypomastigotes in its feces near the site of the bite wound. Trypomastigotes enter the host through the wound or through intact mucosal membranes, such as the conjunctiva <STRONG>(1)</STRONG>. Common triatomine vector species for trypanosomiasis belong to the genera <EM>Triatoma, Phodinius,</EM> and <EM>Panstrongylus</EM>. Inside the host, the trypomastigotes invade cells near the site of inoculation, where they differentiate into intracellular amastigotes <STRONG>(2)</STRONG>. The amastigotes multiply by binary fission <STRONG>(3) </STRONG>and differentiate into trypomastigotes and then are released into the circulation as bloodstream trypomastigotes <STRONG>(4)</STRONG>. Trypomastigotes infect cells from a variety of tissues and transform into intracellular amastigotes in new infection sites. Clinical manifestations can result from this infective cycle. The bloodstream trypomastigotes do not replicate (different from the African trypanosomes). Replication resumes only when the parasites enter another cell or are ingested by another vector. The \"kissing\" bug becomes infected by feeding on human or animal blood that contains circulating parasites <STRONG>(5)</STRONG>. The ingested trypomastigotes transform into epimastigotes in the vector's midgut <STRONG>(6)</STRONG>. The parasites multiply and differentiate in the midgut <STRONG>(7)</STRONG> and differentiate into infective metacyclic trypomastigotes in the hindgut <STRONG>(8)</STRONG>. <EM>Trypanosoma cruzi</EM> can also be transmitted through blood transfusions, organ transplantation, transplacentally, and in laboratory accidents.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. DPDx: American Trypanosomiasis.&nbsp;Available at: <A href=\"http://www.cdc.gov/dpdx/trypanosomiasisAmerican/index.html\">http://www.cdc.gov/dpdx/trypanosomiasisAmerican/index.html</A>.</div><div id=\"graphicVersion\">Graphic 53632 Version 5.0</div></div></div>"},"53633":{"type":"graphic_diagnosticimage","displayName":"Adrenal cancer CT","title":"Adrenal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adrenal cancer</div><div class=\"cntnt\"><img style=\"width:338px; height:252px;\" src=\"images/ENDO/53633_Adrenal_cancer_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced CT scan through the abdomen of a 56-year-old man reveals a complex solid and cystic, calcified mass (arrow) in the right suprarenal fossa extending into the adjacent liver. The tumor proved at surgery to be a carcinoma of the adrenal cortex.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 53633 Version 4.0</div></div></div>"},"53634":{"type":"graphic_table","displayName":"Laboratory evaluation for premenopausal osteoporosis","title":"Laboratory evaluation for premenopausal osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation for premenopausal osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial laboratory tests</td> </tr> <tr> <td>Complete chemistry profile (including alkaline phosphatase)</td> </tr> <tr> <td>Complete blood count</td> </tr> <tr> <td>Calcium, phosphorus</td> </tr> <tr> <td>25-hydroxyvitamin D</td> </tr> <tr> <td>TSH</td> </tr> <tr> <td>24-hour urine for calcium and creatinine</td> </tr> <tr> <td class=\"subtitle1_single\">Additional laboratory tests if indicated</td> </tr> <tr> <td>Estradiol, LH, FSH, prolactin</td> </tr> <tr> <td>PTH</td> </tr> <tr> <td>1,25-dihydroxyvitamin D</td> </tr> <tr> <td>24-hour urine for free cortisol (or dexamethasone suppression test)</td> </tr> <tr> <td>Iron/TIBC, ferritin</td> </tr> <tr> <td>Celiac screen (serologies)</td> </tr> <tr> <td>Serum/urine protein electrophoresis</td> </tr> <tr> <td>Erythrocyte sedimentation rate or C-reactive protein</td> </tr> <tr> <td>Rheumatoid factor</td> </tr> <tr> <td>Vitamin A/retinol level</td> </tr> <tr> <td>Homocysteine</td> </tr> <tr> <td>Specific testing for rare conditions such as Gaucher's disease (glucocerebrosidase activity in peripheral leukocyctes) or mastocytosis (serum tryptase), if clinically indicated</td> </tr> <tr> <td>If genetic diseases such as Gaucher's disease or osteogenesis imperfecta are considered, genetic testing may be pursued</td> </tr> <tr> <td>Bone turnover markers</td> </tr> <tr> <td>Transiliac crest bone biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; PTH: parathyroid hormone; TIBC: total iron-binding capacity.</div><div class=\"graphic_reference\">Courtesy of Carolyn Becker, MD and Adi Cohen, MD.</div><div id=\"graphicVersion\">Graphic 53634 Version 6.0</div></div></div>"},"53635":{"type":"graphic_diagnosticimage","displayName":"Vit D deficiency rickets","title":"Vitamin D deficiency rickets in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vitamin D deficiency rickets in a child</div><div class=\"cntnt\"><img style=\"width:221px; height:320px;\" src=\"images/ENDO/53635_Vit_D_deficiency_rickets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic findings of rickets in children often include radiographic evidence of decreased mineralization around the epiphyses and bowing of the lower extremities.</div><div class=\"graphic_reference\">http://www.asbmr.org.</div><div id=\"graphicVersion\">Graphic 53635 Version 2.0</div></div></div>"},"53637":{"type":"graphic_picture","displayName":"UC cecal patch","title":"\"Cecal patch\" in ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">&quot;Cecal patch&quot; in ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:349px; height:463px;\" src=\"images/PEDS/53637_UC_cecal_patch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periappendiceal inflammation is identified in approximately 15 percent of patients with left sided UC.</div><div class=\"graphic_reference\">Reproduced with permission from: Athos Bousvaros, MD.</div><div id=\"graphicVersion\">Graphic 53637 Version 3.0</div></div></div>"},"53638":{"type":"graphic_waveform","displayName":"Junctional escape tutorial","title":"Junctional escape rhythm","html":"<div class=\"graphic normal\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Junctional escape rhythm</div><div class=\"cntnt\"><img style=\"width:504px; height:83px;\" src=\"images/CARD/53638_Junctional_escape_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Escape junctional beat or rhythm occurs when there is failure of impulse generation from the sinus node or atrial myocardium. The 4th and 5th beats of this tracing are junctional beats that are not preceeded by a P wave and occur after a pause that is longer than the underlying sinus cycle length.</div><div id=\"graphicVersion\">Graphic 53638 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"53639":{"type":"graphic_picture","displayName":"Immature cataract","title":"Immature cataract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immature cataract</div><div class=\"cntnt\"><img style=\"width:286px; height:188px;\" src=\"images/PC/53639_Immature_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilated penlight photo of an immature cataract demonstrates that this amount of opacity transmits a red reflex and allows viewing of the posterior pole.</div><div class=\"graphic_reference\">Courtesy of Deborah S Jacobs, MD.</div><div id=\"graphicVersion\">Graphic 53639 Version 1.0</div></div></div>"},"53642":{"type":"graphic_diagnosticimage","displayName":"Bilateral pneumothoraces PA","title":"Chest radiograph of bilateral pneumothoraces","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of bilateral pneumothoraces</div><div class=\"cntnt\"><img style=\"width:324px; height:316px;\" src=\"images/PULM/53642_Bilateral_pneumothoraces_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with ARDS, increased permeability pulmonary edema, and barotrauma. Supine chest radiograph shows right subpulmonic and left apicolateral pneumothorax. Streaky lucencies are permeating the otherwise consolidated lungs as a reflection of interstitial pulmonary emphysema. Subcutaneous air is also seen &nbsp;in the right hemithorax. The patient has a tracheostomy tube in place with a markedly hyperexpanded cuff, due to tracheomalacia.</div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53642 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"53643":{"type":"graphic_picture","displayName":"Wilson disease simulating AIH","title":"Wilson disease simulating autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wilson disease simulating autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:387px; height:252px;\" src=\"images/GAST/53643_Wilsons_disease_simulating.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy from a patient with Wilson disease shows an island of parenchyma surrounded by thin connective tissue septa and inflammatory cells. These findings are identical to those seen in autoimmune chronic hepatitis, and this patient was treated unsuccessfully with corticosteroids before the correct diagnosis was made.</div><div class=\"graphic_reference\">Courtesy of Marshall M Kaplan, MD.</div><div id=\"graphicVersion\">Graphic 53643 Version 2.0</div></div></div>"},"53647":{"type":"graphic_table","displayName":"Common insecticides","title":"Some common examples of insecticides used to control fire ants*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some common examples of insecticides used to control fire ants*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Treatments</td> <td class=\"subtitle1\">Chemical name</td> </tr> <tr> <td rowspan=\"17\"><strong>Outdoors</strong></td> <td rowspan=\"8\">Baits</td> <td>Abamectin</td> </tr> <tr> <td>Fenoxycarb</td> </tr> <tr> <td>Hydramethylnon</td> </tr> <tr> <td>Metaflumizone</td> </tr> <tr> <td>Methoprene</td> </tr> <tr> <td>Methoprene&nbsp;and hydramethylnon</td> </tr> <tr> <td>Pyriproxyfen</td> </tr> <tr> <td>Indoxacarb</td> </tr> <tr> <td>&nbsp;</td> <td>Spinosad</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Drenches, sprays, dusts, and granules</td> <td>Acephate</td> </tr> <tr> <td>Bifenthrin</td> </tr> <tr> <td>Deltamethrin</td> </tr> <tr> <td>Cypermethrin</td> </tr> <tr> <td>Cyfluthrin</td> </tr> <tr> <td>Tralomethrin</td> </tr> <tr> <td>Lambda-cyhalothrin</td> </tr> <tr> <td>Permethrin</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Indoors</strong></td> <td rowspan=\"3\">Baits </td> <td>Abamectin</td> </tr> <tr> <td>Hydramethylnon</td> </tr> <tr> <td>Orthoboric acid</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Sprays, dusts, and aerosols </td> <td>Cypermethrin</td> </tr> <tr> <td>Deltamethrin</td> </tr> <tr> <td>Boric acid</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Chemical names can be entered into search engines to find the various branded products that contain them.</div><div class=\"graphic_footnotes\">* Pesticide products, registrations, and their uses are constantly changing due to federal and state restrictions. Always check the pesticide label for current recommendations and instructions before using any product.</div><div id=\"graphicVersion\">Graphic 53647 Version 8.0</div></div></div>"},"53650":{"type":"graphic_figure","displayName":"Decline post transfusion HCV","title":"Incidence of posttransfusion hepatitis C","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Incidence of posttransfusion hepatitis C</div><div class=\"cntnt\"><img style=\"width:474px; height:259px;\" src=\"images/GAST/53650_Decline_post_transfusion_HC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Source: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Adapted from: MJ Alter, Tobler LH, Busch MP. Clin Chem 1997.</div><div id=\"graphicVersion\">Graphic 53650 Version 3.0</div></div></div>"},"53651":{"type":"graphic_figure","displayName":"H pylori and GERD","title":"H. pylori and GERD","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">H. pylori and GERD</div><div class=\"cntnt\"><img style=\"width:570px; height:591px;\" src=\"images/GAST/53651_H_pylori_and_GERD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of Helicobacter pylori (H. pylori) on gastroesophageal reflux disease (GERD) is dependent on the distribution of the gastritis and the predisposition for GERD (esophagogastric junction (EGJ) competence, hiatus hernia, esophageal acid clearance).</div><div id=\"graphicVersion\">Graphic 53651 Version 2.0</div></div></div>"},"53653":{"type":"graphic_picture","displayName":"BAL amiodarone lung","title":"BAL in amiodarone pulmonary toxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">BAL in amiodarone pulmonary toxicity</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/53653_BAL_amiodarone_Lung.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoalveolar lavage (BAL) cytopreparation smear with normal differential and marked foamy appearance of alveolar macrophages.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 53653 Version 2.0</div></div></div>"},"53655":{"type":"graphic_diagnosticimage","displayName":"Clavicle osteolysis","title":"Osteolysis of the clavicle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteolysis of the clavicle</div><div class=\"cntnt\"><img style=\"width:396px; height:312px;\" src=\"images/EM/53655_Clavicle_osteolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph depicts osteolysis in the portion of the clavicle adjacent to the acromioclavicular joint. Note the loss of dense white bone and the moth-eaten appearance of this part of the clavicle.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 53655 Version 2.0</div></div></div>"},"53656":{"type":"graphic_table","displayName":"Lithium poisoning - Rapid overview","title":"Emergent management of lithium poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Emergent management of lithium poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,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\" /></a></span>, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">Clinical presentation</td> </tr> <tr> <td>Acute poisoning often presents with nausea, vomiting, and diarrhea; neurologic findings develop late.</td> </tr> <tr> <td>Chronic poisoning often presents with neurologic findings: sluggishness, ataxia, confusion, agitation, and/or neuromuscular excitability.</td> </tr> <tr> <td>Severe poisoning can cause seizures, nonconvulsive status epilepticus, or encephalopathy.</td> </tr> <tr> <td>Elder patients are at higher risk; poisoning may stem from dehydration or decline in renal function.</td> </tr> <tr> <td class=\"subtitle1_single\">History and physical examination</td> </tr> <tr> <td>Determine nature of ingestion (eg, acute or chronic, suicide attempt), including whether ingested drug is standard formulation or sustained release.</td> </tr> <tr> <td>Inquire about recent illness causing dehydration (eg, vomiting, diarrhea, fever, anorexia).</td> </tr> <tr> <td>Assess for signs of dehydration.</td> </tr> <tr> <td>Perform a focused neurologic examination; look for alterations in mentation, ataxia, and neuromuscular excitability (eg, tremors, myoclonus).</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Obtain serum lithium concentration upon presentation and repeat every 2 to 4 hours during initial management; normal range 0.8 and 1.2 mEq/L (mmol/L); drug concentration may <strong>not</strong> correlate with clinical severity.</td> </tr> <tr> <td>Obtain the following blood tests: fingerstick glucose; basic electrolytes (including Na, K, Cl, HCO3); creatinine and BUN; complete blood count (hemoglobin, platelets, white blood cells); acetaminophen and salicylate concentrations (with suicide attempt or possible coingestion); pregnancy test in women of childbearing age; thyrotropin (TSH).</td> </tr> <tr> <td>Obtain an electrocardiogram.</td> </tr> <tr> <td class=\"subtitle1_single\">Management</td> </tr> <tr> <td>Assess and stabilize airway, breathing, and circulation.</td> </tr> <tr> <td class=\"sublist1_start\">Restore sodium and water balance:</td> </tr> <tr> <td class=\"sublist1\">In adults, initiate IV hydration with isotonic saline at twice the maintenance rate for a total of approximately 2 to 3 L, depending upon the patient's fluid status and cardiac function</td> </tr> <tr> <td class=\"sublist1\">Monitor serum sodium closely (every 4 to 6 hours) in patients with lithium-induced nephrogenic diabetes insipidus</td> </tr> <tr> <td>Give whole bowel irrigation with polyethylene glycol (PEG) solution to <strong>AWAKE ASYMPTOMATIC</strong> patients who present within 2 to 3 hours after an ingestion of more than 10 to 15 tablets of sustained-release lithium. The dose of PEG is 500 mL to 2 L of PEG per hour via nasogastric tube until the rectal effluent is clear.</td> </tr> <tr> <td>Obtain nephrology consultation early for significant lithium poisoning, prior to the development of obvious indications for hemodialysis.</td> </tr> <tr> <td class=\"sublist1_start\">Perform hemodialysis for the following indications:</td> </tr> <tr> <td class=\"sublist1\">Serum lithium concentration is greater than 4 mEq/L (or mmol/L), regardless of the clinical status of the patient</td> </tr> <tr> <td class=\"sublist1\">Serum lithium concentration is greater than 2.5 mEq/L (or mmol/L) and the patient manifests signs of significant lithium toxicity (eg, seizures, depressed mental status), has renal insufficiency or other conditions that limit lithium excretion, or suffers from an illness that would be exacerbated by aggressive IV fluid hydration (eg, heart failure)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53656 Version 4.0</div></div></div>"},"53657":{"type":"graphic_figure","displayName":"Insulin secretion in NOD mouse","title":"Recovery of insulin secretion in NOD mice","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Recovery of insulin secretion in NOD mice</div><div class=\"cntnt\"><img style=\"width:488px; height:233px;\" src=\"images/ENDO/53657_Insulin_secretion_in_NOD_mo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin release from isolated pancreatic islets from in 12 to 13 week-old nonobese diabetic (NOD) mice and normal mice on day 0 and day 7 in culture. Measurements were made at baseline during incubation with low glucose medium (B) and after incubation in high glucose medium (G). Insulin release from the islets from NOD mice in response to glucose was low on day 0 (second panel) but above normal by day 7 (fourth panel), suggesting the importance of in vivo inhibitory factors such as locally released cytokines.</div><div class=\"graphic_reference\">Data from: Strandell E, Eizirik DL, Sandler S. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990; 85:1944.</div><div id=\"graphicVersion\">Graphic 53657 Version 2.0</div></div></div>"},"53658":{"type":"graphic_picture","displayName":"IPMN oncocytic","title":"Histologic appearance of intraductal papillary mucinous neoplasm, oncocytic type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of intraductal papillary mucinous neoplasm, oncocytic type</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/ONC/53658_IPMN_oncocytic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intraductal papillary mucinous neoplasm (IPMN) of the oncocytic type. The neoplastic cells have eosinophilic cytoplasm and form multiple small lumens. Hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 53658 Version 3.0</div></div></div>"},"53659":{"type":"graphic_figure","displayName":"Heel pocket out method PI","title":"Heel-pocket-out method to put on compression stockings","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Heel-pocket-out method to put on compression stockings</div><div class=\"cntnt\"><img style=\"width:456px; height:611px;\" src=\"images/PI/53659_Heel_pocket_out_method_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heel-pocket-out method to put on compression stockings is as follows:<br /><ol>&#xD;&#xA;    <li>Turn the leg part of the stocking inside-out down to the heel (as shown in A). </li>&#xD;&#xA;    <li>Put your foot into the stocking, hold onto the folded edge, and pull the stocking onto your foot and over the heel (as shown in B). </li>&#xD;&#xA;    <li>Gently work the stocking up your leg by turning it right-side out (as shown in C). </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53659 Version 7.0</div></div></div>"},"53663":{"type":"graphic_picture","displayName":"Plugged glands","title":"Plugged glands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plugged glands</div><div class=\"cntnt\"><img style=\"width:432px; height:279px;\" src=\"images/PC/53663_Plugged_glands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification view of meibomian gland openings of the eyelid with mounds of thickened, waxy secretions plugging the gland openings.</div><div id=\"graphicVersion\">Graphic 53663 Version 1.0</div></div></div>"},"53664":{"type":"graphic_diagnosticimage","displayName":"Streptococcus pneumoniae pneumonia complications","title":"Complications of <EM>Streptococcus pneumoniae </EM>pneumonia","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Complications of <EM>Streptococcus pneumoniae </EM>pneumonia</div><div class=\"cntnt\"><img style=\"width:469px; height:259px;\" src=\"images/ID/53664_Compl_pneumococcal_pneu_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic images of the complications of pneumococcal pneumonia.<br />(Left panel) Lung abscess with an air-fluid level in the right lung. Abscess cavity material is nearly always culture positive, and patients commonly defervesce within 48 hours of interventional drainage.<br />(Right panel) Radiograph of necrotizing pneumonia in the left lung.</div><div id=\"graphicVersion\">Graphic 53664 Version 8.0</div></div></div>"},"53665":{"type":"graphic_movie","displayName":"Tricuspid valve rupture 2-D echocardiogram","title":"Tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53665_trivarupconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:256px; height:434px;\" src=\"images/CARD/53665_trivarup.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical view from a 2-D echocardiogram shows a flail tricuspid valve leaflet with exaggerated movement. There is a bright echo seen at the tip of the valve, which probably represents a ruptured papillary muscle.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 53665 Version 2.0</div></div></div>"},"53668":{"type":"graphic_picture","displayName":"Breastfeeding side by side","title":"Breastfeeding side by side","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breastfeeding side by side</div><div class=\"cntnt\"><img style=\"width:432px; height:259px;\" src=\"images/PEDS/53668_Breastfeeding_side_by_side.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Side-lying position for breastfeeding.</div><div class=\"graphic_reference\">Reproduced with permission from: Caroline E Brown, DEd, CNS, WHNP.</div><div id=\"graphicVersion\">Graphic 53668 Version 3.0</div></div></div>"},"53669":{"type":"graphic_table","displayName":"Stimulation tests for adrenal insufficiency","title":"Stimulation tests for adrenal insufficiency: Protocols and normal blood and urinary steroid hormone levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stimulation tests for adrenal insufficiency: Protocols and normal blood and urinary steroid hormone levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Adrenal capacity (ACTH stimulation tests)</td> </tr> <tr> <td class=\"subtitle2_single\">Rapid IV ACTH test*:<sup>[1]</sup></td> </tr> <tr> <td class=\"indent2\">Intravenous Cortrosyn: 15 micrograms/kg in neonates, 125 micrograms up to 2 years, 250 micrograms over 2 years of age. Dose is infused IV over one minute. <p>&nbsp;</p> </td> </tr> <tr> <td class=\"indent2\">Sample blood for serum cortisol and ACTH at baseline and for cortisol at one hour after infusion.</td> </tr> <tr> <td class=\"indent1\"><em>Normal response: Serum cortisol at 1 hour is 7 to 10 micrograms/dL (190 to 275 nmol/L) higher than the&nbsp;baseline level, and &#62;18 micrograms/dL (&#62;500 nmol/L).</em></td> </tr> <tr> <td class=\"subtitle2_single\">Prolonged ACTH test*: The response can either be measured as a change in urinary steroid concentrations or a change in serum cortisol levels.</td> </tr> <tr> <td class=\"indent2\">Prior to starting ACTH, obtain baseline (8:00 AM) ACTH and cortisol levels, or obtain two consecutive days of 24 hour urine collections for 17-hydroxycorticosteroids (17OHCS) and free cortisol, ending at 8:00 AM on the morning of ACTH administration.</td> </tr> <tr> <td class=\"indent2\">Give 20 U/m<sup>2</sup> Acthar gel IM every 12 hours for 3 days, or give 250 micrograms/1.73 m<sup>2</sup> Cortrosyn IV over 8 to 12 hours beginning at 8:00 AM for 3 consecutive days.</td> </tr> <tr> <td class=\"indent2\">Measure serum cortisol at the end of the ACTH treatment (after 3 days of Acthar gel, or once daily for three days at the end of the Cortrosyn infusion). If measuring urinary steroids, continue 24 hour urine collections for 17-OHCS and free cortisol during the three days of ACTH treatment.</td> </tr> <tr> <td class=\"indent1\"><em>Normal responses: Serum cortisol increases to &#62;36 micrograms/dL (&#62;993 nmol/L). Urinary 17-OHCS and free cortisol show a three- to five-fold increase over baseline.</em></td> </tr> <tr> <td class=\"subtitle1_single\">ACTH secretory ability</td> </tr> <tr> <td class=\"subtitle2_single\">Insulin-induced hypoglycemia:<sup>[2,3]</sup></td> </tr> <tr> <td class=\"indent2\">After fasting since midnight, the test is performed in the morning. Obtain baseline 8:00 AM serum cortisol and glucose levels.</td> </tr> <tr> <td class=\"indent2\">Give 0.05 units/kg of regular insulin IV, and measure cortisol and glucose levels at 15, 30, 45, and 60 minutes. If desired, samples for growth hormone can be obtained at the same time points to screen for growth hormone deficiency. Blood sugar levels should drop by 50 percent or to &#60;45 mg/dL. If this does not occur by 45 minutes, the dose of insulin can be repeated.</td> </tr> <tr> <td class=\"indent1\"><em>Normal response: The cortisol level should increase to twice the baseline level or above 20 micrograms/dL (&#62;550 nmol/L).</em></td> </tr> <tr> <td class=\"subtitle2_single\">Glucagon stimulation test:<sup>[4]</sup></td> </tr> <tr> <td class=\"indent2\">After fasting since midnight, the test is performed in the morning. Obtain baseline 8:00 AM serum cortisol and glucose.</td> </tr> <tr> <td class=\"indent2\">Give glucagon 0.1 mg/kg IM and obtain blood samples at 15, 30, 45, 60, 90, 120, 150 and 180 minutes for glucose and cortisol levels. If desired, samples for growth hormone measurement can be obtained at the same time points to screen for growth hormone deficiency.</td> </tr> <tr> <td class=\"indent1\"><em>Normal response: The cortisol level normally decreases during the first 60 to 90 minutes, and then reaches a peak of &#62;20 micrograms/dL (&#62;550 nmol/L) by 180 minutes. Hypoglycemia is a risk during the second half of the test.</em></td> </tr> <tr> <td class=\"subtitle2_single\">Single dose Metyrapone Test* (this test should be performed in the hospital):</td> </tr> <tr> <td class=\"indent2\">Obtain baseline blood sample for ACTH, cortisol, and 11-deoxycortisol levels at 8:00 AM.</td> </tr> <tr> <td class=\"indent2\">Give 30 mg/kg (up to 3.0 g) metyrapone orally at midnight with food.</td> </tr> <tr> <td class=\"indent2\">Obtain blood for ACTH, cortisol and 11-deoxycortisol levels at 8:00 AM the following morning.</td> </tr> <tr> <td class=\"indent1\"><em>Normal response: ACTH level rises to over 100 pg/mL (&#62;22 pmol/L), 11-deoxycortisol rises to &#62;7 micrograms/dL, and cortisol drops to &#60;5 micrograms/dL (&#60;138 nmol/L) if there has been adequate suppression of 11-hydroxylase activity.</em></td> </tr> <tr> <td class=\"subtitle2_single\">Prolonged Metyrapone Test* (this test should be performed in the hospital):</td> </tr> <tr> <td class=\"indent2\">Obtain baseline blood sample for ACTH, cortisol, and 11-deoxycortisol at 8:00 AM.</td> </tr> <tr> <td class=\"indent2\">Give 15 mg/kg or 300 mg/m<sup>2</sup> every 4 hours for six doses at 8:00 AM, 12:00 noon, 4:00 PM, 8:00 PM, 12:00 midnight, and 4:00 AM.</td> </tr> <tr> <td class=\"indent2\">Four hours after the last dose, at 8:00 AM, obtain blood for ACTH, cortisol, and 11-deoxycortisol.</td> </tr> <tr> <td class=\"indent1\"><em>Normal response: ACTH level rises to over 100 pg/mL (&#62;22 pmol/L), 11-deoxycortisol rises to &#62;7micrograms/dL, and cortisol drops to &#60;5 micrograms/dL <em>(&#60;138 nmol/L) </em>if there has been adequate suppression of 11-hydroxylase activity.</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: adrenocorticotropic hormone.<br />* Normal ranges and protocols are from Esoterix Laboratories, Calabasas Hills, California, and are used with permission.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.</LI>&#xD;&#xA;<LI>Donohoue PA. The Adrenal Gland and its Disorders. Kappy MS, Allen DB, Geffner ME (eds). Principles and Practice of Pediatric Endocrinology, Charles C. Thomas Publisher, Springfield, IL, 2005, p.381. </LI>&#xD;&#xA;<LI>Schmidt IL, et al. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 88:4193, 2003.</LI>&#xD;&#xA;<LI>Vanderschueren-Lodeweyckx M, et al. The glucagon stimulation test: Effect on plasma growth hormone and on immunoreactive insulin, cortisol, and glucose in children. J Pediatr 1974; 85:182-187.</LI></OL></div><div id=\"graphicVersion\">Graphic 53669 Version 5.0</div></div></div>"},"53670":{"type":"graphic_picture","displayName":"Finger dorsal splint","title":"Finger dorsal splint","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Finger dorsal splint</div><div class=\"cntnt\"><img style=\"width:468px; height:273px;\" src=\"images/EM/53670_Finger_dorsal_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 53670 Version 1.0</div></div></div>"},"53671":{"type":"graphic_diagnosticimage","displayName":"Oblique uncomplicated fracture of the lateral malleolus","title":"Oblique uncomplicated fracture of the lateral malleolus","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Oblique uncomplicated fracture of the lateral malleolus</div><div class=\"cntnt\"><img style=\"width:541px; height:373px;\" src=\"images/EM/53671_Oblique_lat_malleolar_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fracture is best seen on the lateral view (arrow). The anteroposterior (AP) x-ray demonstrates the symmetry of the joint: the distance between the superior aspect of the medial malleolus and the talus is equal to the distance between the tibial plafond and the talus (arrowheads). This relationship must be confirmed on the mortise view. Provided there is no injury to the deltoid ligament, this is a stable injury and surgical intervention is not needed.</div><div class=\"graphic_reference\">Courtesy of Jari Salo, MD.</div><div id=\"graphicVersion\">Graphic 53671 Version 7.0</div></div></div>"},"53672":{"type":"graphic_diagnosticimage","displayName":"Achalasia: Beaking at the gastroesophageal junction ","title":"Achalasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Achalasia</div><div class=\"cntnt\"><img style=\"width:230px; height:307px;\" src=\"images/GAST/53672_Achalasia_Ba_swallow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium&nbsp;esophagram showing a dilated esophagus and bird's beak appearance typical of achalasia. Retained food is also visible.</div><div class=\"graphic_reference\">Courtesy of Ram Dickman, MD.</div><div id=\"graphicVersion\">Graphic 53672 Version 4.0</div></div></div>"},"53673":{"type":"graphic_figure","displayName":"Change BMD with add-back rx","title":"Change in bone mineral density for women on GnRH agonists","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Change in bone mineral density for women on GnRH agonists</div><div class=\"cntnt\"><img style=\"width:511px; height:308px;\" src=\"images/OBGYN/53673_Change_BMD_with_add-back_rx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effects of GnRH agonist on bone density in women with endometriosis and pelvic pain. Women with endometriosis and pelvic pain were treated with the GnRH agonist leuprolide depot for 52 weeks. Group A received GnRH agonist plus placebo pills. Group B received GnRH agonist plus norethindrone acetate 5 mg daily. Group C received GnRH agonist and norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily, and group D received GnRH agonist and norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily. No significant bone density loss occurred in the groups which received the GnRH agonist plus low dose steroid add-back.</div><div class=\"graphic_reference\">Reproduced with permission from: Hornstein MD, Surrey ES, Weinberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16-24.</div><div id=\"graphicVersion\">Graphic 53673 Version 2.0</div></div></div>"},"53674":{"type":"graphic_figure","displayName":"Peripheral chemical mediators of pain and hyperalgesia","title":"Peripheral chemical mediators of pain and hyperalgesia","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Peripheral chemical mediators of pain and hyperalgesia</div><div class=\"cntnt\"><img style=\"width:522px; height:418px;\" src=\"images/PC/53674_Chemical_mediators.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bear MF, Connors BW, and Parasido MA. Neuroscience - Exploring the Brain, 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53674 Version 5.0</div></div></div>"},"53675":{"type":"graphic_diagnosticimage","displayName":"Left ventriculogram Chagas","title":"Left ventriculogram in chronic Chagas disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left ventriculogram in chronic Chagas disease</div><div class=\"cntnt\"><img style=\"width:183px; height:288px;\" src=\"images/CARD/53675_Left_ventriculogram_Chagas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The end-systolic and end-diastolic frames (right anterior oblique view) from the left ventriculogram of a patient with chronic Chagas disease demonstrates preserved global left ventricular function but dyssenergy of the apical, anterio-basal, and infero-basal regions.</div><div id=\"graphicVersion\">Graphic 53675 Version 3.0</div></div></div>"},"53676":{"type":"graphic_picture","displayName":"Vocal fold squamous ca","title":"Squamous cell carcinoma right vocal fold","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma right vocal fold</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PC/53676_Vocal_fold_squamous_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note exophytic, irregular appearing mass arising from the right anterior true vocal fold.</div><div id=\"graphicVersion\">Graphic 53676 Version 2.0</div></div></div>"},"53677":{"type":"graphic_picture","displayName":"Fungal nail infections Hyper-IgE","title":"Destructive fungal nail infections in a patient with hyperimmunoglobulin E syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Destructive fungal nail infections in a patient with hyperimmunoglobulin E syndrome</div><div class=\"cntnt\"><img style=\"width:433px; height:286px;\" src=\"images/ALLRG/53677_Fungal_nail_infections_IgE.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53677 Version 2.0</div></div></div>"},"53678":{"type":"graphic_figure","displayName":"Wedge shoes","title":"Wedge shoes","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Wedge shoes</div><div class=\"cntnt\"><img style=\"width:471px; height:646px;\" src=\"images/SURG/53678_Wedge-shoes.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53678 Version 2.0</div></div></div>"},"53679":{"type":"graphic_table","displayName":"Differential diagnosis of PSP","title":"Differential diagnosis of progressive supranuclear palsy (PSP) by common clinical symptoms and signs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of progressive supranuclear palsy (PSP) by common clinical symptoms and signs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parkinsonism</td> <td class=\"subtitle1\">Falls</td> <td class=\"subtitle1\">Oculomotor abnormalities</td> <td class=\"subtitle1\">Cognitive dysfunction</td> </tr> <tr> <td> <ul> <li>Idiopathic Parkinson disease </li> <li>Corticobasal degeneration </li> <li>Multiple system atrophy </li> <li>Dementia with Lewy bodies </li> <li>Vascular parkinsonism </li> </ul> </td> <td> <ul> <li>Multiple system atrophy </li> <li>Corticobasal degeneration </li> <li>Dementia with Lewy bodies </li> <li>Vascular parkinsonism </li> <li>Vestibulopathy </li> <li>Myelopathy </li> <li>Basilar artery ischemia </li> <li>Cardiac syncope </li> <li>Epilepsy </li> <li>Drop attacks </li> </ul> </td> <td> <ul> <li>Multiple system atrophy </li> <li>Corticobasal degeneration </li> <li>Vascular parkinsonism </li> <li>Alzheimer disease </li> <li>Dementia with Lewy bodies </li> <li>Whipple disease </li> <li>Creutzfeldt-Jakob disease </li> <li>Huntington disease </li> <li>Spinocerebellar ataxias </li> <li>Midbrain/third ventricle tumor </li> <li>Niemann-Pick disease type C </li> <li>Kufor-Rakeb syndrome </li> <li>Perry syndrome </li> </ul> </td> <td> <ul> <li>Alzheimer disease </li> <li>Corticobasal degeneration </li> <li>Frontotemporal dementia </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53679 Version 2.0</div></div></div>"},"53680":{"type":"graphic_movie","displayName":"TEE left atrial myxoma 1","title":"Left atrial myxoma seen on TEE","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma seen on TEE</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53680_teelatm1conv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:248px; height:436px;\" src=\"images/CARD/53680_teelatm1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large atrial myxoma which appears to be attached to the atrial side of the anterior mitral valve leaflet by a narrow stalk.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 53680 Version 3.0</div></div></div>"},"53681":{"type":"graphic_waveform","displayName":"ECG in Duchenne dystrophy","title":"Duchenne muscular dystrophy","html":"<div class=\"graphic normal\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Duchenne muscular dystrophy</div><div class=\"cntnt\"><img style=\"width:463px; height:379px;\" src=\"images/CARD/53681_ECG_in_Duchennes_dystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic findings in Duchenne muscular dystrophy include resting sinus tachycardia, deep infero-lateral Q waves, and a tall R in lead V1 due to the underlying cardiomyopathy, which is often associated with posterobasal fibrosis of the left ventricle. Left atrial enlargement, as indicated by the prominent negative P wave in lead V1, and marked right axis deviation are also present.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 53681 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"53684":{"type":"graphic_diagnosticimage","displayName":"Germinal matrix hemorrhage","title":"Ultrasound of germinal matrix hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of germinal matrix hemorrhage</div><div class=\"cntnt\"><img style=\"width:348px; height:292px;\" src=\"images/PEDS/53684_Germinal_matrix_bleed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonographic image (sagittal view) of a grade I germinal matrix hemorrhage (arrow) in a preterm newborn.</div><div id=\"graphicVersion\">Graphic 53684 Version 3.0</div></div></div>"},"53685":{"type":"graphic_waveform","displayName":"LA PCW pressures","title":"Left atrial and pulmonary capillary wedge pressure tracings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial and pulmonary capillary wedge pressure tracings</div><div class=\"cntnt\"><img style=\"width:408px; height:210px;\" src=\"images/CARD/53685_LA_PCW_pressures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left atrial pressure, obtained directly via a transseptal catheter, and the pulmonary capillary wedge (PCW) pressure, obtained through a balloon-tipped pulmonary artery catheter, are recorded simultaneously and are nearly identical in waveform. However, normal LA pressure wave timing precedes PCW pressure by 40 to 120 msec and often has a slightly higher pressure compared to the PCW pressure due to transmission of pressure backward through the pulmonary capillaries.</div><div class=\"graphic_reference\">Redrawn with permission from Kern MJ (Ed). Cardiac Catheterization Handbook, 2nd ed, Mosby-Year Book, St. Louis, 1995.</div><div id=\"graphicVersion\">Graphic 53685 Version 3.0</div></div></div>"},"53687":{"type":"graphic_figure","displayName":"Closure of myomectomy","title":"Closure of myomectomy","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Closure of myomectomy</div><div class=\"cntnt\"><img style=\"width:517px; height:324px;\" src=\"images/OBGYN/53687_Closure_of_myomectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 53687 Version 1.0</div></div></div>"},"53688":{"type":"graphic_diagnosticimage","displayName":"Wrist osteoarthritis","title":"Wrist osteoarthritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wrist osteoarthritis</div><div class=\"cntnt\"><img style=\"width:313px; height:320px;\" src=\"images/PC/53688_Wristosteoarthritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The articular cartilage between the radius and the scaphoid is narrowed. This finding is characteristic of osteoarthritis.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 53688 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal wrist radiograph</div><div class=\"cntnt\"><img style=\"width:342px; height:297px;\" src=\"images/PC/61652_Normal_wrist_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior view of the wrist is normal. The width of the articular cartilage is 2 mm and is identical to the width of the intercarpal joints.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 61652 Version 3.0</div></div></div>"},"53689":{"type":"graphic_diagnosticimage","displayName":"Paraseptal emphysema I","title":"Paraseptal emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraseptal emphysema</div><div class=\"cntnt\"><img style=\"width:360px; height:329px;\" src=\"images/PULM/53689_Paraseptal_emphysema_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several subpleural emphysematous spaces are present in the periphery of the left upper lobe (arrows) in a patient with accompanying severe centrilobular emphysema.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53689 Version 2.0</div></div></div>"},"53690":{"type":"graphic_picture","displayName":"Pulmonary LAM lung biopsy High","title":"Gross features of pulmonary lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross features of pulmonary lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:220px; height:200px;\" src=\"images/PULM/53690_Pulmonary_LAM_gross_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph of autopsy lung showing advanced lymphangioleiomyomatosis. The lung tissue has been largely replaced by nearly confluent cystic spaces. The rust-brown color of the pulmonary parenchyma attests to the presence of abundant hemosiderin pigment, a frequent finding in late stage lymphangioleiomyomatosis.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 53690 Version 2.0</div></div></div>"},"53691":{"type":"graphic_picture","displayName":"Tracheoplasty surgery","title":"Tracheoplasty surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheoplasty surgery</div><div class=\"cntnt\"><img style=\"width:432px; height:310px;\" src=\"images/PULM/53691_Tracheoplasty_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracheobronchoplasty-appearance from the surgeon's viewpoint. Polypropylene mesh has been fully sutured to the airway.</div><div class=\"graphic_footnotes\">Large single arrow: row of blue non-absorbable sutures; small double arrows: vagus nerve crossing posterior trachea; L MSB: left mainstem bronchus; R MSB: right mainstem bronchus.</div><div class=\"graphic_reference\">Courtesy of Sidhu P Gangadharan, MD.</div><div id=\"graphicVersion\">Graphic 53691 Version 2.0</div></div></div>"},"53692":{"type":"graphic_figure","displayName":"Segments of the ventricular septum","title":"Segments of the ventricular septum","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Segments of the ventricular septum</div><div class=\"cntnt\"><img style=\"width:595px; height:353px;\" src=\"images/CARD/53692_Segments_ventricular_septum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic illustration of the various segments of the ventricular septum as viewed from the left ventricle (panel A) and along the length of interventricular septum (panel B): membranous (MS), infundibular (IS), trabecular (TS), inlet (IN), and atrioventricular (AVS) septum.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventrical; RA: right atrium; RV: right ventricular; AV: aortic valve.</div><div class=\"graphic_reference\">Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). © 2009 American Heart Association, Inc.</div><div id=\"graphicVersion\">Graphic 53692 Version 5.0</div></div></div>"},"53693":{"type":"graphic_picture","displayName":"Pathologic skin picking abdomen","title":"Pathologic skin picking","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathologic skin picking</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53693_Pathologic_skin_pick_abdom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Angulated, linear, and sharply demarcated erosions, ulcerations, and purpuric patches on the abdomen of a healthy 15-year-old girl with a history of acute anxiety. The eruption cleared completely following mental health counseling.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 53693 Version 6.0</div></div></div>"},"53694":{"type":"graphic_figure","displayName":"Decompensation in HBV cirrhosis","title":"Progression to decompensated HBV-related cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progression to decompensated HBV-related cirrhosis</div><div class=\"cntnt\"><img style=\"width:397px; height:239px;\" src=\"images/GAST/53694_Decompensation_in_HBV_cirrh.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative probability of progression to decompensation in patients with compensated cirrhosis related to hepatitis B virus (HBV) infection.</div><div class=\"graphic_reference\">Data from: Fattovich G, Giustina G, Schalm SW, et al. Hepatology 1995; 21:77.</div><div id=\"graphicVersion\">Graphic 53694 Version 3.0</div></div></div>"},"53697":{"type":"graphic_table","displayName":"Causes of glomerulonephritis in children","title":"Causes of glomerulonephritis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of glomerulonephritis in children</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Hypocomplementemic (low C3)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">Primary renal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2_start\">Postinfectious/poststreptococcal glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2\">Membranoproliferative glomerulonephritis (MPGN) Types I, II, III</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">Systemic disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Systemic lupus erythematosus nephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Subacute bacterial endocarditis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Shunt nephritis (ventriculoatrial shunt)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Normocomplementemic (normal C3)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">Primary renal disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">IgA glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Alport syndrome</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">ANCA (+) Pauci-immune glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_single\">Systemic disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Henoch Sch&#246;nlein purpura glomerulonephritis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2_start\">ANCA associated diseases</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2\">Granulomatosis with polyangiitis (formerly Wegener granulomatosis)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist2\">Microscopic polyangiitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Anti-GBM disease (Goodpasture disease)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">ANCA: antineutrophil cytoplasmic antibodies; anti-GBM: anti-glomerular basement membrane.</div><div id=\"graphicVersion\">Graphic 53697 Version 4.0</div></div></div>"},"53698":{"type":"graphic_table","displayName":"Drug and toxin related laboratory changes","title":"Laboratory abnormalities associated with certain toxins or drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory abnormalities associated with certain toxins or drugs</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Rhabdomyolysis</td> </tr> <tr> <td class=\"sublist1_start\">Sympathomimetics</td> </tr> <tr> <td class=\"sublist1\">Cocaine</td> </tr> <tr> <td class=\"sublist1\">Amphetamines</td> </tr> <tr> <td class=\"sublist1\">Cathinones</td> </tr> <tr> <td>Anticholinergics</td> </tr> <tr> <td class=\"sublist1_start\">Central hallucinogens</td> </tr> <tr> <td class=\"sublist1\">Phencyclidine</td> </tr> <tr> <td class=\"sublist1\">LSD</td> </tr> <tr> <td class=\"sublist1\">Designer amphetamine</td> </tr> <tr> <td class=\"sublist1\">Synthetic cannabinoids</td> </tr> <tr> <td>Neuroleptics (NMS)</td> </tr> <tr> <td>Malignant hyperthermia</td> </tr> <tr> <td>Serotonin syndrome</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Toluene</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Strychnine</td> </tr> <tr> <td>Antidepressants</td> </tr> <tr> <td>Sedative-hypnotics</td> </tr> <tr> <td>Snake bite</td> </tr> <tr> <td>Tetanus</td> </tr> <tr> <td>Opioids</td> </tr> <tr> <td>Toxic alcohols</td> </tr> <tr> <td>Cellular asphyxiants</td> </tr> <tr> <td>Corticosteroids</td> </tr> <tr> <td><strong>Any agent that causes extreme agitation, hyperthermia, seizures, prolonged coma</strong></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hepatotoxicity</td> </tr> <tr> <td>Acetaminophen</td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Amanita mushrooms</td> </tr> <tr> <td>Isoniazid</td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td class=\"sublist1_start\">Halogenated hydrocarbons</td> </tr> <tr> <td class=\"sublist1\">Carbon tetrachloride</td> </tr> <tr> <td class=\"sublist1_start\">Heavy metals</td> </tr> <tr> <td class=\"sublist1\">Iron</td> </tr> <tr> <td>Gyromitra mushrooms</td> </tr> <tr> <td>Paraquat</td> </tr> <tr> <td>Phenylbutazone</td> </tr> <tr> <td>Phosphorus (yellow)</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Rifampin</td> </tr> <tr> <td>Oral contraceptives</td> </tr> <tr> <td>Vinyl chloride</td> </tr> <tr> <td>Androgens</td> </tr> <tr> <td>Alpha-methyldopa</td> </tr> <tr> <td>Halothane</td> </tr> <tr> <td>Valproic acid</td> </tr> <tr> <td>Tetracycline</td> </tr> <tr> <td>Erythromycin estolate</td> </tr> <tr> <td>Dimethylformamide</td> </tr> <tr> <td>Allopurinol</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Pennyroyal oil</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Chlorpromazine</td> </tr> <tr> <td>Troglitazone</td> </tr> <tr> <td>Pyrrolizidine alkaloids (plants)</td> </tr> <tr> <td>Nitrofurantoin</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Methemoglobinemia</td> </tr> <tr> <td class=\"sublist1_start\">Nitrates</td> </tr> <tr> <td class=\"sublist1\">Nitroglycerin</td> </tr> <tr> <td class=\"sublist1\">Well water</td> </tr> <tr> <td class=\"sublist1\">Silver nitrate</td> </tr> <tr> <td class=\"sublist1_start\">Nitrites</td> </tr> <tr> <td class=\"sublist1\">Amyl nitrite</td> </tr> <tr> <td class=\"sublist1\">(Iso)butyl nitrite</td> </tr> <tr> <td>Trinitrotoluene</td> </tr> <tr> <td>Aniline dyes</td> </tr> <tr> <td>Phenazopyridine</td> </tr> <tr> <td>Chlorates</td> </tr> <tr> <td>Dapsone</td> </tr> <tr> <td>Hydrazines</td> </tr> <tr> <td class=\"sublist1_start\">Local anesthetics</td> </tr> <tr> <td class=\"sublist1\">Benzocaine</td> </tr> <tr> <td class=\"sublist1\">Lidocaine</td> </tr> <tr> <td class=\"sublist1\">Prilocaine</td> </tr> <tr> <td>Phenacetin</td> </tr> <tr> <td>Toluidine</td> </tr> <tr> <td>Toluenediamine</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Aromatic amines</td> </tr> <tr> <td>Nitrobenzene</td> </tr> <tr> <td>Chloroquine</td> </tr> <tr> <td>Primaquine</td> </tr> <tr> <td>Naphthalene</td> </tr> <tr> <td>Nitroprusside</td> </tr> <tr> <td>Chlorobenzene</td> </tr> <tr> <td>Nitrous gases (arc welders)</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td>Phenols</td> </tr> <tr> <td>Pyridine</td> </tr> <tr> <td>Arsine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53698 Version 5.0</div></div></div>"},"53700":{"type":"graphic_figure","displayName":"Arterial supply to the pancreas","title":"Arterial supply to the pancreas","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Arterial supply to the pancreas</div><div class=\"cntnt\"><img style=\"width:600px; height:432px;\" src=\"images/SURG/53700_Arterial_supply_pancreas.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Original illustration from: Woodburne RT. Essentials of Human Anatomy, New York: Oxford University Press, 1973. Copyright &#169; 1973.</div><div id=\"graphicVersion\">Graphic 53700 Version 1.0</div></div></div>"},"53701":{"type":"graphic_picture","displayName":"Pityriasis rosea dark skin","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:396px; height:299px;\" src=\"images/DERM/53701_Pityriasis_rosea_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pityriasis rosea. Here the &quot;Christmas tree&quot; pattern is evident.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53701 Version 2.0</div></div></div>"},"53702":{"type":"graphic_picture","displayName":"Gastric large cell lymphoma","title":"Gastric large cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Gastric large cell lymphoma</div><div class=\"cntnt\"><img style=\"width:454px; height:310px;\" src=\"images/GAST/53702_High_grade_gastric_MALToma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric large cell lymphoma&#160;manifested as carcinoma-like ulcerative lesion (large arrow) and several variably sized nodules (small arrows) in adjacent mucosa.</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy, III, MD.</div><div id=\"graphicVersion\">Graphic 53702 Version 2.0</div></div></div>"},"53703":{"type":"graphic_figure","displayName":"Complete bicornuate uterus","title":"Uterus bicornuate: Complete (division down to internal os)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus bicornuate: Complete (division down to internal os)</div><div class=\"cntnt\"><img style=\"width:382px; height:213px;\" src=\"images/OBGYN/53703_Completebicornuateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53703 Version 12.0</div></div></div>"},"53704":{"type":"graphic_figure","displayName":"Female external genitalia PI","title":"Adult female external genitalia","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Adult female external genitalia</div><div class=\"cntnt\"><img style=\"width:505px; height:499px;\" src=\"images/PI/53704_Vulvar_anatomy_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the parts of a woman's genitals.</div><div id=\"graphicVersion\">Graphic 53704 Version 8.0</div></div></div>"},"53705":{"type":"graphic_table","displayName":"Dx hepatic mass lesions","title":"Differential diagnosis of hepatic mass lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hepatic mass lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Hepatocellular carcinoma</td> <td class=\"subtitle1\">Metastatic carcinoma</td> <td class=\"subtitle1\">Hepatocellular adenoma</td> <td class=\"subtitle1\">Focal nodular hyperplasia</td> <td class=\"subtitle1\">Cavernous hemangioma</td> <td class=\"subtitle1\">Simple cyst</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Incidence/ 100,000</strong>*</td> <td>1-4800<sup>&#182;</sup></td> <td>8-20</td> <td>1<sup>&#916;</sup>-4<sup>&#9674;</sup></td> <td>3-4</td> <td>400-7500</td> <td>170</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Solitary</strong></td> <td>20-40 percent</td> <td>5-10 percent</td> <td>90 percent</td> <td>90 percent</td> <td>90 percent</td> <td>?</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Coexisting liver disease</strong></td> <td>HBV, HCV, cirrhosis, hemochromatosis</td> <td>Uncommon in cirrhotic liver</td> <td>None</td> <td>None</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pathogenesis</strong></td> <td>HBV, HCV, alcohol, aflatoxin, cirrhosis</td> <td>Hematogenous, lymphatic or direct spread</td> <td>Estrogens, anabolic steroids</td> <td>Congenital, ? estrogens</td> <td>Congenital, estrogens</td> <td>Congenital</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Imaging</strong><sup>&#167;</sup></td> <td>US, CT</td> <td>US, CT, CTAP</td> <td>US, CT, 99mTc</td> <td>US, CT, MRI, 99mTc</td> <td>Dynamic bolus CT, 99mTc-RBC-SPECT scan, MRI</td> <td>US, CT</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Alpha-fetoprotein</strong></td> <td>&#62;300-500 ng/mL</td> <td>Nomal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Characteristic gross features</strong></td> <td>Hemorrhage, necrosis; invasion/ obstruction</td> <td>Hemorrhage, necrosis; umbilicated</td> <td>Hemorrhage, necrosis</td> <td>Central scar</td> <td>Blood filled \"cyst\"</td> <td>Thin walled cyst with clear fluid</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Characteristic microscopic features</strong></td> <td>\"Thick\" (&#62;3-4 cells) trabeculae</td> <td>Replacement of hepatocytes, by malignant cells no portal structures</td> <td>\"Neohepatocytes\", normal cord structure, no portal structures</td> <td>\"Focal cirrhosis\" with pseudoductiles</td> <td>Blood filled spaces lined by single layer of flat epithelium</td> <td>Simple cuboidal endothelium</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diagnosis</strong><sup>&#165;</sup></td> <td>FNAB or core biopsy</td> <td>FNAB or core biopsy</td> <td>Imaging, biopsy</td> <td>Imaging, biopsy</td> <td>Imaging</td> <td>Imaging</td> </tr> <tr> <td><strong>Treatment</strong></td> <td>\"Curative resection\" or ethanol injection if solitary, &#60;5.0 cm; ? transplantation&#177; chemoembolization</td> <td>\"Curative resection\" if &#60;3.0 cm and 3 or fewer nodules especially if large; otherwise periodic imaging; malignant potential</td> <td>Discontinue estrogens/ androgens; resect if possible, especially if large; otherwise periodic imaging; malignant potential</td> <td>Discontinue estrogens; periodic imaging</td> <td>Surgical resection only if symptomatic or &#62;10.0 cm; discontinue estrogens; periodic imaging</td> <td>Usually no treatment percutaneous aspiration or surgical enucleation if symptomatic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasound; CT: computerized axial tomography; dynamic bolus CT: rapid sequential CT images taken at plane of the mass, with delayed images up to 20 minutes; CTAP: computerized axial tomography arterioportogram; MRI: fast spin echo magnetic resonance imaging; 99mTc: 99mTecrictium labelled sulfur colloid scan; RBC-SPECT: 99mTechnetium tagged red blood cell study utilizing single photon emission computerized tomography; FNAB: fine needle aspiration biopsy for cytology.<br />* From autopsy series.<br />¶ Varies with geographic origin.<br />Δ Overall population.<br /><FONT class=lozenge>◊</FONT> Females on birth control pills.<br />§ Most useful imaging technique with which to obtain a diagnosis.<br />¥ Definitive test required for confident diagnosis.</div><div class=\"graphic_reference\">Adapted from: LaBrecque DR, Cakir-Yedidag A. Management of Liver Neoplasms in Medical Management of Liver Disease, EL Krawitt (Ed), Marcel Dekker, Inc. 1999, p.310.</div><div id=\"graphicVersion\">Graphic 53705 Version 3.0</div></div></div>"},"53706":{"type":"graphic_table","displayName":"Clinical dementia rating","title":"Clinical dementia rating (CDR): 0, 0.5, 1, 2, 3","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical dementia rating (CDR): 0, 0.5, 1, 2, 3</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Impairment </td> <td class=\"subtitle1\">None (0) </td> <td class=\"subtitle1\">Questionable (0.5) </td> <td class=\"subtitle1\">Mild (1) </td> <td class=\"subtitle1\">Moderate (2) </td> <td class=\"subtitle1\">Severe (3) </td> </tr> <tr> <td>Memory</td> <td>No memory loss or slight inconstant forgetfulness</td> <td>Consistent slight forgetfulness; partial recollection of events</td> <td>Moderate memory loss; more marked for recent events; defect interferes with everyday activities</td> <td>Severe memory loss; only highly learned material retained; new material rapidly lost</td> <td>Severe memory loss; only fragments remain</td> </tr> <tr> <td>Orientation</td> <td>Fully oriented</td> <td>Fully oriented or slight difficulty with time relationships</td> <td>Moderate difficulty with time relationships; oriented for place at examination; may have geographic disorientation elsewhere</td> <td>Severe difficulty with time relationships; usually disoriented in time, often to place</td> <td>Oriented to person only</td> </tr> <tr> <td>Judgment and problem</td> <td>Solves everyday problems and handles business and financial affairs well; judgment good in relation to past performance</td> <td>Slight impairment to solving problems, similarities, differences</td> <td>Moderate difficulty in handling problems, similarities, differences; social judgment usually maintained</td> <td>Severely impaired in handling problems, similarities, differences; social judgment usually impaired</td> <td>Unable to make judgments or solve problems</td> </tr> <tr> <td>Community affairs</td> <td>Independent function at usual level in job, shopping, volunteer and social groups</td> <td>Slight impairment in these activities</td> <td>Unable to function independently at these activities though may still be engaged in some; appears normal to casual inspection</td> <td>No pretense of independent function outside of home; appears well enough to be taken to functions outside of family home</td> <td>No pretense of independent function outside of home; appears too ill to be taken to functions outside a family home</td> </tr> <tr> <td>Home and hobbies</td> <td>Life at home, hobbies, intellectual interests well maintained</td> <td>Life at home, hobbies, intellectual interests slightly impaired</td> <td>Mild but definite impairment of function at home; more difficult chores abandoned; more complicated hobbies and interests abandoned</td> <td>Only simple chores preserved; very restricted interests, poorly maintained</td> <td>No significant function in home</td> </tr> <tr> <td>Personal care</td> <td>Fully capable of self care</td> <td>Fully capable of self care</td> <td>Needs prompting</td> <td>Requires assistance in dressing, hygiene, keeping of personal effects</td> <td>Requires much help with personal care; frequent incontinence</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Score only as decline from previous usual level due to cognitive loss, not impaired due to other factors.</div><div class=\"graphic_reference\">Reproduced with permission from: Morris JC. The clinical dementia rating (CDR): Current version and scoring rules. Neurology 1993; 43:2412. Copyright © 1993 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53706 Version 13.0</div></div></div>"},"53708":{"type":"graphic_table","displayName":"Neuroblastoma risk categories","title":"Children's Oncology Group risk assignment strata","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Children's Oncology Group risk assignment strata</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n<tr>\r\n<td class=\"subtitle1\">INSS Stage</td>\r\n<td class=\"subtitle1\">Age</td>\r\n<td class=\"subtitle1\">MYCN Status</td>\r\n<td class=\"subtitle1\">Pathology Classification</td>\r\n<td class=\"subtitle1\">DNA Ploidy</td>\r\n<td class=\"subtitle1\">Risk Group Assignment</td>\r\n</tr>\r\n<tr>\r\n<td>1</td>\r\n<td>0-21y</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>Low</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"1\" rowspan=\"4\">2</td>\r\n<td><365 d</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>-</td>\r\n<td>Low</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Non-Amp</td>\r\n<td>Any</td>\r\n<td>-</td>\r\n<td>Low</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Amp</td>\r\n<td>Favorable</td>\r\n<td>-</td>\r\n<td>Low</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Amp</td>\r\n<td>Unfavorable</td>\r\n<td>-</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"1\" rowspan=\"5\">3</td>\r\n<td><365 d</td>\r\n<td>Non-Amp</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>Intermediate</td>\r\n</tr>\r\n<tr>\r\n\r\n<td><365 d</td>\r\n<td>Amp</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Non-Amp</td>\r\n<td>Favorable</td>\r\n<td>-</td>\r\n<td>Intermediate</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Non-Amp</td>\r\n<td>Unfavorable</td>\r\n<td>-</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Amp</td>\r\n<td>Any</td>\r\n<td>-</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"1\" rowspan=\"3\">4</td>\r\n<td><365 d</td>\r\n<td>Non-Amp</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>Intermediate</td>\r\n</tr>\r\n<tr>\r\n\r\n<td><365 d</td>\r\n<td>Amp</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n\r\n<td>>365d-21y</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>_</td>\r\n<td>High</td>\r\n</tr>\r\n<tr>\r\n<td colspan=\"1\" rowspan=\"4\">4S</td>\r\n<td><365 d</td>\r\n<td>Non-Amp</td>\r\n<td>Favorable</td>\r\n<td>> 1</td>\r\n<td>Low</td>\r\n</tr>\r\n<tr>\r\n\r\n<td><365 d</td>\r\n<td>Non-Amp</td>\r\n<td>Any</td>\r\n<td>= 1</td>\r\n<td>Intermediate</td>\r\n</tr>\r\n<tr>\r\n\r\n<td><365 d</td>\r\n<td>Non-Amp</td>\r\n<td>Unfavorable</td>\r\n<td>Any</td>\r\n<td>Intermediate</td>\r\n</tr>\r\n<tr>\r\n\r\n<td><365 d</td>\r\n<td>Amp</td>\r\n<td>Any</td>\r\n<td>Any</td>\r\n<td>High</td>\r\n</tr>\r\n</tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 53708 Version 1.0</div></div></div>"},"53710":{"type":"graphic_table","displayName":"Dietary sources of zinc","title":"Zinc content of selected foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zinc content of selected foods</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Food</td>\n\n      <td class=\"subtitle1\">Amount</td>\n\n      <td class=\"subtitle1\">Zinc</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Oysters</td>\n\n      <td>6 medium</td>\n\n      <td colspan=\"1\" rowspan=\"2\">80 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>84 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Liver</td>\n\n      <td>3.5 oz</td>\n\n      <td colspan=\"1\" rowspan=\"2\">6.1 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>100 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Hamburger</td>\n\n      <td>3.5 oz</td>\n\n      <td colspan=\"1\" rowspan=\"2\">4.9 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>100 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Cheerios</td>\n\n      <td>1 cup</td>\n\n      <td colspan=\"1\" rowspan=\"2\">3.7 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>22.4 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Sunflower seeds</td>\n\n      <td>1 oz</td>\n\n      <td colspan=\"1\" rowspan=\"2\">1.6 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>28 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Pecans</td>\n\n      <td>1 oz</td>\n\n      <td colspan=\"1\" rowspan=\"2\">1.5 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>28 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Chicken (white meat)</td>\n\n      <td>3.5 oz</td>\n\n      <td colspan=\"1\" rowspan=\"2\">1.0 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>100 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Milk (whole, skim)</td>\n\n      <td>1 cup</td>\n\n      <td colspan=\"1\" rowspan=\"2\">0.9 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>240 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Brown rice</td>\n\n      <td>1/2 cup</td>\n\n      <td colspan=\"1\" rowspan=\"2\">0.6 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>97 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Egg (1 whole)</td>\n\n      <td>1 large</td>\n\n      <td colspan=\"1\" rowspan=\"2\">0.5 mg</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>50 g</td>\n      \n    </tr>\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">White rice</td>\n\n      <td>2/3 cup&nbsp;</td>\n\n      <td colspan=\"1\" rowspan=\"2\">0.4 mg</td>\n\n    </tr>\n    <tr>\n      \n      <td>124 g</td>\n      \n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53710 Version 3.0</div></div></div>"},"53711":{"type":"graphic_table","displayName":"Mycosis fungoides clinical staging","title":"Clinical staging system for mycosis fungoides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical staging system for mycosis fungoides</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Clinical stage </td>\r\n            <td class=\"subtitle1\" colspan=\"4\">TNMB classification </td>\r\n        </tr>\r\n        <tr>\r\n            <td>IA</td>\r\n            <td>T<sub>1</sub></td>\r\n            <td>N<sub>0</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0</sub> or B<sub>1</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IB</td>\r\n            <td>T<sub>2</sub></td>\r\n            <td>N<sub>0</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0</sub> or B<sub>1</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IIA</td>\r\n            <td>T<sub>1</sub> or T<sub>2</sub></td>\r\n            <td>N<sub>1 </sub>or N<sub>2</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0 </sub>or B<sub>1</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IIB</td>\r\n            <td>T<sub>3</sub></td>\r\n            <td>N<sub>0</sub> to N<sub>2</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0</sub> or B<sub>1</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IIIA</td>\r\n            <td>T<sub>4</sub></td>\r\n            <td>N<sub>0</sub> to N<sub>2</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IIIB</td>\r\n            <td>T<sub>4</sub></td>\r\n            <td>N<sub>0</sub> to N<sub>2</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>1</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IVA1</td>\r\n            <td>T<sub>1</sub> to T<sub>4</sub></td>\r\n            <td>N<sub>0</sub> to N<sub>2</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>2</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IVA2</td>\r\n            <td>T<sub>1</sub> to T<sub>4</sub></td>\r\n            <td>N<sub>3</sub></td>\r\n            <td>M<sub>0</sub></td>\r\n            <td>B<sub>0</sub> to B<sub>2</sub></td>\r\n        </tr>\r\n        <tr>\r\n            <td>IVB</td>\r\n            <td>T<sub>1</sub> to T<sub>4</sub></td>\r\n            <td>N<sub>0</sub> to N<sub>3</sub></td>\r\n            <td>M<sub>1</sub></td>\r\n            <td>B<sub>0</sub> to B<sub>2</sub></td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_lgnd\">To be used in conjunction with the TNMB classification system for mycosis fungoides.</div><div class=\"graphic_reference\">Modified from: Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.</div><div id=\"graphicVersion\">Graphic 53711 Version 4.0</div></div></div>"},"53713":{"type":"graphic_picture","displayName":"Heliotrope eruption b","title":"Heliotrope eruption in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heliotrope eruption in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/RHEUM/53713_heliotrope_rash_b.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 53713 Version 3.0</div></div></div>"},"53714":{"type":"graphic_figure","displayName":"TDE and diastolic dysfunction","title":"TDE assessment of mitral annulus velocity and diastolic dyfunction","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">TDE assessment of mitral annulus velocity and diastolic dyfunction</div><div class=\"cntnt\"><img style=\"width:553px; height:331px;\" src=\"images/CARD/53714_TDE_mitral_annulus_velocity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tissue Doppler echocardiography (TDE) can be used to assess the motion of the mitral annulus during diastole as a method of detecting diastolic dysfunction. The mitral valve ring moves toward the left ventricular apex (upward on the image) during systole. During diastole, there are two phases of motion. An early phase of movement away from the cardiac apex (downward on the image) corresponds to early diastolic filling and is analogous to the E wave on the Doppler profile of mitral inflow; it is marked E'. A late phase of movement in the same direction corresponds to atrial contraction and is analogous to the A wave; it is marked A'. The E' wave is blunted in the presence of either impaired relaxation or diminished compliance (restrictive physiology).</div><div class=\"graphic_reference\">Reproduced with permission from: Sohn DW, Chai IH, Lee DJ, et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30:474. Copyright © 1997 American College of Cardiology.</div><div id=\"graphicVersion\">Graphic 53714 Version 2.0</div></div></div>"},"53715":{"type":"graphic_picture","displayName":"Scabies burrow 2","title":"Scabetic burrow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabetic burrow</div><div class=\"cntnt\"><img style=\"width:432px; height:347px;\" src=\"images/DERM/53715_Scabies_burrow_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, linear scabetic burrow.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53715 Version 8.0</div></div></div>"},"53716":{"type":"graphic_diagnosticimage","displayName":"Forearm fx","title":"Forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forearm fracture</div><div class=\"cntnt\"><img style=\"width:387px; height:515px;\" src=\"images/EM/53716_Forearm_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">10-year-old with complete fracture of ulna with 30 degrees angulation. Note accompanying buckle fracture of distal radius.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 53716 Version 2.0</div></div></div>"},"53717":{"type":"graphic_picture","displayName":"Wire resection uterine septum","title":"Wire resection of uterine septum via hysteroscope","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Wire resection of uterine septum via hysteroscope</div><div class=\"cntnt\"><img style=\"width:504px; height:393px;\" src=\"images/OBGYN/53717_Wireresectionuterinesept.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53717 Version 12.0</div></div></div>"},"53718":{"type":"graphic_algorithm","displayName":"Atrial tachycardia algorithm","title":"P-wave algorithm to predict anatomic origin of atrial tachycardia","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">P-wave algorithm to predict anatomic origin of atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:517px; height:281px;\" src=\"images/CARD/53718_Atrial_tachycardia_algo_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A P-wave algorithm constructed on the basis of findings from 130 atrial tachycardias correctly localized the focus in 93 percent. The algorithm begins with assessment of the P-wave morphology in lead V1 on the surface electrocardiogram, then utilizes other leads as needed.</div><div class=\"graphic_footnotes\">Neg: negative P-wave morphology; Pos: positive P-wave morphology; Iso: isoelectric P-wave morphology; CS: coronary sinus ostium; CT: crista terminalis; LAA: left atrial appendage; LPV: left inferior pulmonary vein; LS: left superior pulmonary vein; RAA: right atrial appendage; RPV: right inferior pulmonary vein; SMA: superior mitral annulus; TA: tricuspid annulus.</div><div class=\"graphic_reference\">Reproduced with permission from: Kistler, PM, Roberts-Thomson, KC, Haqqani, HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010. Copyright © 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 53718 Version 5.0</div></div></div>"},"53720":{"type":"graphic_table","displayName":"Likelihood distal symmetric polyneuropathy","title":"Estimated likelihood of distal symmetric polyneuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated likelihood of distal symmetric polyneuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neuropathic symptoms</td> <td class=\"subtitle1\">Diminished or absent ankle reflexes*</td> <td class=\"subtitle1\">Diminished distal sensation</td> <td class=\"subtitle1\">Distal muscle weakness or atrophy</td> <td class=\"subtitle1\">Nerve conduction studies</td> <td class=\"subtitle1\">Ordinal likelihood</td> </tr> <tr> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Abnormal</td> <td>4</td> </tr> <tr> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>Abnormal</td> <td>4</td> </tr> <tr> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>Abnormal</td> <td>4</td> </tr> <tr> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Abnormal</td> <td>4</td> </tr> <tr> <td>Yes</td> <td>No</td> <td>Yes</td> <td>No</td> <td>Abnormal</td> <td>4</td> </tr> <tr> <td>No</td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>Abnormal</td> <td>3</td> </tr> <tr> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> <td>Abnormal</td> <td>3</td> </tr> <tr> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Abnormal</td> <td>2</td> </tr> <tr> <td>No</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Abnormal</td> <td>2</td> </tr> <tr> <td>Yes</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>Normal</td> <td>2</td> </tr> <tr> <td>Yes<sup>&#182;</sup></td> <td>No</td> <td>Yes<sup>&#182;</sup></td> <td>No</td> <td>Normal<sup>&#182;</sup></td> <td>1</td> </tr> <tr> <td>Yes<sup>&#916;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Yes<sup>&#916;</sup></td> <td>Normal<sup>&#916;</sup></td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Neuropathic symptoms include numbness, altered sensation, or pain in the feet.</div><div class=\"graphic_footnotes\">* Note that ankle reflexes may be diminished in normal people who are &ge;65 years old.<br />&para; This phenotype is observed in small-fiber sensory polyneuropathy. Intraepithelial nerve fiber density determination by skin biopsy may be helpful to confirm the diagnosis.<br />&Delta; This phenotype is not a distal symmetric polyneuropathy when nerve conduction studies are normal.</div><div class=\"graphic_reference\">Adapted with permission from: England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53720 Version 12.0</div></div></div>"},"53721":{"type":"graphic_picture","displayName":"Foot taping PI","title":"Foot taping for plantar fasciitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Foot taping for plantar fasciitis</div><div class=\"cntnt\"><img style=\"width:540px; height:310px;\" src=\"images/PI/53721_Foot_taping_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This way of taping the foot sometimes helps with plantar fasciitis. You can use&nbsp;sports tape, available at drug stores, for this.&nbsp;Here are the steps involved, from left to right.<br />(1) Wrap a strip of tape around the foot, at the level of the ball of the foot.<br />(2) Wrap a second strip of tape around the heel, starting just below the pinky toe, around the sides of the heel, and back up to the first strip of tape.<br />(3) Wrap a third strip of tape around the heel, starting just below the pinky toe, like you did in step 2. This time, circle the heel and wrap the tape in a criss-cross, so that it ends just below the big toe.<br />(4) Repeat step 3. The tape does not need to align perfectly. The tape can stay in place for 1 week.</div><div id=\"graphicVersion\">Graphic 53721 Version 4.0</div></div></div>"},"53723":{"type":"graphic_table","displayName":"ICD-10 Criteria HKD","title":"International classification of disease (10<SUP>th</SUP> edition) diagnostic criteria for hyperkinetic disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International classification of disease (10<SUP>th</SUP> edition) diagnostic criteria for hyperkinetic disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inattentive symptoms (at least six)</td> </tr> <tr> <td>Often fails to give close attention to details, or makes careless errors in school work, work or other activities.</td> </tr> <tr> <td>Often fails to sustain attention in tasks or play activities.</td> </tr> <tr> <td>Often appears not to listen to what is being said to him or her.</td> </tr> <tr> <td>Often fails to follow through on instructions or to finish school work, chores, or duties in the workplace (not because of oppositional behavior or failure to understand instructions).</td> </tr> <tr> <td>Is often impaired in organizing tasks and activities.</td> </tr> <tr> <td>Often avoids or strongly dislikes tasks, such as homework, that require sustained mental effort.</td> </tr> <tr> <td>Often loses things necessary for certain tasks and activities, such as school assignments, pencils, books, toys, or tools.</td> </tr> <tr> <td>Is often easily distracted by external stimuli.</td> </tr> <tr> <td>Is often forgetful in the course of daily activities.</td> </tr> <tr> <td class=\"subtitle1_single\">Hyperactive symptoms (at least three)</td> </tr> <tr> <td>Often fidgets with hands or feet or squirms on seat.</td> </tr> <tr> <td>Leaves seat in classroom or in other situations in which remaining seated is expected.</td> </tr> <tr> <td>Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, only feelings of restlessness may be present).</td> </tr> <tr> <td>Is often unduly noisy in playing or has difficulty in engaging quietly in leisure activities.</td> </tr> <tr> <td>Exhibits a persistent pattern of excessive motor activity that is not substantially modified by social context or demands.</td> </tr> <tr> <td class=\"subtitle1_single\">Impulsivity symptoms</td> </tr> <tr> <td>Often blurts out answers before questions have been completed.</td> </tr> <tr> <td>Often fails to wait in lines or await turns in games or group situations.</td> </tr> <tr> <td>Often interrupts or intrudes on others (eg butts into others' conversations or games).</td> </tr> <tr> <td>Often talks excessively without appropriate response to social constraints.</td> </tr> <tr> <td class=\"subtitle1_single\">Additional criteria</td> </tr> <tr> <td>At least six inattentive symptoms, three hyperactive symptoms, and one impulsivity symptom have persisted for at least six months, to a degree that is maladaptive and inconsistent with the developmental level of the child.</td> </tr> <tr> <td>Onset of the disorder is no later than the age of seven years.</td> </tr> <tr> <td>Criteria should be met for more than one setting (eg, at home and school).</td> </tr> <tr> <td>The symptoms cause clinically significant distress or impairment in social, academic, or occupational functioning.</td> </tr> <tr> <td>The patient does not meet criteria for pervasive developmental disorders, manic episode, depressive episode, or anxiety disorders.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from International Statistical Classification of Diseases and Related Health Problems (ICD-10), 10<SUP>th</SUP> edition, American Psychiatric Association, 1992.</div><div id=\"graphicVersion\">Graphic 53723 Version 2.0</div></div></div>"},"53727":{"type":"graphic_table","displayName":"Thrombocytopenia in pregnancy clinical features","title":"Clinical features and diagnosis of thrombocytopenic conditions in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features and diagnosis of thrombocytopenic conditions in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Onset during pregnancy</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td>Pseudothrombocytopenia</td> <td>Any time</td> <td>Examine blood smear for platelet clumps, or giant platelets. Repeat platelet count in citrate or heparin anticoagulant. Usually caused by agglutinins dependent upon EDTA, the standard anticoagulant for blood counts.</td> </tr> <tr class=\"divider_top\"> <td>Gestational thrombocytopenia (GT)</td> <td>Typically late in gestation, frequency increases as term approaches</td> <td>Based on five criteria: <ol> <li>Mild thrombocytopenia (most 100,000 to 150,000/microL, rarely &#60;80,000/microL) </li> <li>No thrombocytopenia outside of pregnancy </li> <li>Occurs late in gestation </li> <li>No fetal/neonatal thrombocytopenia </li> <li>Postpartum resolution </li> </ol> </td> </tr> <tr class=\"divider_top\"> <td>Immune thrombocytopenia (ITP)</td> <td>Any time</td> <td>Presence of isolated thrombocytopenia with no evidence for alternative etiologies. May be indistinguishable from gestational thrombocytopenia if mild and occurs late during pregnancy. Platelet count may improve after delivery.</td> </tr> <tr class=\"divider_top\"> <td>Preeclampsia with severe features</td> <td>After 20 weeks gestation</td> <td>Systolic or diastolic hypertension plus proteinuria</td> </tr> <tr class=\"divider_top\"> <td>HELLP syndrome (hemolysis, elevated liver function tests, and low platelets)</td> <td>After 20 weeks gestation</td> <td> <p>Diagnostic criteria for preeclampsia are present in 85% of cases.</p> <p>Hemolysis: Microangiopathic hemolytic anemia with schistocytes, with other signs of hemolysis: increased serum LDH and indirect bilirubin, decreased haptoglobin</p> <p>Elevated liver function tests (eg, AST, ALT), typically &#8805;twice normal</p> <p>Low platelets: Platelet count &#8804;100,000/microL</p> </td> </tr> <tr class=\"divider_top\"> <td>Thrombotic thrombocytopenic purpura (TTP)</td> <td>Typically late in gestation, frequency increases as term approaches. May occur after delivery.</td> <td>Thrombocytopenia and microangiopathic hemolytic anemia without an alternative etiology. May be indistinguishable from severe preeclampsia or HELLP syndrome. Severe neurologic abnormalities and acute renal failure support the diagnosis of TTP. Persistent abnormalities &#8805;3 days after delivery also support the diagnosis of TTP.</td> </tr> <tr class=\"divider_top\"> <td>Drug-induced immune thrombocytopenia (DITP)&nbsp;(except heparin)</td> <td>Any time</td> <td>Complete history of drug ingestion, including non-prescription drugs and herbal remedies. Focus on drugs taken intermittently, or regularly for more than one week. Thrombocytopenia typically resolves in five to seven days after stopping the drug.</td> </tr> <tr class=\"divider_top\"> <td>Heparin-induced thrombocytopenia (HIT)</td> <td>Any time</td> <td> <p>Suspected in patients who have thrombocytopenia (or &#62;50% decrease in platelet count) and who have begun heparin within previous 5 to 10 days.</p> <p>Thrombocytopenia is typically mild; arterial or venous thrombi are commonly present. ELISA assay for heparin-dependent antibodies is sensitive; measurement of heparin-induced platelet serotonin release is more specific.</p> </td> </tr> <tr class=\"divider_top\"> <td>Antiphospholipid syndrome (APS)</td> <td>Any time</td> <td> <p>Requires one clinical and one laboratory criterion:</p> <strong>Clinical:</strong> <ol> <li>Adverse pregnancy outcome: &#8805;3 losses &#60;10 weeks gestation or &#8805;1 loss &#8805;10 weeks gestation, &#60;34 week delivery secondary to preeclampsia or placental insufficiency </li> <li>Arterial or venous thrombosis </li> </ol> <br /> <p><strong>Laboratory:</strong></p> Demonstration of the persistent presence of at least one of the following antiphospholipid antibodies: <ol> <li>Lupus anticoagulant </li> <li>Anticardiolipin antibody </li> <li>Anti-&#946;2 glycoprotein-I </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for additional details of the clinical features.</div><div class=\"graphic_footnotes\">EDTA: ethylenediaminetetraacetic acid; LDH:&nbsp;lactate dehydrogenase;&nbsp;AST: aspartate aminotransferase; ALT: alanine aminotransferase.</div><div class=\"graphic_reference\">Courtesy of James N George, MD and Eric J Knudtson, MD.</div><div id=\"graphicVersion\">Graphic 53727 Version 9.0</div></div></div>"},"53728":{"type":"graphic_diagnosticimage","displayName":"Interstitial pulmonary edema PA","title":"Pulmonary edema","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary edema</div><div class=\"cntnt\"><img style=\"width:378px; height:336px;\" src=\"images/CARD/53728_Interstitialpulmonaryedem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain frontal chest radiograph of a 55-year-old male with known coronary artery disease demonstrates characteristic radiographic features of heart failure with interstitial pulmonary edema, bilateral perihilar alveolar edema producing a characteristic butterfly pattern, and bilateral pleural effusions.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 53728 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"53729":{"type":"graphic_picture","displayName":"Corneal perforation","title":"Corneal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal perforation</div><div class=\"cntnt\"><img style=\"width:324px; height:247px;\" src=\"images/PC/53729_Corneal_perforation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Demonstrated by fluorescein flow.</div><div id=\"graphicVersion\">Graphic 53729 Version 3.0</div></div></div>"},"53730":{"type":"graphic_table","displayName":"Properties of statins","title":"Properties of statins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of statins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Atorvastatin</td> <td class=\"subtitle1\">Fluvastatin</td> <td class=\"subtitle1\">Lovastatin</td> <td class=\"subtitle1\">Pitavastatin</td> <td class=\"subtitle1\">Pravastatin</td> <td class=\"subtitle1\">Rosuvastatin</td> <td class=\"subtitle1\">Simvastatin</td> </tr> <tr class=\"divider_bottom\"> <td>LDL cholesterol reductions (dose range, mg)</td> <td>38 to 54% (10 to 80)</td> <td>17 to 33% (20 to 80)</td> <td>29 to 48% (20 to 80)</td> <td>31 to 41% (1 to 4)</td> <td>19 to 40% (10 to 40)</td> <td>52 to 63% (10 to 40)</td> <td>28 to 41% (10 to 40)</td> </tr> <tr class=\"divider_bottom\"> <td>Elimination half-life, hours</td> <td>15 to 30</td> <td>0.5 to 2.3</td> <td>2.9</td> <td>12</td> <td>1.3 to 2.8</td> <td>19</td> <td>2 to 3</td> </tr> <tr class=\"divider_bottom\"> <td>Bioavailability, percent</td> <td>12</td> <td>19 to 29</td> <td>5</td> <td>51</td> <td>18</td> <td>20</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td>Protein binding, percent</td> <td>80 to 90</td> <td>&#62;99</td> <td>&#62;95</td> <td>99</td> <td>43 to 55</td> <td>88</td> <td>94 to 98</td> </tr> <tr class=\"divider_bottom\"> <td>Solubility</td> <td>Lipophilic</td> <td>Lipophilic</td> <td>Lipophilic</td> <td>Lipophilic</td> <td>Hydrophilic</td> <td>Hydrophilic</td> <td>Lipophilic</td> </tr> <tr class=\"divider_bottom\"> <td>Cytochrome 450 metabolism and lsozyme</td> <td>3A4</td> <td>2C9</td> <td>3A4</td> <td>Limited 2C9, 2C8</td> <td>-</td> <td>Limited 2C9</td> <td>3A4, 3A5</td> </tr> <tr class=\"divider_bottom\"> <td>Active metabolites</td> <td>Yes</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td>Effect of food on absorption of drug</td> <td>None</td> <td>Negligible</td> <td>Increased absorption</td> <td>Decreases</td> <td>Decreased absorption</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Optimal time of administration</td> <td>Anytime</td> <td> <p>IR: evening (or morning and evening if taken twice daily)</p> XR: anytime </td> <td> <p>IR: with evening meal (or with morning and evening meal if taken twice daily)</p> XR: anytime </td> <td>Anytime</td> <td>Anytime</td> <td>Anytime</td> <td>Evening</td> </tr> <tr> <td>Renal excretion of absorbed dose, %</td> <td>2</td> <td>&#60;6</td> <td>10</td> <td>15</td> <td>20</td> <td>10</td> <td>13</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; IR: immediate release; XR: extended release.</div><div id=\"graphicVersion\">Graphic 53730 Version 7.0</div></div></div>"},"53731":{"type":"graphic_table","displayName":"Theophylline guidelines","title":"Maintenance dosage guidelines for theophylline in children older than six months and adults who have no risk factors for decreased theophylline clearance*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maintenance dosage guidelines for theophylline in children older than six months and adults who have no risk factors for decreased theophylline clearance*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Weight-adjusted and maximal dose</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Adjustment to dose</td> </tr> <tr> <td>Initial dose</td> <td>~10 mg/kg of body weight/day; maximum, 300 mg/day</td> <td>If initial dose is tolerated, increase the dose no sooner than 3 days later to the first dose increase.</td> <td>&nbsp;</td> </tr> <tr> <td>First dose increase</td> <td>~13 mg/kg/day; maximum 450 mg/day</td> <td>If the first dose increase is tolerated, increase the dose no sooner than 3 days later to the second dose increase.</td> <td>&nbsp;</td> </tr> <tr> <td>Second dose increase</td> <td>~16 mg/kg/day; maximum 600 mg/day</td> <td>Measure the peak serum concentration after at least 3 days at the highest tolerated dose<sup>&#182;</sup>.</td> <td>&nbsp;</td> </tr> <tr> <td>Serum theophylline concentration (&#181;g/mL)</td> <td colspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">&#60;10</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Increase approximately 25 percent. </td> </tr> <tr> <td class=\"indent1\">10 to 15</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Maintain dose if tolerated.</td> </tr> <tr> <td class=\"indent1\">15.1 to 19.9</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Consider a reduction of approximately 10 percent.</td> </tr> <tr> <td class=\"indent1\">20 to 25</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Withhold next dose, then resume treatment with next lower dose level.</td> </tr> <tr> <td class=\"indent1\">&#62;25</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Withhold next 2 doses, then resume treatment with initial dose or lower dose.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For infants 6 weeks to 6 months of age, the initial daily dose is calculated according to the following regression equation: dose (in milligrams per kilogram per day) = (0.2) (age in weeks) + 5.0. Subsequent increases in the dose in this age group should be based on peak serum concentrations measured no sooner than three days after the start of therapy.<br />¶ The length of time to the peak serum concentration depends on the rate of absorption, the rate of elimination, and the dosing interval.<br />Δ This decreases the likelihood of side effects due to fluctuations in the absorption or elimination rate that may result in serum concentrations above 20 µg per milliliter and is especially important for patients who require doses higher than those used in the second dose increase.</div><div class=\"graphic_reference\">Adapted from Weinberger, M, Hendeles, L, N Engl J Med 1996; 334:1380.</div><div id=\"graphicVersion\">Graphic 53731 Version 2.0</div></div></div>"},"53732":{"type":"graphic_table","displayName":"Post CABG AF risk index","title":"Multivariable risk index for postoperative atrial fibrillation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Multivariable risk index for postoperative atrial fibrillation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Predictor</td> <td class=\"subtitle1\">Risk points*</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Age</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">&#60;30</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">30-39</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">40-49</td> <td class=\"centered\">18</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">50-59</td> <td class=\"centered\">24 </td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">60-69</td> <td class=\"centered\">30</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">70-79</td> <td class=\"centered\">36</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">&#8805;80</td> <td class=\"centered\">42</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Medical history</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">AF</td> <td class=\"centered\">7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">COPD</td> <td class=\"centered\">4</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Concurrent valve surgery</strong></td> <td class=\"centered\">6</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Withdrawal of treatment</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Beta blockers</td> <td class=\"centered\">6</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">ACE inhibitors</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Preoperative and postoperative treatment</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Beta blockers</td> <td class=\"centered\">&ndash;7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">ACE inhibitors</td> <td class=\"centered\">&ndash;5</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>Postoperative beta blocker treatment</strong></td> <td class=\"centered\">&ndash;11</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Other treatment</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Potassium supplementation</td> <td class=\"centered\">&ndash;5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">NSAIDs</td> <td class=\"centered\">&ndash;7</td> </tr> <tr> <td class=\"subtitle1\">Sum of risk points</td> <td class=\"subtitle1\">Risk rank</td> <td class=\"subtitle1\">Postoperative AF risk</td> </tr> <tr> <td class=\"centered\">&#60;14</td> <td class=\"centered\">Low</td> <td class=\"centered\">&#60; 17 percent</td> </tr> <tr> <td class=\"centered\">14-31</td> <td class=\"centered\">Medium</td> <td class=\"centered\">17 to 52 percent</td> </tr> <tr> <td class=\"centered\">&#62;31</td> <td class=\"centered\">High</td> <td class=\"centered\">&#62; 52 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; ACE inhibitors: angiotensin converting enzyme inhibitors; NSAIDs: nonsteroidal antiinflammatory drugs.<br />* To calculate the estimated risk of postoperative atrial fibrillation, the sum of the risk points is determined. Scores are stratified into low risk (&lt;14 points; AF incidence &lt;17 percent), medium risk (14 to 31 points; AF incidence 17 to 52 percent) and high risk (&gt;31 points; AF incidence &gt;52 percent).</div><div class=\"graphic_reference\">Data from: Mathew JP, et al. JAMA 2004; 291:1720.</div><div id=\"graphicVersion\">Graphic 53732 Version 3.0</div></div></div>"},"53733":{"type":"graphic_picture","displayName":"Pyoderma gangrenosum early","title":"Pyoderma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyoderma gangrenosum</div><div class=\"cntnt\"><img style=\"width:360px; height:249px;\" src=\"images/RHEUM/53733_Pyoderma_gangrenosum_early.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early lesion in pyoderma gangrenosum presenting as a pustular and violaceous plaque with incipient breakdown.</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 53733 Version 1.0</div></div></div>"},"53734":{"type":"graphic_table","displayName":"Categories of CRS","title":"Types of chronic rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of chronic rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">AFRS</td> <td class=\"subtitle1\">CRS with NP</td> <td class=\"subtitle1\">CRS without NP</td> </tr> <tr> <td>Bilateral nasal polyps</td> <td><span class=\"red\" style=\"color: #019e30;\">Yes (in most cases)</span></td> <td><span class=\"green\">Yes - Required for diagnosis*</span></td> <td><span style=\"color: #ff0000;\">No - Exclusion of polyps is required for diagnosis</span></td> </tr> <tr> <td>Allergic mucin</td> <td><span style=\"color: #019e30;\">Yes - Required for diagnosis</span></td> <td>May be present</td> <td><span class=\"green\" style=\"color: #000000;\">May be present</span></td> </tr> <tr> <td>Aspirin-associated respiratory disease</td> <td>May be present</td> <td> <p>Asthma present in approximately 40 percent</p> Aspirin intolerance and asthma present in approximately 15 percent</td> <td>Rare</td> </tr> <tr> <td>Evidence of IgE-mediated allergy to fungi</td> <td><span style=\"color: #019e30;\">Yes - Required for diagnosis</span></td> <td>May be present</td> <td><span class=\"green\" style=\"color: #000000;\">May be present</span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AFRS: allergic fungal rhinosinusitis; CRS: chronic rhinosinusitis; NP: nasal polyposis; IgE: immunoglobulin E.<br />* Medical records documenting removal of bilateral NP during surgery would satisfy this requirement.</div><div id=\"graphicVersion\">Graphic 53734 Version 9.0</div></div></div>"},"53736":{"type":"graphic_figure","displayName":"Endarterectomy asymptomatic","title":"Carotid endarterectomy reduces stroke, but not endpoint of stroke and death, in asymptomatic men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carotid endarterectomy reduces stroke, but not endpoint of stroke and death, in asymptomatic men</div><div class=\"cntnt\"><img style=\"width:320px; height:439px;\" src=\"images/CARD/53736_Endarterectomy_asymp_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medical versus surgical (carotid endarterectomy) therapy in 444 men with asymptomatic carotid stenosis ≥50 percent.<br />(Top panel) Carotid endarterectomy reduced the four-year incidence of ipsilateral stroke or TIA compared to medical therapy (8 versus 20.6 percent, p&lt;0.001).<br />(Bottom panel) There was no difference between the two groups in the incidence of stroke and death (41 versus 44 percent).</div><div class=\"graphic_footnotes\">TIA: transient ischemic attack.</div><div class=\"graphic_reference\">Data from: Hobson RW, Weiss DG, Fields WS, et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. The Veterans Affairs Cooperative Study Group.&nbsp;N Engl J Med 1993; 328:221.</div><div id=\"graphicVersion\">Graphic 53736 Version 7.0</div></div></div>"},"53738":{"type":"graphic_form","displayName":"CBT techniques adolescents2","title":"CBT techniques for primary care encounters (continued)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">CBT techniques for primary care encounters (continued)</div><div class=\"cntnt\"><img style=\"width:525px; height:307px;\" src=\"images/PEDS/53738_CBT_techniques_adolescents2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Liza Bonin, PhD.</div><div id=\"graphicVersion\">Graphic 53738 Version 2.0</div></div></div>"},"53739":{"type":"graphic_table","displayName":"ReSoMal composition","title":"Composition of oral rehydration salts solution for severely malnourished children (ReSoMal)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of oral rehydration salts solution for severely malnourished children (ReSoMal)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Component</td>\n\n      <td class=\"subtitle1\">Concentration, mmol/L</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glucose </td>\n\n      <td>125</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sodium </td>\n\n      <td>45</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Potassium </td>\n\n      <td>40</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Chloride </td>\n\n      <td>70</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Citrate </td>\n\n      <td>7</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Magnesium </td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zinc </td>\n\n      <td>0.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Copper </td>\n\n      <td>0.045</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Osmolarity </td>\n\n      <td>300</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &#169; 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 53739 Version 1.0</div></div></div>"},"53740":{"type":"graphic_table","displayName":"AJCC criteria for histologic grading neuroendocrine neoplasms","title":"AJCC criteria for histologic grading of neuroendocrine neoplasms of the gastrointestinal tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AJCC criteria for histologic grading of neuroendocrine neoplasms of the gastrointestinal tract</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Mitotic count (per 10 HPF)*</td> <td class=\"subtitle1\">Ki-67 index (percent)<sup>&#182;</sup></td> </tr> <tr> <td>G1</td> <td>&#60;2</td> <td>&#8804;2</td> </tr> <tr> <td>G2</td> <td>2 to 20</td> <td>3 to 20</td> </tr> <tr> <td>G3</td> <td>&#62;20</td> <td>&#62;20</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Cellular pleomorphism is not a useful feature for grading carcinoid tumors. High proliferative index has been linked with more aggressive behavior. The above grading scheme has been proposed for neuroendocrine tumors of the gastrointestinal tract.</div><div class=\"graphic_footnotes\">* HPF: high power field; 10 HPF = 2 mm<sup>2</sup>, at least 40 fields (at 400x magnification) evaluated in areas of highest mitotic density.<br />&para; MIB1 antibody; percent of 2000 tumor cells in areas of highest nuclear labeling.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 53740 Version 17.0</div></div></div>"},"53741":{"type":"graphic_table","displayName":"T cell subsets","title":"The T cell subsets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The T cell subsets</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subset</td> <td class=\"subtitle1\">Example cytokines</td> </tr> <tr> <td>CD4+ Th1</td> <td>IL-2, IFy</td> </tr> <tr> <td>CD4+ Th2</td> <td>IL-4, IL-5</td> </tr> <tr> <td>CD4+ Th17</td> <td>IL-17, TNF&#945;</td> </tr> <tr> <td>CD4+CD25+Foxp3 Tregs</td> <td>IL-10, IL-35</td> </tr> <tr> <td>CD8+</td> <td>IFy, TNF&#945;, chemokines</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53741 Version 3.0</div></div></div>"},"53742":{"type":"graphic_picture","displayName":"Hyperkyphosis patient","title":"Hyperkyphosis patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hyperkyphosis patient</div><div class=\"cntnt\"><img style=\"width:301px; height:432px;\" src=\"images/PC/53742_Hyperkyphosis_patient.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Marilyn Spievak Brodwick, University of Galveston, TX.</div><div id=\"graphicVersion\">Graphic 53742 Version 2.0</div></div></div>"},"53746":{"type":"graphic_figure","displayName":"Blood supply of the adrenal glands","title":"Blood supply of the adrenal glands","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Blood supply of the adrenal glands</div><div class=\"cntnt\"><img style=\"width:545px; height:473px;\" src=\"images/SURG/53746_Blood-supply-of-the-adrenal-glands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three main groups of vessels supply the adrenal gland: the superior suprarenal arteries, derived from the inferior phrenic arteries; the middle suprarenal artery, derived from the aorta; and the inferior suprarenal renal arteries, derived from the adjacent renal artery.</div><div id=\"graphicVersion\">Graphic 53746 Version 3.0</div></div></div>"},"53747":{"type":"graphic_figure","displayName":"Muscles of gluteal region and posterior thigh","title":"Muscles of gluteal region and posterior thigh","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Muscles of gluteal region and posterior thigh</div><div class=\"cntnt\"><img style=\"width:600px; height:469px;\" src=\"images/EM/53747_Musclesglutealregion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial and deep dissections of the gluteal region (A) and the posterior compartment of the thigh (B) are demonstrated.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53747 Version 11.0</div></div></div>"},"53749":{"type":"graphic_diagnosticimage","displayName":"Histoplasmosis pericarditis chest x-ray","title":"Immune-mediated pericarditis due to histoplasmosis","html":"<div class=\"graphic normal\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Immune-mediated pericarditis due to histoplasmosis</div><div class=\"cntnt\"><img style=\"width:518px; height:259px;\" src=\"images/ID/53749_Histoplasmosis_pericarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: Chest radiograph from a young woman who presented with pulmonary histoplasmosis as evidenced by right paratracheal lymphadenopathy (arrow). The cardiac size was normal and there were no pleural effusions. Right panel: Two weeks later, she experienced dyspnea and now demonstrated a markedly enlarged cardiac silhouette and bilateral pleural effusions. She exhibited signs of pericardial tamponade and underwent percutaneous drainage of the pericardial fluid. Cultures of pericardial fluid were negative.</div><div class=\"graphic_reference\">Courtesy of Joseph Wheat, MD.</div><div id=\"graphicVersion\">Graphic 53749 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"53750":{"type":"graphic_movie","displayName":"TTE sinus venosus defect","title":"Sinus venosus defect viewed via transthoracic echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus venosus defect viewed via transthoracic echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53750_sinvetteconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:433px; height:325px;\" src=\"images/CARD/53750_sinvette.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVC: superior vena cava.</div><div class=\"graphic_reference\">Courtesy of Dr. Brian Soriano.</div><div id=\"graphicVersion\">Graphic 53750 Version 5.0</div></div></div>"},"53752":{"type":"graphic_figure","displayName":"Water shifts in hemodialysis","title":"Water movement during standard hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Water movement during standard hemodialysis</div><div class=\"cntnt\"><img style=\"width:497px; height:202px;\" src=\"images/NEPH/53752_Water_shifts_in_hemodialysi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of water movement during standard hemodialysis. Plasma at an osmolality of 320 mosmol/kg flows into the dialyzer (step 1), which is perfused with a dialysate having an osmolality of 280 mosmol/kg. Diffusive loss of urea (and other small solutes) lowers the osmolality of the fluid returning to the patient (step 2). The ensuing fall in extracellular osmolality creates an osmotic gradient favoring water movement into the cells. This effect, plus water loss by ultrafiltration across the dialyzer, leads to extracellular volume depletion and may cause hypotension. The rapid fall in plasma osmolality also may play a contributory role, perhaps by interfering with sympathetic responsiveness to volume depletion.</div><div id=\"graphicVersion\">Graphic 53752 Version 2.0</div></div></div>"},"53753":{"type":"graphic_diagnosticimage","displayName":"Echogenic bowel1","title":"Echogenic bowel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echogenic bowel</div><div class=\"cntnt\"><img style=\"width:380px; height:337px;\" src=\"images/OBGYN/53753_Echogenic_bowel1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of pelvis in fetus at 18 weeks gestational age shows echogenic bowel. The bowel is as bright as the iliac wing on the left.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 53753 Version 3.0</div></div></div>"},"53754":{"type":"graphic_table","displayName":"Outcome ART v natural conceived","title":"Comparison of selected pregnancy outcomes after ART and natural conception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of selected pregnancy outcomes after ART and natural conception</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Outcome</td>\n\n      <td class=\"subtitle1\">ART, mean percent</td>\n\n      \n\n      <td class=\"subtitle1\">Natural conceptions, mean percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Congenital anomalies [1]</td>\n\n      <td>9</td>\n\n      \n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spontaneous preterm birth before 37 weeks [2,3]</td>\n\n      <td>11 to 12</td>\n\n      \n\n      <td>5 to 6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spontaneous preterm birth before 32 to 33 weeks [2,3]</td>\n\n      <td>2 to 3</td>\n\n      \n\n      <td>0.7 to 1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Low birth weight (&#60;2500 g) [2,3]</td>\n\n      <td>10 to 11</td>\n\n      \n\n      <td>4 to 6</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Very low birthweight (&#60;1500 g) [2,3]</td>\n\n      <td>2.5</td>\n\n      \n\n      <td>1</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">ART: assisted reproductive technology.</div><div class=\"graphic_reference\">Data from studies matching for maternal age and parity<br> 1. Hansen, M, Kurinczuk, JJ, Bower, C, Webb, S. N Engl J Med 2002; 346:725.<br> 2. Helmerhorst, FM, Perquin, DA, Donker, D, Keirse, MJ. BMJ 2004; 328:261.<br> 3. Jackson, RA, Gibson, KA, Wu, YW, Croughan, MS. Obstet Gynecol 2004; 103:551.</div><div id=\"graphicVersion\">Graphic 53754 Version 1.0</div></div></div>"},"53755":{"type":"graphic_figure","displayName":"Cephalosporin side chains: Common moieties","title":"R1 side chains and side chain groups that are shared among cephalosporins","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">R1 side chains and side chain groups that are shared among cephalosporins</div><div class=\"cntnt\"><img style=\"width:722px; height:914px;\" src=\"images/ALLRG/53755_Ceph_sid_chns_Cmmn_moeities.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several cephalosporins share the same moieties at the R1 side chain position (shown in the boxes). The more similar the R1 side chains, the more likely it is that a patient allergic to one will also react to another. Specifically, ceftriaxone, cefuroxime, cefotaxime, and cefepime each have a methoxyimino group (circled) within the R<SUB><SUP>1</SUP></SUB> side chain, and cross-reactivity is observed in patients allergic to these agents. In contrast, ceftazidime has a different structure in the R1 position, and cross-reactivity with the other agents is not frequently observed.</div><div class=\"graphic_reference\">Courtesy of Antonino Romano, MD.</div><div id=\"graphicVersion\">Graphic 53755 Version 9.0</div></div></div>"},"53757":{"type":"graphic_figure","displayName":"Fractionated photothermolysis","title":"Fractionated photothermolysis","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Fractionated photothermolysis</div><div class=\"cntnt\"><img style=\"width:485px; height:382px;\" src=\"images/DERM/53757_Fractionated-photothermolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fractional photothermolysis involves the delivery of narrow columns of infrared light to the target tissue. In skin, this leads to microscopic columns of thermally damaged tissue (microthermal zones).</div><div id=\"graphicVersion\">Graphic 53757 Version 3.0</div></div></div>"},"53758":{"type":"graphic_table","displayName":"Thymic carcinoids: Survival according to stage (SEER database)","title":"Survival according to stage for 160 thymic carcinoids reported to the SEER database","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival according to stage for 160 thymic carcinoids reported to the SEER database</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">SEER stage</td> <td class=\"subtitle1\" colspan=\"3\">Survival rates</td> </tr> <tr> <td class=\"subtitle2\">One year</td> <td class=\"subtitle2\">Three year</td> <td class=\"subtitle2\">Five year</td> </tr> <tr> <td>Localized</td> <td>97 percent</td> <td>91 percent</td> <td>80 percent</td> </tr> <tr> <td>Regional</td> <td>88 percent</td> <td>64 percent</td> <td>48 percent</td> </tr> <tr> <td>Distant</td> <td>81 percent</td> <td>48 percent</td> <td>31 percent</td> </tr> <tr> <td>Overall</td> <td>89 percent</td> <td>66 percent</td> <td>53 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SEER: Surveillance, Epidemiology and End Results database of the United States National Cancer Institute.</div><div class=\"graphic_reference\">Reproduced with permission from: Gaur P, Leary C, Yao JC. Thymic Neuroendocrine Tumors. A SEER database analysis of 160 patients. Ann Surg 2010; 251:1117. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53758 Version 6.0</div></div></div>"},"53759":{"type":"graphic_picture","displayName":"DLBCL BCL-6 staining","title":"Diffuse large B-cell lymphoma BCL-6 staining","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diffuse large B-cell lymphoma BCL-6 staining</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/HEME/53759_DLBCLBCL6staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse large B-cell lymphoma, centroblast variant, with nuclear BCL-6 staining of numerous cells. BCL-6/peroxidase stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Diffuse large B-cell lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53759 Version 6.0</div></div></div>"},"53760":{"type":"graphic_diagnosticimage","displayName":"Complete fracture radius","title":"Complete fracture radius","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete fracture radius</div><div class=\"cntnt\"><img style=\"width:331px; height:525px;\" src=\"images/EM/53760_Complete_fx_radius.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nondisplaced slightly angulated complete fracture of distal radius with normal ulna in 9-year-old. Treated with short arm cast without reduction.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 53760 Version 2.0</div></div></div>"},"53761":{"type":"graphic_diagnosticimage","displayName":"Fetal pericardial effusion","title":"Pericardial effusion in a fetus with congenital heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion in a fetus with congenital heart disease</div><div class=\"cntnt\"><img style=\"width:357px; height:244px;\" src=\"images/OBGYN/53761_Fetal_pericardial_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fetal pericardial effusion. Arrows point to fluid within the pericardial sac. Arrowheads point to the thickened myocardial tissue.</div><div class=\"graphic_reference\">Courtesy of Svena Julien, MD and Charles Lockwood, MD.</div><div id=\"graphicVersion\">Graphic 53761 Version 3.0</div></div></div>"},"53763":{"type":"graphic_table","displayName":"Indications for delivery in preeclampsia PI","title":"Indications for delivery in preeclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for delivery in preeclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8805;37 weeks of pregnancy</td> </tr> <tr> <td>Platelets &#60;100,000/microL (based on blood test)</td> </tr> <tr> <td>Abnormal liver or kidney function</td> </tr> <tr> <td>Placental abruption (when the placenta separates from the uterus)</td> </tr> <tr> <td>Persistent headache or changes in vision</td> </tr> <tr> <td>Persistent severe upper abdominal pain</td> </tr> <tr> <td>Problems with the fetus, such as growth restriction, reduced blood flow through the umbilical cord, or a decrease in amniotic fluid</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53763 Version 4.0</div></div></div>"},"53764":{"type":"graphic_picture","displayName":"Megalocornea","title":"Megalocornea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Megalocornea</div><div class=\"cntnt\"><img style=\"width:432px; height:296px;\" src=\"images/PEDS/53764_Megalocornea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Notice the corneal clarity as revealed by the red reflex. The ruler on the forehead allows the corneal diameter to be measured without an examination under anesthesia.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53764 Version 1.0</div></div></div>"},"53765":{"type":"graphic_figure","displayName":"Tibiofemoral progression","title":"Progression of the tiobiofemoral angle* with age","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progression of the tiobiofemoral angle* with age</div><div class=\"cntnt\"><img style=\"width:312px; height:278px;\" src=\"images/PEDS/53765_Tibio-femoral_progression.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The results are based on 1480 measurements (clinical or radiographic) of the tibiofemoral angle of children at different ages. The standard deviation was ±8°.</div><div class=\"graphic_footnotes\">* The tibiofemoral angle is the angle between the long axis of the femur and the long axis of the tibia. It can be measured clinically with a goniometer or radiographically. Positive values indicate varus angulation, and negative values indicate valgus angulation.</div><div class=\"graphic_reference\">Data from: Salenius P, Vankka E. The development of the tibiofemoral angle in children. J Bone Joint Surg Am 1975; 57:259.</div><div id=\"graphicVersion\">Graphic 53765 Version 2.0</div></div></div>"},"53766":{"type":"graphic_table","displayName":"Therapeutic plan for fibromyalgia or CFS, also known as SEID","title":"Therapeutic plan for fibromyalgia or chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Therapeutic plan for fibromyalgia or chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Step one: Patient and family education</td> </tr> <tr> <td>Validate the diagnosis</td> </tr> <tr> <td>Educate about prognosis, pathophysiology, treatment principles</td> </tr> <tr> <td class=\"subtitle1_single\">Step two: Medication trial</td> </tr> <tr> <td>Tricyclic antidepressant or similar medications: low dose at bedtime</td> </tr> <tr> <td>If no response, consider adding a serotonin-receptor inhibitor in the morning</td> </tr> <tr> <td>If repetitive limb movement is suspected, trial with low-dose benzodiazepine at bedtime</td> </tr> <tr> <td>Analgesics, NSAIDs may be useful to decrease pain</td> </tr> <tr> <td class=\"subtitle1_single\">Step three: Nonmedicinal treatment</td> </tr> <tr> <td>Physical therapy, massage, myofascial release</td> </tr> <tr> <td>Cardiovascular fitness training</td> </tr> <tr> <td>Trigger point or tender point injections</td> </tr> <tr> <td>Cognitive behavioral therapy</td> </tr> <tr> <td class=\"subtitle1_single\">Step four: Specialized evaluation</td> </tr> <tr> <td>Sleep center, if suspect sleep apnea or nocturnal myoclonus</td> </tr> <tr> <td>Mental health professional, if suspect major depression or panic disorder</td> </tr> <tr> <td>Pain or rehabilitation clinic</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NSAIDs: nonsteroidal antiinflammatory drugs.</div><div id=\"graphicVersion\">Graphic 53766 Version 5.0</div></div></div>"},"53767":{"type":"graphic_picture","displayName":"Chronic osteomyelitis light microscopy","title":"Chronic osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic osteomyelitis</div><div class=\"cntnt\"><img style=\"width:314px; height:222px;\" src=\"images/ID/53767_Chronic_osteomyelitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of chronic osteomyelitis of the tibia. Against a background of inflammatory cells (blue arrow), there are thickened bony trabeculae (white arrow) lined by plump osteoblasts, which are actively forming bone. The accumulation of small dark cells (lymphocytes; black arrows) represent sites of perivascular inflammation.</div><div class=\"graphic_reference\">Courtesy of Jon Mader, MD.</div><div id=\"graphicVersion\">Graphic 53767 Version 3.0</div></div></div>"},"53770":{"type":"graphic_figure","displayName":"Temperature after IL-1 antagonist","title":"Temperature readings in a patient receiving the interleukin-1 receptor antagonist, anakinra","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Temperature readings in a patient receiving the interleukin-1 receptor antagonist, anakinra</div><div class=\"cntnt\"><img style=\"width:427px; height:428px;\" src=\"images/ID/53770_Temperature_readings.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings of oral temperature are shown for the specified day intervals shown. Arrow indicates the first injection of anakinra (100 mg).</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzgerald AA, LeClercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52:1794. Copyright © 2005 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 53770 Version 3.0</div></div></div>"},"53771":{"type":"graphic_figure","displayName":"ACEI vs other drugs in DM rats","title":"ACE inhibitor is more effective than triple therapy in protecting against experimental diabetic nephropathy","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor is more effective than triple therapy in protecting against experimental diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:466px; height:225px;\" src=\"images/NEPH/53771_ACEI_vs_other_drugs_in_DM_r.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Efficacy of antihypertensive therapy in diabetic rats in reducing the number of sclerotic glomeruli at 70 weeks. Triple therapy with hydrochlorothiazide, hydralazine, and reserpine was partially protective, but captopril was completely protective, with the degree of glomerulosclerosis being less than that in control (normal) rats (left column). Captopril also normalized the intraglomerular pressure (46 mmHg) versus 64 mmHg in untreated diabetic animals and 56 mmHg with triple therapy.</div><div class=\"graphic_reference\">Data from Anderson S, Rennke HG, Garcia DL, et al. Kidney Int 1989; 36:526.</div><div id=\"graphicVersion\">Graphic 53771 Version 2.0</div></div></div>"},"53773":{"type":"graphic_figure","displayName":"Accessory AV pathways II","title":"AV conduction through an overt accessory pathway","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AV conduction through an overt accessory pathway</div><div class=\"cntnt\"><img style=\"width:425px; height:291px;\" src=\"images/CARD/53773_Accessory_AV_pathway_II_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Compared&nbsp;with normal conduction in the preceding diagram, the accessory pathway (AP) is now overt. As a result, ventricular activation results from both early activation (preexcitation) of the free wall of the left ventricle (shown in blue) and from normal activation (shown in yellow). The degree of unopposed preexcitation depends upon the time required to conduct through the right and left atria, the AP, and the ventricular myocardium as compared&nbsp;with conduction through the normal pathways. The inset on the right shows the ECG timing of these events. The net effect is a QRS complex that is a fusion of ventricular preexcitation (blue) and normal excitation (yellow). Early activation throughout the AP (V<SUB>P</SUB>) occurs at about the same time as His bundle depolarization (H). This leads to a shorter PR interval, a small delta wave (arrow), and some prolongation of the QRS duration.</div><div id=\"graphicVersion\">Graphic 53773 Version 5.0</div></div></div>"},"53774":{"type":"graphic_picture","displayName":"Pseudomembranous colitis scope","title":"Pseudomembranous colitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous colitis</div><div class=\"cntnt\"><img style=\"width:437px; height:216px;\" src=\"images/GAST/53774_Pseudomembranous_colitis_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of <EM>Clostridium difficile</EM>-induced pseudomembranous colitis. Left panel: Scattered pseudomembranes are visible on top of the mucosa, being separated by areas of relatively normal mucosa. Some of the lesions have a red halo (arrows). Right panel: Yellow pseudomembrane circumferentially covering the entire colonic mucosa.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 53774 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal sigmoid colon</div><div class=\"cntnt\"><img style=\"width:216px; height:216px;\" src=\"images/GAST/55563_Normal_sigmoid_colon_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 55563 Version 1.0</div></div></div>"},"53775":{"type":"graphic_table","displayName":"Confirmed autoimmune thyroid disease-associated genes","title":"Confirmed autoimmune thyroid disease-associated genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Confirmed autoimmune thyroid disease-associated genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Gene symbol</td> <td class=\"subtitle1\">Gene name</td> <td class=\"subtitle1\">Chromosome location</td> <td class=\"subtitle1\">Odds ratio</td> </tr> <tr> <td>HLA</td> <td>Major histocompatibility complex</td> <td>6p21</td> <td>2.0-4.0</td> </tr> <tr> <td>CTLA4</td> <td>Cytotoxic T-lymphocyte-associated protein 4</td> <td>2q33</td> <td>1.5-2.2</td> </tr> <tr> <td>PTPN22</td> <td>Protein tyrosine phosphatase, non-receptor type 22 (lymphoid)</td> <td>1p13</td> <td>1.4-1.9</td> </tr> <tr> <td>CD40</td> <td>CD40 molecule, TNF receptor superfamily member 5</td> <td>20q11</td> <td>1.3-1.8</td> </tr> <tr> <td>IL2RA (CD25)</td> <td>Interleukin 2 receptor, alpha</td> <td>10p15</td> <td>1.1-1.4</td> </tr> <tr> <td>FCRL3</td> <td>Fc receptor-like 3</td> <td>1q23</td> <td>1.1-1.3</td> </tr> <tr> <td>TG</td> <td>Thyroglobulin</td> <td>8q24</td> <td>2.0-2.5</td> </tr> <tr> <td>TSHR</td> <td>Thyroid-stimulating hormone receptor</td> <td>14q31</td> <td>1.4-2.6</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53775 Version 2.0</div></div></div>"},"53776":{"type":"graphic_picture","displayName":"Acanthosis nigricans","title":"Acanthosis nigricans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acanthosis nigricans</div><div class=\"cntnt\"><img style=\"width:162px; height:283px;\" src=\"images/ENDO/53776_Crop_Acanthosis_Nigrican.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic hyperpigmented axillary lesion in acanthosis nigricans.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Flier, MD.</div><div id=\"graphicVersion\">Graphic 53776 Version 3.0</div></div></div>"},"53777":{"type":"graphic_table","displayName":"Comorbidities and medications affecting recognition","title":"Anaphylaxis: Comorbidities and concurrent medications that might interfere with recognition of triggers or symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anaphylaxis: Comorbidities and concurrent medications that might interfere with recognition of triggers or symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Comorbidities</td> </tr> <tr> <td class=\"indent1\">Impairment of vision or hearing</td> </tr> <tr> <td class=\"indent1\">Neurologic disease</td> </tr> <tr> <td class=\"indent1\">Psychiatric illness (eg, depression, ADHD, autism spectrum disorder, cognitive disorder, substance abuse)</td> </tr> <tr> <td class=\"subtitle1_single\">Concurrently administered medications</td> </tr> <tr> <td class=\"indent1\">Sedatives (eg, impairing sedating H1 antihistamines)</td> </tr> <tr> <td class=\"indent1\">Hypnotics</td> </tr> <tr> <td class=\"indent1\">Ethanol</td> </tr> <tr> <td class=\"indent1\">Recreational drugs</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: attention deficit hyperactivity disorder.</div><div class=\"graphic_reference\">Modified with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright &copy; 2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 53777 Version 14.0</div></div></div>"},"53778":{"type":"graphic_picture","displayName":"Typical facial features","title":"Typical facial features in a patient with hyperimmunoglobulin E syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical facial features in a patient with hyperimmunoglobulin E syndrome</div><div class=\"cntnt\"><img style=\"width:403px; height:343px;\" src=\"images/ALLRG/53778_Typical_facial_features.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53778 Version 3.0</div></div></div>"},"53780":{"type":"graphic_picture","displayName":"Duplication cyst Endosc","title":"Duplication cyst in the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duplication cyst in the esophagus</div><div class=\"cntnt\"><img style=\"width:320px; height:319px;\" src=\"images/GAST/53780_Duplication_cyst_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of esophageal compression (arrow) due to a duplication cyst.</div><div class=\"graphic_reference\">Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.</div><div id=\"graphicVersion\">Graphic 53780 Version 2.0</div></div></div>"},"53781":{"type":"graphic_table","displayName":"Causes hypocalcemia children","title":"Causes of hypocalcemia in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypocalcemia in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low PTH&nbsp;(hypoparathyroidism)</td> </tr> <tr> <td class=\"sublist1_start\">Impaired&nbsp;synthesis or secretion of PTH</td> </tr> <tr> <td class=\"sublist1\">Genetic</td> </tr> <tr> <td class=\"sublist2\">DiGeorge Syndrome&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Genetic mutations interfering with the production of PTH (autosomal dominant, autosomal recessive)</td> </tr> <tr> <td class=\"sublist2\">HDR Syndrome (hypoparathyroidism, deafness, renal anomaly)</td> </tr> <tr> <td class=\"sublist2\">Sanjad-Sakati or Kenny-Caffey syndromes</td> </tr> <tr> <td class=\"sublist2\">Mutations of the calcium-sensing receptor (CaSR) and related proteins&nbsp;(autosomal dominant hypocalcemia)&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Mutations interfering with parathyroid gland development (X-linked)&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Mitochondrial disorders (eg, MELAS Syndrome, Kearns Sayre syndrome, mitochondrial trifunctional protein deficiency)</td> </tr> <tr> <td class=\"sublist1\">Autoimmune</td> </tr> <tr> <td class=\"sublist2\">Autoimmune polyglandular syndrome type 1 (APS1)</td> </tr> <tr> <td class=\"sublist1\">Other</td> </tr> <tr> <td class=\"sublist2\">Parathyroid or thyroid gland surgery</td> </tr> <tr> <td class=\"sublist2\">Infiltration of parathyroid gland (eg, iron overload)</td> </tr> <tr> <td class=\"subtitle1_single\">High PTH</td> </tr> <tr> <td class=\"sublist1_start\">Hypovitaminosis D (impaired vitamin D intake or synthesis)</td> </tr> <tr> <td class=\"sublist1\">Insufficient dietary intake and/or sun exposure</td> </tr> <tr> <td class=\"sublist1\">Decreased gastrointestinal absorption</td> </tr> <tr> <td class=\"sublist1\">Defects in vitamin D metabolism or action&nbsp;</td> </tr> <tr> <td class=\"sublist2\">Liver disease (including some drugs&nbsp;that increase cytochrome P-450 activity, which&nbsp;accelerate&nbsp;catabolism of vitamin D to inactive metabolites, eg, anticonvulsants, isoniazid, and rifampin).&nbsp; </td> </tr> <tr> <td class=\"sublist2\">Renal disease</td> </tr> <tr> <td class=\"sublist2\">25-hydroxylase deficiency&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Vitamin D \"dependent\" rickets&nbsp;</td> </tr> <tr> <td class=\"sublist1\">1-alpha hydroxylase deficiency&nbsp;(previously known as vitamin D-dependent rickets type 1 or pseudo-vitamin D deficient rickets)</td> </tr> <tr> <td class=\"sublist1\">Hereditary resistance to&nbsp;vitamin D&nbsp;(previously known as vitamin D-dependent rickets type 2)&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Pseudohypoparathyroidism (end-organ resistance to PTH)&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist1\">&nbsp;Type 1 (1a, 1b, and 1c)</td> </tr> <tr> <td class=\"sublist1\">&nbsp;Type 2</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td>Hungry bone syndrome</td> </tr> <tr> <td>Osteopetrosis&nbsp;</td> </tr> <tr> <td>Sepsis or acute severe illness&nbsp;</td> </tr> <tr> <td>Hyperphosphatemia&nbsp;</td> </tr> <tr> <td>Alkalosis&nbsp;</td> </tr> <tr> <td>Intravenous products with citrate or lactate&nbsp;</td> </tr> <tr> <td>Pancreatitis&nbsp;</td> </tr> <tr> <td>Fluoride poisoning</td> </tr> <tr> <td>Drugs &#8212; Bisphosphonates, denosumab, calcimimetics (cinacalcet), foscarnet, and some chemotherapeutic drugs.</td> </tr> <tr> <td>Hypomagnesemia&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTH: parathyroid hormone; HDR: hypoparathyroidism, deafness, renal anomaly; MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; CaSR: calcium-sensing receptor.</div><div id=\"graphicVersion\">Graphic 53781 Version 5.0</div></div></div>"},"53784":{"type":"graphic_diagnosticimage","displayName":"Bronchogenic carcinoma CT II","title":"Peripheral bronchogenic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral bronchogenic carcinoma</div><div class=\"cntnt\"><img style=\"width:270px; height:239px;\" src=\"images/PULM/53784_Bronchogenic_carcinoma_CT1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral bronchogenic carcinoma in left upper lobe, invading the chest wall (arrow). CT shows infiltration of the left pectoralis muscle and tumor extension into the deep axillary subcutaneous fat. The findings are consistent with a T3 lesion.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 53784 Version 3.0</div></div></div>"},"53785":{"type":"graphic_figure","displayName":"Superficial veins of neck","title":"Superficial veins of the neck","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Superficial veins of the neck</div><div class=\"cntnt\"><img style=\"width:501px; height:376px;\" src=\"images/EM/53785_Superficialveinsofneck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The superficial temporal and maxillary veins merge, forming the retromandibular vein, the posterior division of which unites with the posterior auricular vein to form the external jugular vein. The facial vein receives the anterior division of the retromandibular vein before emptying into the internal jugular vein, deep to the sternocleidomastoid muscle. The anterior jugular veins may lie superficial or deep to the investing layer of the deep cervical fascia.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53785 Version 10.0</div></div></div>"},"53786":{"type":"graphic_table","displayName":"Bone penetration for selected antibiotics","title":"Bone penetration for selected antibiotics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bone penetration for selected antibiotics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antibiotic</td> <td class=\"subtitle1\">Range of mean bone to serum concentration ratios</td> </tr> <tr> <td>Levofloxacin</td> <td>0.36 to 1.0</td> </tr> <tr> <td>Ciprofloxacin</td> <td>0.27 to 1.2</td> </tr> <tr> <td>Moxifloxacin</td> <td>0.33 to 1.05</td> </tr> <tr> <td>Vancomycin</td> <td>0.05 to 0.67</td> </tr> <tr> <td>Linezolid</td> <td>0.2 to 0.51</td> </tr> <tr> <td>Daptomycin</td> <td>1.17*</td> </tr> <tr> <td>Clindamycin</td> <td>0.21 to 0.45</td> </tr> <tr> <td>Cefazolin</td> <td>0.179</td> </tr> <tr> <td>Ceftriaxone</td> <td>0.07 to 0.17</td> </tr> <tr> <td>Cefuroxime</td> <td>0.04 to 0.55</td> </tr> <tr> <td>Rifampin (rifampicin)</td> <td>0.08 to 0.57</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Numerous factors account for a wide range of bone to serum concentration ratios reported, including variation in timing/technique of sampling, analytical method, and condition of bone.</div><div class=\"graphic_footnotes\">* Data are limited to a case series of nine diabetic patients with foot infection and osteomyelitis.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48:89. </li> <li>von Baum H, Böttcher S, Abel R, et al. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001; 18:335. </li> <li>Garazzino S, Aprato, A, Baietto, L, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008; 47:793. </li> <li>Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65:1252. </li> </ol></div><div id=\"graphicVersion\">Graphic 53786 Version 3.0</div></div></div>"},"53787":{"type":"graphic_picture","displayName":"Partial mole histo","title":"Partial hydatidiform mole histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Partial hydatidiform mole histology</div><div class=\"cntnt\"><img style=\"width:432px; height:302px;\" src=\"images/OBGYN/53787_Partial_mole_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Partial hydatidiform mole. Two populations of chorionic villi are evident; some are normal, whereas others are conspicuously swollen. Trophoblastic proliferation is focal and less conspicuous than in a complete mole.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53787 Version 1.0</div></div></div>"},"53789":{"type":"graphic_table","displayName":"Benef chemo SB adenoCA","title":"Retrospective reviews suggesting benefit for palliative chemotherapy in small bowel adenocarcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Retrospective reviews suggesting benefit for palliative chemotherapy in small bowel adenocarcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author, year</td> <td class=\"subtitle1\" rowspan=\"2\">Disease status</td> <td class=\"subtitle1\" colspan=\"3\">Number of patients</td> <td class=\"subtitle1\" rowspan=\"2\">Chemotherapy</td> <td class=\"subtitle1\" rowspan=\"2\">RR, percent</td> <td class=\"subtitle1\" colspan=\"2\">Median OS, months</td> </tr> <tr> <td class=\"subtitle2\">Total</td> <td class=\"subtitle2\">Chemo</td> <td class=\"subtitle2\">No chemo</td> <td class=\"subtitle2\">Chemotherapy</td> <td class=\"subtitle2\">No chemotherapy</td> </tr> <tr> <td>Halfdanarson T; 2010</td> <td>IV</td> <td>163</td> <td>NR</td> <td>NR</td> <td>Various agents</td> <td>NR</td> <td>15.5</td> <td>3.3</td> </tr> <tr> <td>Fishman P; 2006</td> <td>Metastatic, LAD</td> <td>113</td> <td>44</td> <td>69</td> <td>Various agents</td> <td>29</td> <td>18.6</td> <td>13.4</td> </tr> <tr> <td>Czaykowski P; 2007</td> <td>Metastatic, LAD</td> <td>37</td> <td>16</td> <td>21</td> <td>5-FU based</td> <td>5</td> <td>15.6</td> <td>7.7</td> </tr> <tr> <td>Dabaja B; 2004</td> <td>Metastatic</td> <td>49</td> <td>34</td> <td>15</td> <td>NR</td> <td>NR</td> <td>12</td> <td>2</td> </tr> <tr> <td>Ouriel K; 1984</td> <td>Metastatic</td> <td>14</td> <td>6</td> <td>8</td> <td>5-FU based</td> <td>NR</td> <td>10.7</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported; 5-FU: 5-fluorouracil; LAD: locally advanced, unresectable, disease; RR: response rate; OS: overall survival.</div><div id=\"graphicVersion\">Graphic 53789 Version 4.0</div></div></div>"},"53790":{"type":"graphic_picture","displayName":"Histol melanoma in situ lentigo","title":"Malignant melanoma in situ, lentigo maligna type","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malignant melanoma in situ, lentigo maligna type</div><div class=\"cntnt\"><img style=\"width:360px; height:264px;\" src=\"images/ONC/53790_Histol_melanoma_in_situ_len.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power light photomicrograph of a lentigo maligna melanoma in situ, in which there is epidermal atrophy associated with replacement of the basal layer of epidermis with melanoma cells, the so-called pattern of lentiginous spread. Lentigo usually arises in chronically sun-damaged skin.</div><div class=\"graphic_reference\">Courtesy of Roy King, MD.</div><div id=\"graphicVersion\">Graphic 53790 Version 2.0</div></div></div>"},"53792":{"type":"graphic_table","displayName":"Breast self-exam PI","title":"How to do a breast self-exam","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How to do a breast self-exam</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"> <p>We do not recommend that women perform breast self-exam. However, for women who feel comfortable examining their breasts and wish to continue doing this, proper technique is important. </p> <p>The best time to do a breast self-exam is a week after your period ends. If you no longer get monthly periods, you can do the exam any time. </p> </td> </tr> <tr> <td> <ul> <li>Start by standing in front of a mirror. Place both hands at your sides. Check your breasts for changes in skin color or texture, and check for dents. Note how your nipples look. Some women have inverted nipples, meaning that their nipples point inward instead of out. This is normal as long as the way they look does not change over time. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lift your hands over your head and turn to the side. Then look at each whole breast in the mirror. If you need to, lift each breast so you can see the skin under the breast. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lie down and put your left hand above your head (this flattens the breast and makes it easier to examine). Use your right hand to examine your left breast, starting in the upper breast near the arm pit and going up and down across the breast (like mowing a lawn). Begin to examine the breast by making small circles with your three middle fingers. Use your finger pads at the end of your fingers but not the tips, and move your fingers in circles as if you were tracing the edge of a dime. At each spot on the breast, make three circles: one very light, one a bit firmer into the breast, and one deep in the breast. Then switch hands and do the same thing on the other breast. </li> </ul> </td> </tr> <tr> <td> <ul> <li>It is normal to feel your ribs in your chest. Abnormal lumps tend to feel firm, have irregular edges, and sometimes feel like they are \"stuck\" to your chest. If you don't know whether a lump is normal or abnormal, see your doctor or nurse. </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53792 Version 10.0</div></div></div>"},"53793":{"type":"graphic_diagnosticimage","displayName":"Intravenous pyelogram in medullary sponge kidney","title":"Intravenous pyelogram in medullary sponge kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravenous pyelogram in medullary sponge kidney</div><div class=\"cntnt\"><img style=\"width:378px; height:257px;\" src=\"images/NEPH/53793_IVP_in_medullary_sponge_kid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intravenous pyelogram with tomography in medullary sponge kidney. All of the calyces are abnormal (seen best in the left kidney), showing a brushlike appearance radiating outward from the calyces (arrows).</div><div class=\"graphic_reference\">From Rose, BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.</div><div id=\"graphicVersion\">Graphic 53793 Version 3.0</div></div></div>"},"53795":{"type":"graphic_picture","displayName":"Rhabdomyoma fetal","title":"Small cardiac rhabdomyomas in a 36 week autolyzed and hydropic stillbirth","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small cardiac rhabdomyomas in a 36 week autolyzed and hydropic stillbirth</div><div class=\"cntnt\"><img style=\"width:396px; height:314px;\" src=\"images/OBGYN/53795_Rhabdomyoma_fetal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Death presumably due to conduction anomalies from the multiple cardiac rhabdomyomata. These are very often associated with tuberous sclerosis and may be the only feature of this disease in the fetus. It necessitates familial genetic counseling when found.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 53795 Version 2.0</div></div></div>"},"53796":{"type":"graphic_picture","displayName":"Normal optic disc","title":"The normal optic disc","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The normal optic disc</div><div class=\"cntnt\"><img style=\"width:277px; height:367px;\" src=\"images/PEDS/53796_Normal_optic_disc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The margins are distinct, the rim has a pinkish color, and there is a central pale cup (arrows). This optic disc has a cup:disc ratio of 0.2.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 53796 Version 1.0</div></div></div>"},"53797":{"type":"graphic_table","displayName":"Pulmonary index score","title":"Pulmonary Index Score (PIS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary Index Score (PIS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Score</td> <td class=\"subtitle1\" colspan=\"2\">Respiratory rate</td> <td class=\"subtitle1\" rowspan=\"2\">Wheezing</td> <td class=\"subtitle1\" rowspan=\"2\">Inspiratory/expiratory ratio</td> <td class=\"subtitle1\" rowspan=\"2\">Accessory muscle use</td> <td class=\"subtitle1\" rowspan=\"2\">Oxygen saturation</td> </tr> <tr> <td class=\"subtitle2\">&#60;6 years old</td> <td class=\"subtitle2\">&#8805;6 years old</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">&#8804;30</td> <td class=\"centered\">&#8804;20</td> <td class=\"centered\">None*</td> <td class=\"centered\">2:1</td> <td class=\"centered\">None</td> <td class=\"centered\">99 to 100</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">31 to 45</td> <td class=\"centered\">21 to 35</td> <td class=\"centered\">End expiration</td> <td class=\"centered\">1:1</td> <td class=\"centered\">+</td> <td class=\"centered\">96 to 98</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">46 to 60</td> <td class=\"centered\">36 to 50</td> <td class=\"centered\">Entire expiration</td> <td class=\"centered\">1:2</td> <td class=\"centered\">++</td> <td class=\"centered\">93 to 95</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">&#62;60</td> <td class=\"centered\">&#62;50</td> <td class=\"centered\">Inspiration and expiration</td> <td class=\"centered\">1:3</td> <td class=\"centered\">+++</td> <td class=\"centered\">&#60;93</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The total score ranges from 0 to 15. In general, a score of less than 7 indicates a mild attack, a score of 7 to 11 indicates a moderately severe attack, and a score of 12 or greater indicates a severe attack. However, the PIS may underestimate the degree of illness in an older child. Older children, with prolonged expiratory phases, may become bradypneic with a moderate to severe attack. As such, their score for respiratory rate may be falsely reassuring.</div><div class=\"graphic_footnotes\">*&nbsp;If no wheezing due to minimal air entry, score 3.</div><div class=\"graphic_reference\">Courtesy of Richard Scarfone, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 53797 Version 10.0</div></div></div>"},"53799":{"type":"graphic_diagnosticimage","displayName":"Ruptured thoracic aortic aneurysm on chest film","title":"Ruptured thoracic aortic aneurysm on chest film","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ruptured thoracic aortic aneurysm on chest film</div><div class=\"cntnt\"><img style=\"width:292px; height:349px;\" src=\"images/CARD/53799_Thoracic_aortic_rupture_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph of the chest demonstrates a large aneurysm of the descending aorta (arrow). The large left pleural effusion (arrowheads) is a result of rupture of the aneurysm.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 53799 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"53801":{"type":"graphic_figure","displayName":"Oxygen sensor model","title":"Oxygen sensor model","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Oxygen sensor model</div><div class=\"cntnt\"><img style=\"width:512px; height:349px;\" src=\"images/HEME/53801_Oxygen_sensor_model.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing a proposed model for the oxygen sensor mechanism of erythropoiesis. Under hypoxic conditions (upper left), both the alpha and beta subunits of HIF are stabilized, leading to subsequent erythropoietin (Epo) gene transcription via the aggregate effects of hepatic nuclear factor (HNF)-4, p300, and HIF-alpha and -beta. The Epo, once formed, binds to Epo receptors on committed erythroid precursor cells. Under normoxic conditions (upper middle), only the beta unit of HIF is fully expressed. The alpha unit undergoes proline hydroxylation (PH) in the presence of iron and oxygen. When hydroxylated HIF-alpha binds to the Von Hippel-Lindau protein (VHL), a ubiquitin ligase complex (UL) is activated, leading to ubiquitination and subsequent degradation of HIF-alpha via the proteasome, preventing the subsequent transcription of Epo. Mutations affecting proteins along this pathway have been associated with congenital erythrocytosis.</div><div class=\"graphic_footnotes\">EpoR: erythropoietin receptor; SF: steel factor; IL-3R: interleukin-3 receptor; BFU-E: erythroid blast-forming units; CFU-E: erythroid colony-forming units.</div><div id=\"graphicVersion\">Graphic 53801 Version 5.0</div></div></div>"},"53802":{"type":"graphic_table","displayName":"Differential Kawasaki disease","title":"Differential diagnosis of Kawasaki disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of Kawasaki disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Kawasaki disease</td> <td class=\"subtitle1\">Toxic shock syndrome</td> <td class=\"subtitle1\">Streptococcal scarlet fever</td> <td class=\"subtitle1\">Stevens-Johnson syndrome</td> <td class=\"subtitle1\">Systemic-onset JIA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age (years)</strong></td> <td>Usually &#60;5</td> <td>Usually &#62;10</td> <td>Usually&nbsp;2 to 8</td> <td>All ages</td> <td>2&nbsp;to 5</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fever</strong></td> <td>Persistent</td> <td>Usually &#60;10 days</td> <td>Variable, usually &#60;10 days</td> <td>Prolonged</td> <td>Prolonged</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Eyes</strong></td> <td>Nonexudative conjunctivitis, limbal sparing, anterior uveitis</td> <td>Conjunctivitis</td> <td>Normal</td> <td>Exudative conjunctivitis, keratitis</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oral mucosa</strong></td> <td>Diffuse erythema, \"strawberry tongue\"</td> <td>Erythematous</td> <td>Pharyngitis, \"strawberry tongue\"</td> <td>Erythema, ulceration, pseudomembrane formation</td> <td>Normal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Peripheral extremities</strong></td> <td>Erythema of palms and soles, indurative edema, periungual desquamation</td> <td>Swelling of hands and feet</td> <td>Flaky desquamation</td> <td>Normal</td> <td>Arthritis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rash</strong></td> <td>Erythematous polymorphous; targetoid or purpuric in 20%</td> <td>Erythroderma</td> <td>Papular erythroderma Pastia's lines, circumoral palor</td> <td>Target lesions</td> <td>Transient, salmon, pink</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cervical lymph nodes</strong></td> <td>Nonpurulent swelling</td> <td>Normal</td> <td>Painful swelling</td> <td>Normal</td> <td>Diffuse adenopathy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other</strong></td> <td>Arthritis</td> <td>Mental status changes, coagulopathy, shock</td> <td>Throat culture positive for group A <em>Streptococcus</em></td> <td>Arthralgia, associated herpesvirus infection (30 to 75%)</td> <td>Arthritis, pericarditis</td> </tr> <tr> <td><strong>Characteristic lab results</strong></td> <td>Systemic inflammation, anemia, transaminitis</td> <td>Thrombocytopenia</td> <td>Positive throat culture</td> <td>Associated herpesvirus infection 30 to 50%</td> <td>Systemic inflammation, anemia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JIA: juvenile idiopathic arthritis.</div><div class=\"graphic_reference\">Adapted from: Yanagihara R, Todd JK. Acute febrile mucocutaneous lymph node syndrome. Am J Dis Childhood 1980; 134:603.</div><div id=\"graphicVersion\">Graphic 53802 Version 8.0</div></div></div>"},"53803":{"type":"graphic_diagnosticimage","displayName":"Radiograph of rheumatoid arthritis of the hips","title":"Radiograph of rheumatoid arthritis of the hips","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Radiograph of rheumatoid arthritis of the hips</div><div class=\"cntnt\"><img style=\"width:504px; height:386px;\" src=\"images/RADIOL/53803_Joint_space_narrowing_in_RA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rheumatoid arthritis of the hips. Radiograph of the pelvis AP view demonstrates diffuse bilateral symmetrical narrowing of the hip joints without hypertrophic changes consistent with rheumatoid arthritis.</div><div class=\"graphic_footnotes\">AP: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 53803 Version 4.0</div></div></div>"},"53804":{"type":"graphic_figure","displayName":"Shoulder arthrocentesis","title":"Shoulder arthrocentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder arthrocentesis</div><div class=\"cntnt\"><img style=\"width:404px; height:370px;\" src=\"images/RHEUM/53804_Shoulder_arthrocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the shoulder externally rotated, the needle is inserted at a point just medial to the head of the humerus and slightly inferior and lateral to the coracoid process. The needle is then directed posteriorly and slightly superiorly and laterally.</div><div class=\"graphic_reference\">Reproduced from Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 53804 Version 2.0</div></div></div>"},"53806":{"type":"graphic_picture","displayName":"Annular lichen planus on penis","title":"Annular lichen planus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Annular lichen planus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53806_Annul_lich_planus_penis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A violaceous annular plaque is present on the penile shaft.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53806 Version 3.0</div></div></div>"},"53807":{"type":"graphic_picture","displayName":"Binder syndrome","title":"Binder syndrome","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Binder syndrome</div><div class=\"cntnt\"><img style=\"width:574px; height:540px;\" src=\"images/ALLRG/53807_Binder_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with Binder syndrome with characteristic shortened nose and convex upper lip.</div><div id=\"graphicVersion\">Graphic 53807 Version 3.0</div></div></div>"},"53809":{"type":"graphic_figure","displayName":"Benefit clopidogrel over time","title":"Benefit of clopidogrel in CURE continues over time","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Benefit of clopidogrel in CURE continues over time</div><div class=\"cntnt\"><img style=\"width:501px; height:286px;\" src=\"images/CARD/53809_Benefit_clopidogrel_over_ti.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impact of clopidogrel compared with placebo on the incidence of cardiovascular death, MI, or stroke in the CURE trial of patients with a non-ST elevation acute coronary syndrome within first 30 days (left panel) and, among those who were event-free at that time, from 31 days to 12 months. In both time periods, clopidogrel therapy was associated with increasing benefit over time (relative risk 0.79 and 0.82, respectively).</div><div class=\"graphic_reference\">Data from Yusuf S, Mehta SR, Zhao F, et al. Circulation 2003; 107:966.</div><div id=\"graphicVersion\">Graphic 53809 Version 3.0</div></div></div>"},"53811":{"type":"graphic_figure","displayName":"HD survival by site","title":"Comparison of survival on dialysis between countries and between diabetic and nondiabetic patients","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Comparison of survival on dialysis between countries and between diabetic and nondiabetic patients</div><div class=\"cntnt\"><img style=\"width:472px; height:232px;\" src=\"images/NEPH/53811_HDsurvivalbysite.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Five-year patient survival rates after the institution of maintenance hemodialysis in the United States (from the USRDS), Europe (from the EDTA), Japan, and Tassin, France. Survival was lowest in the United States and highest in nondiabetics and in Tassin, where the patients were more intensively dialyzed.</div><div class=\"graphic_footnotes\">USRDS: United States Renal Data System; EDTA: European Dialysis and Transplant Association.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hull AR, Parker TF III. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, TX, September 15 to 17, 1989. Am J Kidney Dis 1990; 15:375.</li>&#xD;&#xA;    <li>Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 53811 Version 5.0</div></div></div>"},"53812":{"type":"graphic_table","displayName":"RTOG LENT criteria","title":"Radiation therapy oncology group (RTOG) criteria for long-term normal tissue toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiation therapy oncology group (RTOG) criteria for long-term normal tissue toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Symptoms</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Diarrhea</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Frequent loose bowel movements without associated rectal irritation</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Proctitis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Rectal irritation or urgency, and the presence of mucous or\nblood in the stool, with or without frequent or sometimes loose bowel\nmovements</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Cystitis</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Irritative bladder symptoms such as frequent dysuria; hematuria may or may not be a part of the clinical picture</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1_single\">Grades</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 0</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">No symptoms</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 1</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Minor symptoms requiring no treatment</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 2</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Symptoms that respond to simple outpatient management, and do not affect lifestyle</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 3</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Distressing\nsymptoms affecting lifestyle; may necessitate hospital admission or\nminor surgical intervention (eg, urethral dilation)</td>\n\n\n    </tr>\n\n\n    \n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 4</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Major surgical intervention or long stay in the hospital necessary (eg, laparotomy, colostomy, or cystectomy)</td>\n\n\n    </tr>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle2_single\">Grade 5</td>\n\n\n    </tr>\n\n\n    <tr>\n\n\n      <td class=\"indent1\">Fatal complications</td>\n\n\n    </tr>\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_reference\">Data from Rubin P. Int J Radiat Oncol Biol Phys 1995; 31:1035.</div><div id=\"graphicVersion\">Graphic 53812 Version 2.0</div></div></div>"},"53813":{"type":"graphic_table","displayName":"Low sodium diet 2 PI","title":"Low-sodium diet (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Low-sodium diet (continued)</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1\">\n   Foods to choose\n   </td>\n   <td   class=\"subtitle1\">\n   Foods to avoid\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Breads:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Whole-grain breads, English muffins, bagels\n   </td>\n   <td>Biscuits, prepared mixes (pancake, muffin, cornbread)</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Cereals:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Cooked hot cereals (not instant), such as oatmeal, cream of wheat, rice, or farina; puffed wheat; puffed rice; shredded wheat\n   </td>\n   <td>Instant hot cereals, many boxed cold cereals</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Crackers and snack foods:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   All unsalted crackers and snack foods, unsalted peanut butter, unsalted nuts or seeds\n   </td>\n   <td>Salted crackers and snack items (chips, pretzels, popcorn), regular peanut butter, prepared dips/spreads, salted nuts or seeds</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Pasta, rice, and potatoes:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Any type of pasta; potatoes; white or brown rice\n   </td>\n   <td>Macaroni and cheese mix; rice, noodle, or spaghetti mixes; canned spaghetti; frozen lasagna; instant potatoes; seasoned potato mixes</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Dried beans and peas:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Any dried beans or peas without seasoning\n   </td>\n   <td>Beans or peas prepared with ham, bacon, salt pork, or bacon grease; all canned beans</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Meats and alternatives:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Fresh or frozen beef, poultry, and fish; low-sodium canned tuna and salmon; eggs\n   </td>\n   <td>Salted, smoked, canned, spiced, and cured meat, poultry, or fish; bacon; ham; sausage; lunch meats; hot dogs; breaded frozen meat, fish, or poultry; frozen dinners; pizza</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Fruits and vegetables:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Any fresh, frozen, or canned fruit, any fresh or frozen vegetables without sauce, canned vegetables without salt, low-salt tomato sauce/paste\n   </td>\n   <td>Regular canned vegetables and vegetable juices, regular tomato sauce and tomato paste, olives, pickles, relishes, sauerkraut, frozen vegetables in butter or sauces, crystallized and glazed fruit, maraschino cherries, fruit dried with sodium sulfite</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Dairy products:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Milk, cream, sour cream, non-dairy creamer, yogurt, low-sodium cottage cheese, low-sodium cheese\n   </td>\n   <td>Buttermilk, Dutch processed chocolate milk, processed cheese slices and spreads, processed cheese, cottage cheese, aged or natural cheese</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Fats and oils:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Plant oils (olive, canola, corn, peanut), unsalted butter or margarine\n   </td>\n   <td>Prepared salad dressings, bacon, salt pork, fat back, salted butter or margarine</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Soups:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Salt-free soups and low-sodium bouillon cubes, unsalted broth, homemade soup without added salt\n   </td>\n   <td>Regular canned or prepared soups, stews, broths, or bouillon; packaged and frozen soups</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Desserts:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Gelatin, sherbet, pudding, ice cream, salt-free baked goods, sugar, honey, jam, jelly, marmalade, syrup\n   </td>\n   <td>Packaged baked goods</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Beverages:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Coffee, tea, soft drinks, fruit-flavored drinks, low-salt tomato juice, any fruit juice\n   </td>\n   <td>Softened water; carbonated beverages with sodium or salt added; regular tomato juice (V-8); ask about alcoholic beverages</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle2_left\" colspan=\"2\">\n   Condiments:\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"indent1\">\n   Fresh and dried herbs; lemon juice; low-salt mustard, vinegar, Tabasco sauce; low- or no-salt ketchup; seasoning blends that do not contain salt\n   </td>\n   <td>Table salt, lite salt, bouillon cubes, meat extract, taco seasoning, Worcestershire sauce, tartar sauce, ketchup, chili sauce, cooking sherry and wine, onion salt, mustard, garlic salt, soy sauce, tamari, meat flavoring or tenderizer, steak and barbecue sauce, seasoned salt, monosodium glutamate (MSG), Dutch processed cocoa</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 53813 Version 1.0</div></div></div>"},"53814":{"type":"graphic_table","displayName":"Hypothalamic hormones","title":"Major hypothalamic hormones and their effect on anterior pituitary hormones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major hypothalamic hormones and their effect on anterior pituitary hormones</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Hypothalamic stimulatory hormones</td> <td class=\"subtitle1\">Pituitary hormones</td> </tr> <tr> <td rowspan=\"3\">Corticotropin-releasing hormone -&nbsp;41 amino acids; released from paraventricular neurons as well as supraoptic and arcuate nuclei and limbic system</td> <td>Corticotropin -&nbsp;basophilic corticotrophs represent 20% of cells in anterior pituitary; ACTH is product of <em>POMC </em>gene.</td> </tr> <tr> <td>Melanocyte-stimulating hormone -&nbsp;alternate product of <em>POMC </em>gene</td> </tr> <tr> <td>Endorphins -&nbsp;also products of <em>POMC </em>gene</td> </tr> <tr> <td>Growth hormone-releasing hormone -&nbsp;two forms, 40 and 44 amino acids</td> <td>Growth hormone - acidophilic somatotrophs represent 50% of cells in anterior pituitary</td> </tr> <tr> <td>Gonadotropin-releasing hormone -&nbsp;10 amino acids; mostly released from preoptic neurons</td> <td>Luteinizing hormone and follicle-stimulating hormone - gonadotrophs represent approximately 15% of anterior pituitary cells</td> </tr> <tr> <td>Thyrotropin-releasing hormone - three amino acids; released from anterior hypothalamic area</td> <td>Thyroid-stimulating hormone - thyrotropes represent approximately 5% of anterior pituitary cells</td> </tr> <tr> <td>Prolactin-releasing factors - include serotonin, acetylcholine, opiates, and estrogens</td> <td>Prolactin - lactotrophs represent 10 to 30% of anterior pituitary cells</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Hypothalamic inhibitory hormones</td> </tr> <tr> <td>Somatostatin - 14 amino acids</td> <td>Inhibits the release of growth hormone</td> </tr> <tr> <td>Prolactin-inhibiting factors - includes dopamine</td> <td>Major prolactin control is inhibitory</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACTH: corticotropin; POMC: proopiomelanocortin.</div><div id=\"graphicVersion\">Graphic 53814 Version 4.0</div></div></div>"},"53815":{"type":"graphic_figure","displayName":"3D echo mitral valve","title":"Real-time three-dimensional (3D) echocardiogram showing volumetric imaging and analysis of the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Real-time three-dimensional (3D) echocardiogram showing volumetric imaging and analysis of the mitral valve</div><div class=\"cntnt\"><img style=\"width:515px; height:432px;\" src=\"images/CARD/53815_3d_mitral_valve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>(Top)</strong> Baseline image before mitral balloon valvuloplasty (A) shows a restricted mitral valve opening with bicommissural fusion. Post-valvuloplasty, splitting of the medial commissure and posterior leaflet tear can be seen (B).<br> <strong>(Bottom)</strong> Example of 3D reconstruction of the mitral annulus (C) and leaflets (D) obtained in a patient with dilated cardiomyopathy, demonstrating the saddle shape of the annulus and increased leaflet tenting volume.</div><div class=\"graphic_footnotes\">RV: right ventricle; IVS: interventricular septum.</div><div class=\"graphic_reference\">Courtesy of Victor Mor-Avi, PhD and Roberto M Lang, MD.</div><div id=\"graphicVersion\">Graphic 53815 Version 4.0</div></div></div>"},"53816":{"type":"graphic_diagnosticimage","displayName":"Closed loop obstruction with necrosis of the ileum","title":"Closed loop obstruction with necrosis of the ileum","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Closed loop obstruction with necrosis of the ileum</div><div class=\"cntnt\"><img style=\"width:558px; height:377px;\" src=\"images/SURG/53816_Ileal_necrosis_closed_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT images (coronal view on the left and cross-sectional image on the right) showing a markedly dilated and thick-walled loop of ileum with focal mesenteric edema (arrows). Because the patient developed acute onset of obstruction, the proximal small bowel has not yet dilated.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Anthony Samir, MD.</div><div id=\"graphicVersion\">Graphic 53816 Version 4.0</div></div></div>"},"53817":{"type":"graphic_figure","displayName":"Removal large sessile polyp","title":"Postpolypectomy electrocoagulation syndrome after removal of a large sessile colon polyp","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Postpolypectomy electrocoagulation syndrome after removal of a large sessile colon polyp</div><div class=\"cntnt\"><img style=\"width:542px; height:420px;\" src=\"images/GAST/53817_Removal_large_sessile_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Normally, the snare extends beyond the polyp, and the tip contacts mucosa behind the polyp (point a). B) As the snare is closed, the tip may catch on the mucosa behind the polyp (point a) and draw it toward the polyp. The submucosa is bunched up into the snare, but the entrapped mucosa cannot be seen because it is hidden behind the polyp. Cutting through a broad based polyp may also transfer sufficient thermal energy to the deeper layers to result in a transmural burn. C) After polypectomy, there is a large defect, and the wall beneath the area of denuded mucosa is thinner and more liable to conduct electrical energy (heat) to the serosal surface causing deep thermal damage, resulting in the postpolypectomy electrocoagulation syndrome.</div><div id=\"graphicVersion\">Graphic 53817 Version 4.0</div></div></div>"},"53818":{"type":"graphic_table","displayName":"Pharmacology antidepressants","title":"Unipolar depression in adults: Antidepressant doses*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unipolar depression in adults: Antidepressant doses*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Usual total starting dose per day<br /> (mg)<sup>&#182;</sup></td> <td class=\"subtitle1\">Usual total dose per day<br /> (mg)</td> <td class=\"subtitle1\">Extreme daily dose range<br /> (mg)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Selective serotonin reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>20</td> <td>20 to 40<sup>&#916;</sup></td> <td>10 to 40<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>10</td> <td>10 to 20</td> <td>5 to 30</td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>20</td> <td>20 to 60</td> <td>10 to 80</td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>50</td> <td>50 to 200</td> <td>25 to 300</td> </tr> <tr> <td class=\"indent1\">Fluvoxamine CR</td> <td>100</td> <td>100 to 200</td> <td>100 to 300</td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td>20</td> <td>20 to 40</td> <td>10 to 50</td> </tr> <tr> <td class=\"indent1\">Paroxetine CR</td> <td>25</td> <td>25 to 50</td> <td>12.5 to 62.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sertraline</td> <td>50</td> <td>50 to 200</td> <td>25 to 300</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Serotonin-norepinephrine reuptake inhibitors</td> </tr> <tr> <td class=\"indent1\">Desvenlafaxine</td> <td>25 to 50</td> <td>50 to 100</td> <td>50 to 400<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td>30 to 60</td> <td>60 to 120</td> <td>30 to 120<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Levomilnacipran</td> <td>20</td> <td>40 to 80</td> <td>20 to 120</td> </tr> <tr> <td class=\"indent1\">Milnacipran</td> <td>12.5</td> <td>100 to 200</td> <td>50 to 300</td> </tr> <tr> <td class=\"indent1\">Venlafaxine</td> <td>37.5 to 75</td> <td>75 to 375</td> <td>75 to 375</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venlafaxine XR</td> <td>37.5 to 75</td> <td>75 to 225</td> <td>75 to 375</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Atypical agents</td> </tr> <tr> <td class=\"indent1\">Agomelatine<sup>&#167;</sup> (not available in United States)</td> <td>25</td> <td>25 to 50</td> <td>25 to 50</td> </tr> <tr> <td class=\"indent1\">Bupropion</td> <td>200</td> <td>300 (maximum single dose 150 mg)</td> <td>100 to 450</td> </tr> <tr> <td class=\"indent1\">Bupropion SR 12 hour</td> <td>150</td> <td>300 (maximum single dose 200 mg)</td> <td>150 to 400</td> </tr> <tr> <td class=\"indent1\">Bupropion XL 24 hour</td> <td>150</td> <td>300</td> <td> <p>150 to 450 (United States)</p> 150 to 300 (Europe)</td> </tr> <tr> <td class=\"indent1\">Bupropion hydrobromide 24 hour</td> <td>174</td> <td>348</td> <td>174 to 522</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mirtazapine</td> <td>15</td> <td>15 to 45</td> <td>7.5 to 60</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Serotonin modulators</td> </tr> <tr> <td class=\"indent1\">Nefazodone<sup>&#135;</sup></td> <td>200</td> <td>300 to 600</td> <td>50 to 600</td> </tr> <tr> <td class=\"indent1\">Trazodone</td> <td>100</td> <td>200 to 500</td> <td>100 to 600</td> </tr> <tr> <td class=\"indent1\">Trazodone ER</td> <td>150</td> <td>375</td> <td>150 to 375</td> </tr> <tr> <td class=\"indent1\">Vilazodone</td> <td>10</td> <td>40</td> <td>10 to 40</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vortioxetine</td> <td>10</td> <td>20</td> <td>5 to 20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Tricyclics and tetracyclics<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Amitriptyline</td> <td>25</td> <td>150 to 300</td> <td>10 to 300</td> </tr> <tr> <td class=\"indent1\">Amoxapine</td> <td>25</td> <td>200 to 300</td> <td>25 to 400</td> </tr> <tr> <td class=\"indent1\">Clomipramine</td> <td>25</td> <td>100 to 250</td> <td>25 to 300</td> </tr> <tr> <td class=\"indent1\">Desipramine</td> <td>25</td> <td>150 to 300</td> <td>25 to 300</td> </tr> <tr> <td class=\"indent1\">Doxepin</td> <td>25</td> <td>150 to 300</td> <td>25 to 300</td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>25</td> <td>150 to 300</td> <td>10 to 300</td> </tr> <tr> <td class=\"indent1\">Maprotiline</td> <td>25</td> <td>100 to 225</td> <td>25 to 225</td> </tr> <tr> <td class=\"indent1\">Nortriptyline</td> <td>25</td> <td>50 to 150</td> <td>10 to 150</td> </tr> <tr> <td class=\"indent1\">Protriptyline</td> <td>10</td> <td>15 to 60</td> <td>5 to 60</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimipramine</td> <td>25</td> <td>150 to 300</td> <td>25 to 300</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Monamine oxidase inhibitors<sup>&#134;</sup></td> </tr> <tr> <td class=\"indent1\">Isocarboxazid</td> <td>10</td> <td>10 to 40</td> <td>10 to 60</td> </tr> <tr> <td class=\"indent1\">Phenelzine</td> <td>15</td> <td>15 to 90</td> <td>7.5 to 90</td> </tr> <tr> <td class=\"indent1\">Selegiline transdermal</td> <td>6 mg/24 hour patch</td> <td>6 to 12 mg/24 hour patch</td> <td>6 to 12 mg/24 hour patch</td> </tr> <tr> <td class=\"indent1\">Tranylcypromine</td> <td>10</td> <td>30 to 60</td> <td>10 to 60</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Total daily oral doses shown in table may need to be given as two or three equally divided doses per day, depending on specific antidepressant and other factors. For additional detail, refer to individual Lexicomp drug monographs included with UpToDate.<br />¶ Lower end doses may be useful for initiating or maintaining elderly, medically compromised (eg, renal or hepatic illness), or drug sensitive patients, as well as patients with a low body mass index. High doses may be used for medications that are well tolerated but ineffective at lower doses.<br />Δ Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. For more information refer to the UpToDate topic on unipolar depression in adults and selective serotonin reuptake inhibitors.<br /><FONT class=lozenge>◊</FONT> Although desvenlafaxine doses up to 400 mg per day have been studied, there is no evidence that doses &gt;50 mg per day provide any additional benefit.<br />§ Although duloxetine doses up to 120 mg per day have been used, there is no evidence that doses &gt;60 mg per day provide any additional benefit in treatment of depression.<br />¥ Agomelatine may be hepatotoxic and is contraindicated with any degree of liver impairment. Transaminase monitoring is required according to the product information.<br />‡ Caution: can cause liver failure. Not available in Europe, Canada, and several other countries.<br />† Conservative starting doses shown in table are lower than starting doses shown in some other references. For additional information, refer to UpToDate topics on unipolar depression in adults and cyclic antidepressants and monoamine oxidase inhibitors for treatment of adults with depression.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>The American Psychiatric Publishing Textbook of Psychopharmacology, 4th edition. Schatzberg AF, Nemeroff CB (eds); American Psychiatric Publishing, Inc. Washington, D.C. (2009).</LI>&#xD;&#xA;<LI>Labbate LA, Fava M, Rosenbaum JF, Arana GW. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams and Wilkins, Philadelphia 2010. p.54. </LI>&#xD;&#xA;<LI>Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Curr Psychiatry Rep 2012; 14:360.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 53818 Version 25.0</div></div></div>"},"53819":{"type":"graphic_table","displayName":"Effect of anticholinergics","title":"Effect of anticholinergics on airways hyperresponsiveness in asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of anticholinergics on airways hyperresponsiveness in asthma</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n\n  <tbody>\n\n\n\n    <tr>\n\n\n      <td class=\"subtitle1\">Provocation</td>\n\n\n      <td colspan=\"1\" class=\"subtitle1\">Effect of anticholinergic on responsiveness</td>\n\n\n      \n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Prostaglandin D(2)</td>\n\n\n      <td>12 to 22-fold increase in PC(20)</td>\n\n\n      \n\n      \n\n    </tr>\n\n\n    <tr>\n\n      <td>Thromboxane A(2)</td>\n\n      <td>23-fold increase in PC(20)</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n      <td>Bradykinin</td>\n\n      <td>5-fold increase in PD(35)</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n\n      <td>Histamine</td>\n\n\n      <td>10-fold increase in PC(100)SRaw</td>\n\n\n      \n\n      \n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Capsaicin</td>\n\n\n      <td>PC 60 percent\nreduction in response</td>\n\n\n      \n\n      \n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Distilled water</td>\n\n\n      <td colspan=\"1\">50 - 100 percent reduction in response</td>\n\n\n      \n\n    </tr>\n\n\n    <tr>\n\n      <td>Beta\nblockers</td>\n\n      <td>Abolished\nresponse</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n      <td>Hyperpnea</td>\n\n      <td>Abolished response in children</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n      <td>Psychogenic stimulation</td>\n\n      <td>Abolished response</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n      <td>Exercise</td>\n\n      <td>30 percent\nreduction in response</td>\n\n      \n      \n    </tr>\n\n    <tr>\n\n      <td>Reflux/esophageal\nacidification</td>\n\n      <td>Abolished response</td>\n\n      \n      \n    </tr>\n\n\n\n  \n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Anticholinergics used were either ipratropium bromide or atropine delivered via aerosol.<br> PC(20) and PD(35): provocative concentration (or dose) of agonist producing a 20 or 35 percent fall in forced expiratory volume in 1 second (FEV(1)).<br>  PC(100)SRaw: provocative concentration of agonist producing a 100 percent increase in specific airways resistance.</div><div id=\"graphicVersion\">Graphic 53819 Version 1.0</div></div></div>"},"53820":{"type":"graphic_picture","displayName":"LIP along vessels and bronchi","title":"Lymphocytic interstitial pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphocytic interstitial pneumonia</div><div class=\"cntnt\"><img style=\"width:361px; height:241px;\" src=\"images/PULM/53820_LIP_along_vessels_and_bronc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph shows the cellular infiltrate tracking along vessels and bronchovascular bundles.</div><div class=\"graphic_reference\">From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 53820 Version 2.0</div></div></div>"},"53821":{"type":"graphic_figure","displayName":"Chromosomal abnormalities AML","title":"Chromosomal abnormalities in acute myeloid leukemia","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Chromosomal abnormalities in acute myeloid leukemia</div><div class=\"cntnt\"><img style=\"width:542px; height:728px;\" src=\"images/HEME/53821_Chrom_abnorm_AML_edts4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure illustrates several translocations seen in acute myeloid leukemia. The translocation/inversion illustrated in box \"F\" is a translocation that brings a distal enhancer of the GATA2 gene close to the MECOM gene. </div><div id=\"graphicVersion\">Graphic 53821 Version 10.0</div></div></div>"},"53822":{"type":"graphic_picture","displayName":"Circumscribed morphea - chest","title":"Circumscribed morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumscribed morphea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53822_Circumscribed_morphea_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A shiny, slightly hyperpigmented, indurated oval plaque is present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53822 Version 3.0</div></div></div>"},"53823":{"type":"graphic_picture","displayName":"Tinea corporis leg","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53823_Tinea_corporis_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple round,&nbsp;erythematous plaques of variable size, some with signs of central resolution, on the leg of a patient with tinea corporis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53823 Version 5.0</div></div></div>"},"53826":{"type":"graphic_form","displayName":"Birth center consent 2","title":"Birth center consent form (continued)","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Birth center consent form (continued)</div><div class=\"cntnt\"><img style=\"width:603px; height:720px;\" src=\"images/OBGYN/53826_Birth_center_consent_2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: the American Association of Birth Centers. Copyright ©2007.</div><div id=\"graphicVersion\">Graphic 53826 Version 2.0</div></div></div>"},"53828":{"type":"graphic_figure","displayName":"Bladder exstrophy male","title":"Bladder exstrophy in the male","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Bladder exstrophy in the male</div><div class=\"cntnt\"><img style=\"width:516px; height:290px;\" src=\"images/PEDS/53828_Bladder_exstrophy_male.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Joseph G Borer, MD.</div><div id=\"graphicVersion\">Graphic 53828 Version 3.0</div></div></div>"},"53830":{"type":"graphic_figure","displayName":"Breisky Navratil retractors","title":"Breisky-Navratil vaginal retractors","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Breisky-Navratil vaginal retractors</div><div class=\"cntnt\"><img style=\"width:492px; height:235px;\" src=\"images/OBGYN/53830_Breisky_Navratil_retractors.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53830 Version 1.0</div></div></div>"},"53831":{"type":"graphic_figure","displayName":"Antibody elution technique","title":"Antibody elution technique","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Antibody elution technique</div><div class=\"cntnt\"><img style=\"width:575px; height:367px;\" src=\"images/HEME/53831_Antibody_elution_technique.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53831 Version 1.0</div></div></div>"},"53832":{"type":"graphic_picture","displayName":"Infant with severe intrauterine growth restriction","title":"Infant with severe intrauterine growth restriction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infant with severe intrauterine growth restriction</div><div class=\"cntnt\"><img style=\"width:288px; height:350px;\" src=\"images/PEDS/53832_Severe_SGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infant has the typical shrunken or \"wizened\" appearance of an infant with intrauterine growth restriction.</div><div class=\"graphic_reference\">Courtesy of George T Mandy, MD.</div><div id=\"graphicVersion\">Graphic 53832 Version 5.0</div></div></div>"},"53833":{"type":"graphic_picture","displayName":"Oncocytic oxyphilic carcinoid","title":"Typical carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:385px; height:262px;\" src=\"images/PULM/53833_Oncocytic_oxyphilic_carcino.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of a typical pulmonary carcinoid tumor with oncocytic features and abundant oxyphilic tumor cell cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 53833 Version 1.0</div></div></div>"},"53834":{"type":"graphic_table","displayName":"Water related antigens in HP","title":"Hypersensitivity pneumonitides associated with ventilation and water-related contamination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with ventilation and water-related contamination</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Environmental source</td>\n\n      <td class=\"subtitle1\">Major causative antigen</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"5\">Humidifier fever</td>\n\n      <td>Thermoactinomyces (T vulgaris, T sacchari, T candidus)</td>\n\n    </tr>\n\n\n    <tr>\n\n\n      <td>Klebsiella oxytoca</td>\n\n    </tr>\n\n    <tr>\n      <td>Naegleria gruberi</td>\n    </tr>\n    <tr>\n      <td>Acanthamoeba polyphaga</td>\n    </tr>\n    <tr>\n      <td>Acanthamoeba castellani</td>\n    </tr>\n    <tr>\n\n      <td>Unventilated shower</td>\n\n      <td>Epicoccum nigrum</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"2\">Hot-tub lung (mists; mold on ceiling and around tub)</td>\n\n      <td>Cladosporium sp</td>\n\n    </tr>\n\n    <tr>\n      \n      <td>Mycobacterium avium complex</td>\n    </tr>\n    <tr>\n\n      <td>Sauna taker's lung </td>\n\n      <td>Aureobasidium sp, other sources</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Summer-type pneumonitis</td>\n\n      <td>Trichosporon cutaneum</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lifeguard lung</td>\n\n      <td>Aerosolized endotoxin from pool-water sprays and fountains</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Contaminated basement (sewage) pneumonitis</td>\n\n      <td>Cephalosporium</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53834 Version 1.0</div></div></div>"},"53835":{"type":"graphic_figure","displayName":"Perfusion imaging in ER","title":"Resting SPECT imaging in evaluation of chest pain","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Resting SPECT imaging in evaluation of chest pain</div><div class=\"cntnt\"><img style=\"width:455px; height:216px;\" src=\"images/CARD/53835_Perfusion_imaging_in_ER.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a group of 357 patients presenting to the emergency room, 20 had a documented myocardial infarction (MI). Resting perfusion imaging with technetium-99m tetrofosmin had a sensitivity of 90 percent but a positive predictive value of only 12 percent since most positive tests were false positives. However, a negative study was associated with a very low cardiac event rate (negative PV 99 percent).</div><div class=\"graphic_reference\">Redrawn from: Heller GV, Stowers SA, Hendel RA. J Am Coll Cardiol 1998; 31:1011.</div><div id=\"graphicVersion\">Graphic 53835 Version 2.0</div></div></div>"},"53836":{"type":"graphic_figure","displayName":"Fascio-cutaneous blood supply of amputations flaps of the leg","title":"Fascio-cutaneous blood supply of amputations flaps of the leg","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Fascio-cutaneous blood supply of amputations flaps of the leg</div><div class=\"cntnt\"><img style=\"width:538px; height:612px;\" src=\"images/SURG/53836_Fascio-cutaneous-blood-supply-of-amputations-flaps-of-leg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53836 Version 5.0</div></div></div>"},"53837":{"type":"graphic_figure","displayName":"Acromion types","title":"Types of acromion morphology","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Types of acromion morphology</div><div class=\"cntnt\"><img style=\"width:539px; height:282px;\" src=\"images/EM/53837_Acromion_types.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between the anterior third of the acromion and subacromial structures accounts in part for the development of SIS. Three acromion types have been described: flat, curved, and hooked. The hooked acromion has the highest association with SIS.</div><div id=\"graphicVersion\">Graphic 53837 Version 2.0</div></div></div>"},"53839":{"type":"graphic_picture","displayName":"Lichen planus wrist 2","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/DERM/53839_Lichen_planus_wrist_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus. Flat-topped, violaceous, polygonal papules on the flexor wrists are present. There are active and resolving lesions. Note the postinflammatory hyperpigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53839 Version 2.0</div></div></div>"},"53842":{"type":"graphic_table","displayName":"Causes primary hypogonadism","title":"Causes of primary hypogonadism in males","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of primary hypogonadism in males</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Congenital abnormalities\n   </td>\n   </tr>\n   <tr>\n   <td>Klinefelter syndrome</td>\n   </tr>\n   <tr>\n   <td>Other chromosomal abnormalities</td>\n   </tr>\n   <tr>\n   <td>Mutation in the FSH and LH receptor genes</td>\n   </tr>\n   <tr>\n   <td>Cryptorchidism</td>\n   </tr>\n   <tr>\n   <td>Varicocele</td>\n   </tr>\n   <tr>\n   <td>Disorders of androgen synthesis</td>\n   </tr>\n   <tr>\n   <td>Myotonic dystrophy</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acquired diseases\n   </td>\n   </tr>\n   <tr>\n   <td>Infections, especially mumps</td>\n   </tr>\n   <tr>\n   <td>Radiation</td>\n   </tr>\n   <tr>\n   <td>Alkylating agents</td>\n   </tr>\n   <tr>\n   <td>Suramin</td>\n   </tr>\n   <tr>\n   <td>Ketoconazole</td>\n   </tr>\n   <tr>\n   <td>Glucocorticoids</td>\n   </tr>\n   <tr>\n   <td>Environmental toxins</td>\n   </tr>\n   <tr>\n   <td>Trauma</td>\n   </tr>\n   <tr>\n   <td>Testicular torsion</td>\n   </tr>\n   <tr>\n   <td>Autoimmune damage</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Chronic systemic illnesses\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Hepatic cirrhosis\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Chronic renal failure\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   AIDS\n   </td>\n   </tr>\n   <tr>\n   <td>Idiopathic</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=14242&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Causes_primary_hypogonadism.htm</title></head></div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone; AIDS: acquired immunodeficiency syndrome.</div><div id=\"graphicVersion\">Graphic 53842 Version 3.0</div></div></div>"},"53843":{"type":"graphic_figure","displayName":"Percent change BMD older men","title":"Changes in bone mineral density in older men","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in bone mineral density in older men</div><div class=\"cntnt\"><img style=\"width:414px; height:387px;\" src=\"images/ENDO/53843_Percent_change_BMD_old_men.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annualized percentage change in bone mineral density, measured by dual energy x-ray absorptiometry (DXA), in elderly men measured in the mid-lateral lumbar spine, femoral neck, or anterior-posterior lumbar spine projections. Bone density measured in the anterior-posterior (AP) projection, appears to increase. This is probably due to degenerative changes in the posterior spinous elements. Thus, anterior-posterior DXA is a poor technique for assessing bone density in older men.</div><div class=\"graphic_reference\">Reproduced with modifications from: Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 2000; 15:1417.</div><div id=\"graphicVersion\">Graphic 53843 Version 2.0</div></div></div>"},"53844":{"type":"graphic_movie","displayName":"Mitral valve endocarditis healed parasternal long axis echo","title":"Endocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endocarditis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53844_palaxendconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:256px; height:417px;\" src=\"images/CARD/53844_palaxend.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parasternal long axis view from a 2-D echocardiogram shows a small, fibrotic vegetation on the left atrial surface of the anterior mitral valve leaflet, suggestive of healed endocarditis.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 53844 Version 2.0</div></div></div>"},"53845":{"type":"graphic_form","displayName":"Dietary questionnaire","title":"Dietary questionnaire","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Dietary questionnaire</div><div class=\"cntnt\"><img style=\"width:580px; height:762px;\" src=\"images/OBGYN/53845_Dietary_questionnaire.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WIC: Women, Infants, and Children.</div><div class=\"graphic_reference\">Permission to reproduce from: Nutrition During Pregnancy and Lactation: An Implementation Guide by Subcommittee for Institute of Medicine. 1992, p. 506. Copyright by National Academy Press.</div><div id=\"graphicVersion\">Graphic 53845 Version 3.0</div></div></div>"},"53847":{"type":"graphic_table","displayName":"Properties therap radionuclides","title":"Physical properties of radionuclides for patients with bone metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical properties of radionuclides for patients with bone metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Radionuclide</td> <td class=\"subtitle1\">Particle</td> <td class=\"subtitle1\">Physical half-life</td> <td class=\"subtitle1\">Particle energy</td> </tr> <tr> <td><sup>223</sup>radium</td> <td>Alpha</td> <td>11.4 days</td> <td>5.99 MeV</td> </tr> <tr> <td><sup>153</sup>samarium</td> <td>Beta</td> <td>1.9 days</td> <td>0.81 MeV</td> </tr> <tr> <td><sup>89</sup>strontium</td> <td>Beta</td> <td>50.5 days</td> <td>1.46 MeV</td> </tr> <tr> <td><sup>32</sup>phosphorus</td> <td>Beta</td> <td>14.3 days</td> <td>1.71 MeV</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53847 Version 4.0</div></div></div>"},"53849":{"type":"graphic_picture","displayName":"Advanced RP","title":"Advanced retinitis pigmentosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Advanced retinitis pigmentosa</div><div class=\"cntnt\"><img style=\"width:432px; height:336px;\" src=\"images/PC/53849_Advanced_RP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of the retinal pigment epithelium and choriocapillaris reveals the underlying large choroidal vessels seen as orange stripes throughout the ocular fundus.</div><div id=\"graphicVersion\">Graphic 53849 Version 2.0</div></div></div>"},"53850":{"type":"graphic_figure","displayName":"Cumulative risk of death Turner syndrome","title":"Cumulative risk of death from all causes and from circulatory disease observed in the cohort of patients with Turner syndrome and risk expected based on general population rates for females","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Cumulative risk of death from all causes and from circulatory disease observed in the cohort of patients with Turner syndrome and risk expected based on general population rates for females</div><div class=\"cntnt\"><img style=\"width:582px; height:401px;\" src=\"images/ENDO/53850_Cumulative_risk_of_death.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Schoemaker MJ, Swerdlow AJ, Higgins CD, et al. Mortality in women with Turner syndrome in Great Britain: A national cohort study. J Clin Endocrinol Metab 2008; 93:4735. http://jcem.endojournals.org/. Copyright &#169; 2008 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 53850 Version 7.0</div></div></div>"},"53852":{"type":"graphic_table","displayName":"Lab features in malabsorption","title":"Laboratory features of malabsorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory features of malabsorption</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Decreased\n   </td>\n   </tr>\n   <tr>\n   <td>Hemoglobin</td>\n   </tr>\n   <tr>\n   <td>Serum or RBC folate</td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1_start\">\n   <strong>Serum</strong>\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Iron\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Ferritin\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Vitamin B12\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Calcium\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Magnesium\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Cholesterol\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Carotene\n   </td>\n   </tr>\n   <tr>\n   <td   class=\"sublist1\">\n   Albumin\n   </td>\n   </tr>\n   <tr>\n   <td class=\"sublist1\">25-hydroxyvitamin D</td>\n   </tr>\n   <tr>\n   <td   class=\"subtitle1_single\">\n   Increased\n   </td>\n   </tr>\n   <tr>\n   <td>Oxalate in urine</td>\n   </tr>\n   <tr>\n   <td>Prothrombin time</td>\n   </tr>\n   <tr>\n   <td>Serum total iron binding capacity</td>\n   </tr>\n </table></div><div id=\"graphicVersion\">Graphic 53852 Version 1.0</div></div></div>"},"53853":{"type":"graphic_figure","displayName":"Cyclebeads","title":"CycleBeads® used with the standard days method","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">CycleBeads&#174; used with the standard days method</div><div class=\"cntnt\"><img style=\"width:538px; height:524px;\" src=\"images/OBGYN/53853_Cyclebeads.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 53853 Version 1.0</div></div></div>"},"53854":{"type":"graphic_table","displayName":"Blood components","title":"Blood components: Indications and dosing in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blood components:&nbsp;Indications and dosing in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Component&nbsp;(volume)</td> <td class=\"subtitle1\">Contents</td> <td class=\"subtitle1\">Indications and dose</td> </tr> <tr> <td>Whole blood (1 unit = 500 mL)</td> <td>RBCs, platelets, plasma</td> <td>Rarely required. May be appropriate when massive bleeding requires transfusion of more than 5 to 7 units of RBCs (increasingly used in early trauma management).</td> </tr> <tr> <td>RBCs&nbsp;in additive solution&nbsp;(1 unit = 350 mL)</td> <td>RBCs</td> <td>Anemia, bleeding. The increase in&nbsp;hemoglobin from 1 unit of RBCs will be approximately 1 g/dL; the increase in hematocrit will be approximately&nbsp;3 percentage points.</td> </tr> <tr> <td>FFP or other plasma product* (1 unit = 200 to 300 mL)</td> <td>All soluble plasma proteins and clotting factors</td> <td>Bleeding or expected bleeding (eg, emergency surgery) in individuals with deficiencies of multiple coagulation factors (eg, DIC, liver disease, massive transfusion, anticoagulation with warfarin or warfarin overdose if not corrected by vitamin K and/or PCC, depending on the clinical setting); therapeutic plasma exchange in&nbsp;TTP. FFP may be used to&nbsp;manage bleeding in individuals with isolated factor deficiencies (most often factor V) if a factor concentrate or recombinant factor is not available.&nbsp;In the rare event that FFP is used to replace a clotting factor, the dose is 10 to 20 mg/kg. This dose will raise the level of any factor, including fibrinogen, by close to 30%, which is typically sufficient for hemostasis.</td> </tr> <tr> <td> <p>Cryoprecipitate, also called&nbsp;\"cryo\"&nbsp;(1 unit = 10 to 20 mL)</p> <p>&nbsp;</p> </td> <td> <p>Fibrinogen; factors VIII and&nbsp;XIII; VWF</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td> <p>Bleeding or expected bleeding with low fibrinogen: The increase in plasma fibrinogen from 1 unit of Cryoprecipitate per 10 kg&nbsp;body weight will be approximately 50 mg/dL. </p> <p>Bleeding or expected bleeding&nbsp;in individuals with deficiencies of&nbsp;factor XIII or factor VIII (hemophilia A) if a recombinant product or factor concentrate is unavailable.</p> <p>Bleeding or expected bleeding&nbsp;in individuals with VWD if DDAVP (desmopressin)&nbsp;is ineffective and recombinant VWF&nbsp;or a VWF&nbsp;concentrate is unavailable.</p> <p>Cryoprecipitate is generally provided in&nbsp;pools containing 5 units, and most patients receive one to&nbsp;two pools. </p> </td> </tr> <tr> <td>Platelets (derived from whole blood or apheresis) (1 unit of apheresis platelets or a 5 to 6 unit pool of platelets from whole blood = 200 to 300 mL)</td> <td>Platelets</td> <td>The platelet count increase from 5 to 6&nbsp;units of whole blood-derived platelets or&nbsp;1 unit of apheresis platelets will be approximately 30,000/microL in an average sized adult.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on these products and on specific conditions for details of use. Frozen blood products (FFP, Cryoprecipitate) take 10 to 30 minutes to thaw. It may take the same amount of time to perform an uncomplicated crossmatch.</div><div class=\"graphic_footnotes\">RBCs: red blood cells; FFP: Fresh Frozen Plasma; DIC: disseminated intravascular coagulation; PCC: prothrombin complex concentrate;&nbsp;TTP: thrombotic thrombocytopenic purpura;&nbsp;VWF: von Willebrand factor; VWD: von Willebrand disease.<br />* Other plasma products include Plasma Frozen Within 24 Hours After Phlebotomy (PF24) or Thawed Plasma. PF24 may be used interchangeably with FFP for all of the indications listed above, with the exceptions of factor VIII deficiency&nbsp;or protein C deficiency,&nbsp;which are treated with recombinant products or plasma-derived factor concentrates. In the rare event that specific factor concentrates are unavailable and these deficiencies must be treated with a plasma product, FFP should be used. Thawed Plasma may be used interchangeably with FFP for all of the indications listed above, with the exception of factor VIII deficiency without access to factor VIII concentrates, in which FFP should be used;&nbsp;or factor V deficiency, in which FFP or PF24 should be used.</div><div id=\"graphicVersion\">Graphic 53854 Version 18.0</div></div></div>"},"53856":{"type":"graphic_table","displayName":"Peak flow technique","title":"Technique for peak flow measurement in asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for peak flow measurement in asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Move peak flow meter&nbsp;indicator to zero. </td> </tr> <tr> <td>Sit or stand up straight.</td> </tr> <tr> <td>Take in a deep breath, as deep as&nbsp;you can.</td> </tr> <tr> <td>Place&nbsp;peak flow meter in your mouth and close your&nbsp;lips around the mouthpiece*.</td> </tr> <tr> <td>As soon as your&nbsp;lips are sealed around mouth piece,&nbsp;blow out&nbsp;as hard and fast&nbsp;as you can using your chest and belly muscles<sup>&#182;</sup>. This should take no more than 2 seconds.</td> </tr> <tr> <td>Write down the&nbsp;result.</td> </tr> <tr> <td>Repeat two more times (three total).</td> </tr> <tr> <td>Record the highest of the three values.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Nose clips are not necessary.<br />¶&nbsp;Make sure&nbsp;to use all of your breathing muscles, not just your mouth muscles.&nbsp;This needs a lot of force, like blowing out a candle several feet away.</div><div id=\"graphicVersion\">Graphic 53856 Version 5.0</div></div></div>"},"53857":{"type":"graphic_figure","displayName":"Amniocentesis PI","title":"Amniocentesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amniocentesis</div><div class=\"cntnt\"><img style=\"width:411px; height:496px;\" src=\"images/PI/53857_Amniocentesis-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During amniocentesis the doctor uses a needle to remove a small sample of the fluid that surrounds the fetus. This fluid is called &quot;amniotic fluid.&quot; As part of the procedure, the doctor uses an ultrasound machine to get a picture of the uterus and other organs. The picture shows up on a screen and helps the doctor decide where to place the needle.</div><div id=\"graphicVersion\">Graphic 53857 Version 3.0</div></div></div>"},"53859":{"type":"graphic_figure","displayName":"Left colectomy for malignancy","title":"Left colectomy for malignancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left colectomy for malignancy</div><div class=\"cntnt\"><img style=\"width:434px; height:544px;\" src=\"images/SURG/53859_Lefthemimalignant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the extensive resection of a left colon cancer. Note the ligation of the inferior mesenteric artery at its origin from the aorta and the ligation of the inferior mesenteric vein near the distal pancreas. A minimum 5-cm margin is obtained both proximal and distal to the malignant lesion.</div><div id=\"graphicVersion\">Graphic 53859 Version 4.0</div></div></div>"},"53860":{"type":"graphic_table","displayName":"Heat index and wet bulb globe temperature risk","title":"Heat illness risk based on heat index or wet bulb globe temperature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heat illness risk based on heat index or wet bulb globe temperature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Heat index<br /> &#176;C (&#176;F)*</td> <td class=\"subtitle1\">Wet bulb globe temperature<br /> &#176;C (&#176;F)</td> <td class=\"subtitle1\">Suggested action</td> </tr> <tr class=\"divider_bottom\"> <td>Extreme danger</td> <td>&#8805;52 (&#8805;126)</td> <td>&#62;29 (&#62;85)</td> <td>Cancel organized athletic activities.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Danger</td> <td class=\"divider_bottom\" rowspan=\"3\">40-52 (104-125)</td> <td class=\"divider_bottom\" rowspan=\"3\">26-29 (79-84)</td> <td>Restrict activities for unacclimatized children and those at high risk for heat illness<sup>&#182;</sup>.</td> </tr> <tr> <td>Reschedule activities to a cooler time of day.</td> </tr> <tr class=\"divider_bottom\"> <td>Increase number of rest periods, hydration breaks, and frequency of substitution during practice and competition.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Extreme caution</td> <td class=\"divider_bottom\" rowspan=\"2\">33-40 (91-104)</td> <td class=\"divider_bottom\" rowspan=\"2\">24-25.9 (75-78.6)</td> <td>Reschedule activities to a cooler time of day.</td> </tr> <tr class=\"divider_bottom\"> <td>Increase number of rest periods, hydration breaks, and frequency of substitution during practice and competition.</td> </tr> <tr> <td>Caution</td> <td>27-32 (80-90)</td> <td>&#60;24 (&#60;75)</td> <td>Unrestricted activity but monitor participants for signs of heat illness.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Temperature ranges only are provided. For corresponding humidity values, click <A spellcheck=true href=\"http://www.nws.noaa.gov/om/heat/heat_index.shtml\">here</A>. Full sun exposure may increase the heat index value by as much as 8°C (15°F).<br />¶ Refer to UpToDate topics on heat stroke in children.</div><div class=\"graphic_reference\">Adapted with permission from: Bytomski JR, Squire DL. Heat illness in children. Curr Sports Med Rep 2003; 2:320. Copyright © 2003 Lippincott Williams &amp; Wilkins and NOAA's national weather service heat index. National Oceanic and Atmospheric Administration. http://www.nws.noaa.gov/om/heat/index.shtml (Accessed on September 9, 2015).</div><div id=\"graphicVersion\">Graphic 53860 Version 13.0</div></div></div>"},"53861":{"type":"graphic_picture","displayName":"Florid bile duct lesion PBC","title":"Florid bile duct lesion in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Florid bile duct lesion in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:415px; height:288px;\" src=\"images/GAST/53861_Florid_bile_duct_lesion_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a liver biopsy from a patient with primary biliary cholangitis shows a portal bile duct with degeneration and periductular granulomatous inflammation (\"florid\" bile duct lesion).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 53861 Version 3.0</div></div></div>"},"53864":{"type":"graphic_movie","displayName":"Left coronary artery in Kawasaki disease","title":"Coronary artery aneurysm in Kawasaki","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronary artery aneurysm in Kawasaki</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/53864_ltcorkawconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/53864_ltcorkaw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left anterior oblique projection from a coronary angiogram shows a large aneurysm of the proximal portion of the left coronary artery.</div><div id=\"graphicVersion\">Graphic 53864 Version 2.0</div></div></div>"},"53865":{"type":"graphic_table","displayName":"Discharge crit HF","title":"Discharge criteria for patients with heart failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Discharge criteria for patients with heart failure</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Recommended for all HF patients</td> </tr> <tr> <td>Exacerbating factors addressed</td> </tr> <tr> <td>Near optimal volume status observed</td> </tr> <tr> <td>Transition from intravenous to oral diuretic successfully completed</td> </tr> <tr> <td>Patient and family education completed, including clear discharge instructions</td> </tr> <tr> <td>Left ventricular ejection fraction (LVEF) documented</td> </tr> <tr> <td>Smoking cessation counseling initiated</td> </tr> <tr> <td>Near optimal pharmacologic therapy achieved, including ACE inhibitor and beta blocker (for patients with reduced LVEF), or intolerance documented</td> </tr> <tr> <td>Follow-up clinic visit scheduled, usually for 7 to 10 days</td> </tr> <tr> <td class=\"subtitle1_single\">Should be considered for patients with advanced HF or recurrent admissions for HF</td> </tr> <tr> <td>Oral medication regimen stable for 24 hours</td> </tr> <tr> <td>No intravenous vasodilator or inotropic agent for 24 hours</td> </tr> <tr> <td>Ambulation before discharge to assess functional capacity after therapy</td> </tr> <tr> <td>Plans for postdischarge management (scale present in home, visiting nurse or telephone follow up generally no longer than&nbsp;three days after discharge)</td> </tr> <tr> <td>Referral for disease management, if available</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: heart failure.</div><div class=\"graphic_reference\">Reproduced from: Heart Failure Society Of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail 2010; 16:e134. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53865 Version 4.0</div></div></div>"},"53866":{"type":"graphic_figure","displayName":"Anatomy of brainstem","title":"Anatomy of the brainstem (lateral view)","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Anatomy of the brainstem (lateral view)</div><div class=\"cntnt\"><img style=\"width:523px; height:532px;\" src=\"images/ONC/53866_Anatomy_of_brainstem.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53866 Version 2.0</div></div></div>"},"53867":{"type":"graphic_table","displayName":"Causes of anemia","title":"Differential diagnosis of anemia in the adult","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of anemia in the adult</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Low mean corpuscular volume (microcytic anemia: MCV &#60;80 fL)</td> </tr> <tr> <td class=\"indent1\">Iron deficiency anemia</td> </tr> <tr> <td class=\"indent1\">Thalassemic disorders</td> </tr> <tr> <td class=\"indent1\">Anemia of inflammation/anemia of chronic disease (late; uncommon)</td> </tr> <tr> <td class=\"indent1\">Sideroblastic anemia (eg, congenital, lead, alcohol, drugs; uncommon)</td> </tr> <tr> <td class=\"indent1\">Copper deficiency, zinc poisoning (rare)</td> </tr> <tr> <td class=\"indent1\">Hemolysis*</td> </tr> <tr> <td class=\"subtitle1_single\">Normal mean corpuscular volume (normocytic anemia: MCV 80 to 100 fL)</td> </tr> <tr> <td class=\"indent1\">Acute blood loss</td> </tr> <tr> <td class=\"indent1\">Iron deficiency anemia (early)</td> </tr> <tr> <td class=\"indent1\">Anemia of inflammation/anemia of chronic disease (eg, infection, inflammation, malignancy)</td> </tr> <tr> <td class=\"sublist2_start\">Bone marrow suppression (may also be macrocytic)</td> </tr> <tr> <td class=\"sublist2\">Bone marrow invasion (eg, leukoerythroblastic blood picture)</td> </tr> <tr> <td class=\"sublist2\">Acquired pure red blood cell aplasia</td> </tr> <tr> <td class=\"sublist2\">Aplastic anemia</td> </tr> <tr> <td class=\"indent1\">Chronic renal insufficiency</td> </tr> <tr> <td class=\"sublist2_start\">Endocrine dysfunction</td> </tr> <tr> <td class=\"sublist2\">Hypothyroidism (most commonly normocytic)</td> </tr> <tr> <td class=\"sublist2\">Hypopituitarism</td> </tr> <tr> <td class=\"indent1\">Hemolysis*</td> </tr> <tr> <td class=\"subtitle1_single\">Increased mean corpuscular volume (macrocytic anemia: MCV &#62;100 fL)</td> </tr> <tr> <td class=\"indent1\">Excessive ethanol use</td> </tr> <tr> <td class=\"indent1\">Folate deficiency</td> </tr> <tr> <td class=\"indent1\">Vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Myelodysplastic syndromes</td> </tr> <tr> <td class=\"indent1\">Acute myeloid leukemias (eg, erythroleukemia)</td> </tr> <tr> <td class=\"sublist2_start\">Reticulocytosis</td> </tr> <tr> <td class=\"sublist2\">Response to hemolysis*</td> </tr> <tr> <td class=\"sublist2\">Response to blood loss</td> </tr> <tr> <td class=\"sublist2\">Response to appropriate hematinic (eg, iron, vitamin B12, folic acid)</td> </tr> <tr> <td class=\"indent1\">Drug-induced anemia (eg, hydroxyurea, AZT, chemotherapeutic agents)</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism (less commonly macrocytic)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list is not meant to be exhaustive; only the most common causes are mentioned. In addition, two or more of these conditions may be present (eg, combined iron and folate deficiencies), resulting in a misleadingly normal mean corpuscular volume. Refer to UpToDate for the approach to anemia as well as topics on specific disorders for more details.</div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume; fL: femtoliters; AZT: zidovudine.<br />* Hemolysis is typically associated with some degree of macrocytosis because reticulocytes, which are larger than mature red blood cells, are increased in hemolysis. However, the MCV can be low, normal, or high depending on the degree of reticulocytosis and the underlying cause of hemolysis, which determines the MCV of the remaining cells.</div><div id=\"graphicVersion\">Graphic 53867 Version 6.0</div></div></div>"},"53868":{"type":"graphic_picture","displayName":"Reactive arthritis - oral lesions","title":"Oral lesions in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral lesions in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/53868_React_arthr_oral_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gray plaques are present on the tongue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53868 Version 4.0</div></div></div>"},"53869":{"type":"graphic_waveform","displayName":"Monophasic arterial Doppler waveform","title":"Monophasic arterial Doppler waveform","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Monophasic arterial Doppler waveform</div><div class=\"cntnt\"><img style=\"width:472px; height:242px;\" src=\"images/SURG/53869_Mono_art_Doppler_wave_edt2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The monophasic Doppler signal has a slow upstroke, rounded peak, slow downstroke, no flow reversal, and is nonpulsatile.</div><div class=\"graphic_reference\">Courtesy of the Division of Vascular Surgery at OHSU.</div><div id=\"graphicVersion\">Graphic 53869 Version 3.0</div></div></div>"},"53871":{"type":"graphic_diagnosticimage","displayName":"HACE MRI","title":"HACE MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HACE MRI</div><div class=\"cntnt\"><img style=\"width:380px; height:411px;\" src=\"images/EM/53871_HACE_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With HACE, MRI reveals characteristic intense T2 signal in the white matter, especially the splenium of the corpus callosum, with no grey matter lesions. The MRI may remain abnormal for days to weeks.</div><div class=\"graphic_footnotes\">HACE: high altitude cerebral edema; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Peter Hackett, MD. Copyright &copy; 2009.</div><div id=\"graphicVersion\">Graphic 53871 Version 4.0</div></div></div>"},"53872":{"type":"graphic_picture","displayName":"Surgically-removed polyp","title":"Surgically-removed polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgically-removed polyp</div><div class=\"cntnt\"><img style=\"width:229px; height:467px;\" src=\"images/ALLRG/53872_Surgically_removed_polyp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows resected nasal/sinus polyp tissue. The bottom portion of the specimen demonstrates the characteristic white (or sometimes gray), avascular nature of polyp tissue.</div><div class=\"graphic_reference\">Courtesy of Daniel Hamilos, MD.</div><div id=\"graphicVersion\">Graphic 53872 Version 4.0</div></div></div>"},"53874":{"type":"graphic_picture","displayName":"Pseudopap neo solid","title":"Histology of solid pseudopapillary neoplasm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology of solid pseudopapillary neoplasm</div><div class=\"cntnt\"><img style=\"width:391px; height:272px;\" src=\"images/ONC/53874_Pseudopap_neo_solid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solid pseudopapillary neoplasm of the pancreas. The tumor is largely solid in this field although the slit-like clear spaces represent the beginning of cystic change. Hematoxylin and eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 53874 Version 3.0</div></div></div>"},"53879":{"type":"graphic_diagnosticimage","displayName":"Adult shoulder axillary xray","title":"Axillary radiograph of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axillary radiograph of the shoulder</div><div class=\"cntnt\"><img style=\"width:288px; height:213px;\" src=\"images/EM/53879_Adult_shoulder_axillary_xra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This axillary radiograph of the shoulder shows a normal relationship of the humeral head to the glenoid (arrow), acromion (arrowhead) and the coracoid process (dashed arrow). This view is valuable in assessing for shoulder dislocation.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 53879 Version 3.0</div></div></div>"},"53881":{"type":"graphic_figure","displayName":"Mosquito early life stages","title":"Egg, larva, and pupa stages of Anopheline and Culicine mosquitoes","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Egg, larva, and pupa stages of Anopheline and Culicine mosquitoes</div><div class=\"cntnt\"><img style=\"width:548px; height:600px;\" src=\"images/ID/53881_Mosquito_early_life_stages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) <EM>Culex</EM> mosquitoes lay their eggs in groups (\"rafts\") while <EM>Aedes</EM> and Anopheline mosquitoes lay their eggs individually. In addition, Anopheline eggs have characteristic \"floats.\" <br />(B) Culicine larvae maintain a position vertical to the water surface and breathe via siphon tubes extending to the water surface; the <EM>Culex</EM> siphon is longer than the <EM>Aedes</EM> siphon. In contrast, <EM>Anopheles </EM>larvae lie in a horizontal position parallel to the water surface and do not have a siphon. <br />(C) In the pupa stage, the head and thorax are fused to form a comma-shaped cephalothorax; during this stage, there are no distinguishing characteristics between the genera.</div><div class=\"graphic_reference\">Modified from figures courtesy of Cheryl Whitehorn, MSc.</div><div id=\"graphicVersion\">Graphic 53881 Version 3.0</div></div></div>"},"53885":{"type":"graphic_table","displayName":"Causes of tonic pupil","title":"Etiologies of a tonic pupil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of a tonic pupil</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td>Adie's tonic pupil syndrome</td>\n</tr><tr>\n<td>Infection and inflammation</td>\n</tr><tr>\n<td class=\"sublist1_start\">Ischemia</td>\n</tr><tr>\n<td class=\"sublist1\">Orbital vasculitis</td>\n</tr><tr>\n<td class=\"sublist1\">Lymphomatoid granulomatosis</td>\n</tr><tr>\n<td class=\"sublist1\">Migraine</td>\n</tr><tr>\n<td class=\"sublist1\">Giant cell arteritis</td>\n</tr><tr>\n<td class=\"sublist1\">Orbital or choroidal tumor</td>\n</tr><tr>\n<td class=\"sublist1_start\">Local anesthesia</td>\n</tr><tr>\n<td class=\"sublist1\">Inferior dental block</td>\n</tr><tr>\n<td class=\"sublist1\">Injection of retrobulbar alcohol</td>\n</tr><tr>\n<td class=\"sublist1_start\">Local (ocular or orbital) lesion affecting ciliary ganglion\nor nerve</td>\n</tr><tr>\n<td class=\"sublist1\">Orbital or choroidal tumor</td>\n</tr><tr>\n<td>Neuropathy (autonomic or peripheral)</td>\n</tr><tr>\n<td>Oculomotor nerve palsy</td>\n</tr><tr>\n<td class=\"sublist1_start\">Surgery or laser therapy</td>\n</tr><tr>\n<td class=\"sublist1\">Cataract surgery</td>\n</tr><tr>\n<td class=\"sublist1\">Cryotherapy</td>\n</tr><tr>\n<td class=\"sublist1\">Diathermy</td>\n</tr><tr>\n<td class=\"sublist1\">Penetrating keratoplasty</td>\n</tr><tr>\n<td class=\"sublist1\">Retinal surgery</td>\n</tr><tr>\n<td class=\"sublist1\">Strabismus surgery</td>\n</tr><tr>\n<td class=\"sublist1\">Orbital surgery</td>\n</tr><tr>\n<td class=\"sublist1_start\">Toxicity</td>\n</tr><tr>\n<td class=\"sublist1\">Quinine</td>\n</tr><tr>\n<td class=\"sublist1\">Trichloroethylene</td>\n</tr><tr>\n<td class=\"sublist1_start\">Trauma (non-surgical)</td>\n</tr><tr>\n<td class=\"sublist1\">Blunt trauma to ciliary plexus</td>\n</tr><tr>\n<td class=\"sublist1\">Orbital floor fracture</td>\n</tr><tr>\n<td class=\"sublist1\">Retrobulbar hemorrhage</td>\n</tr><tr>\n<td class=\"sublist1\">Damage to short ciliary nerves</td>\n</tr><tr>\n<td class=\"sublist1_start\">Paraneoplastic</td>\n</tr><tr>\n<td class=\"sublist1\">Eaton-Lambert syndrome</td>\n</tr><tr>\n<td class=\"sublist1\">Carcinomatous neuropathy</td>\n</tr><tr>\n<td class=\"sublist1\">Congenital neuroblastoma with Hirschsprung disease and\ncentral hypoventilation syndrome</td>\n</tr><tr>\n<td class=\"sublist1\">Unilateral Adie pupil with small cell lung cancer and anti-Hu\nantibodies</td>\n</tr></tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53885 Version 2.0</div></div></div>"},"53887":{"type":"graphic_figure","displayName":"Sternal aspiration sites","title":"Sternal bone marrow puncture sites","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Sternal bone marrow puncture sites</div><div class=\"cntnt\"><img style=\"width:478px; height:535px;\" src=\"images/HEME/53887_Sternal_aspiration_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Artist's drawing of the right anterior portion of the chest wall. The first three right intercostal spaces are marked in blue. The bone marrow aspirate needle should be inserted into the sternum either at the level of the 2nd or 3rd intercostal space. The needle is shown about to enter the sternum at the 3rd intercostal space, slightly to the right of center. However, most physicians prefer to enter the sternum in the midline (asterisks), placing fingers of the hand not holding the needle on either side of the sternum for guidance.</div><div id=\"graphicVersion\">Graphic 53887 Version 1.0</div></div></div>"},"53888":{"type":"graphic_figure","displayName":"LASIK PRK LASEK and Epi LASIK procedures","title":"Differences among the LASIK, PRK, LASEK, and Epi LASIK procedures","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Differences among the LASIK, PRK, LASEK, and Epi LASIK procedures</div><div class=\"cntnt\"><img style=\"width:542px; height:463px;\" src=\"images/PC/53888_PRK_LASIK_LASEK_procedures_edit2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In laser-assisted in situ keratomileusis (LASIK, first column), a stromal flap is created mechanically with a microkeratome, or more recently using a femtosecond laser. Part of the stromal bed is then removed with an excimer laser to provide the refractive correction before repositioning the LASIK flap. In photorefractive keratotomy (PRK, second column), the central corneal epithelium is removed and stromal tissue is excised from the stromal surface with an excimer laser. In laser epithelial keratomileusis (LASEK, third column), an epithelial flap is formed with the help of dilute ethanol and special instruments, and stromal tissue is excised from the stromal bed with an excimer laser. The surgeon hopes to retain the epithelium in LASEK, but in some cases it is lost, and then the procedure is then similar to PRK. In epithelial laser-assisted in situ keratomileusis (Epi-LASIK, fourth column), an epikeratome, which is a mechanized blunt blade, is used to separate the epithelium from the underlying stroma.</div><div id=\"graphicVersion\">Graphic 53888 Version 3.0</div></div></div>"},"53889":{"type":"graphic_picture","displayName":"Rosacea papules on face","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/53889_Rosacea_papules_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and centrofacial erythema are present in this patient with rosacea.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53889 Version 3.0</div></div></div>"},"53890":{"type":"graphic_figure","displayName":"Achilles tendon PI","title":"Achilles tendon","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Achilles tendon</div><div class=\"cntnt\"><img style=\"width:525px; height:621px;\" src=\"images/PI/53890_Achilles_tendon_PI_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Achilles tendon is a strong band of tissue that connects the calf muscles to the heel bone.</div><div id=\"graphicVersion\">Graphic 53890 Version 2.0</div></div></div>"},"53891":{"type":"graphic_waveform","displayName":"ECG Torsades de pointes tutorial","title":"Single lead electrocardiogram (ECG) showing torsades de pointes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single lead electrocardiogram (ECG) showing torsades de pointes</div><div class=\"cntnt\"><img style=\"width:450px; height:141px;\" src=\"images/CARD/53891_Torsades_de_pointes_tutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an atypical, rapid, and bizarre form of ventricular tachycardia that is characterized by a continuously changing axis of polymorphic QRS morphologies.</div><div id=\"graphicVersion\">Graphic 53891 Version 4.0</div></div></div>"},"53892":{"type":"graphic_picture","displayName":"Morgan lens removal","title":"Morgan® lens removal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morgan&#174; lens removal</div><div class=\"cntnt\"><img style=\"width:433px; height:385px;\" src=\"images/EM/53892_Morgan_lens_remove.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pH should be rechecked to confirm that a neutral pH has been maintained initially at five minutes and again at thirty minutes after the completion of irrigation.</div><div class=\"graphic_reference\">Reproduced with permission from: MorTan, Inc. Copyright &#169; 2009.</div><div id=\"graphicVersion\">Graphic 53892 Version 4.0</div></div></div>"},"53894":{"type":"graphic_picture","displayName":"Penile scabies","title":"Penile scabies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile scabies</div><div class=\"cntnt\"><img style=\"width:393px; height:259px;\" src=\"images/PC/53894_Penile_scabies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small erythematous papule is visible on the glans penis.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 53894 Version 2.0</div></div></div>"},"53897":{"type":"graphic_figure","displayName":"Posterior pelvic tilt","title":"Posterior pelvic tilt","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Posterior pelvic tilt</div><div class=\"cntnt\"><img style=\"width:459px; height:180px;\" src=\"images/RHEUM/53897_Posterior_pelvic_tilt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posterior pelvic tilt is a basic maneuver in back rehabilitation. The abdominal and gluteal muscles are contracted to flatten the lumbar spine. This position is held for 5 to 10 seconds and can be repeated frequently.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 53897 Version 4.0</div></div></div>"},"53898":{"type":"graphic_picture","displayName":"Granuloma annulare on foot","title":"Granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:370px;\" src=\"images/DERM/53898_Granuloma_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 30 year-old patient with disseminated granuloma annulare shows confluent annular lesions on the right dorsum foot with papules at the periphery and within the center of the patches. Similar patchy involvement was present on the legs, hands, arms, and buttocks.</div><div id=\"graphicVersion\">Graphic 53898 Version 1.0</div></div></div>"},"53899":{"type":"graphic_table","displayName":"ECX for advanced esophagogastric cancer","title":"Epirubicin, cisplatin, and capecitabine (ECX) for advanced esophagogastric cancer<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epirubicin, cisplatin, and capecitabine (ECX) for advanced esophagogastric cancer<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Epirubicin</strong></td> <td>50 mg/m<sup>2</sup> IV</td> <td>Administer into a free flowing IV solution with normal saline (NS)*, generally over 3 to 20 minutes.</td> <td>Day 1</td> </tr> <tr> <td><strong>Cisplatin</strong></td> <td>60 mg/m<sup>2</sup> IV</td> <td>Dilute with at least 250 mL NS and administer over 120 minutes. Do not administer with aluminum needles or IV sets.</td> <td>Day 1</td> </tr> <tr> <td><strong>Capecitabine</strong><sup>&#916;</sup></td> <td>625 mg/m<sup>2</sup> per dose by mouth.<span style=\"color: #ff0000;\"> </span></td> <td>Twice daily (total daily dose 1250 mg/m2). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets<sup>&#9674;</sup>.</td> <td>Days 1 through 21</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hydration:</strong> Give IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on Prevention.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> Epirubicin plus cisplatin: HIGH. Oral capecitabine alone: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There are no recommended premedications to prevent infusion reactions. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Epirubicin is a vesicant; cisplatin is an irritant but can cause significant tissue damage. Avoid extravasation of either agent. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with granulocyte colony stimulating factors is not warranted (incidence of febrile neutropenia with ECX was 0 and 7 percent in two trials<sup>[1,2]</sup>). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. In the original ECX protocol, patients were required to have GFR &#8805;60 mL/min and a serum creatinine within normal range<sup>[2]</sup>. Lower starting doses of capecitabine may be needed in patients with renal impairment<sup>[3]</sup>. Lower starting doses of epirubicin may be needed in patients with preexisting renal or hepatic impairment<sup>[4]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac issues:</strong> Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. In the original protocol, patients were excluded from receiving epirubicin if their LVEF was below the normal range<sup>[2]</sup>.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count on day 1 prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess basic metabolic panel including creatinine and liver function tests on day 1 prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for neurotoxicity prior to each treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for stomatitis, diarrhea, and palmar-plantar erythrodysesthesiass during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor cumulative epirubicin dose. Reassess LVEF periodically as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> Hold epirubicin until the platelets are &#8805;100,000/microL and the absolute neutrophil count is &#8805;1500/microL<sup>[4]</sup>. In the original ECX protocol, cisplatin and epirubicin doses were delayed by one week or until myelosuppression was resolved if the platelet count was &#60;100,000/microL or the total white blood cell count was &#60;2000/microL on day 1<sup>[2]</sup>. The dose of epirubicin was reduced by 25 percent for a second episode of treatment delay due to myelosuppression or for febrile neutropenia. There were no dose reductions for capecitabine based on blood counts.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Renal dysfunction:</strong> Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL<sup>[5]</sup>. In the original trial of ECX, full-dose cisplatin was given if the estimated GFR was &#62;60 mL/min, and the drug was held if the estimated GFR was &#60;40 mL/min<sup>[2]</sup>. For an estimated GFR of 40 to 60 mL/min, the dose of cisplatin (in mg) was equivalent to the estimated GFR (in mL/min).</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Mucositis, diarrhea, nausea and vomiting:</strong> In the original trial, capecitabine was stopped for grade 2 to 3 stomatitis, diarrhea, or nausea and vomiting<sup>[2]</sup>. If grade 3 toxicity was controlled adequately within two days and after resolution of any grade 2 toxicity, capecitabine was continued at full dose. If grade 2 toxicity occurred a second time, the dose was reduced by 25 percent; a third time, by 50 percent; and if it occurred a fourth time, treatment was discontinued. If grade 3 toxicity took longer than two days to resolve, the capecitabine dose for the next cycle was reduced by 25 percent; if grade 3 toxicity recurred, the dose was reduced by 50 percent; and if it recurred, the drug was discontinued. For grade 4 mucositis, diarrhea, or nausea or vomiting, the drug was either discontinued or the dose reduced by 50 percent. Doses of capecitabine that are omitted for toxicity are not replaced or restored. Instead, the patient should resume the planned treatment cycles at the modified dose<sup>[3]</sup>.<span style=\"color: #ff0000;\"> </span><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurotoxicity:</strong> Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. If neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Palmar-plantar erythrodysesthesias:</strong> In the original trial, capecitabine was withheld for grade 2 or worse palmar-plantar erythrodysesthesias until resolution and the subsequent doses reduced by 15 percent for grade 2, 30 percent for grade 3, and 50 percent for grade 4 toxicity<sup>[2]</sup>. Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Other toxicity (including hepatotoxicity):</strong> Hold epirubicin until all non-hematologic toxicity resolved to &#8804; grade 1<sup>[4]</sup>. Reduce epirubicin dose by 25 percent for any grade 3/4 non-hematologic toxicity in previous cycles. </p> <p><span style=\"color: black;\">For capecitabine: For the first, second, and third occurrence of grade 2 toxicity, hold capecitabine<sup>[3]</sup>. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75 percent of the starting dose; third occurrence, 50 percent of the starting dose)</span><span style=\"color: black;\"><span style=\"color: black;\">. For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75 percent of the starting dose; second occurrence, 50 percent of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine. Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50 percent of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for fist recurrence of grade 4 toxicity.&nbsp;Doses of capecitabine that are omitted for toxicity are not replaced or restored. Instead, the patient should resume the planned treatment cycles at the modified dose</span>.</span></p> </td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, dose should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; GFR: glomerular filtration rate; LVEF: left ventricular ejection fraction; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Δ​ No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br /><SPAN style=\"COLOR: black\">◊</SPAN> Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Cunningham D, et al. N Engl J Med 2008; 358:36. </LI>&#xD;&#xA;<LI>Sumpter K, et al. Br J Cancer 2005; 92:1976. </LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016). </LI>&#xD;&#xA;<LI>Epirubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016). </LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 53899 Version 31.0</div></div></div>"},"53902":{"type":"graphic_table","displayName":"Motor and sensory function of the nerves of the arm","title":"Motor and sensory function of the nerves of the arm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor and sensory function of the nerves of the arm</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Nerve</td> <td class=\"subtitle1\">Motor function</td> <td class=\"subtitle1\">Sensory function</td> </tr> <tr> <td>Median</td> <td> <p>Wrist flexion and abduction</p> <p>Thumb and index finger flexion</p> <p>Thumb opposition</p> </td> <td>Palmar thumb, index and middle finger, and radial half of ring finger</td> </tr> <tr> <td>Ulnar</td> <td> <p>Wrist flexion and adduction</p> <p>Finger spread</p> <p>Flexion of distal phalanx of fifth digit</p> </td> <td> <p>Ulnar side of&nbsp;ring finger&nbsp;and associated dorsal hand</p> <p>Little finger&nbsp;and associated dorsal hand</p> </td> </tr> <tr> <td>Radial</td> <td> <p>Wrist extension</p> <p>Supination</p> <p>Thumb extension</p> </td> <td>Dorsal web space between thumb and index finger and dorsal hand, excluding the ulnar distribution</td> </tr> <tr> <td>Musculocutaneous</td> <td>Elbow flexion</td> <td>Lateral forearm</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53902 Version 6.0</div></div></div>"},"53903":{"type":"graphic_table","displayName":"Causes of hearing loss","title":"Causes of hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hearing loss</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Conductive </td> </tr> <tr> <td class=\"subtitle2_single\">Outer-ear causes </td> </tr> <tr> <td class=\"indent1\">Congenital microtia or atresia </td> </tr> <tr> <td class=\"indent1\">External otitis </td> </tr> <tr> <td class=\"indent1\">Trauma </td> </tr> <tr> <td class=\"indent1\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Exostosis</td> </tr> <tr> <td class=\"indent1\">Osteoma </td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Cerumen </td> </tr> <tr> <td class=\"subtitle2_single\">Middle-ear causes </td> </tr> <tr> <td class=\"indent1\">Congenital atresia or ossicular chain malformation </td> </tr> <tr> <td class=\"indent1\">Otitis media </td> </tr> <tr> <td class=\"indent1\">Cholesteatoma </td> </tr> <tr> <td class=\"indent1\">Otosclerosis </td> </tr> <tr> <td class=\"indent1\">Tympanic membrane perforation </td> </tr> <tr> <td class=\"indent1\">Temporal bone trauma </td> </tr> <tr> <td class=\"indent1\">Glomus tumors </td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Sensorineural </td> </tr> <tr> <td class=\"subtitle2_single\">Inner-ear causes </td> </tr> <tr> <td class=\"indent1\">Hereditary hearing loss </td> </tr> <tr> <td class=\"indent1\">Congenital viral infections </td> </tr> <tr> <td class=\"indent1\">Congenital malformations </td> </tr> <tr> <td class=\"indent1\">Presbycusis</td> </tr> <tr> <td class=\"indent1\">Meningitis </td> </tr> <tr> <td class=\"indent1\">Thyrotoxicosis </td> </tr> <tr> <td class=\"indent1\">Viral cochleitis </td> </tr> <tr> <td class=\"indent1\">Ototoxic drugs </td> </tr> <tr> <td class=\"indent1\">Otologic surgery</td> </tr> <tr> <td class=\"indent1\">Meniere disease</td> </tr> <tr> <td class=\"indent1\">Noise exposure </td> </tr> <tr> <td class=\"indent1\">Barotrauma </td> </tr> <tr> <td class=\"indent1\">Penetrating trauma </td> </tr> <tr> <td class=\"indent1\">Acoustic neuroma </td> </tr> <tr> <td class=\"indent1\">Meningioma </td> </tr> <tr> <td class=\"indent1\">Autoimmune disease</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Cerebrovascular ischemia </td> </tr> <tr> <td class=\"indent1\">Arnold-Chiari malformation&nbsp;</td> </tr> <tr> <td class=\"indent1\">Otosyphilis</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 53903 Version 4.0</div></div></div>"},"53904":{"type":"graphic_diagnosticimage","displayName":"Parasternal echo aortic valve vegetations","title":"Parasternal long and short axis echocardiogram views showing aortic valve vegetations in patient with endocarditis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parasternal long and short axis echocardiogram views showing aortic valve vegetations in patient with endocarditis</div><div class=\"cntnt\"><img style=\"width:358px; height:277px;\" src=\"images/CARD/53904_LongaxisvegetationsAV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The precordial views from the transthoracic echocardiogram show multiple bulky vegetations (arrows) and abscesses (arrowheads) of the aortic valve and root. These images were obtained digitally and are displayed in quadrant screen format. In spite of insensitivity for smaller vegetations, precordial transthoracic imaging is often effective for imaging vegetations.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; MV: mitral valve.</div><div id=\"graphicVersion\">Graphic 53904 Version 6.0</div></div></div>"},"53909":{"type":"graphic_picture","displayName":"Benign nephrosclerosis light","title":"Benign nephrosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benign nephrosclerosis</div><div class=\"cntnt\"><img style=\"width:378px; height:257px;\" src=\"images/NEPH/53909_Benign_nephrosclerosis_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in benign nephrosclerosis showing a completely sclerotic glomerulus (upper left) adjacent to two shrunken glomeruli that are still intact. There is also prominent tubular atrophy and dilatation with intratubular hyaline casts (arrows). These changes are induced by ischemia resulting from arterial and arteriolar thickening (not shown).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 53909 Version 2.0</div></div></div>"},"53913":{"type":"graphic_diagnosticimage","displayName":"Intussusception Air contrast","title":"Intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intussusception</div><div class=\"cntnt\"><img style=\"width:359px; height:387px;\" src=\"images/GAST/53913_Intussusception_Air_contras.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air contrast enema showing intussusception in mid-transverse colon (arrow).</div><div class=\"graphic_reference\">Courtesy of Nancy Fitzgerald, MD and Taylor Chung, MD.</div><div id=\"graphicVersion\">Graphic 53913 Version 2.0</div></div></div>"},"53914":{"type":"graphic_table","displayName":"Standard days method","title":"Criteria for starting the standard days method","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for starting the standard days method</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n\t<tr>\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">Women whose menstrual cycles are usually between 26 and 32 days</td>\n   </tr>\n   <tr>\n   <td>Date of last period known</td>\n   <td>Start immediately</td>\n   </tr>\n   <tr>\n   <td>Date of last period unknown</td>\n   <td>Start on first day of next period</td>\n   </tr>\n   <tr>\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle1_single\">\n   Special circumstances\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Postpartum/breastfeeding\n   </td>\n   <td><strong>Wait for at least 4 periods</strong></td>\n   </tr>\n   <tr>\n   <td>Start after two most recent periods are about a month apart</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Three-month DMPA injection used for contraception\n   </td>\n   <td><strong>Wait for at least 90 days after last injection</strong></td>\n   </tr>\n   <tr>\n   <td>Start after two most recent periods are about a month apart</td>\n   </tr>\n   <tr>\n   <td  colspan=\"1\" rowspan=\"2\">\n   Pill, patch, implant, emergency contraception, intrauterine contraception, miscarriage or abortion\n   </td>\n   <td><strong>Cycles before using method or pregnancy were 26 to 32 days long</strong></td>\n   </tr>\n   <tr>\n   <td>Start on first day of next period</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">DMPA: depot-medroxyprogesterone acetate.</div><div class=\"graphic_reference\">Reproduced with permission from the Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 53914 Version 1.0</div></div></div>"},"53915":{"type":"graphic_figure","displayName":"Globin bands Hb H disease","title":"Globin bands attached to the red cell cytoskeleton in hemoglobin H disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Globin bands attached to the red cell cytoskeleton in hemoglobin H disease</div><div class=\"cntnt\"><img style=\"width:359px; height:452px;\" src=\"images/HEME/53915_Globin_bands_Hb_H_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">SDS-PAGE analysis of ghosts and cytoskeletons of red cells from two patients with hemoglobin H (HbH) disease and a normal control. A prominent globin band is seen in both the ghosts and cytoskeletons of the cells from patients with HbH disease.</div><div class=\"graphic_reference\">Reproduced with permission from Advani, S, et al. Blood 1992; 79:1058. Copyright &#169; 1992 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 53915 Version 2.0</div></div></div>"},"53916":{"type":"graphic_figure","displayName":"Serum EPO and anemia","title":"Serum erythropoietin levels in anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum erythropoietin levels in anemia</div><div class=\"cntnt\"><img style=\"width:425px; height:530px;\" src=\"images/HEME/53916_Serum_EPO_and_anemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph indicates the exponential relationship between serum erythropoietin levels (EPO, milliUnits/mL, logarithmic scale) and venous hematocrit (percent, linear scale) in normal and anemic subjects without renal or chronic diseases. EPO was assayed by either bioassay or radioimmunoassay.</div><div class=\"graphic_reference\">Data from: Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med 1987; 109:429.</div><div id=\"graphicVersion\">Graphic 53916 Version 3.0</div></div></div>"},"53917":{"type":"graphic_figure","displayName":"Superficial cervical plexus block","title":"Superficial cervical plexus block","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Superficial cervical plexus block</div><div class=\"cntnt\"><img style=\"width:539px; height:613px;\" src=\"images/SURG/53917_Supcervicalplexusblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For the superficial cervical plexus block using anatomic landmarks,&nbsp;a line is drawn from the mastoid process to the C6 transverse process (ie, Chassaignac tubercle) along the posterior border of the sternocleidomastoid muscle (line shown in blue). The midpoint of this line is marked (red dot) as the injection site. After negative aspiration, 10 to 15 mL of local anesthetic is injected in 5-mL increments along the posterior border of the sternocleidomastoid muscle, fanning the injection 2 to 3 cm above and below the needle insertion site, with gentle aspiration between injections. Injection deeper than 2 cm should be avoided. See topic text for block details.</div><div id=\"graphicVersion\">Graphic 53917 Version 3.0</div></div></div>"},"53918":{"type":"graphic_picture","displayName":"Cutaneous sarcoidosis - annular plaques on neck","title":"Cutaneous sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous sarcoidosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53918_Cut_sarcoid_plaques_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous annular plaques are present on the neck of this patient with cutaneous sarcoidosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53918 Version 3.0</div></div></div>"},"53919":{"type":"graphic_picture","displayName":"Examples of self-expandable esophageal stents","title":"Examples of self-expandable esophageal stents","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Examples of self-expandable esophageal stents</div><div class=\"cntnt\"><img style=\"width:432px; height:354px;\" src=\"images/GAST/53919_Ex_self_expand_esoph_stents.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From left to right: self-expandable plastic stent, partially covered self-expandable metal stent, and two examples of fully covered self-expandable metal stents.</div><div id=\"graphicVersion\">Graphic 53919 Version 1.0</div></div></div>"},"53920":{"type":"graphic_picture","displayName":"Purpura fulminans","title":"Purpura fulminans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura fulminans</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/53920_Purpura_fulminans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply demarcated purpuric lesions were present in this patient with purpura fulminans.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 53920 Version 3.0</div></div></div>"},"53921":{"type":"graphic_figure","displayName":"Types of wound healing","title":"Types of wound healing","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Types of wound healing</div><div class=\"cntnt\"><img style=\"width:463px; height:564px;\" src=\"images/SURG/53921_Types_wound_healing_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Smeltzer SC, Hinkle JL, Cheever KH. Brunner and Suddarth's Textbook of Medical Surgical Nursing, 12th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2009. Copyright &#169; 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53921 Version 1.0</div></div></div>"},"53922":{"type":"graphic_picture","displayName":"Toe stand exercise","title":"Strength exercise: Toe stand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Strength exercise: Toe stand</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/53922_Toe_stand_exercise_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This exercise will help make walking easier by strengthening your calves and ankles. For an added challenge, you can modify the exercise to improve your balance.   <OL>  <LI>Stand behind a sturdy chair, feet shoulder-width apart, holding on for balance. Breathe in slowly. </LI>  <LI>Breathe out and slowly stand on tiptoes, as high as possible. </LI>  <LI>Hold position for one second. </LI>  <LI>Breathe in as you slowly lower heels to the floor. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Rest; then repeat 10 to 15 more times. </LI></OL>As you progress, try doing the exercise standing on one leg at a time for a total of 10 to 15 times on each leg.</div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 53922 Version 3.0</div></div></div>"},"53927":{"type":"graphic_picture","displayName":"Dental caries in SS","title":"Cervical dental caries in Sjögren's Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical dental caries in Sj&#246;gren's Syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/RHEUM/53927_Dental_caries_in_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absence of a normal quantity of saliva in Sj&#246;gren's Syndrome leads to a greatly increased incidence of dental caries. The cavities occur in particular in the apical area of the tooth, near the gum line.</div><div class=\"graphic_reference\">Courtesy of Robert Fox, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53927 Version 1.0</div></div></div>"},"53928":{"type":"graphic_figure","displayName":"Early and late phases of an allergic reaction in nasal tissues","title":"Early and late phases of an allergic reaction in the nasal tissues","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Early and late phases of an allergic reaction in the nasal tissues</div><div class=\"cntnt\"><img style=\"width:461px; height:604px;\" src=\"images/RHEUM/53928_Pathophys_allergic_rhinitis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic showing pathways (including significant cells and cytokines) underlying early (left) and late (right) phase nasal reactions.</div><div class=\"graphic_footnotes\">IgM: immunoglobulin M; IgE: immunoglobulin E; LTB<sub>4</sub>: leukotriene B<sub>4</sub>; PAF: platelet-activating factor; TNF-alpha: tumor necrosis factor-alpha; LTC<sub>4</sub>: leukotriene C<sub>4</sub>; PGD<sub>2</sub>: prostaglandin D<sub>2</sub>; MHC-Ag: major histocompatibility complex bound to antigen; TCR: T cell receptor; CD40L: CD40 ligand; Th0: undifferentiated T cell; IL: interleukin; Th2: T helper type 2.</div><div class=\"graphic_reference\">Reproduced with permission from: deShazo RD. In: Cecil Textbook of Medicine, 5th ed, Goldman (Ed), 2002. Copyright &copy; 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 53928 Version 4.0</div></div></div>"},"53931":{"type":"graphic_figure","displayName":"Survival benefit with pulmonary metastasectomy","title":"Survival benefit with repeat metastasectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival benefit with repeat metastasectomy</div><div class=\"cntnt\"><img style=\"width:398px; height:303px;\" src=\"images/ONC/53931_Surv_benefit_metastasectomy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival benefit in repeat metastasectomy is dependent upon thoracic control of disease with increasing number of metastasectomies.</div><div id=\"graphicVersion\">Graphic 53931 Version 2.0</div></div></div>"},"53932":{"type":"graphic_figure","displayName":"Partial septate uterus PI","title":"Uterine birth defect","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Uterine birth defect</div><div class=\"cntnt\"><img style=\"width:525px; height:343px;\" src=\"images/PI/53932_Partial_septate_uterus_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some women are born with a uterus that is divided by a band of tissue called a septum. This piece of abnormal tissue can contribute to infertility.</div><div id=\"graphicVersion\">Graphic 53932 Version 3.0</div></div></div>"},"53933":{"type":"graphic_form","displayName":"Checklist chronically ill child","title":"Sample parent-professional worksheet","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Sample parent-professional worksheet</div><div class=\"cntnt\"><img style=\"width:505px; height:430px;\" src=\"images/PEDS/53933_Checklist_chronic_ill_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Trachtenberg S, Lewis D. Interdisciplinary team process. In: Handbook of Developmental Disabilities: Resources for Interdisciplinary Care, Kurtz L, Dowrick P, Levy SE, et al (Eds), Aspen Publishers, Inc, 1996. p.206. Figure 36.1. Copyright © 1996 Aspen Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 53933 Version 5.0</div></div></div>"},"53938":{"type":"graphic_figure","displayName":"Thoracic dermatomes","title":"Thoracic dermatomes","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Thoracic dermatomes</div><div class=\"cntnt\"><img style=\"width:539px; height:447px;\" src=\"images/ID/53938_Thoracic_dermatomes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the thoracic dermatomes, which are bands of skin that are supplied by the thoracic nerves of the spine.</div><div id=\"graphicVersion\">Graphic 53938 Version 2.0</div></div></div>"},"53940":{"type":"graphic_diagnosticimage","displayName":"Choledochal cyst type 1-C","title":"Choledochal cyst type 1-C","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledochal cyst type 1-C</div><div class=\"cntnt\"><img style=\"width:287px; height:388px;\" src=\"images/PEDS/53940_Choledochal_cyst_type_1-C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Choledochal cyst type 1-C with cystolithiasis.</div><div class=\"graphic_reference\">Reproduced with permission from: Guelrud M, Carr-Locke DL, Fox VL. ERCP in Pediatric Practice: Diagnosis and Treatment. Isis Medical Media, London 1997. Copyright © 1997 Taylor and Francis.</div><div id=\"graphicVersion\">Graphic 53940 Version 9.0</div></div></div>"},"53941":{"type":"graphic_figure","displayName":"T3 resin test FDH","title":"T3-resin test in familial dysalbuminemic hyperthroxinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T3-resin test in familial dysalbuminemic hyperthroxinemia</div><div class=\"cntnt\"><img style=\"width:295px; height:351px;\" src=\"images/ENDO/53941_T3_resin_test_FDH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiolabeled T3 (*T3) binds normally to available binding sites on TBG, but cannot bind to available sites on the abnormal albumin; as a result, the amount left over to bind to the resin is normal. The serum total T4 is high due to excess binding to the abnormal albumin, the T3-resin uptake and THBR are normal, and the serum free T4 index is high.</div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine; TBG: thyroxine-binding globulin; THBR: thyroid hormone binding ratio.</div><div id=\"graphicVersion\">Graphic 53941 Version 2.0</div></div></div>"},"53942":{"type":"graphic_picture","displayName":"Leiomyosarcoma B","title":"Poorly differentiated uterine leiomyosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Poorly differentiated uterine leiomyosarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/53942_Leiomyosarcoma_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William Mann, MD.</div><div id=\"graphicVersion\">Graphic 53942 Version 2.0</div></div></div>"},"53943":{"type":"graphic_diagnosticimage","displayName":"Intracardiac echocardiography PMBV","title":"This two panel figure shows a balloon inflation (inoue catheter) by both intracardiac echocardiography visualization and fluoroscopy","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">This two panel figure shows a balloon inflation (inoue catheter) by both intracardiac echocardiography visualization and fluoroscopy</div><div class=\"cntnt\"><img style=\"width:468px; height:263px;\" src=\"images/CARD/53943_ICE_PMBV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ICE image shows the mitral valve and the fully inflated balloon. The fluoroscopic image shows the indented mid section of the valve from the fused commissures immediately before full inflation splits the scar tissue and relieves the obstruction.</div><div id=\"graphicVersion\">Graphic 53943 Version 4.0</div></div></div>"},"53944":{"type":"graphic_picture","displayName":"Cholesteatoma associated with old temporal bone fracture","title":"Cholesteatoma in an old temporal bone fracture line","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholesteatoma in an old temporal bone fracture line</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/53944_Temporal_bone_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratinizing squamous epithelium can enter the middle ear through a temporal bone fracture. The above image depicts a cholesteatoma in an old temporal bone fracture line (arrows).</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 53944 Version 2.0</div></div></div>"},"53945":{"type":"graphic_figure","displayName":"Umbilical hernia repair","title":"Umbilical hernia repair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Umbilical hernia repair</div><div class=\"cntnt\"><img style=\"width:370px; height:573px;\" src=\"images/SURG/53945_Umbilical_hernia_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repair of an umbilical hernia. A) Diagram of longitudinal section through the hernia. B) Subumbilical &quot;smile&quot; incision. The hernial sac is excised. C) Waistcoat type of closure.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53945 Version 1.0</div></div></div>"},"53947":{"type":"graphic_figure","displayName":"Anatomic position","title":"Anatomic position","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Anatomic position</div><div class=\"cntnt\"><img style=\"width:484px; height:362px;\" src=\"images/EM/53947_Anatomic_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary, 27th ed. Baltimore: Lippincott Williams &amp; Wilkins 2000. Copyright &#169;2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53947 Version 1.0</div></div></div>"},"53948":{"type":"graphic_table","displayName":"Class snake bite US","title":"Clinical classification of United States Crotalinae* envenomation to guide FabAV administration","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical classification of United States Crotalinae* envenomation to guide FabAV administration</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Tissue effect</td> <td class=\"subtitle1\">Systemic signs</td> <td class=\"subtitle1\">Coagulopathy and bleeding</td> </tr> <tr> <td>Minimal</td> <td>Swelling, pain, and ecchymosis adjacent to the bite site</td> <td>None</td> <td>Normal coagulation parameters<sup>&#182;</sup>; no bleeding</td> </tr> <tr> <td>Moderate</td> <td>Swelling, pain, and ecchymosis less than full extremity or less than 50 cm if bite on head, neck, or trunk</td> <td>Present but not life-threatening (eg, nausea, vomiting, diarrhea, oral paresthesia, unusual tastes, tachycardia, tachypnea, mild hypotension [systolic BP &#62;90 mmHg in an adult])</td> <td>Abnormal coagulation parameters<sup>&#182;</sup>; no bleeding or minor hematuria, gum bleeding, and/or epistaxis </td> </tr> <tr> <td>Severe</td> <td>Swelling, pain, ecchymosis involving more than the entire extremity; greater than 50 cm if bite on head, neck, or trunk; threatens the airway; OR signs of compartment syndrome</td> <td>Present and life-threatening (eg, respiratory insufficiency, marked tachycardia for age with severe hypotension, obtundation, seizures)</td> <td>Markedly abnormal coagulation parameters<sup>&#182;</sup> with serious bleeding</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FabAV: polyvalent Crotalidae ovine immune Fab (Crofab, Protherics); BP: blood pressure.<br />* Includes bites by rattlesnakes, water moccasins (cottonmouths), and copperheads.<br />¶ Coagulation parameters include platelet count, prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, and fibrin degradation products (fibrin split products [FSP]).</div><div class=\"graphic_reference\">Data from: Goto, CS, Feng, SY. Crotalidae polyvalent immune fab for the treatment of pediatric crotaline envenomation. Pediatr Emerg Care 2009; 25:273.</div><div id=\"graphicVersion\">Graphic 53948 Version 3.0</div></div></div>"},"53951":{"type":"graphic_diagnosticimage","displayName":"CT bifrontal cerebral contusions","title":"Frontal cerebral contusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal cerebral contusion</div><div class=\"cntnt\"><img style=\"width:380px; height:442px;\" src=\"images/NEURO/53951_Frontal_cerebral_contusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the brain depicting cerebral contusions. The basal frontal areas (as shown) are particularly susceptible.</div><div class=\"graphic_reference\">Reproduced with permission from: J Claude Hemphill III, MD and Nicholas Phan, MD, FRCSC.</div><div id=\"graphicVersion\">Graphic 53951 Version 3.0</div></div></div>"},"53952":{"type":"graphic_figure","displayName":"Hair follicle","title":"Anatomy of the hair follicle","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Anatomy of the hair follicle</div><div class=\"cntnt\"><img style=\"width:540px; height:526px;\" src=\"images/ONC/53952_Hair_follicle.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 53952 Version 2.0</div></div></div>"},"53953":{"type":"graphic_table","displayName":"Sources of lead exposure","title":"Sources of lead exposure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of lead exposure</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Occupational </td> </tr> <tr> <td>Plumbers, pipe fitters</td> </tr> <tr> <td>Lead miners</td> </tr> <tr> <td>Lead smelters and refiners</td> </tr> <tr> <td>Auto repairers</td> </tr> <tr> <td>Glass manufacturers</td> </tr> <tr> <td>Shipbuilders</td> </tr> <tr> <td>Printers</td> </tr> <tr> <td>Plastic manufacturers</td> </tr> <tr> <td>Police officers</td> </tr> <tr> <td>Steel welders or cutters</td> </tr> <tr> <td>Construction workers (especially renovation and rehabilitation)</td> </tr> <tr> <td>Rubber product manufacturers</td> </tr> <tr> <td>Gas station attendants (past exposure)</td> </tr> <tr> <td>Battery manufacturers</td> </tr> <tr> <td>Battery recyclers</td> </tr> <tr> <td>Bridge reconstruction workers</td> </tr> <tr> <td>Firing range instructors</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Homes/Buildings </td> </tr> <tr> <td>Lead-containing paint/pigment</td> </tr> <tr> <td>Soil/dust near lead industries, roadways, lead-painted homes</td> </tr> <tr> <td>Plumbing leachate</td> </tr> <tr> <td>Ceramic ware (especially imported)</td> </tr> <tr> <td>Leaded gasoline</td> </tr> <tr> <td>Vinyl miniblinds*</td> </tr> <tr> <td class=\"subtitle1_single\">Hobbies and related activities </td> </tr> <tr> <td>Glazed pottery making</td> </tr> <tr> <td>Target shooting at firing ranges</td> </tr> <tr> <td>Lead soldering (eg, electronics)</td> </tr> <tr> <td>Painting</td> </tr> <tr> <td>Preparing lead shot, fishing sinkers</td> </tr> <tr> <td>Stained-glass making</td> </tr> <tr> <td>Car or boat repair</td> </tr> <tr> <td>Home remodeling</td> </tr> <tr> <td class=\"subtitle1_single\">Other sources </td> </tr> <tr> <td>Folk remedies (Mexican: azarcon, greta, alarcon, coral liga, Maria Luisa, rueda; Asian: ba-baw-san, bali goli, chuifong, ghasard, kandu, tokuwan)</td> </tr> <tr> <td>Tobacco smoking</td> </tr> <tr> <td>Cosmetics</td> </tr> <tr> <td>Moonshine whiskey</td> </tr> <tr> <td>Gasoline \"huffing\"</td> </tr> <tr> <td>Ayurvedic medications</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Made outside the United States and purchased before 1997.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Environmental Health and Medicine Education. Lead Toxicity: Who Is at Risk of Lead Exposure? Agency for Toxic Substances &amp; Disease Registry. Available at: <A spellcheck=true href=\"http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=7\"target=_blank>http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=7</A>.</LI>&#xD;&#xA;<LI>Environmental Health and Medicine Education. Lead Toxicity: Where is Lead Found? Agency for Toxic Substances &amp;&nbsp;Disease Registry. Available at: <A spellcheck=true href=\"http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=5\"target=_blank>http://www.atsdr.cdc.gov/csem/csem.asp?csem=7&amp;po=5</A>.</LI></OL></div><div id=\"graphicVersion\">Graphic 53953 Version 4.0</div></div></div>"},"53954":{"type":"graphic_picture","displayName":"Tinel sign for ulnar neuropathy","title":"Tinel sign for ulnar neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tinel sign for ulnar neuropathy</div><div class=\"cntnt\"><img style=\"width:387px; height:321px;\" src=\"images/EM/53954_Tinel_sign_for_ulnar_neurop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed at about 90 degrees and the arm externally rotated, the medial epicondyle and the olecranon process are identified.&nbsp;The ulnar nerve travels within&nbsp;this groove. The examiner taps this area&nbsp;repeatedly with the tip of the finger.&nbsp;Lancinating pain or numbness or an electric sensation&nbsp;that travels along the ulnar nerve distribution (which extends distally as far as the ring and little&nbsp;fingers) marks a positive Tinel sign. Assuming the ulnar neuropathy is unilateral, the sensation should be distinctly different on the uninvolved side.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 53954 Version 3.0</div></div></div>"},"53955":{"type":"graphic_figure","displayName":"Testosterone preparations","title":"Structure of the different testosterone preparations","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Structure of the different testosterone preparations</div><div class=\"cntnt\"><img style=\"width:593px; height:469px;\" src=\"images/ENDO/53955_Testost_preparations_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Structure of the testosterone preparations available for the treatment of men with hypogonadism.</div><div id=\"graphicVersion\">Graphic 53955 Version 2.0</div></div></div>"},"53956":{"type":"graphic_diagnosticimage","displayName":"Crohn abscess SBFT","title":"Crohn disease with abscess and fistulae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease with abscess and fistulae</div><div class=\"cntnt\"><img style=\"width:291px; height:285px;\" src=\"images/GAST/53956_Crohns_abscess_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through study demonstrates an abscess cavity (arrow) with fistulae connecting the cavity to the adjacent small bowel (arrowheads). Note the marked thickening of the inflamed mucosal folds (dashed arrows).</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53956 Version 4.0</div></div></div>"},"53961":{"type":"graphic_picture","displayName":"Bile duct stone seen on cholangioscopy","title":"Bile duct stone seen on direct cholangioscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bile duct stone seen on direct cholangioscopy</div><div class=\"cntnt\"><img style=\"width:386px; height:378px;\" src=\"images/GAST/53961_Bile_duct_stone_cholang_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct cholangioscopy showing a large stone within the bile duct.</div><div id=\"graphicVersion\">Graphic 53961 Version 2.0</div></div></div>"},"53962":{"type":"graphic_table","displayName":"Further dietary modifications for elevated LDL-C in children","title":"2011 NHLBI* expert panel recommended diet for children with elevated low-density lipoprotein cholesterol (LDL-C) refractory to initial low-saturated fat diet","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2011 NHLBI* expert&nbsp;panel recommended diet for children with elevated low-density lipoprotein cholesterol (LDL-C)&nbsp;refractory to initial low-saturated fat diet</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Refer to a registered dietitian for family medical nutrition therapy</td> </tr> <tr> <td>Dietary components include: 25 to 30 percent of calories from fat, &#8804;7 percent from saturated fat, ~10 percent from monounsaturated fat; &#60;200 mg/d of cholesterol; avoid trans fats as much as possible</td> </tr> <tr> <td class=\"sublist1_start\">Other supportive actions include:</td> </tr> <tr> <td> <ul> <li>Plant sterol esters and/or plant stanol esters up to 2 g/d as replacement for usual fat sources can be used after age&nbsp;two years in children with familial hypercholesterolemia. Plant stanol esters as part of a regular diet are marketed directly to the public. Short-term studies show no harmful effects in healthy children. These can be added to some foods, such as margarine. </li> <li>The water-soluble fiber psyllium can be added to a low fat, low saturated fat diet as cereal enriched with psyllium at a dose of 6 g/d for children 2 to 12 years, and 12 g/d for those &#8805;12 years. </li> <li>As in all children, 1 h/d of moderate to vigorous physical activity and &#60;2 h/d of sedentary screen time are recommended. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">d: day; h: hour.<BR>* NHLBI: National Heart, Lung, and Blood Institute.</div><div class=\"graphic_reference\">Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div><div id=\"graphicVersion\">Graphic 53962 Version 3.0</div></div></div>"},"53963":{"type":"graphic_figure","displayName":"Anteroposterior paddle position","title":"Anteroposterior paddle placement","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Anteroposterior paddle placement</div><div class=\"cntnt\"><img style=\"width:526px; height:339px;\" src=\"images/EM/53963_Antpostpaddleposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An anterior/posterior pad or paddle placement may be used with the center of the anterior pad or paddle applied slightly to the left of the sternum and the posterior pad or paddle applied to the middle of the upper back. The patient may be sitting or rolled onto their right side. This position may be preferred if adult electrodes must be used to deliver a countershock to an infant &lt;10 kilograms wwhen infant paddles are unavailable. In this situation, the anterior/posterior placement avoids the possibility of the large paddles contacting each other during shock delivery.</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53963 Version 11.0</div></div></div>"},"53966":{"type":"graphic_figure","displayName":"Ring cutter","title":"Ring cutter method of ring removal","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Ring cutter method of ring removal</div><div class=\"cntnt\"><img style=\"width:566px; height:230px;\" src=\"images/EM/53966_Ringcutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Use ring cutters with care in patients with lacerations because metal filings may cause foreign body reaction and/or chronic synovitis. Check the saw blade to ensure it is sharp and clean. Note that standard ring cutters are usually not effective for removing hardened steel rings (eg, steel nuts, washers). Place the guard of the ring cutter under the ring on the plamar aspect of the hand or plantar aspect of the foot. Apply the saw blade to the ring using the lever (large arrow) and turn the wheel of the blade using the handle (lines). Heat from friction may develop and necessitate periodic cooling with cold water or ice. Once the ring is cut, remove it from the finger by pulling it apart with hemostats. Two cuts may be necessary to permit removal.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuchs SM. Ring removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 53966 Version 9.0</div></div></div>"},"53967":{"type":"graphic_table","displayName":"Regulation insulin release","title":"Regulation of insulin release","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Regulation of insulin release</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Factors that stimulate insulin release</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Glucose, mannose</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Leucine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vagal stimulation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sulfonylurea drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Factors that amplify glucose-induced insulin release</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Enteric hormones</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Glucagon-like peptide 1</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Gastric inhibitory peptide</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Cholecystokinin</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Secretin</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Gastrin</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Neural amplifiers</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Beta-adrenergic stimulation</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Amino acids</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Arginine</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Prostaglandin E2</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Inhibitors of insulin release</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Neural</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Alpha-adrenergic effect</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Humoral</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Somatostatin</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Drugs</td>\n\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Diazoxide</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Phenytoin</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Vinblastine</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Colchicine</td>\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Masharani U, Karam JH. Pancreatic hormones and diabetes mellitus. In: Basic and Clinical Endocrinology, 6th ed, Greenspan, FS, Gardner, DC (eds), McGraw-Hill, 2001. p. 627. Copyright © 2001. McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 53967 Version 2.0</div></div></div>"},"53968":{"type":"graphic_picture","displayName":"Xillix Barretts high grade","title":"Autofluorescence images of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Autofluorescence images of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:537px; height:509px;\" src=\"images/GAST/53968_Xillix_Barretts_high_grade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of Barretts esophagus with high-grade intra-epithelial neoplasia imaged with the LIFE-II system. The images on the left show the views obtained with the fibre optic white light mode of the system, the images on the right show the corresponding views obtained with LIFE.</div><div class=\"graphic_reference\">Reproduced with permission from: www.Barrett.nl. Copyright &#169; Amsterdam Esophageal Research Foundation.</div><div id=\"graphicVersion\">Graphic 53968 Version 1.0</div></div></div>"},"53969":{"type":"graphic_table","displayName":"Na balance in cirrhotic ascites","title":"Estimation of sodium balance in patients with cirrhosis and ascites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimation of sodium balance in patients with cirrhosis and ascites</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"sublist1_start\">The following calculations can be used to estimate sodium balance in a patient with ascites and advanced cirrhosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Mean serum sodium concentration = ascitic fluid sodium concentration = 130 meq/L</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\">Daily net positive balance is 78 meq if intake is 88 meq, excretion is close to zero, and nonurinary losses are 10 meq</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td class=\"sublist1\">Total sodium accumulation over 14 days is 1092 meq (78 x 14)</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Increase in extracellular fluid volume (most of which will accumulate as ascites) is 8.4 liters (1092 meq &#247; 130 meq/L)</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Thus, if a patient is complying with dietary sodium\nexcretion, an 8.4 liter paracentesis will remove 14 days of accumulated\nsodium. Paracentesis can be performed less often in compliant patients\nwho still have some urinary sodium excretion.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 53969 Version 1.0</div></div></div>"},"53970":{"type":"graphic_picture","displayName":"Long standing Buruli ulcer","title":"Long standing Buruli ulcer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Long standing Buruli ulcer</div><div class=\"cntnt\"><img style=\"width:384px; height:504px;\" src=\"images/ID/53970_Long_standing_Buruli_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-standing, progressive ulceration at the left leg of an 11-year-old girl. Earlier attempts to control progression failed, and severe contracture in the knee has already occurred.</div><div class=\"graphic_reference\">Courtesy of Tjip S van der Werf, MD.</div><div id=\"graphicVersion\">Graphic 53970 Version 1.0</div></div></div>"},"53973":{"type":"graphic_figure","displayName":"Electrical fields","title":"Electrical dipole","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrical dipole</div><div class=\"cntnt\"><img style=\"width:439px; height:160px;\" src=\"images/CARD/53973_Electrical_fields.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dipole is created when one part of the muscle strip becomes electrically negative relative to the rest of the muscle strip. Movement of the dipole from negative to positive (arrow) creates an electrical field.</div><div id=\"graphicVersion\">Graphic 53973 Version 1.0</div></div></div>"},"53974":{"type":"graphic_table","displayName":"Skull base tumors diff dx","title":"Differential diagnosis of tumors at the base of the skull","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of tumors at the base of the skull</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Site of lesion</td>\n\n      <td class=\"subtitle1\">Associated tumors</td>\n\n      <td class=\"subtitle1\">Clinical findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anterior parts</td>\n\n      <td>Carcinoma invasive from frontal and ethmoid sinuses; meningiomas</td>\n\n      <td>Unilateral anosmia, frontal lobe syndrome, seizures</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Superior orbital fissure</td>\n\n      <td>Meningiomas, carcinoma of nasopharynx</td>\n\n      <td>III, IV, V, VI cranial nerve lesions with ophthalmoplegia. Pain and hypesthesia in distribution of V.</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Cavernous sinus</td>\n\n      <td>Chordomas, meningiomas, sellar, and parasellar tumors</td>\n\n      <td>III, IV, VI, and sometimes V nerve involvement with ophthalmoplegia</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Apex of the petrous temporal bone</td>\n\n      <td>Cholesteatoma, chordoma, meningioma, neurinoma, sarcoma</td>\n\n      <td>V and VI nerve involvement with sensory and motor findings and diplopia</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Sphenoid and petrous bone</td>\n\n      <td>Meningioma, chordoma, nasopharyngeal carcinoma, metastasis</td>\n\n      <td>III, IV, VI nerve lesions result in ophthalmoplegia; V may be associated with trigeminal neuralgia syndrome</td>\n\n    </tr>\n\n\n\n    <tr>\n\n      <td>Jugular foramen</td>\n\n      <td>Glomus jugulare tumors, neurinomas, chordomas, cholesteatoma, meningiomas, nasopharyngeal carcinoma</td>\n\n      <td>IX, X, XI nerves producing difficulty with swallowing, speaking, and weakness of strap muscles of neck</td>\n\n    </tr>\n\n\n\n\n    <tr>\n\n      <td>Cerebellopontine angle</td>\n\n      <td>Neurinoma, meningioma, cholesteatoma, metastasis cerebellar tumors</td>\n\n      <td>VII nerve lesions causing loss of hearing, vertigo, and nystagmus; cerebellar lesions producing ataxia of limbs and gait; V, VII, and occasionally IX and XII nerve lesions; brainstem symptoms and signs of increased intracranial pressure</td>\n\n    </tr>\n\n\n\n\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Bingas, B. Tumors of the base of the skull. In: Vinken, PJ, Bruyn, GW (Eds), Handbook of Clinical Neurology: Tumors of the Brain and Skull, vol 17. Amsterdam, North Holland, 1974:136.</div><div id=\"graphicVersion\">Graphic 53974 Version 1.0</div></div></div>"},"53975":{"type":"graphic_figure","displayName":"Survival in asymptomatic AS","title":"Survival in asymptomatic aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival in asymptomatic aortic stenosis</div><div class=\"cntnt\"><img style=\"width:368px; height:244px;\" src=\"images/CARD/53975_Survival_in_asymptomatic_AS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier analysis shows survival without valve replacement for 123 patients with valvular aortic stenosis who were initially asymptomatic.</div><div class=\"graphic_reference\">Data from: Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262.</div><div id=\"graphicVersion\">Graphic 53975 Version 3.0</div></div></div>"},"53976":{"type":"graphic_diagnosticimage","displayName":"Abdominal paragonimiasis","title":"Abdominal paragonimiasis","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Abdominal paragonimiasis</div><div class=\"cntnt\"><img style=\"width:583px; height:261px;\" src=\"images/ID/53976_Abdominal_paragonimiasis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatic paragonimiasis in a two-year-old female with epigastric pain and remittent fever for about two months.<br />(A) Plain multidetector computed tomography (MDCT) scan shows slightly hypodense lesion with heterogeneous attenuation and obscure margin in left lateral lobe.<br />(B) Contrast-enhanced MDCT scan at portal venous phase shows multilocular lesion with enhanced septa. The margin and internal detail are clearly demonstrated. Some of the cysts in the lesion are mutually connected.</div><div class=\"graphic_reference\">Reproduced from: Li XM, Yu JQ, Yang ZG, Chu ZG, Peng LQ, Kushwaha S. Correlations between MDCT features and clinicopathological findings of hepatic paragonimiasis. Eur J Radiol 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 53976 Version 2.0</div></div></div>"},"53979":{"type":"graphic_figure","displayName":"Pancreas anatomy","title":"Pancreas anatomy","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Pancreas anatomy</div><div class=\"cntnt\"><img style=\"width:546px; height:571px;\" src=\"images/GAST/53979_Pancreas_anatomy_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pancreas is a combination exocrine and endocrine organ. Exocrine tubuloacinar glands are responsible for secreting the digestive juices into the pancreatic ducts and, subsequently, the&nbsp;gastrointestinal tract. Approximately 1 million Islets of Langerhans responsible for the endocrine function of the pancreas are distributed throughout the exocrine pancreas. Beta and alpha cells of the endocrine islets are respectively responsible for secreting insulin and glucagon, while delta cells secrete somatostatin and PP cells secrete pancreatic polypeptide.</div><div id=\"graphicVersion\">Graphic 53979 Version 12.0</div></div></div>"},"53980":{"type":"graphic_picture","displayName":"Eosinophilia","title":"Eosinophilia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilia</div><div class=\"cntnt\"><img style=\"width:444px; height:287px;\" src=\"images/HEME/53980_Eosinophilia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral blood smear on the left is from a five-month-old boy with eosinophilia of unknown cause. Eosinophil granules are normal in number and size. Nuclei are slightly hyperlobulated (ie, more than the usual two lobes). Eosinophilia gradually regressed with no residual organ dysfunction. The peripheral blood smear on the right is from a 50-year-old male with hypereosinophilic syndrome and a three-year history of eosinophilia, bone marrow failure, and multiple end-organ involvement. The eosinophils show marked hypogranulation.</div><div class=\"graphic_reference\">From Brunning RD, McKenna RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 53980 Version 5.0</div></div></div>"},"53984":{"type":"graphic_table","displayName":"Classification of scleroderma","title":"Classification of scleroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of scleroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pre-scleroderma</td> </tr> <tr> <td>Raynaud phenomenon</td> </tr> <tr> <td>Nailfold capillary changes and evidence of digital ischemia</td> </tr> <tr> <td>Specific circulating autoantibodies - anti-topoisomerase-I (Scl-70), ACA, or anti-RNA polymerase-I, II, or III</td> </tr> <tr> <td>Many patients progress to systemic sclerosis within&nbsp;three years</td> </tr> <tr> <td class=\"subtitle1_single\">Scleroderma sine scleroderma</td> </tr> <tr> <td>Presentation with pulmonary fibrosis or renal, cardiac, or gastrointestinal disease</td> </tr> <tr> <td>No skin involvement</td> </tr> <tr> <td>Raynaud phenomenon may be present</td> </tr> <tr> <td>Antinuclear antibodies may be present - anti-Scl-70, ACA, or anti-RNA polymerase-I, II, or III</td> </tr> <tr> <td class=\"subtitle1_single\">Limited cutaneous scleroderma</td> </tr> <tr> <td>Raynaud phenomenon for years, occasionally decades</td> </tr> <tr> <td>Skin involvement limited to hands, face, feet, and forearms (acral distribution)</td> </tr> <tr> <td>Dilated nailfold capillary loops, usually without capillary drop-out</td> </tr> <tr> <td>A significant (10 to 15 percent) late incidence of pulmonary hypertension, with or without skin calcification, gastrointestinal disease, telangiectasiae (CREST syndrome), or interstitial lung disease</td> </tr> <tr> <td>Renal disease rarely occurs</td> </tr> <tr> <td>ACA in 70 to 80 percent</td> </tr> <tr> <td>Anti-Scl-70 in 10 percent</td> </tr> <tr> <td class=\"subtitle1_single\">Diffuse cutaneous scleroderma</td> </tr> <tr> <td>Raynaud phenomenon followed, within one year, by puffy or hidebound skin changes</td> </tr> <tr> <td>Truncal and acral skin involvement; tendon friction rubs; myositis; arthritis</td> </tr> <tr> <td>Nailfold capillary dilatation and capillary drop-out</td> </tr> <tr> <td>Early and significant incidence of renal, interstitial lung, diffuse gastrointestinal, and myocardial disease</td> </tr> <tr> <td>Anti-Scl-70 (30 percent), anti-RNA polymerase-I, II, or III (12 to 25 percent), ACA (&#60;5 percent) antibodies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACA: anti-centromere.</div><div id=\"graphicVersion\">Graphic 53984 Version 2.0</div></div></div>"},"53985":{"type":"graphic_diagnosticimage","displayName":"Obstructed incisional hernia","title":"Obstructed incisional hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Obstructed incisional hernia</div><div class=\"cntnt\"><img style=\"width:400px; height:304px;\" src=\"images/SURG/53985_Obstruct_incisional_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At the site of a prior surgical incision, dilated loops of bowel (B) can be seen&nbsp;extending through an abdominal wall defect in the region of the linea semilunaris (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. Clinical imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 53985 Version 3.0</div></div></div>"},"53986":{"type":"graphic_picture","displayName":"Morphea with features of lichen sclerosus","title":"Morphea with features of lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morphea with features of lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:422px; height:422px;\" src=\"images/DERM/53986_Morphea_lichen_sclerosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen sclerosus (indicated by arrows) overlying a plaque of linear morphea (hyperpigmented plaque with dermal atrophy cliff drop border).</div><div id=\"graphicVersion\">Graphic 53986 Version 1.0</div></div></div>"},"53988":{"type":"graphic_waveform","displayName":"ECG atrial fibrillation 2","title":"Single-lead electrocardiogram (ECG) showing atrial fibrillation with minimally apparent atrial activity","html":"<div class=\"graphic normal\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing&nbsp;atrial fibrillation with minimally apparent atrial activity</div><div class=\"cntnt\"><img style=\"width:520px; height:79px;\" src=\"images/CARD/53988_Atrial_fibrillation_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">F waves are not apparent in this lead, as the only finding suggestive of AF is the irregularly irrregular ventricular response.</div><div class=\"graphic_footnotes\">AF: atrial fibrillation. </div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 53988 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"53989":{"type":"graphic_picture","displayName":"Gangrenous myositis Light","title":"Spontaneous gangrenous myositis","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Spontaneous gangrenous myositis</div><div class=\"cntnt\"><img style=\"width:533px; height:188px;\" src=\"images/ID/53989_Gangrenous_myositis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Muscle biopsy from a patient with spontaneous gangrenous myositis due to <EM>Streptococcus pyogenes</EM> (group A <EM>Streptococcus</EM>). Left panel: Necrotic muscle fibers with numerous infiltrating leukocytes. Right panel: Gram stain shows gram-positive bacteria in an area of muscle necrosis.</div><div class=\"graphic_reference\">Courtesy of Larry M Baddour, MD.</div><div id=\"graphicVersion\">Graphic 53989 Version 3.0</div></div></div>"},"53990":{"type":"graphic_table","displayName":"Rx strep NVE II","title":"Treatment regimens for native valve endocarditis due to strains of viridans streptococci and <EM>Streptococcus gallolyticus (bovis)</EM> relatively resistant to penicillin G (MIC >0.12 mcg/mL and <0.5 mcg/mL)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment&nbsp;regimens for native valve endocarditis due to strains of viridans streptococci and <EM>Streptococcus gallolyticus (bovis)</EM> relatively resistant to penicillin G (MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">American Heart Association (AHA)</td> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;European Society of&nbsp;Cardiology*<sup>&#182;</sup> (ESC)</td> <td class=\"subtitle1\" rowspan=\"2\">British Society for Antimicrobial Chemotherapy (BSAC)</td> </tr> <tr> <td class=\"subtitle2\">Adult</td> <td class=\"subtitle2\">Pediatric</td> </tr> <tr> <td> <p><strong>Combination:&nbsp;</strong></p> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV either continuously or in&nbsp;four or&nbsp;six divided doses for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Ampicillin 2 g IV every 4 hours for four weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#916;</sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose for first two weeks</p> <p><strong>or</strong></p> <p><strong>Monotherapy:</strong></p> <p><strong>Either</strong></p> <p>Vancomycin<sup>&#9674;</sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone 2 g per 24 hours IV or IM in one dose for four weeks</p> </td> <td> <p><strong>Combination:&nbsp;</strong></p> <p><strong>Either</strong>&nbsp;</p> <p>Aqueous penicillin G 200,000 to 300,000 units/kg per 24 hours IV in&nbsp;six divided doses (maximum dose: 24 million units per&nbsp;24 hours)&nbsp;for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Ampicillin&nbsp;200 to 300&nbsp;mg/kg per 24 hours IV divided in four&nbsp;or six divided doses&nbsp;(maximum dose: 12 g per 24 hours) for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone 100 mg/kg per 24 hours IV​<sup><span style=\"font-size: 13px;\">&#135;</span></sup> in two divided doses or 80 mg/kg in one daily dose (maximum dose: 4 g per 24 hours; if dose is &#62;2 g per 24 hours, use divided dosing every 12 hours) for four weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup>&#916;</sup> 3 to 6 mg/kg per 24 hours IV&nbsp;in&nbsp;three divided doses for&nbsp;first two weeks</p> <p>&nbsp;</p> <p><strong>Beta-lactam-intolerant patients:</strong></p> <p>Vancomycin<sup><span style=\"font-size: 13px;\">&#9674;</span></sup> 40 mg/kg per 24 hours IV in two or three divided doses (maximum dose: 2 g per 24 hours unless levels are inappropriately low)&nbsp;<strong>plus</strong> gentamicin (dosing as above) for four weeks</p> <p>&nbsp;</p> </td> <td> <p><strong>Combination:&nbsp;</strong></p> <p><strong>Either</strong></p> <p>Aqueous penicillin G 24 million units per 24 hours IV in&nbsp;four or six divided doses or continuous infusion&nbsp;for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Amoxicillin 200 mg/kg per 24 hours IV in&nbsp;four or&nbsp;six divided doses for&nbsp;four weeks</p> <p><strong>or</strong></p> <p>Ampicillin 12 g per 24 hours (200 mg/kg per 24 hours) in six divided doses for four weeks</p> <p><strong>or</strong></p> <p>Ceftriaxone<sup>&#167;</sup> 2 g per 24 hours IV or IM in one dose for four weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style=\"font-size: 13px;\">&#916;</span></sup><sup>&#167;</sup> 3 mg/kg per 24 hours IV or IM in one dose for two weeks</p> <p><strong>OR</strong></p> <p>Vancomycin<sup><span style=\"font-size: 13px;\">&#9674;</span></sup> 30 mg/kg per 24 hours IV in&nbsp;two divided doses for&nbsp;four weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style=\"font-size: 13px;\">&#916;</span></sup> 3 mg/kg per 24 hours IV or IM in&nbsp;one dose for first&nbsp;two weeks</p> </td> <td> <p><strong>Combination:</strong>&nbsp;</p> <p>Benzylpenicillin<sup>&#165;</sup> 2.4 g every 4 hours IV for&nbsp;four to&nbsp;six weeks</p> <p><strong>plus</strong></p> <p>Gentamicin<sup><span style=\"font-size: 13px;\">&#916;</span></sup> 1 mg/kg every 12 hours IV for&nbsp;two weeks</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the individual&nbsp;Lexicomp drug monographs for renal dose adjustments.<br />​Wherever intramuscular administration is provided as an alternative, intravenous route is preferred, particularly in infants and children.</div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration;&nbsp;IV: intravenously; IM: intramuscularly.<br />* AHA adult guidelines define relatively resistant streptococcal strains as MIC &gt;0.12 mcg/mL and &lt;0.5 mcg/mL; AHA pediatric guidelines use MIC ≥0.1 and &lt;0.5 mcg/mL; BSAC guidelines use MIC &gt;0.125 mcg/mL and ≤0.5 mcg/mL; ESC guidelines use MIC 0.25 to 2 mcg/mL. Patients with&nbsp;infective&nbsp;endocarditis&nbsp;due to isolates with MICs that exceed these thresholds should receive treatment as for enterococcal infective endocarditis, as summarized in separate tables.<br />¶&nbsp;Pediatric doses (should not exceed adult doses): Penicillin G 200,000 units/kg per 24 hours IV in&nbsp;four to&nbsp;six divided doses; amoxicillin 300 mg/kg per 24 hours IV in&nbsp;four to&nbsp;six divided doses; ceftriaxone 100 mg/kg per dose IV or IM daily; vancomycin 40 mg/kg per 24 hours IV in&nbsp;two or&nbsp;three divided doses; gentamicin 3 mg/kg per 24 hours IV or IM in a single daily dose or in&nbsp;three divided doses.<br />Δ Renal function and gentamicin serum concentrations should be monitored at least once per week. Gentamicin dosage adjusted for peak serum concentration 3 to 4 mcg/mL, trough &lt;1 mcg/mL when&nbsp;two to three&nbsp;divided doses used; when given in a single daily dose, pre-dose (trough) concentrations should be &lt;1 mcg/mL. Per ESC guidelines, post-dose (peak, one hour after injection) serum concentrations should be approximately 10 to 12 mcg/mL (per AHA guidelines, there is no role for measuring peak gentamicin concentration following single daily dosing).<br /><FONT class=lozenge>◊</FONT> Vancomycin therapy only recommended for patients allergic to penicillins and cephalosporins; dose adjusted for trough concentration of 10 to 15 mcg/mL. Penicillin desensitization can be attempted in stable patients.<br />§ Preferred for outpatient therapy.<br />¥ Amoxicillin 2 g every&nbsp;four to&nbsp;six hours may be used in place of benzylpenicillin 1.2 to 2.4 g every four hours.<br />‡ In infants and children, intravenous antibiotics are recommended rather than intramuscular agents.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<DIV>&#xD;&#xA;<OL>&#xD;&#xA;<LI>&#xD;&#xA;<DIV><br />Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</DIV></LI>&#xD;&#xA;<LI>&#xD;&#xA;<DIV>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</DIV></LI>&#xD;&#xA;<LI>&#xD;&#xA;<DIV>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</DIV></LI>&#xD;&#xA;<LI>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</LI></OL></DIV></div><div id=\"graphicVersion\">Graphic 53990 Version 15.0</div></div></div>"},"53992":{"type":"graphic_diagnosticimage","displayName":"Dark flow void from AVM on MRI","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:269px; height:360px;\" src=\"images/NEURO/53992_Dark_flow_void_from_AVM_on.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dark flow void is seen on MRI (arrow) surrounding the nidus of an arteriovenous malformation.</div><div class=\"graphic_reference\">Courtesy of Guy Rordorf, MD.</div><div id=\"graphicVersion\">Graphic 53992 Version 3.0</div></div></div>"},"53993":{"type":"graphic_diagnosticimage","displayName":"Choledochoduodenal stricture","title":"Choledochoduodenal anastomotic stricture","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Choledochoduodenal anastomotic stricture</div><div class=\"cntnt\"><img style=\"width:528px; height:294px;\" src=\"images/GAST/53993_Choledochoduodenal_strictur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this patient with a choledochoduodenal anastomosis, injection of contrast material into the bile ducts shows dilatation of the intrahepatic ducts (arrow) with no passage of contrast through the anastomosis. A catheter (arrowhead) has been inserted through the bile ducts into the duodenum. Using a transhepatic approach (B), a catheter has been inserted through the stricture and a balloon inflated (dashed arrows) to dilate the stricture.</div><div class=\"graphic_reference\">Courtesy of Jonathan B Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 53993 Version 5.0</div></div></div>"},"53994":{"type":"graphic_picture","displayName":"Hepatic hemangioma Gross","title":"Hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:400px; height:255px;\" src=\"images/GAST/53994_Hepatic_hemangioma_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross specimen of a hepatic hemangioma. The cut surface demonstrates a brown to red appearance with areas of focal hemorrhage and fibrosis.</div><div class=\"graphic_reference\">Courtesy of Imad Nasser, MD.</div><div id=\"graphicVersion\">Graphic 53994 Version 1.0</div></div></div>"},"53997":{"type":"graphic_table","displayName":"Manifestations of polyarteritis nodosa","title":"Clinical manifestations of systemic polyarteritis nodosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of systemic polyarteritis nodosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Manifestation</td> <td class=\"subtitle1\">Frequency, percent</td> </tr> <tr> <td class=\"sublist1_start\">Systemic symptoms</td> <td rowspan=\"2\">80</td> </tr> <tr> <td class=\"sublist1\">Fever, malaise, weight loss</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Neuropathy</td> <td rowspan=\"2\">75</td> </tr> <tr> <td class=\"sublist1\">Mononeuritis multiplex, polyneuropathy</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Arthralgias and/or myalgias</td> <td rowspan=\"2\">60</td> </tr> <tr> <td class=\"sublist1\">Articular and/or diffuse extremity pain</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Cutaneous</td> <td rowspan=\"2\">50</td> </tr> <tr> <td class=\"sublist1\">Livedo reticularis, purpura, ulcers</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Renal disease</td> <td rowspan=\"2\">50</td> </tr> <tr> <td class=\"sublist1\">Elevated creatinine, hematuria, glomerulonephritis</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Gastrointestinal symptoms</td> <td rowspan=\"2\">40</td> </tr> <tr> <td class=\"sublist1\">Abdominal pain, rectal bleeding</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Hypertension</td> <td rowspan=\"2\">35</td> </tr> <tr> <td class=\"sublist1\">New onset</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Respiratory manifestations</td> <td rowspan=\"2\">25</td> </tr> <tr> <td class=\"sublist1\">Infiltrates, nodules, cavities</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Central nervous system disease</td> <td rowspan=\"2\">20</td> </tr> <tr> <td class=\"sublist1\">Stroke, confusion</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Orchitis</td> <td rowspan=\"2\">20</td> </tr> <tr> <td class=\"sublist1\">Testicular pain, swelling</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Cardiac involvement</td> <td rowspan=\"2\">10</td> </tr> <tr> <td class=\"sublist1\">Cardiomyopathy, pericarditis</td> </tr> <tr class=\"divider_top\"> <td class=\"sublist1_start\">Peripheral vascular disease</td> <td rowspan=\"2\">10</td> </tr> <tr> <td class=\"sublist1\">Claudication, ischemia, necrosis</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">15</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=71515&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Adapted from: Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa. Arthritis Rheum 2010; 62:616.</div><div id=\"graphicVersion\">Graphic 53997 Version 6.0</div></div></div>"},"53998":{"type":"graphic_diagnosticimage","displayName":"2D TTE Parasternal views descending thoracic aorta","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal long and short axis views showing the descending thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the parasternal long and short axis views showing the descending thoracic aorta</div><div class=\"cntnt\"><img style=\"width:408px; height:269px;\" src=\"images/CARD/53998_Precordial_views_thoracic_a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The descending thoracic aorta can be seen from the parasternal long axis view. Both the long (panel A) and short axis (panel B) precordial views show the descending thoracic aorta (TAo). Note that the short axis imaging plane demonstrates the long axis of the TAo.</div><div class=\"graphic_footnotes\">LV: left ventricle; RA: right atrium; LA: left atrium; Ao R: aortic root.</div><div id=\"graphicVersion\">Graphic 53998 Version 4.0</div></div></div>"},"53999":{"type":"graphic_table","displayName":"Bone mineral density T-score","title":"Bone mineral density T-score criteria for osteoporosis and low bone mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bone mineral density T-score criteria for osteoporosis and low bone mass</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis</td> <td class=\"subtitle1\">T-score</td> </tr> <tr> <td>Normal</td> <td>&#8805;-1.0</td> </tr> <tr> <td>Low bone mass (osteopenia)</td> <td>Between -1.0 and -2.5</td> </tr> <tr> <td>Osteoporosis</td> <td>&#8804;-2.5</td> </tr> <tr> <td>Severe (established) osteoporosis</td> <td>&#8804;-2.5 and fragility fracture</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted for clinical use from the World Health Organization: <a href=\"http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf\">http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf</a> (accessed November 9, 2010).</div><div id=\"graphicVersion\">Graphic 53999 Version 2.0</div></div></div>"}};